[{"title":"Celltrion's Record Profit Starts in Its Own Factories","url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity-en.html","date":"2026-10-15","lang":"en","category":"商業分析系列","tags":["Biosimilars","Sandoz","Celltrion","Manufacturing capacity","Business analysis"],"summary":"Celltrion's third-quarter operating profit exceeded KRW 500 billion for the first time, with a margin of about 34%, powered by its own factories. Sandoz is also turning its European plants into a network capable of accommodating more than 100 medicines. The next round in biosimilars is about whose new products sell fast enough to fill the new capacity.","key_points":[],"excerpt":"KRW 510 billion. That is the preliminary third-quarter operating profit Celltrion announced on October 12, the first time it has crossed KRW 500 billion since the company was founded. Revenue reached KRW 1.5 trillion, up 45.8% year on year. Operating profit rose 69.2%, putting the operating margin at about 34%. Profit grew faster than revenue. The company gave two reasons: it sold more high-margin products, and its factories made those medicines more cheaply. Our view: after a decade of price competition in biosimilars, the money is flowing toward companies that make the medicines themselves. "},{"title":"Celltrion 獲利破紀錄，贏在自己的工廠","url":"https://drugnews.com.tw/articles/2026-10-15-sandoz-celltrion-biosimilar-profit-capacity.html","date":"2026-10-15","lang":"zh-Hant","category":"商業分析系列","tags":["生物相似藥","Sandoz","Celltrion","製造產能","商業分析"],"summary":"Celltrion 第三季營業利益首破 5,000 億韓元，利益率約 34%，靠的是自己的工廠。Sandoz 也在把歐洲工廠改成能裝下上百種藥的網路。生物相似藥的下一局，比的是誰的新藥賣得夠快、填得滿新產能。","key_points":[],"excerpt":"5,100 億韓元。這是 Celltrion 10 月 12 日公布的第三季暫定營業利益，公司成立以來第一次突破 5,000 億韓元。 營收 1.5 兆韓元，年增 45.8%；營業利益年增 69.2%，利益率約 34%。 利益長得比營收快。公司給的理由只有兩個：高毛利的產品賣得更多，工廠把藥做得更便宜。 我們的判斷是：生物相似藥打了十年降價戰，錢正在流向「自己把藥做出來」的公司。瑞士的 Sandoz 也看懂了，正把歐洲工廠改造成能裝下上百種藥的網路。但工廠是先付錢的生意，接下來比的是誰的新藥賣得夠快，填得滿新產能。 01｜從替人代工，到自己決定做什麼藥 Celltrion 起家時，是替別人做藥。 2005 年，它和必治妥施貴寶簽約，在仁川松島的工廠替對方生產類風濕關節炎藥 Orencia。代工讓這家韓國公司先學會一件難事：把大型抗體工廠蓋起來，並通過美國 FDA 的檢查。後來，它開始用自己的工廠，做自己的生物相似藥。 今天，松島一到三廠合計有 25 萬公升的原料藥產能。9 月 22 日，三座廠一起完成歐盟 GMP 更新。2024 年底才開始商業生產的三廠，今年預計做 128 批，比去年多約 142%；整個松島的產量則預計增加約 15%。 這兩個數字要一起看。新廠從低點爬升，成長率才會這麼高；真正多出來、可以拿去賣的藥，是 15% 這個量級。 工廠的成本大多是固定的。同一批廠房和品管"},{"title":"The Two-Drug Bet in Weight-Loss Injections","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence-en.html","date":"2026-10-14","lang":"en","category":"商業分析系列","tags":["EloraTZP","eloralintide","tirzepatide","obesity","clinical trials"],"summary":"In a Phase 2 trial, Lilly added eloralintide to tirzepatide, gaining additional weight-loss potential but also facing higher rates of treatment discontinuation due to adverse events. Whether Phase 3 dose escalation and co-formulation can turn that efficacy into a product upgrade patients are willing to continue remains to be demonstrated.","key_points":[],"excerpt":"The comparator Lilly chose this time was its own tirzepatide. In Phase 2 results announced on September 30, it added investigational eloralintide to tirzepatide to create EloraTZP. Among adults with type 2 diabetes and obesity or overweight, the highest-dose combination produced an estimated mean weight reduction of 23.3% at 48 weeks, versus 14.8% with tirzepatide alone in the same trial: a difference of 8.5 percentage points. These figures assume continued treatment. That increment gives Lilly a reason to keep investing. A challenge emerged alongside it: a higher proportion of participants in"},{"title":"瘦瘦針的雙藥賭注","url":"https://drugnews.com.tw/articles/2026-10-14-eloratzp-weight-loss-tolerability-persistence.html","date":"2026-10-14","lang":"zh-Hant","category":"商業分析系列","tags":["EloraTZP","eloralintide","tirzepatide","肥胖","臨床試驗"],"summary":"禮來在第二期試驗把eloralintide加入tirzepatide，換到額外減重潛力，也遇到較高的因不良事件停藥比例。第三期的加量節奏與共製劑，能否讓這段藥效成為病人願意持續接受的產品升級，仍待驗證。","key_points":[],"excerpt":"禮來這次拿來比較的對手，正是自家的tirzepatide。 9月30日公布的第二期試驗裡，它把研發中的eloralintide加到tirzepatide上，組成EloraTZP。在有第二型糖尿病、肥胖或過重的成人中，最高劑量組合的48週平均減重估計達23.3%，同場tirzepatide單藥為14.8%，相差8.5個百分點。這組數字採持續治療假設。 這個增量值得禮來繼續投入。難題也跟著出現：組合組因不良事件停藥的比例，比單藥高。加進第二個分子，減重曲線往下走，治療的負擔卻往上走。 公司仍計畫在2026年底前推進第三期，改良加量節奏，並開發兩藥共製劑。這場雙藥賭注接下來的勝負，就看它能保住多少額外藥效，又能讓多少人繼續治療。 01｜新搭檔先得勝過自家的現成選項 tirzepatide已是Mounjaro與Zepbound的有效成分。禮來手上有現成選項，新組合要成立，就得回答一個更難的問題：病人為什麼需要多加一個分子？ eloralintide提供了另一條路。tirzepatide作用於GIP與GLP-1受體，參與食慾與血糖調節；eloralintide則瞄準胰澱素受體，透過另一條參與進食調節的訊號，幫助產生飽足感、減少攝食。這是兩個分子、三條受體路徑，並非單純把tirzepatide的劑量再往上加。 禮來也讓eloralintide以單藥進行第三期試驗。新分子能否獨立成為產品、能替既"},{"title":"滴血驗癌真的來了？","url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey.html","date":"2026-10-13","lang":"zh-Hant","category":"商業分析系列","tags":["GRAIL","Galleri","多癌症早期偵測","癌症篩檢","NHS-Galleri","FDA","Theranos","Guardant Health","Shield","液體活檢"],"summary":"Theranos曾以指尖少量血液做多種臨床檢驗為訴求；Galleri採靜脈抽血兩管、每管10毫升。產品已有訂單，但主要晚期癌症終點未達標，「早」仍須更多證據。","key_points":[],"excerpt":"從指尖取幾滴血，就能完成多種臨床檢驗。矽谷新創 Theranos 曾用這個承諾吸引投資人，最後卻走進詐欺案。2022年，創辦人 Elizabeth Holmes 因詐騙投資人相關罪名，被判刑11年3個月。 如今，另一家公司 GRAIL 正把抽血檢測帶進癌症篩檢。它的 Galleri 實際使用靜脈抽血，標準採集兩管、每管10毫升，再從血液中的 DNA 尋找多種癌症訊號。產品已經賣起來，一季檢測量超過六萬次；現在要回答的，是癌症找到了，究竟夠不夠早？ 2026年9月23日，FDA 諮詢委員以6比4支持 Galleri 的有效性，對效益大於風險也投下多數贊成票。但約14.2萬人參與的英國 NHS-Galleri 試驗，主要的第三、第四期癌症合併終點並未達標。有檢測、有訂單，與證明它能讓族群少一點晚期癌症，仍是不同的成績。 依 FDA 會議摘要，委員普遍對「early」用語有疑慮，部分贊成票附上移除這個字、追加研究等條件。這場投票是諮詢意見；GRAIL 的10月5日公告仍明列，Galleri 尚未獲 FDA 許可或批准。 公司正在走的路，是先服務願意付費的客戶，再爭取讓更大的醫療支付體系接手。卡在中間的，正是這個「早」字能替付款人換到什麼。 圖1｜FDA 諮詢委員會三項投票：多數支持，但「early」宣稱仍被質疑；諮詢投票不等於正式批准 01｜癌症還小，血裡的線索也可能太少 Galleri"},{"title":"Has Cancer Detection from a Blood Sample Really Arrived?","url":"https://drugnews.com.tw/articles/2026-10-13-galleri-positive-signal-diagnostic-journey-en.html","date":"2026-10-13","lang":"en","category":"商業分析系列","tags":["GRAIL","Galleri","Multi-cancer early detection","Cancer screening","NHS-Galleri","FDA","Theranos","Guardant Health","Shield","Liquid biopsy"],"summary":"Theranos promised multiple clinical tests from a small finger-prick sample. Galleri uses two 10 mL tubes of venous blood. Orders are growing, but the primary late-stage cancer endpoint was not met, leaving “early” in need of more evidence.","key_points":[],"excerpt":"A few drops of blood from a fingertip, enough to perform a wide range of clinical tests. Silicon Valley startup Theranos once used that promise to attract investors, only to end up at the center of a fraud case. In 2022, founder Elizabeth Holmes was sentenced to 11 years and three months in prison on charges related to defrauding investors. Now another company, GRAIL, is bringing blood testing into cancer screening. Its Galleri test actually uses a venous blood draw, with a standard collection of two tubes containing 10 milliliters each, and looks for signals of multiple cancers in DNA circula"},{"title":"乾燥症三期喊停，argenx 押錯的是機制不是藥","url":"https://drugnews.com.tw/articles/2026-10-13-argenx-sjogrens-unity-futility-mechanism.html","date":"2026-10-13","lang":"zh-Hant","category":"商業分析系列","tags":["argenx","efgartigimod","Vyvgart","FcRn","Sjögren's disease","乾燥症","ianalumab","Novartis","dazodalibep","Amgen","nipocalimab","自體免疫"],"summary":"argenx 10 月 8 日因無效性中止乾燥症三期 UNITY；同一個月諾華與 Amgen 的 B 細胞與 CD40L 路線相繼達標。差別不在藥，在機制動到免疫系統的哪一層，這也重畫了 efgartigimod 擴張清單的分類。","key_points":[],"excerpt":"乾燥症三期喊停，argenx 押錯的是機制不是藥 2026 年 10 月 8 日，argenx 宣布中止 efgartigimod 皮下劑型在乾燥症（Sjögren's disease）的第三期 UNITY 試驗。獨立資料監測委員會在期中分析後建議「因無效性停止」，結論是這項試驗無法達到主要終點。公司原本預計 2027 年下半年才會有結果，現在提前一年出局。[1][2] 同一天，argenx 也公布了 FB102 在乳糜瀉第二期的正向結果。市場看到的是「一勝一敗」，但對投資人真正重要的是另一個問題：efgartigimod 在重症肌無力、CIDP、ITP 都成功，為什麼到了乾燥症就失靈？答案指向 argenx 整個擴張清單的篩選邏輯，而不只是一個適應症。[3] 圖1｜三種機制攻乾燥症，只有直接動 B 細胞與 T–B 共刺激的達標 01｜三週內，三家公司給了乾燥症三個答案 乾燥症是第二常見的風濕免疫病，美國估計有 100 萬到 400 萬名患者，九成是女性，三到四成血清抗體陰性。幾十年來沒有一款針對病因的藥獲准：rituximab 在 TEARS 與 TRACTISS 兩項試驗都沒達到主要終點，belimumab 有訊號但沒走到核准。[4] 2026 年秋天局面突然改變。9 月 22 日，Amgen 宣布 CD40 配體拮抗劑 dazodalibep 的第三期 OASIZ 301（約"},{"title":"Defending its blockbuster, Merck hits a patent wall","url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value-en.html","date":"2026-10-12","lang":"en","category":"商業分析系列","tags":["Keytruda","QLEX","PD-1","皮下注射","藥物遞送","默沙東"],"summary":"One drug accounts for half a company's revenue. That does not give its patents any extra years.","key_points":[],"excerpt":"One drug accounts for half a company's revenue. That does not give its patents any extra years. Merck chose South Korea's Alteogen to turn Keytruda into a more convenient subcutaneous formulation. Work on the next blockbuster must continue. For now, the company is trying to secure another chapter in the commercial life of its current mainstay. The product was developed, and the FDA approved it. But another US company, Halozyme, now stands in the way of its launch. On October 7, Halozyme announced that a Dutch court had issued an injunction concerning the MDASE patent EP622, restricting Merck s"},{"title":"藥王保衛戰，默沙東撞上專利牆","url":"https://drugnews.com.tw/articles/2026-10-12-keytruda-qlex-subcutaneous-delivery-value.html","date":"2026-10-12","lang":"zh-Hant","category":"商業分析系列","tags":["Keytruda","QLEX","PD-1","皮下注射","藥物遞送","默沙東"],"summary":"一支藥撐起半家公司的營收，專利卻不會因此多給幾年。","key_points":[],"excerpt":"一支藥撐起半家公司的營收，專利卻不會因此多給幾年。 默沙東選了韓國Alteogen，把Keytruda做成更方便的皮下劑型。下一支重磅新藥還得繼續開發，眼前這支藥王，先爭取下一段商業生命。 產品做出來了，FDA也核准了。擋在上市路上的，卻是另一家美國公司Halozyme。 10月7日，Halozyme宣布，荷蘭法院就MDASE專利EP622下達禁令，限制默沙東旗下MSD BV在荷蘭、法國、義大利等八個市場製造、銷售皮下版Keytruda。 靜脈版不受這道禁令影響。上述範圍來自Halozyme披露，法院判決全文尚未取得。 默沙東已經付錢買進合作夥伴的技術，為什麼還會被第三家公司攔下？這張禁令，又會讓原本談好的生意多付出什麼代價？ 01｜半家公司的營收，不能只等下一支藥來接 2026年第二季，Keytruda與皮下版Qlex合計帶來83.66億美元營收，約占默沙東當季營收的一半。 這個數字背後，是一家大藥廠很難迴避的問題：最能帶來營收的產品，正在接近專利期限；接班的新藥，卻不能按公司的需要指定哪一天成功。 默沙東2025年報列明，Keytruda在美國的主要化合物專利將於2028年到期。同專利族另有兩件延至2029年，公司預期可能面臨訴訟；主要歐洲市場的期限則列在2031年。 美國與歐洲各有時鐘。2028不是全球同時失去所有保護的日期，也不能拿來推定歐洲同年就會出現替代品。 找新靶點、"},{"title":"兒少肥胖用藥：Novo 的先發優勢，為何還要靠 Wegovy 接棒？","url":"https://drugnews.com.tw/articles/2026-10-11-pediatric-obesity-novo-wegovy-lilly-product-strategy.html","date":"2026-10-11","lang":"zh-Hant","category":"商業分析系列","tags":["兒少肥胖","GLP-1","Novo Nordisk","Eli Lilly","Saxenda","Wegovy","tirzepatide","orforglipron"],"summary":"Novo 已有低齡證據與歐盟標籤，Saxenda 原品牌卻準備退出美國；Wegovy 的 STEP Young 與 Lilly 的共病、口服開發路徑，如何改變兒少肥胖用藥的產品競爭？","key_points":[],"excerpt":"圖1｜劑型不同，不一定換了靶點 Liraglutide、semaglutide與orforglipron活化GLP-1受體，tirzepatide則同時活化GLP-1與GIP受體；這是給藥方式與受體作用的比較，雙受體不代表已證兒科療效較佳。Semaglutide的每週注射標示僅指本文兒科注射劑，該分子另有成人口服產品。圖為作用機制示意，不是受體結構或人體神經迴路。Tirzepatide與orforglipron的兒少肥胖用途仍在研究。〔3、6、7、12〕 01 同一個孩子，指引與藥品標籤可能給出不同答案 一款藥已在歐盟核准用於符合條件的六歲兒童，全球照護指引卻不建議九歲以下用藥。兒少肥胖的競爭，就從這個落差開始。〔2、15〕 WHO 在2026年10月7日發布兒少肥胖照護指引。依公告，0–9歲不建議藥物治療；10–19歲則要在受監督的多模式生活介入未達預期後，才考慮已核准藥物。另一方面，歐盟 Saxenda（liraglutide）標籤已涵蓋6至未滿12歲、體重至少45公斤且符合肥胖條件的兒童。WHO 提供照護建議，EMA 評估產品核准，兩者作用不同，前者沒有撤銷後者的標籤。〔2、15〕 這讓 Novo Nordisk 的領先多了一道考題：它已有低齡藥物證據與歐盟標籤，但每週注射、已有青少年標籤的 semaglutide，還要取得自己的低齡核准。對手 Eli Lilly 則正在研究"},{"title":"From a Daily Tablet to Factory Orders: Who Can Profit from Oral Cyclic Peptides?","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026-en.html","date":"2026-10-05","lang":"en","category":"商業分析系列","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"On September 17, 2026, Novo Nordisk and Orbis Medicines announced a collaboration to develop oral macrocycles for cardiometabolic diseases. Upfront payments and potential development and commercial milestones total up to US$1.4 billion, with additional sales royalties; Novo will also make a strategic investment in Orbis. A large drugmaker is buying opportunities to discover new medicines. That headline ceiling is not yet an order held by a raw-material factory, and the announcement does not disclose commercial purchase volumes or suppliers.","key_points":[],"excerpt":"On September 17, 2026, Novo Nordisk and Orbis Medicines announced a collaboration to develop oral macrocycles for cardiometabolic diseases. Upfront payments and potential development and commercial milestones total up to US$1.4 billion, with additional sales royalties; Novo will also make a strategic investment in Orbis. A large drugmaker is buying opportunities to discover new medicines. That headline ceiling is not yet an order held by a raw-material factory, and the announcement does not disclose commercial purchase volumes or suppliers. At the product end, Merck’s oral cyclic peptide enlic"},{"title":"從每天一顆藥到工廠訂單：口服環肽的錢，誰賺得到？","url":"https://drugnews.com.tw/articles/2026-10-05-cyclic-peptide-upstream-2026.html","date":"2026-10-05","lang":"zh-Hant","category":"商業分析系列","tags":["口服環肽","enlicitide","Orbis","Novo Nordisk","製程"],"summary":"2026年9月17日，諾和諾德（Novo Nordisk）與Orbis Medicines宣布合作，開發心血管代謝疾病的口服大環肽。前期款與可能達成的開發、商業里程碑合計最高14億美元，另計銷售權利金，Novo亦將策略投資Orbis。大藥廠正在買新的藥物發現機會；這筆上限金額，還不是原料工廠手上的訂單，公告也未披露商業採購量或供應商。","key_points":[],"excerpt":"2026年9月17日，諾和諾德（Novo Nordisk）與Orbis Medicines宣布合作，開發心血管代謝疾病的口服大環肽。前期款與可能達成的開發、商業里程碑合計最高14億美元，另計銷售權利金，Novo亦將策略投資Orbis。 大藥廠正在買新的藥物發現機會；這筆上限金額，還不是原料工廠手上的訂單，公告也未披露商業採購量或供應商。 另一端，Merck的口服環肽enlicitide，商品名Lipfendra，已在7月15日獲美國FDA核准，用於降低成人高膽固醇血症患者的低密度脂蛋白膽固醇。它提供了可核的產品與劑量；實際放量及心血管事件效益則是另外的問題。 一顆藥走向口服，看起來會帶動更多原料生意，製程卻可能先把這個算式改掉。Enlicitide的研究已展示如何減少組裝步驟；同樣一公斤合格產品，材料與工時都可能不同。真正值得追的，是誰能跟著新路線一起進化，而不只是誰有一座原料工廠。 每天一顆，先算成品需要多少 Enlicitide藉由結合PCSK9，阻止它促使肝臟的低密度脂蛋白受體降解，讓更多受體參與清除膽固醇。這說明大環肽可以瞄準蛋白質之間的作用；對上游而言，真正能開始計量的是正式產品的劑量。 依美國標籤，每日一顆含20毫克enlicitide的錠劑。假設有10萬人連續使用30天，用量就是20毫克×30天×10萬人＝60公斤有效成分。10萬人與30天只是透明的需求情境，不是公司"},{"title":"Migraine Around Your Period? How Much Can a Seven-Day Prevention Strategy Help?","url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026-en.html","date":"2026-10-04","lang":"en","category":"商業分析系列","tags":["LUNA","atogepant","AbbVie","CGRP","偏頭痛"],"summary":"The days around menstruation can already be uncomfortable. Add migraine, sensitivity to light or nausea, and work, school pickups and carefully planned activities can be disrupted. For people whose attacks repeatedly cluster in this window, the question is straightforward: can the burden be reduced before the headache arrives?","key_points":[],"excerpt":"The days around menstruation can already be uncomfortable. Add migraine, sensitivity to light or nausea, and work, school pickups and carefully planned activities can be disrupted. For people whose attacks repeatedly cluster in this window, the question is straightforward: can the burden be reduced before the headache arrives? On September 10, 2026, AbbVie announced the initial main results, or topline findings, from its Phase 3 LUNA study. The study enrolled 468 adult women and compared seven-day short-term prevention with placebo across three menstrual cycles. Perimenstrual migraine days dec"},{"title":"偏頭痛總挑月經前後來？7天預防研究，能少痛多少？","url":"https://drugnews.com.tw/articles/2026-10-04-luna-atogepant-menstrual-migraine-2026.html","date":"2026-10-04","lang":"zh-Hant","category":"商業分析系列","tags":["LUNA","atogepant","AbbVie","CGRP","偏頭痛"],"summary":"月經前後已經不好受，再碰上偏頭痛、怕光或噁心，工作、接送與原本排好的行程都可能被打亂。對發作時間反覆落在這個窗口的人，問題很直接：能不能在頭痛來之前，先降低那幾天的負擔？","key_points":[],"excerpt":"月經前後已經不好受，再碰上偏頭痛、怕光或噁心，工作、接送與原本排好的行程都可能被打亂。對發作時間反覆落在這個窗口的人，問題很直接：能不能在頭痛來之前，先降低那幾天的負擔？ 2026年9月10日，AbbVie公布LUNA第三期研究的初步主要結果（topline）。研究納入468名成年女性，在三個月經週期比較7天短程預防與安慰劑；圍月經期偏頭痛日數相對基線平均減少1.20天對0.40天，組間多減少0.80天，P<0.0001。 公司也報告功能障礙等次要終點達標。LUNA的吸引力，在於把預防放進患者能預先安排的幾天：不是等頭痛打亂行程才處理，而是試著在高風險窗口之前介入。對AbbVie，這同時是一條讓既有藥物走進新使用情境的路。 時間可預期，讓預防多了一個切入點 LUNA研究藥物atogepant，是美國QULIPTA的有效成分，也是口服小分子CGRP受體拮抗劑。CGRP中文為降鈣素基因相關胜肽，是參與偏頭痛的訊號分子；「受體拮抗」可理解成占住訊號的接收位置，減少CGRP啟動這條路徑。 月經週期與這條訊號的關係，有人體研究提供線索。2023年Charité研究團隊比較不同荷爾蒙狀態的女性，觀察到在自然月經週期中，有偏頭痛者於月經期間的CGRP濃度高於無偏頭痛對照。這是荷爾蒙狀態與CGRP的關聯線索，尚未確立每次經期頭痛的單一原因。 LUNA利用的是發作風險較集中的時間，介入偏頭痛相關訊號"},{"title":"PharmaEssentia Acquires FormuRx. Could Making Drugs Inside Cells Be Next?","url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026-en.html","date":"2026-10-03","lang":"en","category":"商業分析系列","tags":["PharmaEssentia","FormuRx","RNA","LNP"],"summary":"PharmaEssentia (6446) has acquired FormuRx for approximately NT$168 million. According to company-provided news published by Global Bio & Investment, FormuRx develops delivery technologies for getting RNA into cells. The acquisition brings lipid nanoparticle (LNP) formulations, microfluidic processes, analytical capabilities, equipment and a team.","key_points":[],"excerpt":"PharmaEssentia (6446) has acquired FormuRx for approximately NT$168 million. According to company-provided news published by Global Bio & Investment, FormuRx develops delivery technologies for getting RNA into cells. The acquisition brings lipid nanoparticle (LNP) formulations, microfluidic processes, analytical capabilities, equipment and a team. The company's formal English name is FormuRx Pharmaceuticals Co., Ltd. (FormuRx). FINDIT's public company profile lists its establishment in 2019. National Taiwan University's Chinese- and English-language incubator directories record its residency f"},{"title":"藥華藥買下予宇，下一步讓細胞造藥？","url":"https://drugnews.com.tw/articles/2026-10-03-pharmaessentia-formurx-rna-lnp-acquisition-2026.html","date":"2026-10-03","lang":"zh-Hant","category":"商業分析系列","tags":["PharmaEssentia","FormuRx","RNA","LNP"],"summary":"藥華藥（6446）買下予宇生技，交易金額約新台幣1.68億元。依環球生技刊載的公司消息，予宇做的是把RNA送進細胞的遞送研發，帶進來的包括脂質奈米顆粒（LNP）配方、微流體製程、分析、設備與團隊。","key_points":[],"excerpt":"藥華藥（6446）買下予宇生技，交易金額約新台幣1.68億元。依環球生技刊載的公司消息，予宇做的是把RNA送進細胞的遞送研發，帶進來的包括脂質奈米顆粒（LNP）配方、微流體製程、分析、設備與團隊。 予宇的正式英文名是FormuRx Pharmaceuticals Co., Ltd.（FormuRx）。FINDIT公開基本資料列示公司2019年成立；臺大中文育成名錄與英文名錄則記錄它在2021年9月至2026年8月進駐，專注脂質奈米載體新藥、遞送系統與劑型設計。這段經歷是育成關係，不等於臺大衍生公司身分。 FINDIT的技術簡介進一步把脂質載體、微流體製程與「品質源於設計」（QbD）放在一起。這描述的是團隊的製劑開發方法：從設計時就把品質與製造問題納入，而非只追求實驗裡的表現訊號。它是技術介紹，不是政府認證。 公司供稿也說明，予宇已有FR-202、FR-201兩項核心研發專案。這讓收購有具體的產品承接點：藥華藥取得的是可繼續調整的技術與團隊，並可把研發排序納入自身決策。對已有蛋白藥、罕病與TCR-T經驗的公司，這可能比只取得單一分子的授權，更適合拓展RNA工具；它是從取得範圍推想的策略，未被公告確認為完整選標理由。 藥華藥已把長效蛋白做成藥；RNA則能探索讓細胞製造指定蛋白。同樣要讓蛋白質發揮作用，做法卻換了一層。這筆收購的野心，可能是把既有的蛋白與疾病研究，延伸到更多新藥設計，而配"},{"title":"Novo Nordisk Already Has Weight-Loss Injections. Why Pursue Another Path?","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs-en.html","date":"2026-09-30","lang":"en","category":"製藥巨頭系列","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"Why pursue non-incretin programs alongside an established GLP-1 franchise? K-554’s neural-circuit hypothesis, human evidence and usable dose range frame the relationship between efficacy, tolerability, persistence and product value.","key_points":[],"excerpt":"────────── In September 2026, Novo Nordisk executive Jacob Petersen publicly stated that the company had signed an asset purchase agreement to acquire three non-incretin obesity development programs originating at Kallyope. The lead peptide candidate, K-554, was described as IND-ready, while the other two are earlier-stage small-molecule programs. The public post disclosed neither financial terms nor confirmation that the transaction had closed. [1] Novo Nordisk already has weight-management medicines such as Wegovy, or semaglutide. Why look beyond GLP-1? The question behind this move is more "},{"title":"已有瘦瘦針，諾和諾德為何還要布局另一條減重路？","url":"https://drugnews.com.tw/articles/2026-09-30-novo-kallyope-non-incretin-obesity-programs.html","date":"2026-09-30","lang":"zh-Hant","category":"製藥巨頭系列","tags":["Novo Nordisk","Kallyope","肥胖症","GLP-1","非腸泌素","K-554"],"summary":"諾和諾德已有GLP-1減重產品，為何仍布局非腸泌素計畫？從K-554的神經迴路假說、人體證據進度與可用劑量，分析效果、耐受性及持續使用如何影響產品價值。","key_points":[],"excerpt":"────────── 2026年9月，諾和諾德（Novo Nordisk）高管Jacob Petersen公開表示，公司已簽署資產購買協議，擬取得Kallyope發起的三項非腸泌素肥胖症研發計畫。領先胜肽候選K-554被描述為IND-ready，另兩項是更早期的小分子；公開貼文未披露金額，也沒有確認交割完成。[1] 諾和諾德已擁有Wegovy（semaglutide）這類減重藥，為何仍要走出GLP-1？這筆布局對準的問題，比「能不能再少幾公斤」更細：能否從不同的食慾調節入口，找到兼顧效果與耐受性的治療，甚至與既有藥物搭配？公司把單用與併用都列為研發方向。[1][6] 對投資人來說，三項計畫增加的是未來產品的選擇空間。其價值要看新的生物學能否讓患者得到既有療法以外的實際好處，而非靠「新標的」三個字，就把尚待驗證的計畫算成下一款重磅藥。 圖1｜既有腸泌素生物學與新增非腸泌素研究選項並列；新計畫的部分標的未披露，人體價值仍待驗證。[1][2] 【01｜少吃，與不舒服得吃不下，是兩個研究問題】 食慾並非由單一開關控制。腸道、腦部與其他器官透過神經和循環中的訊號交換資訊，影響何時開始進食、吃多少與何時停止。所謂神經迴路，可以理解成一組接收訊號、傳遞訊息，再改變行為的細胞網路。[3] GLP-1是類升糖素胜肽-1，屬腸泌素訊號之一。Wegovy透過活化GLP-1受體影響食慾與熱量攝取；相關受體"},{"title":"Drug Approval in Hand—But Is the Cash in the Bank? How Formosa and PharmaEngine Turn Licensing Payments Into Cash","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html","date":"2026-09-29","lang":"en","category":"商業分析系列","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"Historical Genmab milestones, Formosa's equity settlement and gross-profit-based collaboration, and PharmaEngine's first-half 2026 accounts show how contractual achievements become—or differ from—collectable proceeds.","key_points":[],"excerpt":"────────── Formosa Pharmaceuticals’ ophthalmic drug received U.S. FDA approval in March 2024. Once the marketing authorization transfer was completed, the first US$2 million development milestone from licensing partner Eyenovia was triggered. Yet the payment was half cash and half shares. The collaboration subsequently ended, with US$2.2 million of obligations released. In 2026, PharmaEngine’s half-year financial report illustrated another gap: royalties had been recognized, while part of the amount remained reflected in contract assets and tax-related entries. [1][2][7] For investors, these d"},{"title":"藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html","date":"2026-09-29","lang":"zh-Hant","category":"商業分析系列","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"藥證、付款事件與實際收款之間，有哪些條件？以Genmab歷史里程碑、台新藥的股票結算與毛利合作，以及智擎2026上半年財報，解析新藥授權生意如何從進展走向可運用資源。","key_points":[],"excerpt":"────────── 台新藥的眼科新藥在2024年3月取得美國FDA核准，完成藥證移轉後，觸發授權夥伴Eyenovia第一筆200萬美元開發里程碑。但真正支付時，一半是現金，一半是股票；後來合作終止，還有220萬美元義務被免除。到了2026年，智擎半年報又展示另一種差距：權利金已認列，部分款項仍在合約資產與稅務項目裡。[1][2][7] 對投資人而言，這些金額會影響公司能不能支應下一個試驗。看到「達標」就把整筆金額放進現金預算，可能連資金缺口都算錯。先看台新藥這筆已經走過核准、支付與換約的交易。 【01｜200萬美元達標，銀行收到多少？】 Eyenovia的2024年報記載，這筆里程碑除了FDA核准，還包括藥證移轉與承接生效；條件在2024年3月14日達成。4月26日支付100萬美元現金，4月29日再以股票完成另一部分支付。[1] 股票數量依契約約定的100萬美元及先前股價計算；到了交付日，財報列出的股票公允價值約40萬美元。這裡同時存在三個量：契約計數基礎、交付日估值，以及真正進銀行的現金。[1] 💵 已支付100萬美元現金，並不代表另外100萬美元也能原額拿去付研發費。股票若要變成現金，還得看實際出售價格與可變現條件；40萬美元也不是台新藥最後賣股所得的證明。 這種安排讓付款方保留現金，也把一部分資金風險交給收款方。對台新藥的資金規劃而言，里程碑達成與股票入帳之間，仍有一道流"},{"title":"US$9.2 Billion in Annual Sales—Why Does J&J Still Want to Separate Orthopaedics?","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation-en.html","date":"2026-09-28","lang":"en","category":"商業分析系列","tags":["Johnson & Johnson","DePuy Synthes","Orthopaedics","Business separation","Apollo","United Orthopedic"],"summary":"Why might an orthopaedics business with US$9.2 billion in annual sales lose priority for J&J’s next investment? Growth differences, the value flows in a spin-off versus a sale, and the costs of implants and surgical support explain the economic questions behind the proposed DePuy Synthes separation.","key_points":[],"excerpt":"────────── In 2024, Johnson & Johnson’s orthopaedics business generated approximately US$9.2 billion in sales. Yet in October 2025, the company announced a plan to separate the business so that DePuy Synthes could operate independently. Now a potential buyer has emerged for this substantial medical-device business: on September 11, Bloomberg reported, citing unnamed people familiar with the matter, that Apollo was discussing an acquisition at a potential valuation close to US$20 billion. [1][3] The J&J and Apollo announcements and J&J second-quarter filing reviewed as of September 27 do not es"},{"title":"年營收 92 億美元，強生為什麼還想把骨科拆出去？","url":"https://drugnews.com.tw/articles/2026-09-28-jnj-orthopaedics-separation.html","date":"2026-09-28","lang":"zh-Hant","category":"商業分析系列","tags":["強生","DePuy Synthes","骨科","業務分離","Apollo","聯合骨科"],"summary":"一年銷售92億美元的骨科業務，為何仍可能排不到強生下一筆資金？從成長差異、分拆與出售的價值流向，到人工關節與手術支援的經營成本，拆解DePuy Synthes分離案真正要算的帳。","key_points":[],"excerpt":"────────── 2024 年，強生（Johnson & Johnson，J&J）的骨科業務賣了約 92 億美元。到了 2025 年 10 月，公司仍宣布分離計畫，打算讓 DePuy Synthes 獨立經營。如今，這塊大型醫材資產又傳出買家：Bloomberg 9 月 11 日引述匿名知情人士報導，Apollo 正洽談收購，可能估值接近 200 億美元。【1】【3】 截至 9 月 27 日查閱的 J&J、Apollo 公告與 J&J 第二季財報，尚未取得本案正式簽約或交割的證據；公司仍保留多種分離途徑。分離計畫有正式文件，200 億美元則是洽談消息，兩者的確定程度不同。【2】【3】【4】 一個一年能賣 90 多億美元的事業，為什麼母公司想放手，外部資金卻想接手？這個反差，比傳聞中的價碼更能說明大型藥廠正在算哪一筆帳。 【01｜骨科還在成長，卻未必排得到下一筆資金】 J&J 在宣布分離時，把未來的重心放在創新藥的腫瘤、免疫、神經科學，以及 MedTech 的心血管、外科與視力。公司希望藉由調整組合，往成長更快、利潤率更高的市場集中。【1】 今年的數字，讓這個選擇更容易理解。 📊 2026 年上半年，J&J 骨科銷售為 48.01 億美元，排除匯率影響的營運成長為 3.7%；同期心血管醫材的營運成長為 6.6%。骨科並沒有停止成長，但兩塊業務的速度不同。【2】 排除匯率，是為了"},{"title":"Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html","date":"2026-09-04","lang":"en","category":"商業分析系列","tags":["Ivonescimab","HARMONi-GI1","biliary tract cancer","Akeso","Summit Therapeutics","durvalumab","PD-1 VEGF bispecific","Phase 3"],"summary":"Ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase 3 HARMONi-GI1 interim analysis, but the hazard ratio, median survival, curves, safety and subgroup results remain undisclosed.","key_points":[],"excerpt":"For the past several years, the most recognizable part of the ivonescimab story has been its willingness to challenge Keytruda directly in lung cancer. Now, for the first time, that story has moved beyond lung cancer. On August 26, 2026, Akeso announced that ivonescimab plus chemotherapy met the primary endpoint of overall survival in the prespecified interim analysis of HARMONi-GI1, a Phase 3 study in first-line advanced biliary tract cancer. The comparator was not placebo or chemotherapy alone. It was durvalumab, marketed as Imfinzi, plus chemotherapy, one of the current first-line standards"},{"title":"Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html","date":"2026-09-04","lang":"zh-Hant","category":"商業分析系列","tags":["Ivonescimab","HARMONi-GI1","膽道癌","康方生物","Summit Therapeutics","Durvalumab","PD-1 VEGF 雙抗","臨床三期"],"summary":"Ivonescimab 合併化療在一線晚期膽道癌三期 HARMONi-GI1 達到總生存期主要終點，正面勝過 durvalumab 合併化療；完整風險比、生存曲線、安全性與亞組數據仍待公布。","key_points":[],"excerpt":"━━━━━━━━━━━━ 過去幾年，ivonescimab（依沃西）最響亮的標籤，是敢在肺癌正面挑戰 Keytruda。 現在，它第一次把戰線推到了肺癌之外。 2026 年 8 月 26 日，康方生物宣布，ivonescimab 合併化療，在一線晚期膽道癌三期 HARMONi-GI1 研究的預設期中分析中，達到總生存期主要終點。更關鍵的是，對照組並非安慰劑或單純化療，而是目前一線標準之一：durvalumab（度伐利尤單抗，商品名 Imfinzi）合併化療。 換句話說，新藥被直接推上世界級標準治療的擂台，眼前的欄杆一點也不低。 康方同時表示，無惡化生存期（PFS，疾病沒有惡化的時間）與客觀緩解率（ORR，腫瘤縮小達到標準的患者比例）也達到關鍵次要終點。ivonescimab 因此拿下第一個消化道腫瘤三期陽性結果，也第一次證明它的故事有機會從肺癌延伸到另一個癌種。 市場最想看的數字，卻還沒有出現。 公司目前沒有公布死亡風險降低多少、兩組中位總生存期相差多久、生存曲線何時分開，也沒有交代完整安全性與不同膽道癌亞型的結果。現階段可以確認的是「試驗成功」，還不能回答「成功得有多漂亮」。 這場勝利很重要；真正決定它能走多遠的比賽，才剛開始。 ──────────────────── 🩺 01｜膽道癌的難，不只在於病人少 膽道癌是一組從膽管、膽囊與相關部位長出的惡性腫瘤。它不像肺癌、乳癌那樣"},{"title":"Claude Starts Running Experiments: AI Enters the Physical Lab","url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html","date":"2026-09-03","lang":"en","category":"商業分析系列","tags":["Anthropic","Claude","Model Hardware Standard","MHS","AI for Science","Claude Science","laboratory automation","scientific instruments"],"summary":"Anthropic's Model Hardware Standard research preview gives AI agents a shared interface for microscopes, liquid handlers, robots and laser-control systems. The proof-of-concept results are important, but they do not mean autonomous laboratories are already mature.","key_points":[],"excerpt":"At 2 a.m., a laser in a quantum computer loses lock. At 4 a.m., a graduate student must return to the lab to change a plate in a PCR instrument. AI could already read papers, propose hypotheses and write analysis code. Faced with a droplet, a pipette or a real instrument, however, it stopped at the screen. On August 27, 2026, Anthropic moved that boundary forward. The company released a research preview of the Model Hardware Standard (MHS), a shared interface through which AI agents can read and operate microscopes, liquid-handling workstations, robotic arms, plate readers and laser-control sy"},{"title":"Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了","url":"https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html","date":"2026-09-03","lang":"zh-Hant","category":"商業分析系列","tags":["Anthropic","Claude","Model Hardware Standard","MHS","AI for Science","Claude Science","實驗室自動化","科學儀器"],"summary":"Anthropic 公開模型硬體標準 MHS 研究預覽，讓 AI 代理透過共通介面讀取與操作顯微鏡、移液工作站、機械手臂與雷射控制系統；這是概念驗證，不是無人實驗室已成熟。","key_points":[],"excerpt":"──────────────────── 半夜兩點，量子電腦裡的雷射突然失去鎖定；凌晨四點，博士生又得回實驗室替聚合酶連鎖反應儀換板。過去，人工智慧可以讀完論文、提出假說、寫出分析程式，碰到真實世界裡的一滴液體、一支移液器，卻只能停在螢幕前。 2026 年 8 月 27 日，Anthropic 把這條界線往前推了一步。 公司公開「模型硬體標準」（Model Hardware Standard，MHS）的研究預覽版，讓人工智慧代理透過共通介面，讀取並操作顯微鏡、移液工作站、機械手臂、酵素標定儀，甚至量子電腦裡的雷射控制系統。它可以觀察設備狀態、安排實驗順序、依結果調整參數，某些情況下還能從故障中自行恢復。 這不是「Claude 已經接管實驗室」，也不是科學家準備失業。MHS 目前只開放給首批研究機構與先進製造夥伴，案例多是概念驗證；複雜實驗、物理直覺與安全責任仍牢牢握在人手上。 但一個更重要的變化已經出現：AI for Science（人工智慧科學研究）不再只比誰能提出更多答案，開始比誰能把答案送進真實設備、拿回新數據，再展開下一輪實驗。 ──────────────────── 🧪 一、科學 AI 最缺的，從來不是點子 生成式人工智慧進入科學界後，最常遇到的質疑很合理：模型可以一口氣提出一萬個蛋白質設計，但誰來把它們做出來？它可以預測哪個分子可能有效，卻不能自己吸取試劑、控制溫度"},{"title":"A New Drug Launched. Seven Months Later, the Company Sought Liquidation","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html","date":"2026-09-02","lang":"en","category":"商業分析系列","tags":["biotech commercialization","Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","drug launch","biotech finance","cash runway","biopharma"],"summary":"FDA approval does not erase business risk. Iterum, Karyopharm and Theravance show how revenue, cost, pipeline and capital clocks can begin running at the same time after a drug reaches the market.","key_points":[],"excerpt":"Iterum's ORLYNVAH generated just $0.4 million in net product revenue in its first quarter on the market, while selling, general and administrative expense was about $6.5 million. From commercial launch in August 2025 to its application for liquidation in March 2026 took roughly seven months. This was not a clinical failure. It was a case in which post-approval commercialization cash flow did not have time to grow. One case does not represent every biotech company, but it is a reminder that launch replaces development risk with revenue, cost and financing risk. This article is not investment ad"},{"title":"新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後","url":"https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html","date":"2026-09-02","lang":"zh-Hant","category":"商業分析系列","tags":["Iterum Therapeutics","ORLYNVAH","Karyopharm","XPOVIO","Theravance Biopharma","生技商業化","現金流","新藥上市"],"summary":"ORLYNVAH 上市第一季只有 40 萬美元淨產品收入，同季銷售、一般與管理費約 650 萬美元；約七個月後，Iterum 聲請清盤。Karyopharm 與 Theravance 的情況不同，卻共同顯示新藥核准後，收入、成本、管線與資本四座時鐘會同時啟動。","key_points":[],"excerpt":"Iterum 的 ORLYNVAH 上市第一季僅有 40 萬美元淨產品收入，銷售、一般與管理費卻約達 650 萬美元；從 2025 年 8 月上市到 2026 年 3 月聲請清盤，約七個月。這不是新藥臨床失敗，而是核准後的商業化現金流來不及長大。單一案例不代表所有 Biotech，卻提醒投資人：上市只是把研發風險換成收入、成本與融資風險；本文不構成投資建議。 01｜Iterum：40 萬美元收入，撞上 650 萬美元費用 Iterum 的故事最像一場上市後的自由落體。 ORLYNVAH 是一款口服青黴烯類抗生素，2024 年 10 月獲 FDA 核准，用於治療特定成年女性的單純性尿路感染；適用對象必須是由指定細菌引起，而且可用的口服抗菌選擇有限或沒有替代方案。 這段標籤裡，每一個限定詞都會縮小市場。 抗生素不是一般慢性病藥。醫師要考慮抗藥性、培養結果、用藥管理與支付規則；一款新抗生素即使具有臨床價值，也不代表處方會像降血壓藥一樣自然流進來。醫療體系往往希望把新抗生素留到真正需要時才用，這對公共衛生是好事，對一家只靠單一產品活命的小公司卻很殘酷。 Iterum 原本期待 ORLYNVAH 成為公司翻身的最後籌碼。它花了將近一年準備市場，搭建商業團隊，也與外部公司合作。2025 年 8 月，產品正式上市。 第一季成績很快揭曉：淨產品收入只有 40 萬美元，而且這個數字還包含通路最初備貨"},{"title":"Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here","url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html","date":"2026-09-01","lang":"en","category":"商業分析系列","tags":["AIDO Cell","GenBio AI","virtual cell","AI drug discovery","single-cell biology","drug discovery","New Approach Methodologies","X-Cell"],"summary":"GenBio AI's AIDO Cell attempts to connect DNA, RNA, proteins and cell phenotypes through a shared state that supports sequential perturbations. The company says it matched or exceeded specialist models on 24 of 31 internal metrics, but the preview covers only K-562 and Hep-G2 cells, and novel predictions still require physical experiments, external replication and blinded testing.","key_points":[],"excerpt":"What if a candidate drug could be “fed” to a cell inside a computer before it ever reached a person? Could drug developers avoid more dead ends? In a 31-metric benchmark built by GenBio AI, the company says its AIDO Cell matched or outperformed the specialist models used for comparison on 24 metrics. Yet the current preview focuses on just two cancer cell lines, K-562 and Hep-G2. This is a noteworthy engineering prototype, not a substitute for cell experiments. New predictions still require physical experiments, external replication and blinded testing. 01 Earlier Models Could Answer Questions"},{"title":"新藥能先在電腦裡試？「虛擬細胞」來了！","url":"https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html","date":"2026-09-01","lang":"zh-Hant","category":"商業分析系列","tags":["AIDO Cell","GenBio AI","虛擬細胞","AI 製藥","單細胞","藥物發現","新方法學","X-Cell"],"summary":"GenBio AI 的 AIDO Cell 嘗試用共享狀態串起 DNA、RNA、蛋白質與細胞表型，並連續模擬基因、藥物與抗藥性擾動。公司基準顯示 31 項指標中有 24 項追平或超越專用模型，但目前只有 K-562、Hep-G2 兩種原型細胞，新預測仍待實體實驗、外部重現與盲測。","key_points":[],"excerpt":"如果新藥進入人體前，能先在電腦裡「餵」給細胞，研發是否能少走冤枉路？GenBio AI 的 AIDO Cell 在公司自建 31 項指標中，有 24 項追平或超越專用模型；但目前只聚焦 K-562 與 Hep-G2 兩種癌細胞株。這是值得注意的工程原型，不是細胞實驗的替代品；新預測仍需實體實驗、外部重現與盲測。 01｜以前的模型會回答，虛擬細胞想學會「經歷」 過去幾年，人工智慧已經能處理不少生物學問題。 給它一段胺基酸序列，它可以預測蛋白質可能折成什麼形狀；輸入一批單細胞資料，它可以辨認細胞類型；告訴它某個基因被關閉，它也可能預測部分基因表現會怎麼改變。 這些工具很有用，卻多半像不同科別的專家：有人懂蛋白質，有人懂基因表現，有人懂細胞影像。研究者把上一個模型的答案交給下一個模型，最後拼成一條工作流程。問題是，真實細胞並不是幾張彼此獨立的報表。 一個基因被關閉，可能改變 RNA 的轉錄與剪接；蛋白質數量、位置和交互作用跟著變；訊號路徑受到牽動；最後細胞的外觀、生長速度與藥物反應也可能改寫。每一層都在互相回饋。 AIDO Cell 的野心，就是讓這些層級從同一個「細胞狀態」讀出。研究者可以先關閉一個基因，再加入一種藥，接著模擬抗藥性突變；第二步不是重新面對一顆乾乾淨淨的細胞，而是接在第一步造成的狀態上。 這就是所謂「有狀態」的模型。 更直白地說，普通預測工具像拍一張照片；AIDO Ce"},{"title":"GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue?","url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift-en.html","date":"2026-08-31","lang":"en","category":"商業分析系列","tags":["GLP-1","luxury hospitality","hotel food and beverage","consumer spending","zero-proof beverages","wellness tourism","service design","semaglutide"],"summary":"A U.S. household transaction study found that grocery spending fell 5.3% on average six months after GLP-1 adoption and 8.2% among higher-income households. Some luxury hotels are already testing smaller portions, protein-forward menus, zero-proof drinks and wellness services. The strategic question is whether hospitality operators can translate lower food volume into better service, pricing and repeat demand.","key_points":[],"excerpt":"The champagne is cold. The dessert tower is full. The guest paying several thousand dollars for a luxury stay takes one look and says, “I really cannot eat any more.” That scene captures a new operating question for hospitality. GLP-1 medicines are best known for transforming obesity and diabetes treatment. Their commercial spillover, however, is reaching restaurants, grocery baskets, alcohol occasions, wellness services and the economics of a hotel stay. A U.S. household transaction study found that grocery spending fell 5.3% on average six months after GLP-1 adoption. Among households earnin"},{"title":"減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？","url":"https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html","date":"2026-08-31","lang":"zh-Hant","category":"商業分析系列","tags":["GLP-1","五星級飯店","高端旅宿","餐飲消費","無酒精飲品","健康旅遊","服務設計","semaglutide"],"summary":"美國家戶交易研究顯示，採用 GLP-1 六個月後，雜貨支出平均下降 5.3%，高收入家庭下降 8.2%；部分高端飯店也開始測試小份餐、高蛋白、無酒精飲品與健康陪伴服務。真正的商業題目，不是客人吃少了多少，而是飯店能否把食物的量重新翻譯成服務、價格與回購。","key_points":[],"excerpt":"香檳冰好了、甜點塔疊滿了，住一晚幾萬元的客人卻只說：「我真的吃不下。」一項美國家戶研究顯示，使用 GLP-1 六個月後，雜貨支出平均下降 5.3%，高收入家庭下降 8.2%。高端飯店也開始測試小份餐、高蛋白與無酒精選項；但這只是第一波案例，不能直接推論全球五星飯店營收，更不能把所有改變都歸因於減重藥。 01｜五星級飯店最熟悉的語言，原本叫做「多」 傳統奢華飯店很懂得把價值做成看得見的東西。 自助早餐要像一座小型市集，下午茶要有三層甜點塔，客房冰箱裡從巧克力、堅果到烈酒一格不缺。房費裡還包含一種「任何時刻都有人替我準備好」的感覺。 這套公式的核心，是豐盛。 可是一旦客人開始使用 GLP-1（類升糖素胜肽－1）類藥物，身體對豐盛的回應可能改變。 這類藥物會影響食慾與飽足訊號；以美國食品藥物管理局核准的 semaglutide（司美格魯肽）減重產品 Wegovy 為例，仿單明確記載它會延緩胃排空，成人減重試驗中常見噁心、嘔吐、腹瀉、便祕與胃食道逆流等腸胃道反應。 不是每個人都會出現相同反應，也不是每位使用者都突然不碰甜食。但對部分客人來說，一盤過大的高脂餐點，不再代表慷慨，反而可能變成壓力。 更值得飯店緊張的，是這件事已經開始出現在消費資料裡。 2026 年刊登於《Journal of Marketing Research》的研究，把美國家戶用藥調查與實際交易資料連在一起，追蹤 2,60"},{"title":"Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html","date":"2026-08-30","lang":"en","category":"基本面系列","tags":["Amylyx","avexitide","GLP-1","post-bariatric hypoglycemia","PBH","LUCIDITY","Relyvrio","MBX Biosciences","biotech asset acquisition"],"summary":"Avexitide reduced the combined rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo in Amylyx's Phase 3 LUCIDITY trial, sending the shares up about 64% in one session. This analysis examines the GLP-1 mechanism in post-bariatric hypoglycemia, the evidence still missing from the topline release, Amylyx's $35.1 million asset acquisition, its $500.2 million financing and the regulatory and commercial gates ahead.","key_points":[],"excerpt":"Bariatric surgery can produce durable weight loss, yet some patients later face a disturbing paradox: eating a meal can send their blood glucose low enough to cause confusion, loss of consciousness or a seizure. Amylyx Pharmaceuticals is trying to treat that condition with avexitide, a drug that moves in the opposite direction from the GLP-1 medicines now reshaping obesity care. Rather than activating the GLP-1 receptor, avexitide blocks it. In the Phase 3 LUCIDITY trial, the combined rate of Level 2 and Level 3 hypoglycemic events was 55% lower with avexitide than with placebo. Amylyx shares "},{"title":"減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！","url":"https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html","date":"2026-08-30","lang":"zh-Hant","category":"基本面系列","tags":["Amylyx","avexitide","GLP-1","減重手術後低血糖","PBH","LUCIDITY","Relyvrio","MBX Biosciences","生技資產交易"],"summary":"Amylyx 的 avexitide 在 LUCIDITY 三期試驗中，讓第二級與第三級低血糖事件合併發生率較安慰劑降低 55%，帶動股價單日上漲約 64%。本文拆解 PBH 的 GLP-1 機制、三期證據、3,510 萬美元資產收購、5 億美元募資，以及核准與商業化前仍須跨越的關卡。","key_points":[],"excerpt":"減重手術能讓體重下降，部分患者吃完飯後卻可能因血糖急降而昏倒。Amylyx 的 avexitide 反向阻斷 GLP-1 訊號；三期試驗中，第二級與第三級低血糖事件的合併發生率較安慰劑降低 55%，消息公布當天股價上漲約 64%。但這仍是頂線資料，藥物尚未獲 FDA 核准，完整數據、長期安全性與商業化仍待驗證。 01｜為什麼有人減重手術成功，吃完飯卻可能昏倒？ 先理解疾病，才知道這顆藥為何走反方向。 減重手術能幫助許多重度肥胖患者改善體重與代謝疾病，但有一部分人在手術數月或數年後，會出現「減重手術後低血糖」（post-bariatric hypoglycemia，PBH）。 患者吃完飯後，營養更快進入小腸，腸道釋放大量類升糖素胜肽-1（glucagon-like peptide-1，GLP-1）。GLP-1 原本會提醒胰臟分泌胰島素，協助餐後血糖回落；問題是 PBH 患者的反應太強，胰島素像煞車踩過頭，血糖快速墜落。 輕一點，可能是心悸、冒汗、顫抖、頭暈；嚴重時，大腦得不到足夠葡萄糖，會出現混亂、認知受損、失去意識，甚至癲癇。這些事件難以預測，患者可能不敢獨自開車、不敢照顧孩子，也不敢在沒有他人的情況下吃飯。 市場最熟悉的 semaglutide、tirzepatide 等藥物，是利用 GLP-1 訊號降低食慾、改善血糖；avexitide 則是一種 GLP-1 受體拮抗劑，目標是"},{"title":"Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval","url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html","date":"2026-08-29","lang":"en","category":"基本面系列","tags":["Revolution Medicines","RASONQUE","daraxonrasib","RAS(ON)","pancreatic cancer","FDA","BeOne Medicines","Royalty Pharma","biotech commercialization"],"summary":"The FDA approved Revolution Medicines' RASONQUE 6.5 months ahead of schedule for a defined metastatic pancreatic adenocarcinoma population. This analysis examines the RASolute 302 survival data, the RAS(ON) mechanism, Revolution's eleven-year strategic pivot and the pricing, access, safety and global execution tests that begin after approval.","key_points":[],"excerpt":"Pancreatic cancer is devastating not only because it is often detected late. The deeper frustration is that researchers have known for decades that RAS sits behind most pancreatic tumors, yet the protein resisted conventional drug design for more than forty years. On August 26, 2026, the U.S. Food and Drug Administration approved Revolution Medicines' RASONQUE, or daraxonrasib, 6.5 months ahead of the agency's original action date. It is the first approved broad RAS(ON) inhibitor capable of targeting several activated RAS forms, and the first approved therapy to directly address the dominant o"},{"title":"胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥","url":"https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html","date":"2026-08-29","lang":"zh-Hant","category":"基本面系列","tags":["Revolution Medicines","RASONQUE","daraxonrasib","RAS(ON)","胰臟癌","FDA","BeOne Medicines","Royalty Pharma","生技商業化"],"summary":"FDA 提前 6.5 個月核准 Revolution Medicines 的 RASONQUE，用於特定轉移性胰臟腺癌成人。本文拆解 RASolute 302 的生存數據、RAS(ON) 技術、Revolution 十一年轉向史，以及藥證之後的定價、給付、安全性與全球商業化考驗。","key_points":[],"excerpt":"──────────────────── 胰臟癌最令人絕望的地方，不只是發現得晚。 更殘酷的是，人類早就知道多數胰臟癌背後站著 RAS，卻用了四十多年，始終很難真正抓住它。 2026 年 8 月 26 日，美國食品藥物管理局（FDA）提前 6.5 個月批准 Revolution Medicines 的 RASONQUE，通用名 daraxonrasib。這是第一款獲准、可同時瞄準多種活化態 RAS 的廣譜標靶藥，也是首款直接針對胰臟癌主要致癌驅動因素的核准療法。 在 500 人第三期試驗裡，RASONQUE 把中位總生存期從化療組的 6.7 個月拉到 13.2 個月，死亡風險降低 60%；中位無惡化生存期則從 3.6 個月延長至 7.2 個月。 兩條曲線幾乎都翻了一倍。 但「胰臟癌被攻克」仍然不是正確答案。這次核准只適用於已接受至少一次全身治療，或不適合多藥全身治療的轉移性胰臟腺癌成人；它不是早期患者的萬用藥，也不是所有人都能長期控制疾病。 真正值得寫下來的，是另一件事：一家 2015 年還在做抗黴菌藥的新創，如何在十一年裡換掉原始劇本、買下一套當時沒有人體證據的技術、用股票買回 11 億美元現金，最後把一個被稱為「不可成藥」的靶點推到市場。 這不是一路看對答案。 而是每次證據改變時，都敢重新下注。 一、RAS 為什麼難了四十年？ RAS 像細胞裡的生長開關。 正常狀態下，它會在「"},{"title":"A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million","url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html","date":"2026-08-28","lang":"en","category":"基本面系列","tags":["Zealand Pharma","Royalty Pharma","rusfertide","Protagonist Therapeutics","Takeda","PharmaEssentia","BESREMi","polycythemia vera","royalty financing"],"summary":"Zealand Pharma sold rusfertide-related milestones and a 1% global net-sales royalty for up to $100 million, not control of the drug itself. The transaction clarifies how Zealand, Protagonist and Takeda hold very different economics—and what rusfertide could mean for PharmaEssentia's BESREMi.","key_points":[],"excerpt":"With rusfertide approaching the final stretch of FDA review, Zealand Pharma has already signed a transaction worth up to $100 million, selling selected economics tied to the drug to Royalty Pharma. The transaction closed on August 12, 2026. Zealand received $50 million at closing and is due another $50 million on the first anniversary. But Zealand did not sell the drug itself. What changed hands were regulatory and sales milestones inherited from an earlier collaboration, plus a 1% royalty on global net sales. Takeda—not Zealand—holds the exclusive worldwide rights to develop and commercialize"},{"title":"藥華藥迎新對手？1 億美元賣分潤","url":"https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html","date":"2026-08-28","lang":"zh-Hant","category":"基本面系列","tags":["Zealand Pharma","Royalty Pharma","rusfertide","Protagonist Therapeutics","Takeda","藥華藥","BESREMi","真性紅血球增多症","權利金交易"],"summary":"Zealand Pharma 以總對價 1 億美元出售 rusfertide 的里程碑與 1% 全球淨銷售權利金，交易不是出售藥物控制權。本文拆解 Zealand、Protagonist 與武田的不同經濟位置，並分析 rusfertide 對藥華藥 BESREMi 的競爭、互補與治療分層。","key_points":[],"excerpt":"FDA 審查只差最後一段，Zealand Pharma 卻先簽下總對價 1 億美元的交易，把 rusfertide 的經濟權益賣給 Royalty Pharma。 交易已在 2026 年 8 月 12 日完成交割：5,000 萬美元立即支付，另外 5,000 萬美元在交割滿一周年時支付。 但這不是「賣掉一款新藥」。 Zealand 交出的是歷史合作留下的監管與銷售里程碑，以及全球淨銷售額 1% 的權利金；武田才是 rusfertide 的全球獨家開發與商業化權利人。 投資人真正該問的，是一條等待 FDA 決定、尚未開始銷售的 1% 現金流，為什麼買方願意給出總對價 1 億美元？以及 rusfertide 若核准，會怎麼影響台股藥華藥（6446）的 BESREMi？ 一、1 億美元不是藥價，是未來現金流的折現 Zealand 交出的權利包括兩部分：rusfertide 的監管與商業里程碑，以及全球淨銷售額 1% 的權利金。 公司仍留下一小段上行空間：如果年度全球淨銷售額超過 15 億美元，超出部分 Zealand 可繼續拿 0.25%，Royalty Pharma 拿 0.75%。 這個 15 億美元是合約門檻，不是 Zealand 對峰值銷售的公司指引，更不能拿來推論管理層「內心至少看 15 億美元」。 交易的本質，是時間與風險交換。 Zealand 把 FDA 審查、上市定價、給"},{"title":"DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet","url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html","date":"2026-08-27","lang":"en","category":"商業分析系列","tags":["Twist Bioscience","TWST","AI drug discovery","DNA synthesis","protein engineering","wet lab automation","Design-Build-Test-Learn","biotech investing"],"summary":"Twist Bioscience is seeing rapid growth in AI-enabled drug-discovery orders and DSPS revenue, but demand growth, unit value and industry moat are not the same thing. The scarce asset may be the full wet-lab system that converts massive sequence volumes into proteins, functional data and model feedback.","key_points":[],"excerpt":"DNA synthesis has suddenly been elevated to the throne of “the Nvidia of AI drug discovery.” Twist Bioscience’s latest results are undeniably strong. Fiscal third-quarter 2026 revenue reached $118.4 million, up 23% year over year. DNA Synthesis and Protein Solutions, or DSPS, generated $56.6 million, up 39%. Revenue from therapeutics customers, a customer-industry classification rather than a separate product segment, reached $40.4 million, up 49%. The company also said orders tied to AI-enabled drug discovery are expected to grow at a triple-digit percentage in fiscal 2026 versus fiscal 2025,"},{"title":"DNA 不是 AI 製藥的輝達，至少現在還不是","url":"https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html","date":"2026-08-27","lang":"zh-Hant","category":"商業分析系列","tags":["Twist Bioscience","TWST","AI 製藥","DNA 合成","蛋白質工程","濕實驗室","Design-Build-Test-Learn","生技投資"],"summary":"Twist Bioscience 的 AI 輔助藥物發現訂單與 DSPS 營收快速成長，但需求增加、單位價值與產業壁壘不是同一件事。真正稀缺的，可能不是單一 DNA 合成步驟，而是能把海量序列轉成蛋白質、功能數據並回饋模型的整座濕實驗工廠。","key_points":[],"excerpt":"DNA 合成，忽然被抬上了「AI 製藥的輝達」神壇。 Twist Bioscience 的財報確實亮眼。會計年度 2026 第三季營收 1.184 億美元，年增 23%；DNA 合成與蛋白質解決方案（DSPS）營收 5,660 萬美元，年增 39%。按客戶產業分類的治療領域營收則達 4,040 萬美元，年增 49%。 公司還表示，AI 輔助藥物發現的訂單，2026 會計年度對 2025 年預計出現三位數百分比成長；對 2027 年也看得到同等量級的訂單成長。 景氣來了，這點不必否認。但訂單不是營收，營收成長也不會自動長成壟斷。市場正把三個層次疊在一起：需求增加、單位價值上升、供應商擁有難以取代的壁壘。 輝達之所以可怕，是三件事曾在同一時間成立。DNA 合成才剛證明第一件。 01｜AI 設計得越快，濕實驗室反而越忙 Twist 給市場最有力的證據，落在實際訂單與工作流：AI 正把數位世界的序列洪水，引進真實實驗室。 模型先生成數不清的 DNA 或蛋白質序列；候選分子被合成、表現成蛋白質，再接受結合力、穩定性、可開發性與功能性測試。實驗數據回灌模型，開始下一輪設計。 這就是 Design–Build–Test–Learn 的循環。Twist 把客戶分成三個階段：先建立模型所需的生物資料；然後持續轉動設計、構建、測試；最後用新數據迭代模型，並擴充 IgG、雙特異性抗體等新類型。 公司對自"},{"title":"Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses?","url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html","date":"2026-08-26","lang":"en","category":"商業分析系列","tags":["Merck","Lipfendra","enlicitide","PCSK9","LDL cholesterol","cardiovascular outcomes","Novartis","Leqvio","Taiwan market access"],"summary":"Lipfendra is the first FDA-approved oral PCSK9 inhibitor, lowering LDL-C by 56% and 59% in two Phase 3 trials. Oral dosing opens a major market, but cardiovascular outcomes, fasting adherence, payer access and Taiwan approval will decide whether it expands the category or displaces injections.","key_points":[],"excerpt":"For the past decade, patients seeking a large LDL-cholesterol reduction through PCSK9 inhibition have generally needed an injection. Merck has now turned that therapeutic route into a once-daily pill. On July 15, 2026, the U.S. Food and Drug Administration approved Lipfendra, or enlicitide. It is the first FDA-approved oral PCSK9 inhibitor for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise. Across two pivotal Phase 3 trials enrolling 3,207 patients, placebo-adjusted LDL-C reductions at Week 24 were 56% and 59%. Those n"},{"title":"默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？","url":"https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html","date":"2026-08-26","lang":"zh-Hant","category":"商業分析系列","tags":["默沙東","Lipfendra","enlicitide","PCSK9","膽固醇","心血管","諾華","Leqvio","台灣健保"],"summary":"FDA 核准首款每日口服 PCSK9 抑制劑 Lipfendra，兩項第三期試驗在第 24 週降低 LDL-C 56% 與 59%。但口服不等於針劑退場：心血管硬終點、每日空腹依從性、保險准入與台灣核准，才會決定市場如何重切。","key_points":[],"excerpt":"過去十年，想用 PCSK9 這個靶點把壞膽固醇大幅壓低，幾乎都得接受注射。 現在，默沙東把這條路做成一顆每天吞的藥。 2026 年 7 月 15 日，美國食品藥物管理局（FDA）正式核准 Lipfendra（學名 enlicitide）。它是第一款獲 FDA 核准的口服 PCSK9 抑制劑，用於成人高膽固醇血症，包括異合子家族性高膽固醇血症（HeFH），需搭配飲食與運動。 兩項關鍵第三期試驗共 3,207 人。第 24 週時，Lipfendra 相較安慰劑校正後，讓低密度脂蛋白膽固醇（LDL-C，俗稱壞膽固醇）下降 56% 與 59%。 這個數字，足以讓市場開始想像：一顆藥，會不會把針劑的市場整碗端走？ 先別急著替針劑辦告別式。 Lipfendra 確實跨過一道大門，但降脂藥真正的勝負，還要看心血管硬終點、長期依從性、醫師處方與保險給付。口服只是開門方式改了，門後的仗才剛開始。 01｜第一顆口服 PCSK9，突破在哪裡？ PCSK9（會加速肝臟 LDL 受體被分解的蛋白）像一個「拆除標記」。它和 LDL 受體結合後，受體容易被帶進細胞內分解；肝臟能回收壞膽固醇的受體變少，血中的 LDL-C 就會堆高。 過去，臨床多靠抗體藥物在血液中抓住 PCSK9，像安進的 Repatha、再生元／賽諾菲的 Praluent；諾華 Leqvio 則用小干擾 RNA（siRNA）降低肝臟製造 PCS"},{"title":"The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD?","url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html","date":"2026-08-25","lang":"en","category":"商業分析系列","tags":["AnBogen Therapeutics","ABT-301","imofinostat","Combination Layer","colorectal cancer","University of Tokyo","oncology BD","Taiwan biotech"],"summary":"Big Pharma is paying for incremental efficacy around established therapies. ABT-301 has completed Phase 1; the CRC triplet's efficacy, sustainable dosing, durability and biomarker readouts will determine whether it can become a Combination Layer and open substantive partnering opportunities.","key_points":[],"excerpt":"From Revolution x BeOne and PD-1/VEGF to ADCs: Big Pharma is paying for incremental efficacy, and the next re-rating of Ambogen (7784) will hinge on positive readout of the CRC triplet of ABT-301, positioning as a combination foundation and opening the door to strategic partnering By Drugnews Data cut: August 24, 2026 Drugnews Insight Big Pharma is paying for incremental efficacy around established therapies. Anbogen (7784) has completed a 23-patient Phase 1 study of ABT-301, with 1 PR and 8 SD, and is now advancing a BeOne-supported global Phase 1/2 triplet trial of ABT-301 + tislelizumab + b"},{"title":"主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？","url":"https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html","date":"2026-08-25","lang":"zh-Hant","category":"商業分析系列","tags":["安邦生技","ABT-301","imofinostat","Combination Layer","大腸直腸癌","東京大學","腫瘤BD","台灣生技"],"summary":"大藥廠正為主藥旁的增量療效付費。安邦ABT-301已完成Phase I，接下來由CRC三聯的療效、劑量持續性、耐久性與biomarker決定其能否走向Combination Layer與大型藥廠合作。","key_points":[],"excerpt":"從Revolution × BeOne、PD-1／VEGF到ADC：大藥廠正為「增量療效」付錢，安邦下一次估值轉折將由CRC三聯人體療效決定ABT-301聯合用藥基石，打開大型藥廠合作 撰文｜藥時事 Drugnews 資料基準日｜2026年8月24日 藥時事觀點Drugnews Insight 大藥廠正為補強主藥「增量療效」付錢。安邦（7784）ABT-301一期23人已見1人腫瘤縮小、8人病情穩定，目前已與BeOne展開供藥合作，推進ABT-301＋tislelizumab＋bevacizumab全球I/II期pMMR大腸直腸癌三聯試驗（NCT07244705）。下一步就看：療效是否更好、能否持續用、效 果是否持久、哪些人最受益；四關成立，就有機會打開大藥廠合作與估值重估。 2026年8月，手握後期RAS資產的Revolution Medicines，將其中一款候選藥的全球註冊性Phase III交由BeOne Medicines出資並執行。BeOne另取得四款RAS(ON)抑制劑在部分亞洲市場的開發或商業化權益，雙方也把PRMT5抑制劑、EGFR×MET×MET三特異性抗體接進RAS聯合治療。 這筆合作受到關注，先看Revolution的份量。2026年7月底，公司市值逼近400億美元；daraxonrasib的胰臟癌Phase III已公布陽性結果，FDA也受理上市申請。公司"},{"title":"Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html","date":"2026-08-24","lang":"en","category":"商業分析系列","tags":["Curium","Lantheus","radiopharma","theranostics","PSMA","PYLARIFY","Pluvicto","M&A","nuclear medicine","Taiwan biotech"],"summary":"The $7 billion Curium-Lantheus rumor covered in June became a definitive agreement on August 3: $102.50 in cash plus up to $12.00 per share in CVRs, for total consideration of up to $8 billion. The strategic prize is an integrated chain spanning isotopes, manufacturing, distribution, diagnostics, therapy and U.S. hospital access.","key_points":[],"excerpt":"00 The story has moved from a $7 billion rumor to a definitive agreement worth up to $8 billion Radiopharma is entering a different phase of competition. On August 3, 2026, Curium and Lantheus Holdings announced that they had signed a definitive merger agreement. Under the agreement, Lantheus shareholders would receive $102.50 per share in cash at closing, together with contingent value rights worth up to another $12.00 per share if specified commercial milestones are achieved. The maximum aggregate transaction value is approximately $8.0 billion. The status boundary matters. A definitive agre"},{"title":"核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額","url":"https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html","date":"2026-08-24","lang":"zh-Hant","category":"商業分析系列","tags":["Curium","Lantheus","核藥","放射性藥物","診療一體化","PSMA","PYLARIFY","Pluvicto","併購","長佳智能","商之器"],"summary":"6 月官網追蹤的 Curium–Lantheus 70 億美元收購傳聞，已在 8 月 3 日推進為最終合併協議：每股 102.50 美元現金加最高 12 美元 CVR，總交易價值最高約 80 億美元。真正被整合的是核素、製造、配送、診斷、治療與美國院端網絡。","key_points":[],"excerpt":"00｜從 70 億美元傳聞，走到最高 80 億美元最終協議 核藥產業的競爭，正在進入新的階段。 2026 年 8 月 3 日，Curium 與 Lantheus Holdings 宣布簽署最終合併協議。依協議，Lantheus 股東在交易完成時可取得每股 102.50 美元現金，另有最高每股 12 美元、綁定特定商業里程碑的或有價值權利（CVR）；總交易價值最高約 80 億美元。 這裡先把狀態說清楚： 簽署最終協議不等於交易已完成 。交易仍須經 Lantheus 股東表決、監管核准與其他成交條件；CVR 對應的里程碑也不保證達成。 [藥時事 6 月 9 日的早期文章](https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html)討論的是 Curium 擬以約 70 億美元收購 Lantheus 的傳聞與產業邏輯。本篇則是 8 月 3 日最終協議公布後的後續：價格、交易結構與雙方整合方向都已進一步明確，卻仍不是已交割併購。 這筆交易真正值得看的，不是 80 億美元本身，而是核藥產業的併購邏輯正在改變。過去幾年，Eli Lilly 收購 POINT Biopharma、Bristol Myers Squibb 收購 RayzeBio、AstraZeneca 收購 Fus"},{"title":"Who Could Be Big Pharma's Next Major Biotech Acquisition?","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html","date":"2026-08-23","lang":"en","category":"商業分析系列","tags":["biotech M&A","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","Pharmosa Biopharm","Belite Bio","BD licensing"],"summary":"Biopharma acquisition capital in 2026 is clustering around a narrow window: human risk has started to fall, but strategic value is not yet fully priced. Alkermes, Dyne, First Tracks, Legend and Sail illustrate five ways a biotech can enter that window, while Taiwan's Pharmosa Biopharm and Belite Bio show how late-stage assets can speak the same global language.","key_points":[],"excerpt":"The global biotech M&A market is making one preference unusually clear in 2026. Large pharmaceutical companies still have cash, and the need to refill portfolios ahead of major patent expirations has not disappeared. What has changed is the distribution of that capital. Buyers are no longer spreading it evenly across the biotech universe. They are concentrating on a much smaller group of companies positioned at a particular point on the risk curve: clinical uncertainty has begun to fall, while commercial and strategic value has not yet been fully priced. Big Pharma is not out of money. It has "},{"title":"Biotech 下一筆重磅併購，會落在誰身上？","url":"https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html","date":"2026-08-23","lang":"zh-Hant","category":"商業分析系列","tags":["生技併購","Big Pharma","Alkermes","Dyne Therapeutics","First Tracks Biotherapeutics","Legend Biotech","Sail Biomedicines","國邑","仁新","BD 授權"],"summary":"2026 年的生技併購資金，正集中到臨床風險開始下降、商業價值尚未完全定價的公司。從 Alkermes、Dyne、First Tracks、Legend 到 Sail，再回看國邑與仁新，真正值得追的是人體概念驗證、平台外延、商業化距離與買方策略契合度。","key_points":[],"excerpt":"2026 年的全球 Biotech 併購市場，出現一個很清楚的變化。 大型藥廠手上仍有現金，專利懸崖帶來的產品補洞壓力也沒有消失。但錢不再平均灑向所有 Biotech，而是集中流向一小群「剛好站在臨床風險下降、商業價值還沒完全定價」的公司。 換句話說，Big Pharma 不是沒錢，只是變得更挑。 能進入收購視野的 Biotech，通常有幾個共同特徵：核心資產已經有初步人體數據；所處領域已有大型交易驗證；產品可以擴展到多個適應症；技術平台能補足買方現有版圖；更重要的是，時間點不能太早，也不能太晚。 太早，科學風險太高；太晚，價格已經貴到難以下手。這也是為什麼 2026 年的併購交易，越來越像一場對「時點」的競賽。 01｜過去一年的交易，已經把新標準寫出來 過去一年幾筆交易，幾乎把大型藥廠的新審美說得很清楚。 Novartis 以約 120 億美元收購 Avidity Biosciences，取得肌肉靶向 Antibody Oligonucleotide Conjugate（AOC）平台，以及多個後期神經肌肉疾病管線。Novartis 表示，這筆交易可望在 2030 年前帶來多個產品上市機會，並打開數十億美元級市場。 Gilead Sciences 則以約 78 億美元收購長期合作夥伴 Arcellx，把 anito-cel（anitocabtagene autoleucel）這款 "},{"title":"BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html","date":"2026-08-22","lang":"en","category":"商業分析系列","tags":["BeOne Medicines","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","biotech licensing","oncology","drug development"],"summary":"BeOne is taking regional rights to four RAS(ON) programs, opening two candidate combination routes and funding one global registrational Phase 3. The strategic asset is not the sum of four drugs, but the optionality to decide where capital and development speed matter most.","key_points":[],"excerpt":"On August 10, BeOne Medicines and Revolution Medicines laid out a collaboration spanning four RAS(ON) programs, two BeOne combination assets, commercialization rights in selected Asian markets and one global registrational Phase 3 study. This is not an acquisition, and the global rights to all four drugs have not changed hands. BeOne is gaining a development and commercialization entry point in selected Asian markets, together with opportunities to test its own oncology assets alongside Revolution Medicines' RAS portfolio. Revolution Medicines retains rights outside the licensed territory whil"},{"title":"百濟神州一口氣押上 4 款 RAS 新藥","url":"https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html","date":"2026-08-22","lang":"zh-Hant","category":"商業分析系列","tags":["BeOne Medicines","百濟神州","Revolution Medicines","RAS(ON)","daraxonrasib","zoldonrasib","BGB-58067","BG-T187","BD 授權","腫瘤"],"summary":"百濟神州一次接進四款成熟度不同的 RAS(ON) 資產、兩條候選聯用路線與一項全球註冊三期。真正值得追的不是四藥相加，而是區域權利、開發分工與選擇權如何替雙方搶時間。","key_points":[],"excerpt":"8 月 10 日，百濟神州（BeOne Medicines）與 Revolution Medicines，把一張「四款 RAS(ON) 新藥、兩款聯用資產、亞洲商業化、全球三期」的合作網攤上桌。 這筆交易沒有買下一家公司，也沒有把四款藥的全球權利整批搬走。百濟神州拿到的，是部分亞洲市場的開發與商業化入口，加上把自家腫瘤資產接進 RAS 管線的試驗機會；Revolution Medicines 則保留區域外權利，同時多了一支能出資並執行全球註冊性三期的隊伍。 四款資產很搶眼；更關鍵的問題是，誰在替誰搶時間。 01｜一次接進四種 RAS 戰法 RAS 可以想成癌細胞裡的分子開關。突變讓它長時間卡在啟動狀態，持續把生長訊號往下游送。早期藥物多半抓住關閉狀態；Revolution Medicines 的 RAS(ON) 平台，鎖定正在驅動腫瘤的活化狀態。 這次納入合作的四款臨床資產，成熟度並不相同： daraxonrasib（RMC-6236） 多重選擇性 RAS(ON) 抑制劑，可涵蓋多種常見 RAS 基因型。美國 FDA 已在 2026 年 7 月 22 日受理其用於既往治療過的轉移性胰臟導管腺癌 NDA，背後已有全球隨機三期資料。 zoldonrasib（RMC-9805） 鎖定 RAS G12D。公司已啟動全球三期 RASolute 305，測試它搭配標準化療，用於未治療的轉移性 "},{"title":"Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html","date":"2026-08-21","lang":"en","category":"商業分析系列","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","personalized cancer vaccine","melanoma","mRNA manufacturing","Phase 3"],"summary":"Positive topline results from INTerpath-001 sent Moderna shares up 176.97% in one session. The deeper valuation question is whether patient-specific design, manufacturing, release and clinical delivery can become a scalable platform.","key_points":[],"excerpt":"Start with the boundary: this is not a cure for cancer, it is not evidence across every tumor type, and intismeran is not approved. What Moderna and Merck have reported is a positive Phase 3 topline result in patients with high-risk cutaneous melanoma whose tumors had already been completely removed. It is not a product that can be ordered for a patient tomorrow. On August 19, Moderna shares closed at $174.38, up $111.42, or 176.97%, in a single session. The arithmetic matters. Subtracting the $111.42 gain from the closing price gives a prior close of $62.96. Dividing $174.38 by $62.96 yields "},{"title":"再見癌症？癌症疫苗來了！莫德納單日暴漲176.97%","url":"https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html","date":"2026-08-21","lang":"zh-Hant","category":"商業分析系列","tags":["Moderna","Merck","intismeran autogene","INTerpath-001","mRNA 癌症疫苗","黑色素瘤","個人化醫療","臨床三期"],"summary":"INTerpath-001 第三期頂線結果讓莫德納股價單日上漲 176.97%。真正被重新估價的，不只是一款黑色素瘤療法，而是個人化設計、製造、質控與臨床交付能否成為可擴張的平台。","key_points":[],"excerpt":"先說答案：這不是「癌症治癒」，不是所有癌種通用，intismeran 也尚未獲核准。現在看到的，是已切除高風險皮膚黑色素瘤的第三期頂線陽性，而非明天能在醫院施打的成品。 8 月 19 日，莫德納（Moderna，股票代號 MRNA）收在 174.38 美元，一天上漲 111.42 美元，漲幅高達 176.97%。 一家公司，股價在一個交易日被重新定到前一天的近 2.77 倍。 這筆帳可以直接驗算：174.38 美元減去當日上漲的 111.42 美元，前一日收盤是 62.96 美元；174.38 除以 62.96，約為 2.77。所謂上漲 176.97%，是原價之外又增加 1.7697 倍，不是漲到原價的 176.97%。 這組數字證明市場反應有多劇烈，不能直接代替精確市值增量。市值還需要同一時點的流通股數與公司行動口徑；本文不採用未另行核實的「一夜增加 445 億美元」，也不以未驗證交易量替行情加戲。 引爆行情的，是莫德納與默沙東公布的一則三期消息：個人化新抗原信使核糖核酸（mRNA）療法 intismeran autogene，聯用 Keytruda（帕博利珠單抗），在 INTerpath-001 試驗達到兩項終點。 它目前驗證的是：在已完成手術切除、仍有高復發風險的皮膚黑色素瘤患者中，個人化療法加上 Keytruda，比 Keytruda 單藥更能延後復發與遠端轉移。標題可以追"},{"title":"NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion","url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html","date":"2026-08-20","lang":"en","category":"商業分析系列","tags":["AI drug discovery","NVIDIA","Bristol Myers Squibb","Eli Lilly","Roche","drug development","GPU infrastructure","Taiwan semiconductor supply chain"],"summary":"BMS is preparing to deploy what NVIDIA's published specifications imply is a 576-GPU Rubin system, while Lilly and NVIDIA plan to commit up to $1 billion over five years. The real contest is whether proprietary data, wet-lab execution and clinical evidence can become one learning loop.","key_points":[],"excerpt":"Bristol Myers Squibb is preparing to deploy eight NVIDIA DGX Vera Rubin NVL72 systems. Based on NVIDIA's published specifications, the installation implies a total of 576 Rubin GPUs. Eli Lilly has gone even further. The company and NVIDIA are establishing a joint AI laboratory with a planned five-year commitment of up to $1 billion. What Big Pharma fears now is falling behind the learning curve. Compute, models, laboratory robotics, clinical documentation and decades of accumulated failure data are being connected into a single research-and-development chain. This contest has moved far beyond "},{"title":"輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元","url":"https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html","date":"2026-08-20","lang":"zh-Hant","category":"商業分析系列","tags":["AI 製藥","NVIDIA","BMS","禮來","Roche","新藥研發","GPU","台灣供應鏈"],"summary":"BMS 準備部署依 NVIDIA 規格推算共 576 顆 Rubin GPU，禮來與 NVIDIA 五年共同投入上限 10 億美元；真正的競爭不只在算力，而在能否把專有資料、濕實驗與臨床證據接成研發閉環。","key_points":[],"excerpt":"BMS 準備部署 8 套 NVIDIA DGX Vera Rubin NVL72。按 NVIDIA 公布的規格推算，裡面合計有 576 顆 Rubin GPU。 禮來更直接：與 NVIDIA 共建 AI 實驗室，五年投入上限 10 億美元。 大藥廠現在怕的，是學習曲線落後。 算力、模型、實驗機器人、臨床文件與數十年累積的失敗資料，正被接成同一條研發鏈。這場競爭早已超過「買幾個聊天機器人、替員工寫報告」的層次。 當 BMS、禮來、Roche、默沙東、諾和諾德、Sanofi 同時加碼，AI 製藥的勝負也換了題目：模型能不能跑得快，只是起點；誰能讓下一次實驗更快、更準，最後把候選藥送過人體試驗，才有資格談贏家。 01｜BMS 一口氣補齊三層 BMS 今年的動作很有代表性。 5 月，公司宣布把 Anthropic 的 Claude Enterprise 導入全球營運，服務超過 3 萬名員工，範圍橫跨研究、臨床開發、製造、品質、商務與企業知識。BMS 希望它能協助整理開發文件、串接內部知識，甚至讓 AI 代理人參與部分工作流程。 7 月，BMS 再宣布建置 NVIDIA DGX SuperPOD。NVIDIA 隨後披露，系統由 8 套 DGX Vera Rubin NVL72 組成；每套搭載 72 顆 Rubin GPU，換算就是 576 顆。 BMS 把它稱為生命科學界最強大的單一公司自有"},{"title":"Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King?","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html","date":"2026-08-19","lang":"en","category":"商業分析系列","tags":["Skyrizi","Humira","AbbVie","Psoriasis","Autoimmune","IL-23","ICOTYDE","Biopharma"],"summary":"Skyrizi generated $5.505 billion in Q2 2026, only $74 million below Humira's historic quarterly peak. The real succession test spans efficacy, treatment burden, multi-indication reach and access.","key_points":[],"excerpt":"Humira spent years at the summit of global prescription-drug sales. Its patent cliff has only just arrived, yet AbbVie's Skyrizi is already closing in on the quarterly record Humira itself left behind. Skyrizi generated $5.505 billion in the second quarter of 2026, up 24.4% year over year. Humira's quarterly peak was $5.579 billion in the fourth quarter of 2022. The gap is only $74 million. The jump is not a one-quarter anomaly. Skyrizi generated $4.483 billion in the first quarter and grew another 22.8% sequentially in the second. If that momentum holds, the Humira record that has stood for f"},{"title":"55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？","url":"https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html","date":"2026-08-19","lang":"zh-Hant","category":"商業分析系列","tags":["Skyrizi","喜開悅","Humira","復邁","AbbVie","乾癬","自體免疫","IL-23","ICOTYDE"],"summary":"Skyrizi 2026 年第二季收入達 55.05 億美元，距 Humira 的歷史單季高點只差 7,400 萬美元；真正的接班考驗，是療效、治療負擔、多適應症與支付能力能否一起延續。","key_points":[],"excerpt":"Humira（復邁）曾連續多年站在全球處方藥銷售頂峰。它的專利懸崖剛落下，AbbVie 手中的 Skyrizi（喜開悅）已逼近 Humira 自己留下的單季紀錄。 2026 年第二季，Skyrizi 單季收入衝到 55.05 億美元，年增 24.4%。Humira 在 2022 年第四季寫下 55.79 億美元的單季高點。 兩者只差 7,400 萬美元。 單季跳升背後還有連續性。Skyrizi 第一季收入 44.83 億美元，第二季再成長 22.8%。若接下來維持目前動能，Humira 封存四年的單季紀錄，真的可能很快被自家後輩改寫。 但先把一條重要界線說清楚：這 55.05 億美元，是 Skyrizi 橫跨乾癬、乾癬性關節炎、克隆氏症與潰瘍性結腸炎等適應症的總收入；AbbVie 沒有拆出乾癬單項銷售，不能把整筆收入都算到銀屑病頭上。 這組數字的分量，在於 Skyrizi 已從乾癬新藥長成 AbbVie 的新免疫平台。自體免疫藥王的接力賽，療效表只是第一關。 01｜Humira 退場，AbbVie 又養出一個 55 億美元產品 Humira 在 2022 年全年收入達 212.37 億美元，第四季單季 55.79 億美元，之後隨美國專利獨占期結束、生物相似性藥品進場而快速下滑。 明星藥總會退場，危險往往出在接班人還沒長大。 艾伯維如今交出的答案很直接：2026 年第二季，Skyri"},{"title":"Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King?","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html","date":"2026-08-18","lang":"en","category":"商業分析系列","tags":["Eli Lilly","Eli Lilly","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","Caliway"],"summary":"Tirzepatide has allowed Eli Lilly to dominate both diabetes and obesity, but revenue concentration, pricing pressure and the next product relay are the investment questions that matter now.","key_points":[],"excerpt":"Eli Lilly has delivered another set of results that almost do not look like a traditional Big Pharma quarter. Second-quarter 2026 revenue reached $22.974 billion, up 48% year over year. Net income was $7.095 billion, up 25%. The company also raised full-year revenue guidance to $85 billion to $87 billion. Mounjaro, the diabetes brand, generated $9.943 billion. Zepbound, the obesity brand, generated $4.928 billion. Together, the two brands produced $14.871 billion, or 64.7% of Lilly's quarterly revenue. But investors should not be fooled by the two names. Mounjaro and Zepbound are both powered "},{"title":"一季狂賣 230 億美元，禮來卻急著買下一個藥王","url":"https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html","date":"2026-08-18","lang":"zh-Hant","category":"商業分析系列","tags":["Eli Lilly","禮來","Tirzepatide","Mounjaro","Zepbound","GLP-1","Retatrutide","Orforglipron","康霈"],"summary":"Tirzepatide 讓禮來同時吃下糖尿病與減重兩個大市場，但收入集中、價格壓力與下一代產品接班，才是市場真正該看的投資問題。","key_points":[],"excerpt":"禮來又交出一張幾乎不像大藥廠的成績單。 2026 年第二季營收 229.74 億美元，年增 48%；淨利 70.95 億美元，年增 25%。公司也把全年營收指引上調至 850 億至 870 億美元。其中，糖尿病藥 Mounjaro 賣了 99.43 億美元，減重藥 Zepbound 賣了 49.28 億美元。 兩個品牌加起來 148.71 億美元，占禮來整季營收 64.7%。 但別被兩個名字騙了：Mounjaro 與 Zepbound 背後，都是同一個分子 tirzepatide（替爾泊肽）。 換句話說，禮來目前看似有兩台印鈔機，核心引擎其實只有一具。 這也解釋了為什麼業績越好，禮來買公司的速度反而越快。最舒服的順風局，最怕只有一個引擎。 ——— 【01｜同一個分子，吃下兩個大市場】💉 Tirzepatide 是 GIP／GLP-1 雙重腸泌素促效劑。用在第二型糖尿病時，以 Mounjaro 銷售；用在肥胖或符合條件的過重成人體重管理時，美國品牌是 Zepbound。 這個分子的厲害之處，先在臨床端建立。 在 751 人參與的 SURMOUNT-5 第三期頭對頭研究中，沒有糖尿病的肥胖或過重成人治療 72 週後，tirzepatide 組平均減重 20.2%，semaglutide 組為 13.7%。這項結果支持 tirzepatide 在該研究條件下的減重優勢；它不代表所有患者"},{"title":"Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business?","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html","date":"2026-08-17","lang":"en","category":"商業分析系列","tags":["Iovance","Amtagvi","TIL","cancer cell therapy","melanoma","cell therapy","Timing Pharma"],"summary":"Iovance's Amtagvi rebounded sharply in the second quarter, but the central question is no longer whether TIL therapy can work. It is whether a personalized cell therapy can become a reproducible, reimbursable and scalable medical service.","key_points":[],"excerpt":"A year ago, the market was still asking whether a cancer cell therapy manufactured individually for every patient could ever become a real business. In the second quarter of 2026, Iovance gave investors a much stronger answer than before. Total product revenue reached $99.31 million, up 66% year over year and 39% sequentially. U.S. Amtagvi revenue was about $90.72 million, above the company's prior quarterly guidance range of $79 million to $81 million. The numbers are bright. But the important question is no longer the old one: whether TIL therapy can work. Amtagvi is already the first FDA-ap"},{"title":"營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？","url":"https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html","date":"2026-08-17","lang":"zh-Hant","category":"商業分析系列","tags":["Iovance","Amtagvi","TIL","癌症細胞療法","黑色素瘤","細胞治療","天明製藥"],"summary":"Iovance 的 Amtagvi 第二季營收明顯反彈，但真正要驗證的不是 TIL 是否有療效，而是個人化細胞療法能否被做成可複製、可支付、可放大的醫療服務。","key_points":[],"excerpt":"一年前，市場還在懷疑：這種每位患者都要重新製造一次的癌症細胞療法，真的能做成生意嗎？ 2026 年第二季，Iovance 給出一張明顯反彈的成績單。總產品營收 9,931 萬美元，年增 66%、季增 39%；其中，美國 Amtagvi 營收約 9,072 萬美元，也高於公司先前提出的 7,900 萬至 8,100 萬美元季度指引。 數字很亮眼，真正重要的卻不是「TIL（腫瘤浸潤淋巴球）有沒有用」這個老問題。 Amtagvi 已經是 FDA 核准的第一款腫瘤浸潤淋巴球療法。現在市場要驗證的是：一個必須開刀取腫瘤、替每位患者個別培養細胞、再送回醫院輸注的療程，能不能被做成穩定、可複製、付得起錢的醫療服務？ 這場競爭，勝負早已走出實驗室。 ——— 【01｜這次反彈，賣的是流程開始順了】📈 Iovance 第二季揭露，Amtagvi 的授權治療中心（ATC）網路已超過 95 家，約三分之一是社區型中心；從接收腫瘤組織到產品可運送的周轉時間，已壓到 31 天以內。 但有一個口徑必須說清楚：95 家是美國、加拿大與澳洲合計，不是全在美國。31 天也是公司的營運揭露，不等於每位患者都能在 31 天內完成治療。 另一個關鍵，是 Iovance 在 2026 年第一季把商業與臨床製造集中到自有細胞治療中心（iCTC）。公司表示，這座工廠潛在年產能超過 5,000 名患者。中央製造、中心擴張與周轉縮"},{"title":"Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses?","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html","date":"2026-08-16","lang":"en","category":"商業分析系列","tags":["Business Analysis","obesity","weight-loss drugs","GLP-1","Pfizer","Roche","Amgen","Metsera","Caliway","ANYA Biopharm"],"summary":"Pfizer, Roche and Amgen are pruning obesity programs that lack clear differentiation. The GLP-1 market has moved from a race to enter the clinic to a contest across efficacy, safety, convenience and commercial execution.","key_points":[],"excerpt":"------------------------------------------------ Another Wave of Obesity Drugs Falls: Ordinary Players No Longer Have a Ticket to the GLP-1 Market The obesity-drug shakeout is accelerating. During the second-quarter 2026 earnings season, several obesity programs that had once carried substantial expectations were removed from Big Pharma pipelines. The most visible example came from Pfizer. Multiple oral GLP-1 assets obtained through its expensive acquisition of Metsera were rapidly cleared out. Roche has also begun to prune parts of the obesity portfolio it acquired with Carmot Therapeutics. A"},{"title":"百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？","url":"https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html","date":"2026-08-16","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","肥胖症","減重藥","GLP-1","Pfizer","Roche","Amgen","Metsera","康霈","奧孟亞"],"summary":"Pfizer、Roche 與 Amgen 同步清理缺乏差異化的肥胖症管線，顯示 GLP-1 下半場的門檻已從「有藥可做」升高為療效、安全、便利性與商業化能力的全面競爭。","key_points":[],"excerpt":"------------------------------------------------ 【又一批減重藥倒下：GLP-1 的下半場，普通玩家已經沒有門票】 減重藥的淘汰賽，還在加速。 2026 年第二季財報季，一批原本被寄予厚望的 obesity 管線被大型藥廠直接砍掉。 最受矚目的，是 Pfizer 以高價收購 Metsera 後取得的多款口服 GLP-1 資產，快速被清理；Roche 從 Carmot Therapeutics 收進來的部分減重管線，也開始陸續退出；Amgen 則關閉早期減重候選藥，把火力集中到真正有機會突圍的核心資產。 表面上，這些項目被砍，是因為數據不夠好、安全性不夠漂亮、或內部優先順序改變。 但更深層的原因，是減重市場的門檻已經被徹底拉高。 當 tirzepatide 和 semaglutide 已經建立療效、支付、醫師使用經驗與品牌信任之後，市場不再需要一款「差不多」的減重藥。 後來者若想進場，必須回答一個非常殘酷的問題：你到底比 Lilly 和 Novo Nordisk 好在哪裡？ 📌 是減重更多？ 📌 安全性更好？ 📌 給藥更方便？ 📌 能改善更多併發症？ 📌 還是能吃下 GLP-1 沒有覆蓋的新需求？ 如果答案不清楚，就算已經進入臨床，也可能被快速放棄。這一輪管線調整，不是大型藥廠集體退縮，而是它們開始承認：減重藥市場已經不再是「"},{"title":"GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html","date":"2026-08-15","lang":"en","category":"商業分析系列","tags":["Business Analysis","GSK","camlipixant","P2X3","refractory chronic cough","CALM-1","CALM-2","Phase 3","drug development","biopharma M&A"],"summary":"After GSK's roughly US$2 billion acquisition of BELLUS Health, CALM-1 met its endpoint but CALM-2 did not reproduce the result. The divergence shows why Phase 2 promise, patient experience and reproducibility must move together.","key_points":[],"excerpt":"GSK paid roughly US$2 billion for a chronic-cough drug. Three years later, the programme stopped in Phase 3. On 17 July 2026, GSK said it would discontinue development of camlipixant for refractory chronic cough (RCC). The uncomfortable part was not a clean sweep of negative trials. CALM-1 met its primary endpoint, while CALM-2 failed to reproduce the result. When GSK acquired BELLUS Health in 2023, the investment case looked unusually coherent: a large patient population, no approved treatment in the United States or Europe, encouraging Phase 2 data, and a P2X3 inhibitor that might avoid the "},{"title":"GSK 砸 20 億美元買止咳新藥，三期卻翻車！","url":"https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html","date":"2026-08-15","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","GSK","camlipixant","P2X3","慢性咳嗽","CALM-1","CALM-2","臨床三期","新藥研發","生技併購"],"summary":"GSK 約 20 億美元收購 BELLUS Health 後，camlipixant 的 CALM-1 達標、CALM-2 卻未能複製。這場第三期落差揭示：二期訊號、患者感受與可重現性必須一起過關。","key_points":[],"excerpt":"GSK 砸 20 億美元買止咳新藥，三期卻翻車！ ────────── GSK 曾花約 20 億美元買下一款慢性咳嗽新藥。三年後，它停在第三期。 2026 年 7 月 17 日，GSK 宣布停止 camlipixant 在難治性慢性咳嗽的開發。更棘手的是：CALM-1 過關，CALM-2 卻無法複製。 2023 年收購 BELLUS Health 時，市場看到的是一個很完整的故事：患者多、歐美缺乏核准治療、二期訊號漂亮，camlipixant 還可能避開同類藥最麻煩的味覺副作用。 CALM-1 的 50 mg 每日兩次，在第 12 週達到主要終點；問題是 CALM-2 的同一劑量，在第 24 週沒有達到統計顯著。25 mg 每日兩次則在兩項研究都沒過，慢性咳嗽日記等關鍵次要終點也沒有達到預設門檻。 一個試驗過、一個試驗沒過，聽起來比「全面失敗」好一點；對一個想成為新標準的藥，卻仍然不夠。 GSK 花 20 億美元押下的 P2X3 資產，在三期撞上了「無法重現」。這沒有替整個止咳靶點判死刑，卻把 CALM 最昂貴的教訓攤在桌上：早期訊號，能不能再做一次？ ────────── 📌 01｜先把 CALM-1 與 CALM-2 分開看 GSK 在 2026 年 7 月 17 日公布 CALM-1 與 CALM-2 綜合結果。 兩項都是針對成人難治性慢性咳嗽（refractory chr"},{"title":"This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html","date":"2026-08-13","lang":"en","category":"商業分析系列","tags":["Intelligene","RNA delivery","oligonucleotide therapeutics","siRNA","ASO","extracellular vesicles","LNP","extrahepatic delivery","Taiwan biotech"],"summary":"Oligonucleotide therapeutics are moving from sequence design to extrahepatic delivery. Intelligene is using EV and LNP platforms to target the lung and airways, testing whether RNA medicines can truly reach disease sites beyond the liver.","key_points":[],"excerpt":"The sequence is the payload. Delivery is the rocket. The company that can move RNA beyond the liver may hold the key to the next valuation cycle in oligonucleotide therapeutics. Source date: August 3, 2026 Some technologies begin as scientific experiments. Only after major pharmaceutical companies commit meaningful capital does the market recognize that they have become durable industry themes. Oligonucleotide (Small RNA) therapeutics are approaching that inflection point. In 2026, Alnylam Pharmaceuticals entered into a collaboration with AI biotech company Inceptive Nucleics valued at up to $"},{"title":"這家台灣Biotech正在打造人體內奈米火箭","url":"https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html","date":"2026-08-13","lang":"zh-Hant","category":"商業分析系列","tags":["智新生物","Intelligene","RNA 遞送","小核酸藥物","siRNA","ASO","EV 外泌體","LNP","肝外遞送","台灣生技"],"summary":"小核酸藥物的競爭正從 RNA 序列設計走向肝外遞送；智新生技以 EV 與 LNP 平台切入肺部與呼吸道，挑戰小核酸下半場最值錢的問題：能否真正抵達病灶。","key_points":[],"excerpt":"【序列是有效載荷，遞送才是火箭；誰能把 RNA 送到肝臟以外，誰才握住下一輪小核酸估值密碼】 有些技術，剛開始像是一場科學實驗；等到大藥廠真金白銀砸下去時，才會被市場看見它其實是一條產業主線。 小核酸藥物正在走到這個位置。 今年 Alnylam Pharmaceuticals 與 AI 生技公司 Inceptive Nucleics 簽下最高 20 億美元合作，表面上是 RNAi 龍頭押注人工智慧；更深一層看，這筆交易其實在宣告：小核酸藥物的競爭，已經不只是在比誰能寫出更好的序列，而是比誰能更快、更穩、更有效地把 RNA 藥物推向臨床。Alnylam 這筆合作包含 3,000 萬美元前期對價、股權投資，以及臨床前、監管與銷售里程碑，目標是用 AI 加速 RNA 藥物候選分子的設計與篩選。 小核酸之所以特別適合 AI，不難理解。傳統小分子藥物要尋找蛋白質上的結合口袋，抗體藥物多半要鎖定細胞外或細胞膜上的蛋白；但小核酸更像是在生命訊息的上游動刀。siRNA（小干擾核酸） 可以讓目標 mRNA 被降解，ASO（反義寡核苷酸） 可以影響 mRNA 降解或剪接，miRNA（微小核糖核酸） 則有機會調節一整串基因網路。 換句話說，小核酸把藥物開發從「尋找結構」推向「設計序列」。 當藥物變得更像序列工程，AI 自然會成為加速器。它可以協助序列設計、脫靶風險預測、化學修飾優化，也可以減少過去大量濕"},{"title":"Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html","date":"2026-08-13","lang":"en","category":"商業分析系列","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","cardiovascular outcomes","Phase 3","biomarker risk"],"summary":"ZEUS showed the central translational risk in cardiovascular drug development: ziltivekimab suppressed the IL-6 pathway, but the 6,300-patient outcomes trial did not reduce three-point MACE.","key_points":[],"excerpt":"Novo Nordisk’s Phase 3 Setback: A 6,300-Patient Textbook Lesson On July 31, 2026, Novo Nordisk disclosed the Phase 3 ZEUS outcome trial for ziltivekimab. The drug had looked almost ideal in Phase 2: inflammation markers fell sharply, dose response was clear, and the same pharmacodynamic signal was reproduced in Japanese participants. The market was waiting for the next step: proof that lowering inflammation could translate into fewer heart attacks or strokes. What ZEUS delivered instead was blunt. More than 6,300 patients. Primary endpoint hazard ratio 0.99. 95% confidence interval 0.88–1.11. "},{"title":"諾和諾德大三期慘敗！6,300 人的教科書級教訓","url":"https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html","date":"2026-08-13","lang":"zh-Hant","category":"商業分析系列","tags":["Novo Nordisk","ziltivekimab","ZEUS","MACE","IL-6","hsCRP","心血管","慢性腎臟病","NVO","合一生技"],"summary":"ZEUS 超過 6,300 人卻交出 HR 0.99：ziltivekimab 壓低 free IL-6 與 hsCRP，卻沒有證明能降低三點 MACE。這不是抗發炎假說死亡，而是 biomarker 不能替患者硬終點預支成功。","key_points":[],"excerpt":"諾和諾德大三期慘敗！6,300 人的教科書級教訓 2026 年 7 月 31 日，諾和諾德公布 ziltivekimab 的 ZEUS 第三期結果。 這款藥在第二期幾乎交出一張滿分成績單：發炎指標大幅下降、劑量反應清楚，日本受試者也重現相同訊號。市場原本等著它證明「降發炎可以少一次心肌梗塞或中風」，最後等到的卻是—— 超過 6,300 人，主要終點風險比（HR）0.99，95% 信賴區間 0.88–1.11。 ZEUS 給的答案很乾脆：在這群患者、這個劑量與追蹤條件下，ziltivekimab 沒有證明能降低重大心血管事件。 更強烈的反差是：藥效學訊號仍在。諾和諾德表示，游離 IL-6 與高敏感度 C 反應蛋白（hsCRP，常用的發炎指標）都如預期下降；但由心血管死亡、非致命心肌梗塞與非致命中風構成的三點重大心血管事件（MACE），就是沒有跟著下降。 這款藥確實打中 IL-6 通路，卻沒讓患者少一次心肌梗塞或中風。對生技產業來說，這種失敗比「藥完全沒作用」更值得記住。 為什麼第一、二期把發炎指標幾乎打穿，仍然推不出第三期硬終點成功？ZEUS 是最新的一堂課。 圖1｜ZEUS 超過 6,300 人、HR 0.99，發炎指標下降但三點 MACE 未降低 01｜二期明星，三期翻車 ZEUS 是一項大型、隨機、雙盲、安慰劑對照、事件驅動的心血管結局試驗。 受試者已確診動脈粥樣硬化心血管疾病"},{"title":"Can $1.2 Billion Help AI Double the Pace of Drug R&D?","url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd-en.html","date":"2026-08-12","lang":"en","category":"商業分析系列","tags":["Bio Genesis Mission","AI drug discovery","NIH","DOE","biomedical data","drug development","digital pathology","multi-omics","Taiwan biotech"],"summary":"The Bio Genesis Mission is an attempt to connect supercomputing, biomedical data, AI agents, automated laboratories, clinical networks, and regulation into one R&D loop. Its real test is whether governed data and reproducible experiments can reach patients faster.","key_points":[],"excerpt":"From target discovery and experimental design to clinical development, the United States is trying to reconnect the entire drug R&D process around AI. On July 22, the US National Institutes of Health launched the Bio Genesis Mission, aligning more than $1.2 billion in funding. Its official ambition is larger still: double the pace of biomedical innovation over the next five to ten years, or cut the time from scientific discovery to patients in half within a decade. Bio Genesis is meant to connect national-laboratory supercomputing, federal genomic and clinical data, AI agents, automated labora"},{"title":"美國砸 12 億美元，想用 AI 把新藥研發快一倍！","url":"https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html","date":"2026-08-12","lang":"zh-Hant","category":"商業分析系列","tags":["Bio Genesis Mission","AI製藥","NIH","DOE","生醫資料","藥物研發","數位病理","多體學","雲象科技","基米"],"summary":"美國以 Bio Genesis Mission 串起超算、生醫資料、AI 代理、自動化實驗、臨床與監管能力；真正的成敗不在模型口號，而在資料治理、實驗重現與患者轉譯能否形成閉環。","key_points":[],"excerpt":"從找靶點、做實驗到進臨床，美國想用 AI 把整條新藥研發流程重接一次。 7 月 22 日，美國國家衛生研究院（NIH）啟動「生物創世紀計畫」（Bio Genesis Mission），對齊超過 12 億美元資金。官方目標更大：未來 5 至 10 年讓生醫創新速度加倍，或在 10 年內把科學發現走到患者的時間縮短一半。 Bio Genesis 要接起國家實驗室超算、聯邦基因體與臨床資料、AI 代理、自動化實驗室、醫院、癌症中心與 FDA 監管能力。美國想重做的，是整個生醫研究作業系統。 但 12 億美元不是一筆剛核定、全數撥付的新基金；其中同時包含 2026 會計年度已承諾與 2027 會計年度規劃中的相關資金。白宮所說超過 50 億美元的聯邦承諾，也屬於涵蓋能源、製造、國防與健康任務的整體 Genesis Mission，不能全部算給 Bio Genesis。 接下來最難的未必是 AI 夠不夠聰明，而是敏感資料能不能安全互通、AI 提出的假說能不能被實驗重現，以及研究結果能不能真的走進患者身上。 圖1｜Bio Genesis Mission 想把生醫資料、AI 超算、假說、自動化實驗與臨床證據接成可反覆驗證的研發閉環。 一、能源部先搭科研底座，NIH 再把生醫接上去 Bio Genesis 的母體，是 2025 年 11 月由行政命令啟動的 Genesis Mission。美國能源"},{"title":"After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html","date":"2026-08-11","lang":"en","category":"商業分析系列","tags":["AnBogen Therapeutics","ABT-301","imofinostat","HDAC inhibitor","Chidamide","pMMR colorectal cancer","cancer immunotherapy","Taiwan biotech"],"summary":"Chidamide has brought HDAC inhibition back into solid-tumor development. ABT-301 must now show that a wider therapeutic window, triplet combinability, and human immune-mechanism data can support a next-generation combination backbone.","key_points":[],"excerpt":"From two decades of clinical setbacks and Chidamide’s two solid-tumor validations to Anbogen’s bid to unlock pMMR colorectal cancer through a differentiated therapeutic window, immune remodeling, and the HDAC3–NRF2 axis Data cutoff: August 5, 2026 11.7 months and 44% have brought HDAC inhibitors back to the solid-tumor stage after two decades. Anbogen’s 66-patient colorectal cancer triplet trial could open a path for ABT-301 to become a next-generation combination backbone. Two numbers — 11.7 months and 44% — have reset the conversation around HDAC inhibitors in solid tumors. In July 2026, HUY"},{"title":"20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹","url":"https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html","date":"2026-08-11","lang":"zh-Hant","category":"商業分析系列","tags":["安邦生技","ABT-301","imofinostat","HDAC抑制劑","Chidamide","pMMR大腸直腸癌","癌症免疫治療","台灣生技"],"summary":"Chidamide以pMMR大腸癌44% ORR與黑色素瘤第三期PFS達標，重新降低HDAC抑制劑的類別風險；安邦ABT-301接下來必須用治療窗口、三聯可組合性與人體免疫機轉，證明資產差異。","key_points":[],"excerpt":"從二十年臨床卡關 、Chidamide（西達本胺）兩項實體瘤驗證，到安邦如何以治療窗口、免疫重塑與HDAC3–NRF2路徑，挑戰pMMR大腸癌 資料基準日｜2026年8月5日 11.7個月、44%，讓沉寂20年的HDAC抑制劑重回到實體瘤舞台。安邦ABT-301的66人的大腸癌三聯試驗打開下一代HDAC抑制劑成為聯合治療骨幹的可能 11.7個月與44%，是HDAC抑制劑二十年實體瘤開發的兩個新座標。2026年7月，HUYABIO公布HBI-8000（即Chidamide／西達本胺）加Nivolumab治療晚期黑色素瘤的全球第三期初步結果：404位病人、15個國家，聯合組中位無惡化存活期為11.7個月，對照組7.4個月，主要終點達標；完整風險比、安全性、整體存活期與次族群資料仍待發表。 更早之前，CAPability-01以Chidamide、Sintilimab與Bevacizumab治療MSS／pMMR大腸直腸癌，三聯組客觀緩解率達44%，中位無惡化存活期7.3個月。這兩項研究把HDAC抑制劑重新帶回實體瘤開發的核心舞台。 但「類別重新成立」不等於「ABT-301已經成功」。真正需要拆開的是三層問題：Chidamide是否已替HDAC抑制劑降低類別風險；ABT-301能否用更好的治療窗口，用66位病人的pMMR晚期大腸癌三聯試驗證明成為下一代聯合治療骨幹，打開冷腫瘤與多種藥物聯合"},{"title":"禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html","date":"2026-08-10","lang":"zh-Hant","category":"商業分析系列","tags":["生技併購","藥廠併購","專利懸崖","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","Biotech"],"summary":"2026 年上半年生技製藥併購總額約 1,300 億美元，買家偏向臨床後期與接近上市的資產。這一輪不是全面牛市，而是大藥廠在專利懸崖前，用交易結構與現金購買可計算的開發時間。","key_points":[],"excerpt":"禮來、默沙東、艾伯維、吉利德、GSK，全都在買。 2026 年上半年，IQVIA 統計 42 筆生技製藥併購，總額約 1,300 億美元，幾乎追平 2025 全年；BioSpace 的完整公司收購口徑則數到 52 筆，明顯高於去年同期約 30 筆。最積極的禮來，一家公司就完成 9 筆、承諾金額超過 250 億美元。 有趣的是，上半年沒有標的價值超過 300 億美元的巨型合併，卻有 9 筆交易達 50 億美元以上。藥廠把目光移到臨床後期、即將讀出或接近上市的資產。 因為本十年有超過 3,000 億美元品牌藥收入暴露在市場獨占權到期風險。這波併購搶的，是一段能被計算、也趕得上專利懸崖的時間。 圖 1｜半年千億美元併購的核心，不只是買公司，而是在專利懸崖前買進臨床與商業化時間。 01｜52 筆與 42 筆，來自兩套統計口徑 BioSpace 依 S&P Capital IQ 統計到 52 筆交易，納入的是至少 1,000 萬美元、收購完整治療藥物公司的交易，交易價值還可能包含債務與其他調整；IQVIA 的口徑則是取得生技製藥標的多數股權、交易值至少 2.5 億美元，因此得到 42 筆、合計約 1,300 億美元。 IQVIA 的原文寫得很清楚：2026 上半年約 1,300 億美元，幾乎追平 2025 全年的 1,330 億美元。 52 筆與 42 筆，是兩種不同交易口徑 BioSpac"},{"title":"$130 Billion in Six Months: Big Pharma Is Buying Time","url":"https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html","date":"2026-08-10","lang":"en","category":"商業分析系列","tags":["biopharma M&A","pharma acquisitions","patent cliff","Eli Lilly","Merck","AbbVie","Gilead","GSK","IQVIA","biotech"],"summary":"Biopharma M&A reached approximately $130 billion in the first half of 2026 as buyers favored late-stage and near-launch assets. This is not a broad biotech bull market; it is Big Pharma using cash and contingent deal structures to buy measurable development time before the patent cliff.","key_points":[],"excerpt":"Eli Lilly, Merck, AbbVie, Gilead and GSK are all buying. In the first half of 2026, IQVIA counted 42 biopharma mergers and acquisitions worth approximately $130 billion, nearly matching the total for all of 2025. BioSpace, using a methodology focused on acquisitions of entire companies, counted 52 deals, well above roughly 30 in the same period last year. Lilly was the most active buyer, completing nine deals and committing more than $25 billion on its own. The striking part is that the first half produced no megamerger involving a target valued above $30 billion, yet nine transactions were wo"},{"title":"J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables?","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html","date":"2026-08-09","lang":"en","category":"商業分析系列","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","Psoriasis","IL-23R","Oral Peptide","Drug Commercialization"],"summary":"ICOTYDE logged more than 18,000 prescriptions in its first full quarter. The oral IL-23R peptide has earned entry into the high-efficacy psoriasis market, but durable value still depends on paid fills, persistence, payer quality, safety, and additional indications.","key_points":[],"excerpt":"One of the hardest rules to break in psoriasis may be starting to loosen: patients who want biologic-like efficacy have generally had to accept an injection. In the first full quarter after launch, Johnson & Johnson's ICOTYDE (icotrokinra) accumulated more than 18,000 prescriptions, reached roughly 11,000 patients, and was prescribed by about 6,000 healthcare professionals. A once-daily oral medicine is beginning to enter a high-efficacy market that injectables have long dominated. The U.S. Food and Drug Administration approved ICOTYDE on March 18, 2026. It is the first and currently the only "},{"title":"嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？","url":"https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html","date":"2026-08-09","lang":"zh-Hant","category":"商業分析系列","tags":["ICOTYDE","icotrokinra","Johnson & Johnson","乾癬","IL-23R","口服胜肽","新藥商業化"],"summary":"ICOTYDE 上市後第一個完整季度累積逾 18,000 張處方。口服 IL-23R 胜肽已取得進入高療效市場的資格，真正的商業答案仍取決於續方、支付品質、長期留存與多適應症。","key_points":[],"excerpt":"乾癬市場最難撼動的一條規則，可能開始鬆了：想追上生物製劑的療效，通常就得接受注射。 嬌生（J&J）的 ICOTYDE（icotrokinra）上市後第一個完整季度，就累積超過 18,000 張處方、約 11,000 位病人與 6,000 位開方者。一顆每天服用的口服藥，開始把手伸進原本由針劑主導的高療效市場。 ICOTYDE 於 2026 年 3 月 18 日獲美國食品藥物管理局（FDA）核准。它是第一款、也是目前唯一獲 FDA 核准、直接阻斷 IL-23 受體（乾癬發炎的重要訊號開關）的標靶口服胜肽，適用於 12 歲以上、體重至少 40 公斤，且適合全身性治療或光照治療的中重度斑塊型乾癬患者。 乾癬病人想要的其實不複雜：皮膚清得夠乾淨、效果維持得夠久，而且最好不要一直打針。過去的問題是，口服藥方便，療效常和 IL-23、IL-17 生物製劑有一段差距；注射型生物製劑能把皮膚廓清率拉得很高，卻要面對針劑、回診、保存與長期治療負擔。 ICOTYDE 讓口服藥第一次有資格進入高療效的對話。18,000 張處方證明市場願意試；商業成績要等續方、實際支付與長期留存接棒。 它正在搶針劑的飯碗，現在只是拿到入場券。 01｜每天一顆，嬌生怎麼把胜肽送進體內？ ICOTYDE 的學名是 icotrokinra，每日一次、空腹口服 200 mg。它會阻斷 IL-23 receptor，抑制與乾癬發炎"},{"title":"Why These Four Biotechs Can Afford Not to Sell","url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling-en.html","date":"2026-08-08","lang":"en","category":"商業分析系列","tags":["Biotech","Biopharma","argenx","Insmed","Revolution Medicines","Incyte","Royalty Pharma","Drug Development","Biotech Investing"],"summary":"argenx, Insmed, Incyte, and Revolution Medicines show why biotech independence depends on product evidence, cash generation, a second growth curve, global execution, and financing without surrendering control.","key_points":[],"excerpt":"Evidence cut-off: August 7, 2026. This analysis puts product evidence, cash generation, a second growth curve, global execution, and financing options on the same scorecard to examine what it really costs a biotech to remain independent. For years, the market compressed a biotech company's future into two outcomes. One was clinical failure, followed by a rapid collapse in asset value. The other was clinical success, followed by a sale to a large pharmaceutical company. Both outcomes are real. But treating an acquisition as the only successful finish line misses a question that is becoming incr"},{"title":"不賣給大藥廠，4 家生技公司憑什麼自己做大？","url":"https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html","date":"2026-08-08","lang":"zh-Hant","category":"商業分析系列","tags":["Biotech","Biopharma","argenx","Insmed","Revolution Medicines","Incyte","Royalty Pharma","新藥開發","生技投資"],"summary":"argenx、Insmed、Incyte 與 Revolution Medicines 選擇保留獨立經營權。真正的不賣資格，來自產品證據、現金引擎、第二曲線、全球執行與不交出控制權也能取得資金的能力。","key_points":[],"excerpt":"生技公司做出好藥，最常見的結局是被大藥廠買走。但 argenx、Insmed、Incyte 與 Revolution Medicines，選擇了另一條更難的路：自己把藥推到全球、自己養下一條管線，也自己承擔失敗。 它們的底氣都可以換算成數字。argenx 靠 VYVGART（降低致病性 IgG 抗體的自體免疫暢銷藥）在 2025 年賣出 42 億美元，首度全年營業獲利；Insmed 的第二款藥 BRINSUPRI 在 2026 年第二季又賣出 3.092 億美元，季增 49%；Revolution 還沒有核准產品，卻在 4 月透過股票與可轉債取得約 21 億美元淨收入。 它們用現金與產品，替自己換到拒絕整家公司出售的底氣。時間，則是這份底氣最昂貴的成本。 這正是生技公司最難跨過的一關。臨床成功後，被大型藥廠收購通常是最快的變現路；但如果第一款藥已經能養研發、第二款產品開始成形、全球商業化有人做，公司繼續獨立，可能比一次出售更值錢。 判斷一家公司是否真的有「不賣資格」，不能只看創辦人的態度，而要看五件現實的事：產品證據夠不夠、第一款藥能不能變成現金引擎、第二條曲線有沒有出現、全球商業化能不能自己做，以及公司能否在不交出控制權的前提下拿到資金。 四家公司走在不同位置，剛好把生技公司從一項資產長成一家企業的分水嶺攤在桌上。第二曲線決定獨立能走多遠；資金與商業化能力，決定科學價值能否活著抵"},{"title":"22 億美元，買下一個自體免疫藥王？","url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html","date":"2026-08-07","lang":"zh-Hant","category":"商業分析系列","tags":["argenx","Forte Biosciences","FB102","VYVGART","CD122","自體免疫","白斑","乳糜瀉","健喬","安立璽榮","安成生技"],"summary":"argenx 擬以 22 億美元現金收購 Forte，把早期抗 CD122 抗體 FB102 納入管線。真正的考題不是一組一期 p 值，而是 VYVGART 的單品成功能否被複製成可重複的公司能力。","key_points":[],"excerpt":"靠 VYVGART（可降低致病性 IgG 抗體、用於重症肌無力等自體免疫疾病的暢銷藥）崛起的 argenx，現在拿出約 22 億美元現金，準備收購 Forte Biosciences。 買方與賣方的座位，換了。 這個轉身的底氣，來自 VYVGART。2026 年第二季，VYVGART 產品淨銷售達 15.16 億美元；上半年累計 28.13 億美元。到 6 月底，argenx 持有 36 億美元現金與約當現金，加上 16 億美元流動金融資產，合計流動性約 52 億美元。 但這筆交易最值得看的，並不是「一家有錢的新藥公司開始買東西」這麼簡單。 Forte 沒有上市產品，核心資產 FB102 還停在早期臨床。argenx 卻願意用相當於自身期末流動性約四成的價格，提前買走它的未來。 所以，22 億美元買的究竟是什麼？ 是一支抗 CD122 抗體（CD122 是會影響 T 細胞與自然殺手細胞的免疫受體元件）？兩組一期訊號？還是 argenx 相信，自己已經把 VYVGART 從一顆藥的成功，提煉成一套可以再做一次的公司能力？ 先把答案說在前面： 1️⃣ 已經證明的，是 argenx 能把一個新機制做成全球大藥。 2️⃣ 目前買到的，是 FB102 在白斑與乳糜瀉出現的早期概念驗證訊號。 3️⃣ 還沒證明的，是這些訊號能否在第二期重現，並長成另一個「一藥多適應症」平台。 第一顆大藥，證明一"},{"title":"$2.2 Billion for the Next Autoimmune Blockbuster?","url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition-en.html","date":"2026-08-07","lang":"en","category":"商業分析系列","tags":["argenx","Forte Biosciences","FB102","VYVGART","CD122","autoimmune disease","vitiligo","celiac disease","biotech M&A","Taiwan biotech"],"summary":"argenx plans to pay $2.2 billion in cash for Forte and its early anti-CD122 antibody FB102. The real test is not one Phase 1b p-value, but whether VYVGART's product success reflects a development engine the company can repeat.","key_points":[],"excerpt":"argenx built its rise on VYVGART, a blockbuster that reduces pathogenic immunoglobulin G antibodies and is used across diseases such as generalized myasthenia gravis. Now the company is preparing to spend approximately $2.2 billion in cash to acquire Forte Biosciences. The buyer and seller have changed seats. VYVGART made that reversal possible. The product generated $1.516 billion in net sales in the second quarter of 2026 and $2.813 billion in the first half. At the end of June, argenx held $3.6 billion in cash and cash equivalents plus $1.6 billion in current financial assets, for total liq"},{"title":"Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html","date":"2026-08-06","lang":"en","category":"商業分析系列","tags":["AnHorn Medicines","AH-001","Androgenetic Alopecia","Hair-Loss Drug","AR Degrader","PROTAC","Eli Lilly","Veradermics","Absci","Taiwan Biotech"],"summary":"Lilly has placed a $40 million bet on next-generation hair-loss drugs. With roughly 80 million U.S. patients still constrained by two legacy therapies, AH-001's Phase 2 data could become the next global asset-revaluation trigger.","key_points":[],"excerpt":"Lilly has placed a $40 million bet on hair-loss innovation. With roughly 80 million patients in the United States and only two legacy therapies, could AnHorn's AH-001 place topical AR degradation at the center of the next global revaluation of hair-loss drug assets? The next biotech market capable of being propelled at the same time by global pharmaceutical companies, Wall Street, and consumers may not be in oncology or rare disease. It may be hiding in something people see in the mirror every day: their hair. In 2026, a series of signals began to emerge around next-generation hair-loss drugs,"},{"title":"投資人請注意，下一個減肥藥級別賽道來了！","url":"https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html","date":"2026-08-06","lang":"zh-Hant","category":"商業分析系列","tags":["安宏生醫","AH-001","雄性禿","掉髮新藥","AR 降解劑","PROTAC","禮來","Veradermics","Absci","台灣生技"],"summary":"禮來用 4,000 萬美元卡位掉髮新藥；當美國約 8,000 萬名患者仍受限於兩款老藥，安宏 AH-001 的二期數據可能成為下一次全球資產重估關鍵。","key_points":[],"excerpt":"禮來用 4,000 萬美元卡位：當 8,000 萬名美國患者只有兩款老藥，安宏 AH-001 為什麼可能站在掉髮新藥重估中心？ 如果要找下一個可能被全球藥廠、華爾街與消費者同時推動的生醫賽道，答案未必還在癌症或罕病，也可能藏在每個人每天照鏡子都看得見的地方：頭髮。 2026 年，掉髮新藥開始出現一連串過去從未同時發生的訊號。Veradermics 的一顆緩釋口服 minoxidil，靠 Phase 2/3 數據把公司市值推向近 50 億美元；禮來先在 Veradermics IPO 文件中表達認購意向，接著又以 4,000 萬美元實際買進 Absci 股份，卡位 AI 設計的掉髮抗體 ABS-201。全球大藥廠已不再只把掉髮當成洗髮精、植髮或醫美服務，而是開始把它當成一個可以誕生 blockbuster 的慢性處方藥市場。 這個市場真正驚人的地方，不只是美國有約 8,000 萬名患者，而是大多數需求根本還沒有被釋放。現有藥物上市數十年，患者仍必須在性功能與荷爾蒙疑慮、心血管風險、頭皮刺激、每日塗抹與效果有限之間做選擇。當一款新藥能把療效、安全性與便利性同時往前推，增量不只是搶走舊藥市占，而是讓原本不治療的人重新走進市場。 而台灣的安宏生醫 AH-001 已經在最值得關注的牌桌上。它不是另一款 minoxidil，也不是傳統的雄激素阻斷劑，而是一款外用小分子 AR protein d"},{"title":"More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%?","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html","date":"2026-08-05","lang":"en","category":"商業分析系列","tags":["Alnylam","Amvuttra","RNA interference","ATTR amyloidosis","small nucleic acid drugs","biotech valuation","Taiwan biotech","clinical data","biotech business analysis"],"summary":"Amvuttra surpassed $1 billion in quarterly sales, yet Alnylam cut its TTR guidance and lost 28% in one day. The reset was not about RNAi technology failing; it was about pent-up demand normalizing, revenue concentration and the timing gap before a second commercial pillar arrives.","key_points":[],"excerpt":"Figure 1. Alnylam and Amvuttra: TTR growth shifts gears. --- If a drug generates more than $1 billion in quarterly sales and grows 106% year over year, while its maker delivers $231 million in GAAP operating income in the same quarter, what could the market possibly be seeing when the stock still falls 28.5% in a single day? On July 30, RNA interference leader Alnylam reported its financial results for the second quarter of 2026. Product net revenues reached $1.172 billion, up 74% year over year. Amvuttra alone generated $1.012 billion for the quarter, while total TTR product revenues came to "},{"title":"一季賣破 10 億，Alnylam 為何崩 28%？","url":"https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html","date":"2026-08-05","lang":"zh-Hant","category":"商業分析系列","tags":["Alnylam","Amvuttra","RNAi","ATTR","小核酸藥物","生技股","合一","中天","智新生技","基米"],"summary":"Amvuttra 單季銷售突破 10 億美元，Alnylam 卻下修 TTR 指引並重挫 28%。真正被重估的不是 RNAi 技術，而是積壓需求退潮、收入集中與下一個商業支柱的時間差。","key_points":[],"excerpt":"如果一款藥單季賣破 10 億美元、年增 106%，公司同季也交出 2.31 億美元 GAAP 營業利益，股價卻在一天內跌掉 28.5%，市場究竟看見了什麼？ 7 月 30 日，RNAi 龍頭 Alnylam 公布 2026 年第二季財報。產品淨收入 11.72 億美元、年增 74%；其中 Amvuttra 單季 10.12 億美元，TTR 產品合計 10.30 億美元。這不是一份「業績暴雷」的成績單。 但同一天，公司把 2026 年 TTR 產品收入指引從 44 億至 47 億美元，下修到 42 億至 45 億美元。以區間中位數計算，市場少掉的是 2 億美元，不到 Amvuttra 一季收入的五分之一；Nasdaq 資料卻顯示，ALNY 收盤從前一日 286.62 美元跌到 204.84 美元，單日下跌約 28.5%。 這個反差才是整件事的核心。 市場砍的不是 RNAi 技術，而是把 Amvuttra 上市初期的積壓需求，錯當成可以永久線性外推的成長斜率。當下一個能分攤 TTR 依賴的商業支柱還沒接上，2 億美元的指引下修，就足以讓整家公司的估值模型重新計算。 換句話說，Alnylam 沒有突然賣不動；它只是從「每一季都要超預期」的故事，進入必須證明成長品質的階段。 圖 1｜Amvuttra 單季銷售突破 10 億美元，但收入增長並不必然帶來估值擴張。 01｜財報很好，壞消息藏在未"},{"title":"A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking","url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks-en.html","date":"2026-08-04","lang":"en","category":"商業分析系列","tags":["AstraZeneca","Bristol Myers Squibb","BMS","pharma M&A","patent cliff","oncology","antibody-drug conjugates","ADC","CAR-T","antitrust","biotech business analysis"],"summary":"AstraZeneca and BMS reportedly explored a combination with a combined market value approaching $400 billion. There is no announced transaction. The real questions are AstraZeneca's 2030 growth target, BMS's Eliquis and Opdivo exclusivity timeline, oncology-pipeline overlap, antitrust and whether integration can actually buy time.","key_points":[],"excerpt":"The global pharmaceutical industry may be considering a combination on a scale it has never seen before. The Financial Times, citing people familiar with the matter, reported that AstraZeneca and Bristol Myers Squibb (BMS) had discussed a possible combination in recent months. At the share prices prevailing when the report emerged, the two companies had a combined market value approaching $400 billion. If the discussions ever turn into a transaction, this would not simply be a case of two large drugmakers becoming one even larger company. Tagrisso, Imfinzi, Enhertu, Opdivo, Yervoy, Eliquis, Re"},{"title":"超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！","url":"https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html","date":"2026-08-04","lang":"zh-Hant","category":"商業分析系列","tags":["AstraZeneca","阿斯特捷利康","Bristol Myers Squibb","BMS","百時美施貴寶","生技併購","大藥廠","專利懸崖","腫瘤新藥","ADC","CAR-T","反壟斷"],"summary":"Financial Times 報導 AstraZeneca 與 BMS 曾探討結合，合計市值接近 4,000 億美元。這不是已簽交易；真正的產業問題是 2030 成長、Eliquis／Opdivo 獨占期、腫瘤管線重疊、反壟斷與整合能否買到時間。","key_points":[],"excerpt":"全球製藥業，可能正在醞釀一場史上最大級的合併。 Financial Times 引述知情人士報導，AstraZeneca（阿斯特捷利康）與 Bristol Myers Squibb（BMS，百時美施貴寶）近幾個月曾討論結合的可能性。 以報導當時的股價計算，兩家公司合計市值接近 4,000 億美元。 如果真的走到合併，這不只是兩家大藥廠變成一家更大的藥廠。 Tagrisso、Imfinzi、Enhertu、Opdivo、Yervoy、Eliquis、Reblozyl、Breyanzi、Abecma……一整排橫跨肺癌、乳癌、肝癌、血液腫瘤、抗凝血與 CAR-T 的產品，可能被放進同一張資產負債表。 以 2025 年公開財報粗略相加，兩家公司年度營收超過 1,000 億美元。阿斯特捷利康在實體瘤精準治療與 ADC 的深度，若接上 BMS 的免疫治療、血液腫瘤、細胞治療與美國商業網絡，幾乎可以拼出一個覆蓋腫瘤治療主要模態的超級平台。 這就是消息一出，市場立刻炸鍋的原因。 但這場可能的合併，並不是單純的強強聯手。 阿斯特捷利康想追的是 2030 年 800 億美元營收目標；BMS 要趕的是 Eliquis 與 Opdivo 走向獨占期轉折前的產品接棒。兩家公司坐上同一張桌，真正想買的可能都不是規模，而是時間。 而藥廠合併最難買到的，偏偏也是時間。 圖 1｜接近 4,000 億美元的是報導當時"},{"title":"Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint","url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3-en.html","date":"2026-08-03","lang":"en","category":"商業分析系列","tags":["Alzheimer's disease","tau","diranersen","BIIB080","IONIS-MAPTRx","Biogen","Ionis","antisense oligonucleotide","ASO","CDR-SB","clinical data","drug development"],"summary":"CELIA missed its prespecified dose-response primary endpoint, yet the lowest dose produced a 0.54-point CDR-SB difference, or 26% slowing, while CSF total tau and tau PET moved in the expected direction. That is enough to justify Phase 3 planning, but not enough to declare tau a validated second disease-modifying pathway.","key_points":[],"excerpt":"A Phase 2 study missed its primary endpoint, yet the sponsor says it intends to move the drug into confirmatory Phase 3 testing. That can sound like an exercise in explaining away failure. But after Biogen presented the complete CELIA dataset for diranersen at the 2026 Alzheimer's Association International Conference, the discussion did not end with the word “failed.” It reopened a more consequential question: can lowering tau genuinely alter the course of early Alzheimer's disease? The most defensible interpretation sits between two extremes. Tau has not made a clinical comeback, but the fail"},{"title":"Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？","url":"https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html","date":"2026-08-03","lang":"zh-Hant","category":"商業分析系列","tags":["阿茲海默症","Tau","Diranersen","BIIB080","IONIS-MAPTRx","Biogen","Ionis","反義寡核苷酸","ASO","CDR-SB","臨床數據","新藥研發"],"summary":"CELIA 未達預設劑量反應主要終點，最低劑量卻在 CDR-SB 看到 26% 惡化減緩，CSF total tau 與 Tau PET 也同向下降。這些訊號足以讓 Biogen 與 Ionis 規劃三期，還不足以宣布 Tau 已成為第二條獲確認的疾病修飾路線。","key_points":[],"excerpt":"一個二期試驗沒有達到主要終點，公司卻說要把藥推進確認性三期。 這通常會被解讀成硬拗。但 2026 年阿茲海默症協會國際會議（AAIC）上，Biogen 公布 diranersen 的 CELIA 完整資料後，市場討論沒有停在「失敗」，反而重新問起：降低 Tau，是否真的可能改變早期阿茲海默症的病程？ 目前最合理的讀法介於兩個極端之間：Tau 尚未翻身；主要終點失敗，也沒有抹掉其餘訊號。 藥時事的主判斷是： Tau 還沒有正式翻身。CELIA 沒有證明劑量愈高、效果愈好，因而未達預設的劑量反應主要終點；最低劑量在 CDR-SB 看到 26% 的惡化減緩，腦脊髓液與 Tau PET 又同時往靶點預期方向移動。這組訊號足以支持 Biogen／Ionis 規劃三期；要宣布「Aβ 之外的第二條疾病修飾路線成立」，還少一場確認性試驗。 同一份資料裡，統計問題、臨床訊號與生物標記一致性同時出現。主終點失敗沒有突然變成功；它讓下一步要回答的問題變得更清楚。 01｜先把試驗問題說對：CELIA 問的是劑量反應 Diranersen 也叫 BIIB080、IONIS-MAPTRx，是 Biogen 與 Ionis 共同開發的反義寡核苷酸（ASO）。它和 MAPT mRNA 結合，目的是在蛋白質製造之前降低 Tau 生成；作用位置不同於抓取既有 Tau 聚集體的抗體。 這類藥物要進入中樞神經系統，目前採"},{"title":"Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html","date":"2026-08-02","lang":"en","category":"商業分析系列","tags":["alopecia areata","bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK inhibitors","SALT","biotech valuation","clinical data","drug development"],"summary":"Q32 Bio nearly doubled after a 33-patient, single-arm Phase 2a readout. The investable questions are whether efficacy survives randomization, whether responses persist after treatment stops, and whether a larger safety database can support a differentiated place beside JAK inhibitors.","key_points":[],"excerpt":"A Phase 2 trial with just 33 patients and no placebo group nearly doubled the market value of a small biotechnology company in a single day. On July 13, 2026, Q32 Bio reported topline results from Part B of SIGNAL-AA, evaluating bempikibart in severe alopecia areata. QTTB shares closed 90.72% higher that day. The next day, the company priced an offering at $18.25 per share, targeting approximately $200 million in gross proceeds to fund further clinical development. Hair regrew, the stock surged and the company raised capital. It is tempting to turn that sequence into a simple headline: a non-J"},{"title":"鬼剃頭新藥，先別封神","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html","date":"2026-08-02","lang":"zh-Hant","category":"商業分析系列","tags":["斑禿","鬼剃頭","Bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK 抑制劑","SALT","生技股","新藥研發"],"summary":"33 人、單臂、開放標籤的 Phase 2a 資料讓 Q32 Bio 股價近乎翻倍；真正的問題是療效能否重現、停藥後能否維持，以及安全性是否足以改變 JAK 抑制劑的臨床位置。","key_points":[],"excerpt":"一個只有 33 人、沒有安慰劑對照的二期試驗，讓一家小型生技公司的股價一天近乎翻倍（+90.72%）。 2026 年 7 月 13 日，Q32 Bio 公布 bempikibart 治療重度斑禿的 SIGNAL-AA Part B 頂線結果。當天 QTTB 收盤上漲 90.72%。隔天，公司就以每股 18.25 美元定價增資，預計募得約 2 億美元毛額，資金將支應 bempikibart 後續臨床開發。 頭髮長回來、股價漲上去、錢也募到了。這個故事很容易被寫成：「非 JAK 新藥終於打敗 JAK 抑制劑。」 資料真正說的是：這只是一張進入下一階段的門票。 藥時事的主判斷是： Q32 股價近乎翻倍，反映市場有多渴望非 JAK 的斑禿治療。Bempikibart 目前只有 33 人、單臂、開放標籤的 Phase 2a 資料；這張門票能把它送進更嚴格的對照試驗，還無法證明它已勝過 JAK。 這個區別很重要。因為斑禿的下一場競爭，不會只問「有沒有長頭髮」，而會問三件更難的事：療效能不能在大樣本重現？停藥後能不能維持？安全性是否真的足以換掉已經建立臨床位置的 JAK 抑制劑？ 圖1｜33 人讓股價近乎翻倍，但證據成熟度仍只支持進入下一階段。 01｜先看清楚：SALT 代表什麼？ 斑禿是免疫系統攻擊毛囊造成的疾病，影響遠超過美容。它可能表現為硬幣大小的禿髮，也可能進展到幾乎整個頭皮、眉毛、睫毛"},{"title":"AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html","date":"2026-07-31","lang":"en","category":"商業分析系列","tags":["AnBogen Therapeutics","ABT-301","Cancer Immunotherapy","PD-1","Metastatic Colorectal Cancer","HDAC","Taiwan Biotech","Oncology"],"summary":"Can a small molecule from Taiwan extend the $30 billion PD-1 ecosystem into the 95% of metastatic colorectal cancer patients still beyond immunotherapy’s reach?","key_points":[],"excerpt":"Can a small molecule from Taiwan extend the $30 billion PD-1 ecosystem into the 95% of metastatic colorectal cancer patients still beyond immunotherapy’s reach? $30B+ ~95% 66 Patients --- --- --- PD-1 Blockbuster Ecosystem of mCRC is pMMR / non-MSI-H Planned Phase 1/2 Enrollment As SpaceX stepped into the public-market spotlight this year, Starlink stood out as the asset generating its most important source of commercial cash flow. Terrestrial broadband already reaches much of the globe, but large pockets remain underserved. Starlink uses a constellation of low-Earth-orbit satellites to bring "},{"title":"安邦生技：免疫治療的「星鏈計畫」","url":"https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html","date":"2026-07-31","lang":"zh-Hant","category":"商業分析系列","tags":["安邦生技","ABT-301","癌症免疫治療","PD-1","轉移性大腸直腸癌","HDAC","台灣生技","腫瘤"],"summary":"一顆台灣小分子，有機會把三百億美元級PD-1藥王送進九成五患者仍無法受益的治療盲區嗎？","key_points":[],"excerpt":"一顆台灣小分子，能否把300億美元級PD-1生態，連進95%的大腸癌免疫盲區？ 300億美元級 約95% 66名 --- --- --- PD-1藥王生態 mCRC為pMMR／non-MSI-H Phase 1/2預計收案 馬斯克旗下的SpaceX今年上市首秀，然而多數虧損的資產中，星鏈Starlink帶來了其目前最重要的商業現金流。即便當今的網路基站已經遍佈全球大部分的角落，但是依然留有大片面積是無法被覆蓋的。星鏈就是透過低軌衛星把訊號送偏遠地區、海上船舶到災區通訊。[1]如今美國多數的航空公司都透過星鏈的服務，提供人們在飛機上的網路服務，將網際網路的世界無時無刻地傳遞覆蓋全球。 而在癌症免疫治療也存在類似的「通訊覆蓋缺口」。 眾所週知的PD-1藥物已經改寫全球腫瘤治療，但它並不是對所有腫瘤都有效。部分腫瘤能被免疫系統辨認，T細胞也能順利進入；另一些腫瘤卻會降低抗原呈現、排斥免疫細胞，甚至在腫瘤內建立強烈的免疫抑制環境。藥物已經存在，訊號卻送不進去。 安邦生技的核心藥物ABT-301，試圖處理的正是這個問題。 透過重塑腫瘤微環境、擴大既有免疫療法治療範圍的小分子藥物。若這顆藥物與機制能在人體臨床中成功，安邦的價值將成為與不同藥物連用於多種癌種的「免疫治療星鏈」。 Starlink擴張的是網路覆蓋；ABT-301挑戰擴張的，是免疫治療覆蓋。 圖1｜免疫治療的「星鏈計畫」：ABT-3"},{"title":"Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html","date":"2026-07-30","lang":"zh-Hant","category":"製藥巨頭系列","tags":["Astellas","Xtandi","Padcev","Vyloy","腫瘤","藥物開發"],"summary":"Xtandi 仍主導安斯泰來腫瘤收入；Padcev、Vyloy 與下一代 CLDN18.2 資產能否在 LOE 後形成可重複的產品平台，才是下一段考題。","key_points":[],"excerpt":"2026 年 7 月 10 日，美國 FDA 再度擴大 Padcev（enfortumab vedotin-ejfv）聯合 Keytruda（pembrolizumab）的使用範圍：這次進入的是肌層浸潤性膀胱癌（MIBC）手術前後的圍手術期治療，而且不再受患者是否適合 cisplatin 限制。 對安斯泰來而言，這不只是一張新適應症標籤。它真正回答的是更大的問題：當 Xtandi 的專利與市場獨占壓力逐步逼近，安斯泰來是否已經從「一款超級產品撐起腫瘤業務」，跨進能持續產生下一款產品的腫瘤平台？ 答案不是簡單的「是」或「否」。 Padcev、Vyloy 與 Xospata 已證明安斯泰來不再只有 Xtandi；但從產品組合、權益結構、臨床採納到下一批管線的兌現速度來看，平台雛形已經出現，平台能力仍在驗證途中。 本文所稱 FY2025，是安斯泰來截至 2026 年 3 月 31 日的會計年度，不等於曆年 2025。所有產品數字均按公司 FY2025 補充財務資料口徑整理。 第一層：四款產品已成形，但營收重心仍高度集中 安斯泰來 FY2025 的四款主要腫瘤產品全球銷售分別為： - Xtandi：9,608 億日圓 - Padcev：2,212 億日圓 - Xospata：718 億日圓 - Vyloy：631 億日圓 Padcev、Xospata 與 Vyloy 三款非 Xtandi "},{"title":"After Xtandi: Can Astellas Build an Oncology Platform?","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html","date":"2026-07-30","lang":"en","category":"製藥巨頭系列","tags":["Astellas","Xtandi","Padcev","Vyloy","oncology","drug development"],"summary":"Xtandi still dominates Astellas oncology sales. The real test is whether Padcev, Vyloy and the next CLDN18.2 assets can become a repeatable post-LOE platform.","key_points":[],"excerpt":"What Comes After Xtandi? Four Tests for Astellas’ Emerging Oncology Platform On July 10, 2026, the US Food and Drug Administration expanded the use of Padcev (enfortumab vedotin-ejfv) plus Keytruda (pembrolizumab) once again. The combination can now be used before and after surgery for muscle-invasive bladder cancer (MIBC), regardless of whether a patient is eligible for cisplatin. For Astellas, this is more than another indication on a label. It speaks to a larger question: as patent and market-exclusivity pressure builds around Xtandi, has Astellas moved from an oncology business supported b"},{"title":"Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events?","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html","date":"2026-07-29","lang":"en","category":"商業分析系列","tags":["Business Analysis","pelacarsen","Lp(a)","HORIZON","cardiovascular disease","clinical trials","antisense oligonucleotide","Novartis","Ionis","biotech investing"],"summary":"Pelacarsen can substantially lower Lp(a), but HORIZON must show whether biomarker reduction on top of standard care translates into fewer cardiovascular deaths, myocardial infarctions, strokes and urgent revascularizations.","key_points":[],"excerpt":"Start with the timing, because this is a topic where one premature verb can distort the entire investment and clinical thesis. As of July 19, 2026, the phase 3 Lp(a) HORIZON trial of pelacarsen has not reported results. ClinicalTrials.gov still lists the study as active, not recruiting, and contains no results section. Novartis' latest quarterly investor presentation places the event-driven readout in the second half of 2026. Ionis says results are expected later this year. That means it is not accurate to write that the trial has unblinded, that the result is imminent within a specific number"},{"title":"HORIZON：Lp(a) 降了，心梗會少嗎？","url":"https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html","date":"2026-07-29","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","Pelacarsen","Lp(a)","HORIZON","心血管疾病","臨床試驗","ASO","Novartis","Ionis","生技投資"],"summary":"Pelacarsen 已證明能大幅降低 Lp(a)，但 HORIZON 真正要回答的是：在標準治療之上，生物標記下降能否轉成更少的心血管死亡、心肌梗塞、中風與緊急再血管化。","key_points":[],"excerpt":"先把時間講清楚。 截至 2026 年 7 月 19 日，pelacarsen 的第三期 Lp(a) HORIZON 試驗還沒有公布結果。ClinicalTrials.gov 顯示研究仍是「Active, not recruiting」，也沒有結果資料；Novartis 最新一季投資人資料把事件驅動讀出放在 2026 年下半年，Ionis 則說結果預計在今年稍晚公布。 所以，現在不能寫「正式揭盲」、不能寫「結果出爐」，也不能把「2026 下半年」改寫成「未來幾週」。 但這不代表 HORIZON 只是又一個等待中的藥廠催化劑。它真正要回答的，是心血管藥物開發裡一個拖了很多年的問題： 把 Lp(a) 大幅壓低，能不能在既有心血管疾病、而且已接受標準治療的人身上，進一步減少心血管死亡、心肌梗塞、中風與緊急冠狀動脈再血管化？ 這個答案會決定 Lp(a) 是從「很有說服力的風險因子」，走到「值得被藥物直接治療的事件標的」；也會影響後面一整批 ASO、siRNA 與口服小分子，究竟是在追一個漂亮的生物標記，還是在建立新的心血管治療類別。 資料狀態：ClinicalTrials.gov NCT04023552（2026 年 7 月 19 日重查）；Novartis 2026 Q1 investor presentation；Ionis 2026 Q1 financial results。 01｜L"},{"title":"T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability","url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html","date":"2026-07-28","lang":"en","category":"商業分析系列","tags":["T-cell exhaustion","immunotherapy","PD-1 blockade","CAR-T","T-cell engager","bispecific antibody","TCF1","Taiwan biotech","Shine-On Biomedical","Ever Supreme","Pell Biomedical","AP Biosciences","AcePodiA","SOA101","CAR001","PL001","AP203","ACE1831"],"summary":"PD-1 blockade, CAR-T and T-cell engagers ultimately depend on T cells that can expand, renew and persist. This analysis connects exhaustion biology, product engineering and clinical evidence to the next competitive threshold in immunotherapy.","key_points":[],"excerpt":"A tumor cell being killed makes for a striking image. The harder question is what remains on day 30, day 90, and beyond: how many T cells can still expand, find the tumor, and complete another round of killing? PD-1 antibodies, CAR-T cells, and T-cell engagers, or TCEs, take three different routes. All three ultimately rely on the functional state, differentiation quality, and persistence of T cells. 1. PD-1 blockade releases an inhibitory signal and reactivates T cells that still retain the capacity to respond. 2. CAR-T therapy removes T cells, engineers them with a tumor-recognition receptor"},{"title":"T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後","url":"https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html","date":"2026-07-28","lang":"zh-Hant","category":"商業分析系列","tags":["T 細胞耗竭","免疫治療","PD-1","CAR-T","TCE","雙特異性抗體","TCF1","聖安生醫","長聖","沛爾生醫","圓祥生技","育世博","SOA101","CAR001","PL001","AP203","ACE1831"],"summary":"PD-1、CAR-T 與 TCE 最後都仰賴可增殖、可補充且能持久的 T 細胞戰力。本文從耗竭分化、產品工程與臨床資料，拆解免疫治療下半場的真正競爭門檻。","key_points":[],"excerpt":"一顆腫瘤細胞被殺掉，畫面很有衝擊力。 真正困難的是第 30 天、第 90 天，甚至更久以後，還剩多少 T 細胞能繼續擴增、找到腫瘤，再完成下一輪殺傷。 PD-1 抗體、CAR-T 與 T-cell engager（TCE，T 細胞銜接器）走的是三條路，最後都得靠 T 細胞的功能狀態、分化品質與持久性完成殺傷。 1️⃣ PD-1 阻斷解除抑制訊號，讓仍有反應能力的 T 細胞重新動起來。 2️⃣ CAR-T 把 T 細胞取出改造，裝上辨識腫瘤的受體，再送回體內作戰。 3️⃣ TCE 一端抓腫瘤抗原、一端抓 CD3，把患者現有的 T 細胞拉到腫瘤旁邊。 藥時事團隊的判斷是：這三類療法共同依賴同一種底層資產——具有持續增殖能力的 T 細胞戰力。免疫治療下一輪的產品差距，會落在誰能把這筆「免疫資本」用得久，而不是第一天就燒完。 這個判斷不等於把所有治療失敗都歸因於耗竭。抗原消失、抗原呈現異常、T 細胞進不了腫瘤、藥物暴露不足，以及腫瘤以其他路徑逃脫，都可能讓療效停下來。耗竭真正改變的是我們讀數據的方式：除了問腫瘤縮了多少，還要追問是哪一群 T 細胞完成殺傷、這群細胞能不能補充，以及功能維持了多久。 早期反應率相近，不代表產品續航相同。要分辨差異，得把反應維持時間、細胞動力學與復發時的抗原狀態放在一起看；一次掃描只看得到腫瘤縮小，看不到是哪一批 T 細胞把效果撐住。 01｜耗竭不是「累了」而已"},{"title":"半年千億，買的是時間","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html","date":"2026-07-27","lang":"zh-Hant","category":"商業分析系列","tags":["生技併購","藥廠併購","Biopharma M&A","專利懸崖","Lilly","Merck","AbbVie","Gilead","GSK","Terns","Apogee","Arcellx","Tubulis","Nuvalent","Organon","CVR","里程碑"],"summary":"2026 上半年生醫併購轉熱，但 BioSpace 的 52 筆與 IQVIA 的 42 筆不能硬拼。真正的主線，是專利懸崖迫使大藥廠用現金購買可計算的臨床時間。","key_points":[],"excerpt":"2026 年上半年，生技併購真的回來了。 但先別急著把「超過 50 筆、接近 1,300 億美元」排在同一句，做成一個看起來很完整的大數字。這兩個數字來自不同資料庫，篩選門檻也不同。 BioSpace 依 S&P Capital IQ 統計到 52 筆交易，納入的是至少 1,000 萬美元、收購完整治療藥物公司的交易，交易價值還可能包含債務與其他調整；IQVIA 的口徑則是取得生技製藥標的多數股權、交易值至少 2.5 億美元，因此得到 42 筆、合計約 1,300 億美元。 兩個數字都可以用，不能把它們拼成同一份統計。 而且 IQVIA 的原文是：2026 上半年約 1,300 億美元，幾乎追平 2025 全年的 1,330 億美元，不是「已經超過去年全年」。 這個小小的口徑差，正好提醒我們：併購熱度固然回來了，真正值得追的卻不是一個越喊越大的總額，而是藥廠正在買什麼。 藥時事的主判斷是： 2026 年的生醫併購不是單純從冷轉熱，而是專利懸崖把大藥廠的選擇題改了。買家不再優先追求「公司越大越好」，而是用更高價格搶臨床後期、接近讀出或接近上市的資產，買下一段可以被計算的時間。 52 筆和 42 筆，差的不是 10 筆而已 BioSpace 的 52 筆，是一張「完整公司收購」清單。它告訴我們，2025 年同期約 30 筆，2026 年確實明顯變多；其中禮來以 9 筆居首，承諾金額超過"},{"title":"$130 Billion in Six Months: Big Pharma Is Buying Time","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html","date":"2026-07-27","lang":"en","category":"商業分析系列","tags":["biopharma M&A","Big Pharma","patent cliff","loss of exclusivity","Lilly","Merck","AbbVie","Gilead","GSK","Terns","Apogee","Arcellx","Tubulis","Nuvalent","Organon","CVR","milestones","biotech valuation"],"summary":"Biopharma M&A accelerated in the first half of 2026, but BioSpace's 52 deals and IQVIA's 42 deals cannot be combined. The deeper story is that patent cliffs are pushing Big Pharma to pay for measurable clinical time.","key_points":[],"excerpt":"Biopharma M&A is back. But before placing “more than 50 deals” and “nearly $130 billion” in the same sentence and presenting them as one neat market statistic, there is an important methodological problem: those figures come from different databases with different inclusion rules. BioSpace, using S&P Capital IQ, counted 52 transactions. Its screen includes acquisitions of whole drug-development companies valued at no less than $10 million, and reported deal value can include debt and other adjustments. IQVIA applied a different threshold: a buyer had to obtain majority ownership of a biopharma"},{"title":"Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html","date":"2026-07-25","lang":"en","category":"商業分析系列","tags":["Roche","Big Pharma","pharma strategy","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","BRIM Biotechnology","BD licensing","drug development","biotech valuation","Taiwan biotech"],"summary":"Roche generated CHF 47.669 billion in pharmaceutical sales in 2025, with Ocrevus, Hemlibra, and Vabysmo already accounting for roughly one-third of the total. The number that matters is not simply 19 potential new molecules, but whether giredestrant, fenebrutinib, obesity, Alzheimer's, and protein-degradation assets can inherit Roche's existing clinical, diagnostic, and commercial infrastructure on time.","key_points":[],"excerpt":"When one company is placing bets across breast cancer, multiple sclerosis, Alzheimer's disease, obesity, and targeted protein degradation, the easy description is \"portfolio diversification.\" It is a safe phrase. It is also nearly devoid of information. Put Roche's moves over the past year on a single timeline and the picture looks less like diversification than a relay race. Roche's pharmaceutical division generated CHF 47.669 billion in sales in 2025. Three non-oncology products — Ocrevus, Hemlibra, and Vabysmo — contributed CHF 15.866 billion, or roughly one-third of pharmaceutical revenue."},{"title":"羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？","url":"https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html","date":"2026-07-25","lang":"zh-Hant","category":"商業分析系列","tags":["Roche","羅氏","Big Pharma","製藥巨頭","giredestrant","fenebrutinib","trontinemab","petrelintide","bexobrutideg","全福生技","BRIM Biotechnology","BD 授權","藥物研發","生技估值"],"summary":"羅氏 2025 年製藥銷售 476.69 億瑞士法郎，Ocrevus、Hemlibra 與 Vabysmo 已撐起約三分之一收入。真正值得追的不是 19 個新分子的總數，而是 giredestrant、fenebrutinib、減重、阿茲海默症與蛋白質降解資產能否沿既有臨床、診斷與商業通路準時接棒。","key_points":[],"excerpt":"一家公司同時在乳癌、多發性硬化症、阿茲海默症、減重與蛋白質降解下注，很容易被寫成「多元布局」。 這四個字很安全，也幾乎沒有資訊量。 把羅氏近一年的動作排在一起，畫面更像一場接力賽。 2025 年，羅氏製藥事業銷售 476.69 億瑞士法郎。Ocrevus、Hemlibra、Vabysmo 三款非腫瘤產品合計 158.66 億瑞士法郎，已經撐起約三分之一的製藥收入。到了 2026 年，乳癌口服新藥 giredestrant 有兩項申請進入 FDA 審查；多發性硬化症新藥 fenebrutinib 連續完成三個陽性三期；減重、阿茲海默症與蛋白質降解療法也往後排出新的棒次。 羅氏在 2025 年藥品日提出，2030 年前最多有 19 個新分子具備上市潛力。這個數字很大，卻還不是最關鍵的答案。 真正值得算的，是下一棒有多少能準時接上。 - 近端，看兩項 FDA 申請與三個陽性三期。 - 中段，看減重和阿茲海默症能否長成新支柱。 - 遠端，看剛買進的技術能否沿著既有通路放大。 01｜轉型早已發生，收入表先說了 市場談羅氏，第一個想到的仍常是 HER2 乳癌、血液腫瘤與幾款經典抗體藥。這個印象沒有錯，只是少看了半張收入表。 2025 年，Ocrevus 銷售 70.10 億瑞士法郎，Hemlibra 為 47.54 億，眼科藥 Vabysmo 也來到 41.02 億。羅氏前五大成長動能合計貢獻"},{"title":"SpaceX Goes to Orbit. Is the Money in the Crystals?","url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals-en.html","date":"2026-07-24","lang":"en","category":"商業分析系列","tags":["SpaceX","microgravity","space pharmaceuticals","drug crystallization","Keytruda","Redwire","SpaceMD","Varda","formulation development","Taiwan biotech"],"summary":"SpaceX is making low-Earth-orbit round trips more routine, but rockets do not discover drugs. From Keytruda crystallization and SpaceMD to Varda, UK regulation, and a Taiwan mission, this analysis asks whether microgravity-enabled manufacturing can pass the tests of repetition, scale-up, and regulation.","key_points":[],"excerpt":"Evidence cut-off: July 19, 2026. SpaceX supplies transportation to and from low Earth orbit; it does not develop medicines. The commercial question is whether a better crystal grown in microgravity can be converted into a repeatable, scalable, and regulator-ready process on Earth. On June 17, 2026, a SpaceX Dragon spacecraft splashed down in the Pacific Ocean carrying biological, materials-science, and medical research samples. It was NASA's 34th SpaceX commercial resupply mission. Launching a payload, entering the International Space Station, completing an experiment, and returning the sample"},{"title":"SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金","url":"https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html","date":"2026-07-24","lang":"zh-Hant","category":"商業分析系列","tags":["SpaceX","微重力","太空製藥","藥物結晶","Keytruda","Redwire","SpaceMD","Varda","製劑開發","台灣生技"],"summary":"SpaceX 讓低軌往返逐漸有了班次，但火箭不是新藥公司。本文從 Keytruda 結晶、SpaceMD、Varda、英國監管與台灣任務，拆解微重力製藥能否通過重複、放大與監管三道商業考驗。","key_points":[],"excerpt":"查證截止：2026-07-19。SpaceX 提供的是往返低軌的交通，不是新藥研發；真正的商業考題，是微重力能否把更好的晶體轉化成可重複、可放大、可監管的地面製程。 2026 年 6 月 17 日，一艘 SpaceX Dragon 太空船濺落太平洋，帶回滿艙的生物、材料與醫學研究樣本。這是 NASA 第 34 次 SpaceX 商業補給任務。上太空、進入國際太空站、完成實驗、再把樣本送回地球，已經慢慢有了固定班次的樣子。 三週後，Redwire 旗下 SpaceMD 找來兩位新顧問：曾參與 Keytruda 早期結晶研究的 Merck 前研究主持人 Paul Reichert，以及曾管理逾 15 億美元技術投資的 NASA 前主管 Niki Werkheiser。 Reichert 懂晶體，Werkheiser 懂如何讓太空技術走出實驗。SpaceMD 要補的，正是從「做得出來」到「有人願意反覆買」之間那段路。 - SpaceX 與 Dragon 打通了「上去做實驗、下來看結果」的往返路線。 - 微重力讓對流與沉降安靜下來，某些蛋白質與小分子能長出更均一的晶體。 - 商業成敗仍要回到地面：晶體好多少、製程能否放大、改善值不值得支付太空成本。 藥時事團隊的判斷是，太空製藥的第一桶金，最可能落在體積最小、價值最高、最難在地球完成的那一步：晶型探索、晶種培養與製劑條件篩選。 火箭把每公斤"},{"title":"When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma","url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines-en.html","date":"2026-07-24","lang":"en","category":"商業分析系列","tags":["Biotech","Biopharma","argenx","Insmed","Incyte","Revolution Medicines","Royalty Pharma","business development","commercialization","biotech investing"],"summary":"An acquisition is not the only successful outcome for a biotech. Using argenx, Insmed, Incyte, and Revolution Medicines as four operating snapshots, this analysis tests product evidence, cash generation, a second growth curve, global execution, and financing options—and shows what retaining control really costs.","key_points":[],"excerpt":"Evidence cut-off: July 15, 2026. This analysis puts product evidence, cash generation, a second growth curve, global execution, and financing options on the same scorecard to examine what it really costs a biotech to remain independent. For years, the market compressed a biotech company's future into two outcomes. One was clinical failure, followed by a rapid collapse in asset value. The other was clinical success, followed by a sale to a large pharmaceutical company. Both outcomes are real. But treating an acquisition as the only successful finish line misses a question that is becoming incre"},{"title":"Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma","url":"https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html","date":"2026-07-24","lang":"zh-Hant","category":"商業分析系列","tags":["Biotech","Biopharma","argenx","Insmed","Incyte","Revolution Medicines","Royalty Pharma","BD","商業化","生技投資"],"summary":"被收購不是 Biotech 唯一的成功終點。本文以 argenx、Insmed、Incyte 與 Revolution Medicines 為四個截面，檢驗產品證據、現金引擎、第二曲線、全球執行與融資選項，並拆解保留控制權的真實成本。","key_points":[],"excerpt":"查證截止：2026-07-15。本文將產品證據、現金引擎、第二曲線、全球執行與融資選項放在同一張表上，拆解 Biotech 保留獨立經營權的真正代價。 過去談 Biotech，市場常把結局壓成兩種： 一種是臨床失敗，資產價值快速歸零；另一種是臨床成功，被大型藥廠買走。 這兩條路都是真實的。但把「被收購」當成成功的唯一終點，會漏看一個正在變重要的問題： 如果公司繼續獨立，能創造的價值已經高於今天一次賣掉的價格，它還需要急著出售嗎？ 這不是創辦人有沒有骨氣，也不是「小公司對抗 MNC」的浪漫故事。真正能讓 Biotech 說不的，是五項很現實的能力：產品證據、現金流、第二條成長曲線、全球商業化，以及不讓渡控制權也能拿到資金的選項。 argenx、Insmed、Revolution Medicines 與 Incyte，剛好展示了四種不同狀態。前三家不是同一套成功模板，Incyte 也不是「失敗公司」；把它們並排，反而能看出一家公司從資產走向企業時，最容易被忽略的分水嶺。 藥時事的主判斷是： Biotech 的獨立，不是拒絕 MNC 的勇氣，而是保留核心權利後，仍有能力把第一個成功再投資成下一個成功。沒有第二曲線，獨立可能只是在延後出售；沒有資金與商業化能力，拒絕收購甚至會把科學價值變成執行風險。 第一關：一款藥能不能從產品，變成資本引擎？ argenx 已經跨過這一關。 VYVGART"},{"title":"Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html","date":"2026-07-20","lang":"en","category":"商業分析系列","tags":["Business Analysis","MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3","PNPLA3","THR-beta","FGF21","GLP-1","BD licensing","Taiwan biotech"],"summary":"Rezdiffra has opened the MASH market and built its commercialization infrastructure. Madrigal is now adding six Ribo siRNA programs and Arrowhead's ARO-PNPLA3 to create a cornerstone-plus-precision-combination treatment matrix.","key_points":[],"excerpt":"MASH, once regarded as a drug-development graveyard where global pharmaceutical companies repeatedly failed, is being redefined. The company that truly opened the market was Madrigal Pharmaceuticals, with Rezdiffra (resmetirom). Rezdiffra is a once-daily, oral, liver-directed THR-beta agonist. In March 2024, the FDA granted accelerated approval for adults with noncirrhotic MASH accompanied by moderate to advanced liver fibrosis, or stages F2 to F3. The decision was based on histologic surrogate endpoints; continued approval remains contingent on confirmatory studies verifying and describing cl"},{"title":"聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒","url":"https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html","date":"2026-07-20","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","MASH","Madrigal Pharmaceuticals","Rezdiffra","resmetirom","siRNA","Ribo Life Science","Ribocure","Arrowhead Pharmaceuticals","ARO-PNPLA3","PNPLA3","THR-beta","FGF21","GLP-1","BD 授權","台灣生技"],"summary":"Rezdiffra 已把 MASH 市場與商業化基礎設施打開；Madrigal 再以 Ribo 六條 siRNA 管線與 Arrowhead ARO-PNPLA3，建立基石藥加精準聯用矩陣。","key_points":[],"excerpt":"MASH 這個曾經讓全球藥廠屢戰屢敗的「藥物墳場」，正在被重新定義。 第一個真正把市場打開的，是 Madrigal Pharmaceuticals 的 Rezdiffra（resmetirom）。Rezdiffra 是一款每日一次口服、肝臟導向的 THR-beta agonist，也就是甲狀腺激素受體 beta 促效劑。2024 年 3 月，FDA 透過加速核准途徑，核准 Rezdiffra 用於成人非肝硬化 MASH，且已伴隨中度至重度肝纖維化，也就是 F2 至 F3 族群。這項核准依據組織學替代終點；持續核准仍取決於確認性研究能否驗證並描述臨床效益。 這是 MASH 領域第一個獲 FDA 核准的藥物，也讓一個長期只有生活型態介入、卻沒有真正藥物治療的巨大市場，終於看見商業化入口。 上市後的速度，比市場原先想像更快。Madrigal 2025 年 Rezdiffra 全年淨銷售額達 9.584 億美元，雖然嚴格來說還差一點才到 10 億美元，但到 2026 年第一季，Rezdiffra 單季銷售已達 3.113 億美元。過去 12 個月銷售額已突破 11 億美元，正式站上重磅藥門檻；截至 2026 年 3 月底，已有超過 42,250 名患者使用 Rezdiffra。 這件事的重要性不只是銷售額。 而是 Madrigal 正在用 Rezdiffra 打通 MASH 這條路。從臨床"},{"title":"Animal Studies Are Not Disappearing. Drug Development Rules Are Changing.","url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift-en.html","date":"2026-07-19","lang":"en","category":"商業分析系列","tags":["NAMs","CDE","Regulatory Science","Organoids","Organ-on-a-Chip","AI Drug Discovery"],"summary":"China's CDE PIONEER program opens a regulatory pathway for new approach methodologies. The real test is whether human-relevant evidence becomes reproducible, validated and reusable.","key_points":[],"excerpt":"On July 7, 2026, China's Center for Drug Evaluation (CDE) opened a consultation on its program to propel the research and application of New Approach Methodologies, or NAMs. The English title, Propel Innovation and Operation of NAMs to Enhance Efficiency in R&D , gives the program its PIONEER acronym. The point is not that drug developers can suddenly abandon animal studies. It is that nonclinical evidence is beginning to be judged more explicitly by its fitness for purpose. Organoids, organ-on-a-chip systems, human-cell assays, in vitro tests, computational models, AI prediction and real-worl"},{"title":"動物實驗不是消失，而是藥物研發規則開始換代","url":"https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html","date":"2026-07-19","lang":"zh-Hant","category":"商業分析系列","tags":["NAMs","CDE","監管科學","類器官","器官晶片","AI 製藥"],"summary":"CDE 的 NAMs 先鋒計畫為藥企與方法開發者開出雙軌入口；真正的考題是可重複、可驗證且被監管接受的人體相關證據。","key_points":[],"excerpt":"2026 年 7 月 7 日，中國國家藥品監督管理局藥品審評中心，也就是 CDE，一次公開徵求「推進新方法（NAMs）研究和應用試點計畫」相關文件意見。 這項計畫英文全名是 Propel Innovation and Operation of NAMs to Enhance Efficiency in R&D，簡稱 PIONEER，中文則被稱為「先鋒計畫」。 CDE 同步釋出介紹、申報指南、申請表與實施框架，徵求意見期為一個月。 官方文件也明確指出，計畫目標是促進 organoids（類器官）、organ-on-a-chip（器官晶片）等 New Approach Methodologies（NAMs，新方法學）在藥物研發中的研究與應用。 這件事的意義，不只是多了一個試點計畫，它代表中國藥品監管正式進入全球 NAMs 競賽。NAMs 說白了，就是藥物安全性與有效性評估不再只能依賴動物模型。類器官、器官晶片、人體細胞模型、體外檢測、in silico 模型、AI 預測、真實世界資料，只要能在明確使用情境下提供可驗證、可重複、可解釋的證據，都可能成為非臨床評估的一部分。這不是「反動物實驗」的口號。而是藥物研發正在面對一個老問題：動物不是人。 很多藥在動物身上看起來安全有效，進入人體卻失敗；也有些創新療法本來就找不到合適動物模型。當細胞治療、基因治療、RNA 藥物、抗體藥物與 AI 藥物"},{"title":"When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html","date":"2026-07-18","lang":"en","category":"商業分析系列","tags":["Business Analysis","antibody-drug conjugates","autoimmune disease","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","immune modulation","rheumatoid arthritis","biotech investing"],"summary":"The opportunity for autoimmune ADCs is not to transplant oncology cytotoxins into immune cells. It is to deliver powerful glucocorticoids, small molecules, ASOs or siRNAs selectively to the cells that drive disease. LFD-200 offers an early human proof-of-mechanism signal for that thesis.","key_points":[],"excerpt":"Over the past several years, antibody-drug conjugates, or ADCs, have become almost synonymous with oncology drugs. Mention an ADC and most people think of HER2, TROP2 or Nectin-4. They think of linkers, payloads, bystander effects and the engineering required to deliver a cytotoxic drug more precisely into a tumor cell. Yet if the platform is stripped back to its core, an ADC is not an oncology-only technology. Its fundamental capability is antibody-mediated targeted delivery. Once the platform is understood as a delivery system, its boundaries no longer have to stop at oncology. Autoimmune di"},{"title":"當 ADC 走進自體免疫：不是殺得更狠，而是調得更準","url":"https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html","date":"2026-07-18","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","ADC","自體免疫疾病","LFD-200","Lifordi Immunotherapeutics","VISTA","glucocorticoid","免疫調節","類風濕性關節炎","生技投資"],"summary":"自體免疫 ADC 的價值不在把腫瘤細胞毒 payload 搬到免疫細胞，而在把 glucocorticoid、ASO、siRNA 等強效免疫調節作用定向送到真正需要干預的細胞；LFD-200 的早期人體訊號，是這條路第一次重要的機制驗證。","key_points":[],"excerpt":"過去幾年，ADC（antibody-drug conjugate，抗體藥物複合體）幾乎被等同於腫瘤藥。 一談 ADC，大家想到的是 HER2、TROP2、Nectin-4。想到的是 linker（連接子）、payload（藥物載荷）、bystander effect（旁觀者效應），以及如何把細胞毒藥物更精準地送進腫瘤細胞。 但如果把 ADC 拆回本質，它其實不是「腫瘤專用技術」。 ADC 的真正核心，是抗體介導的定向遞送。既然是定向遞送，它的邊界就不必停在 oncology，也就是腫瘤領域。 自體免疫疾病，正在成為 ADC 技術下一個值得觀察的試驗場。 只是，ADC 一旦進入自體免疫，就不能再照搬腫瘤裡「精準化療」的邏輯。 腫瘤 ADC 追求的是把癌細胞殺得更乾淨；自體免疫 ADC 要回答的問題，則是能否把強效免疫調節作用，更精準地送到真正需要被干預的免疫細胞與發炎組織。 這不是腫瘤 ADC 的簡單外溢。 這是 ADC 技術本質的一次重新定義： 從選擇性殺傷，走向選擇性免疫調節。 01｜自體免疫治療，正在從壓制發炎走向重塑免疫 要理解自體免疫 ADC，不能只從 ADC 談起。 更重要的是，自體免疫治療本身已經走到新階段。 過去，自體免疫疾病主要靠廣譜免疫抑制。Glucocorticoids（糖皮質素）、methotrexate（甲氨蝶呤）、cyclophosphamide（環磷醯胺"},{"title":"又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html","date":"2026-07-17","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","Revolution Medicines","RevMed","胰臟癌","KRAS G12D","RAS(ON)","Zoldonrasib","Daraxonrasib","ESMO GI 2026","臨床數據","組合療法","腫瘤"],"summary":"Daraxonrasib 已用第三期總生存期資料抬高胰臟癌 RAS 賽道門檻；zoldonrasib 與 pan-RAS 或化療的早期組合訊號，則把競爭從單藥推向治療生態系。","key_points":[],"excerpt":"胰臟癌這個「癌王」，可能真的要被 RAS 藥物撬開一道縫了。 過去，胰臟癌最可怕的地方，不只是死亡率高，而是長期缺乏真正能改寫治療路徑的標靶藥。 KRAS 突變明明出現在超過九成胰臟導管腺癌（PDAC）患者身上，卻因為蛋白結構太滑、缺乏好口袋，長期被視為「不可成藥」。 直到 Revolution Medicines，也就是 RevMed，把 RAS(ON) 抑制劑推到三期陽性。 它的核心藥物 daraxonrasib（RMC-6236），是一款口服 RAS(ON) multi-selective inhibitor，也就是 RAS 活化狀態多選擇性抑制劑。在先前 RASolute-302 三期試驗中，daraxonrasib 用於既往治療過的轉移性 PDAC，將中位整體存活期拉到 13.2 個月，對照化療約 6.7 個月，死亡風險顯著下降，幾乎把後線胰臟癌治療標準直接重寫。 但 RevMed 想要的，顯然不只是二線胰臟癌。 7 月 2 日，RevMed 在 2026 ESMO GI 公布另一組更有想像力的資料：KRAS G12D 抑制劑 zoldonrasib（RMC-9805）聯合 daraxonrasib，在 RAS G12D 轉移性胰臟癌患者中展現強勁訊號。 二線患者中，zoldonrasib 加 daraxonrasib 的 ORR，也就是客觀緩解率，達 50%；DCR，也"},{"title":"RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived","url":"https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html","date":"2026-07-17","lang":"en","category":"商業分析系列","tags":["Business Analysis","Revolution Medicines","RevMed","pancreatic cancer","KRAS G12D","RAS(ON)","zoldonrasib","daraxonrasib","ESMO GI 2026","clinical data","combination therapy","oncology"],"summary":"Daraxonrasib has already raised the bar with phase 3 overall-survival data. Early zoldonrasib combinations now suggest that pancreatic cancer's RAS competition is shifting from single agents to treatment ecosystems.","key_points":[],"excerpt":"For years, pancreatic cancer's most frightening feature was not only its mortality. It was the absence of a targeted therapy capable of changing the treatment path in a meaningful way. More than 90% of pancreatic ductal adenocarcinomas carry a RAS mutation, and KRAS G12D is the largest single molecular subgroup. Yet RAS spent decades labeled “undruggable.” Its surface offered few stable pockets, its signaling changed shape dynamically, and even successful target engagement could be followed by pathway rebound. That old framework is now breaking apart. Revolution Medicines, better known as RevM"},{"title":"Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype","url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html","date":"2026-07-16","lang":"en","category":"商業分析系列","tags":["Business Analysis","Big Pharma","biotech M&A","Vertex","Crinetics","AbbVie","Apogee Therapeutics","Novartis","Avidity Biosciences","Merck","Cidara Therapeutics","BD licensing","Taiwan biotech"],"summary":"Vertex's roughly $10 billion deal for Crinetics captures a wider change in Big Pharma's acquisition taste: away from scale and fashionable platforms, toward niche leadership, technological step-changes and commercial visibility.","key_points":[],"excerpt":"00 Big Pharma's acquisition taste has changed Another $10 billion pharmaceutical acquisition has arrived. On July 6, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, implying an equity value of approximately $10 billion. If completed, the transaction will give Vertex PALSONIFY, Crinetics' marketed oral therapy for acromegaly, together with atumelnant, a late-stage asset for congenital adrenal hyperplasia and other ACTH-driven endocrine disorders. Vertex estimates that the portfolio carries roughly $5 billion in peak-sales potential. The deal also tu"},{"title":"百億美元併購新狂潮","url":"https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html","date":"2026-07-16","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","Big Pharma","生技併購","Vertex","Crinetics","AbbVie","Apogee Therapeutics","Novartis","Avidity Biosciences","Merck","Cidara Therapeutics","BD 授權","台灣生技"],"summary":"Vertex 以約 100 億美元收購 Crinetics，映照 Big Pharma 併購審美的轉向：不再只買規模或熱門平台，而是買細分市場統治力、技術代差與商業確定性。","key_points":[],"excerpt":"00｜大藥廠的「審美」變了 又一筆百億美元級併購誕生。 7 月 6 日，Vertex Pharmaceuticals 宣布以每股 85 美元、總股權價值約 100 億美元的全現金交易，收購專注於內分泌罕見病的 Crinetics Pharmaceuticals。交易完成後，Crinetics 將為 Vertex 帶來已上市的肢端肥大症口服藥 PALSONIFY，以及處於後期開發階段的 atumelnant。 Atumelnant 瞄準先天性腎上腺增生症與其他 ACTH 相關內分泌疾病。Vertex 官方也表示，這組資產具備約 50 億美元峰值銷售潛力，並將內分泌學納入公司第五大治療領域。 至此，2026 年全球製藥產業的百億美元級併購已經一筆接一筆。 大型藥廠加大併購力度並不意外。專利懸崖逼近，內部研發不可能永遠準時交卷，手上又握有大量現金，併購本來就是 Big Pharma 填補成長缺口最直接的工具。 真正值得注意的，不是它們又開始買了，而是它們開始買得不一樣了。 過去十年，跨國藥廠的併購審美經歷過兩個階段：第一個階段是規模崇拜，越大越好；第二個階段是風口崇拜，越熱門越好。 到了 2026 年，新的審美正在成形：不再追逐最大聲量的賽道，而是尋找最不內卷、最具差異化、最能形成細分統治力的資產。 這才是 Vertex 收購 Crinetics 背後真正值得看的地方。 01｜百億美元新"},{"title":"After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product","url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html","date":"2026-07-15","lang":"en","category":"商業分析系列","tags":["Business Analysis","regulatory T cells","Treg","immune tolerance","cell therapy","autoimmune disease","transplantation","CMC","Taiwan Bio Therapeutics","Taiwan biotech","clinical development"],"summary":"The Nobel Prize illuminated Treg biology, but commercial value will depend on whether immune tolerance can become a releasable, trackable, scalable and reimbursable product, not on an unverified first-approval headline.","key_points":[],"excerpt":"For some scientific themes, the most dangerous moment comes just after they are discovered by the wider market. That is when conclusions arrive too quickly. Regulatory T cells have returned to the spotlight. The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for discoveries concerning peripheral immune tolerance. A term that once belonged mainly to the inner circle of immunology has now been pulled to the front of industry and capital-market conversations. Treg stands for regulatory T cell. Its story is very different from the aggr"},{"title":"諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品","url":"https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html","date":"2026-07-15","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","Treg","免疫耐受","細胞療法","自體免疫","移植","CMC","台寶生醫","臨床開發","生技投資"],"summary":"諾貝爾獎照亮 Treg 科學，但產業價值要看免疫耐受能否被做成可放行、可追蹤、可定價、可複製的產品，而不是急著追逐未經核實的第一款獲批敘事。","key_points":[],"excerpt":"有些題材，最危險的時刻，是剛被看見的時候。 是大家太快替它下結論。 Treg 最近重新站回聚光燈。2025 年諾貝爾生理學或醫學獎頒給 Mary E. Brunkow、Fred Ramsdell 與 Shimon Sakaguchi，表彰他們在 peripheral immune tolerance 上的發現。這件事讓一個原本偏免疫學核心圈的名詞，被拉回產業和資本市場前台。 Treg，全名 regulatory T cell，調節性 T 細胞。 它不像 CAR-T 那樣有很強的攻擊敘事。CAR-T 的語言是找到、鎖定、殺掉；Treg 的語言安靜得多，它談的是煞車、容忍、重建秩序。 可是安靜不代表不重要。 很多疾病的底層問題，並非免疫系統不夠強，常常是它太會誤傷自己。自體免疫疾病、移植排斥、發炎失控，單純多踩一腳油門解不了。這時候，真正有價值的問題變成：能不能讓免疫系統重新學會分寸？ 藥時事團隊的判斷是：Treg 的產業價值，不在一句「第一個獲批藥」有多吸睛，而在免疫耐受能否被做成可放行、可追蹤、可定價、可複製的產品。 諾貝爾獎點亮的是科學。市場接下來要看的，是製程、品質、臨床場景和商業化。 01｜諾貝爾獎照亮的，是免疫系統的煞車 免疫系統如果只會攻擊，人不會活得比較安全。 我們每天都靠免疫系統辨識外來病原，也靠它放過自己的組織。這個「放過」不是消極，它是一套高度精密的秩序。Treg"},{"title":"The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class","url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html","date":"2026-07-14","lang":"en","category":"商業分析系列","tags":["Business Analysis","ADC","Novartis","Myricx Bio","NMT inhibitor","ADC payload","BD licensing","oncology","Taiwan biotech","biotech valuation","drug development"],"summary":"Novartis is paying up to $1.5 billion for Myricx. The strategic prize is not merely two ADC assets, but an NMT-inhibitor payload platform that could reopen the questions of therapeutic window, resistance and platform value.","key_points":[],"excerpt":"The antibody-drug conjugate market has become crowded enough to feel overheated. HER2, TROP2, B7-H3 and Nectin-4 have been pursued by wave after wave of companies. Topoisomerase I inhibitors, microtubule inhibitors, bispecific ADCs and dual-payload ADCs now appear in almost every oncology R&D presentation. Over the past several years, ADCs have been one of the brightest tables in innovative drug development, drawing capital, business-development budgets, clinical programs and large-pharma attention. Yet the hotter the table becomes, the clearer the genuinely scarce resource is. The market does"},{"title":"ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload","url":"https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html","date":"2026-07-14","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","ADC","Novartis","Myricx Bio","NMTi","payload","BD 授權","腫瘤","浩鼎","諦醫生技","嘉正生技"],"summary":"諾華最高 15 億美元收購 Myricx，真正買下的不只是兩條 ADC 管線，而是可能改寫安全窗、耐藥與平台估值的新型 NMTi payload。","key_points":[],"excerpt":"ADC 賽道已經熱到有點擁擠。 HER2、TROP2、B7-H3、Nectin-4，熱門靶點被一輪又一輪公司追著做；Topo I payload、微管抑制劑、雙抗 ADC、雙 payload ADC，也被放進幾乎每一場腫瘤研發簡報。過去幾年，ADC 像是創新藥產業裡最亮的牌桌，資本、BD、臨床與大藥廠預算都往這裡聚。 可是牌桌越熱，真正稀缺的東西反而越清楚。 現在不缺「又一個 ADC」。市場缺的是能把療效、安全窗、耐藥問題重新打開的底層技術。 7 月 6 日，諾華宣布簽署協議收購英國生技公司 Myricx Bio。這筆交易最高可達 15 億美元，其中 11 億美元是 upfront，另外最高 4 億美元為潛在里程碑付款。交易預計在 2026 年下半年完成，仍需監管核准與慣例成交條件。 諾華這次沒有急著追熱鬧。它像是等到 ADC 競爭進入下一階段，才出手買一張新規則的門票。 藥時事團隊的判斷是：諾華買 Myricx，表面上拿到 B7-H3 與 HER2 兩條 lead assets，真正的戰略位置在新型 payload。ADC 的下一場戰爭，會從「靶點誰更熱門」推進到「載荷能不能換一種臨床語言」。誰能把耐藥、安全窗與可複製平台一起講清楚，誰才可能在下一輪 BD 裡被重新定價。 01｜ADC 的老問題：好靶點不等於好藥 ADC 常被形容成生物導彈：抗體負責找癌細胞，連接子負責控制釋放，"},{"title":"Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena","url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html","date":"2026-07-13","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Claude Science","Anthropic","foundation models","drug development","AnHorn Medicines","PROTAC","CMC","clinical assets","biotech business analysis","Taiwan biotech"],"summary":"Anthropic's launch of Claude Science and its move into drug discovery show foundation-model companies shifting from research tools into real R&D workflows. AI drug discovery will ultimately be judged by experiments, clinical data and tradable assets.","key_points":[],"excerpt":"On June 30, Anthropic pushed Claude into a field where polished demos rarely survive contact with reality: drug development. Software can go through ten revisions in a day. A presentation can be rebuilt around three different narratives overnight. A drug cannot. It must pass through target selection, disease biology, molecular design, wet-lab experiments, toxicology, CMC, human trials, regulatory review and commercialization. Every gate pulls an ambitious AI narrative back toward evidence. That is why the real industry significance of Claude Science is not simply another product launch. Anthro"},{"title":"大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場","url":"https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html","date":"2026-07-13","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","AI 製藥","Claude Science","Anthropic","大型語言模型","新藥研發","安宏生醫","PROTAC","CMC","臨床資產"],"summary":"Anthropic 推出 Claude Science 並啟動藥物發現計畫，顯示大模型公司正從科研工具走向真實研發工作流；AI 製藥最終仍要用實驗、臨床資料與可交易資產證明價值。","key_points":[],"excerpt":"6 月 30 日，Anthropic 把 Claude 推進一個很少能靠漂亮 demo 蒙混過關的領域：新藥研發。 程式可以一天改十版，簡報可以一晚換三種故事。藥不行。藥物要走過靶點、生物學、分子設計、濕實驗、毒理、CMC、人體試驗、法規審查與商業化。每一道門都會把宏大的 AI 敘事拖回現實。 所以 Claude Science 的出現，真正牽動產業神經的，是 Anthropic 把科研工作台、生命科學工作流與自家藥物發現放到同一張桌上。 我們團隊的判斷是：大模型公司正在把生命科學當成最硬的產品回饋場。過去它們賣模型、賣 API、賣企業助理；現在開始進入科研工作流，甚至親自參與藥物發現。模型公司想證明的，已經從「能不能回答問題」，推進到「能不能在真實實驗與臨床資產裡創造價值」。 這會讓 AI 製藥進入下一個階段。 01｜Claude Science：工作台只是入口，回饋閉環才是核心 Anthropic 官方把 Claude Science 定位成面向科學研究的 AI 工作台，目標是協助研究者處理文獻、資料、程式、分析與研究流程。對生命科學公司來說，這類工具很容易先落在幾個場景：讀 paper、整理實驗資料、寫分析程式、做研究計畫、協助臨床或法規文件的前期工作。 這些功能本身有價值，但還沒有碰到製藥最深的價值出口。 真正讓市場停下來看的，是 Anthropic 同步啟動自家藥物發現計"},{"title":"Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race","url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html","date":"2026-07-12","lang":"en","category":"商業分析系列","tags":["Business Analysis","KRAS G12C","divarasib","Roche","oncology","clinical data","PFS","OS","biotech business analysis","Taiwan biotech"],"summary":"Roche's divarasib beat first-generation KRAS G12C inhibitors in a head-to-head Phase III study, moving the RAS field from proving druggability to replacing earlier products with harder clinical evidence.","key_points":[],"excerpt":"When sotorasib was approved in 2021, the industry finally felt that the KRAS mountain had been breached. At that point, the question was whether a cancer driver long described as “undruggable” could be reached by a medicine at all. The question has now changed. Roche's divarasib has gone head to head against the marketed KRAS G12C inhibitors sotorasib and adagrasib in Phase III, and Roche reported that the study met its primary and key secondary objectives. RAS competition is no longer about who first proved that KRAS could be drugged. It is about who can enter the same target class and displa"},{"title":"先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰","url":"https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html","date":"2026-07-12","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","KRAS G12C","divarasib","Roche","腫瘤新藥","臨床數據","PFS","OS","生技投資"],"summary":"Roche 的 divarasib 在頭對頭三期試驗中擊敗第一代 KRAS G12C 抑制劑，代表 RAS 賽道已從證明可成藥，進入用臨床硬終點淘汰上一代產品的競爭。","key_points":[],"excerpt":"2021 年，sotorasib 獲批上市，很多人第一次覺得 KRAS 這座山真的被鑿開了。 那一刻的問題是：這個曾經被說成「不可成藥」的癌症靶點，到底能不能被藥物打中？ 現在問題換了。 Roche 的 divarasib 在一項頭對頭三期試驗中，對上已上市的 sotorasib 與 adagrasib，公開資料顯示試驗達到主要與關鍵次要目標。也就是說，RAS 賽道的競爭已經從「誰先證明 KRAS 可以成藥」，進到「誰能在同一個靶點裡，把上一代產品淘汰掉」。 藥時事團隊的判斷是：這不是 Roche 贏了一場臨床而已，而是 RAS 產業開始換尺。先發上市可以打開市場，但不能永久鎖住市場；真正能留下來的，會是能用 PFS、OS、安全性、聯用策略與患者分層證明自己有代際差異的分子。 先贏不是贏。這句話在 RAS 賽道，正在變得越來越現實。 01｜KRAS 從不可成藥，走到同靶點淘汰賽 KRAS 不是小靶點。 它長期被視為癌症裡最重要、也最難處理的驅動基因之一，出現在肺癌、胰臟癌、結直腸癌等多種實體瘤。問題是，KRAS 蛋白過去被認為表面太滑、口袋太少、與 GTP / GDP 結合太緊，藥物很難找到真正能穩定卡住的位置。 所以 sotorasib 的意義很大。它讓市場第一次看到 KRAS G12C 可以被小分子藥物打中，也讓 RAS 從「科學上很重要，但商業上很難做」的領域，正式變成大型藥"},{"title":"社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格","url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html","date":"2026-07-11","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"一款藥最迷人的時候，常常也是它最危險的時候：市場先愛上故事，臨床才慢慢追問證據。","key_points":[],"excerpt":"一款藥最迷人的時候，常常也是它最危險的時候：市場先愛上故事，臨床才慢慢追問證據。 真正值得看的，是 Fasedienol 這個故事原本非常漂亮：鼻噴、微量、快速起效、不是傳統口服鎮靜藥，也不是要病人每天吃好幾週才慢慢等效果。它想回答的是一個很真實的需求：有些人不是每一天都需要被治療，而是在上台、會議、面試、聚會之前，突然被社交焦慮壓住。 所以 Fasedienol 的故事很容易被市場喜歡。它不像 SSRI / SNRI 那樣需要時間堆疊，也不像 benzodiazepine 那樣天然背著鎮靜、耐受性與依賴性的陰影。它說自己走的是鼻腔到神經迴路的路徑，試圖用「急性、按需、快速」切進社交焦慮症。 但 2026 年 6 月 30 日，Vistagen 公布 PALISADE-4 三期結果後，故事被臨床終點狠狠拉回現實。 這不是說社交焦慮市場不存在，也不是說 Fasedienol 完全沒有任何訊號。更準確地說，它提醒市場一件事：CNS 新藥最難的地方，常常不是機制講不講得漂亮，而是你能不能在一個高度主觀、安慰劑效應強、病人差異很大的疾病裡，把效果穩定證明出來。 01｜PALISADE-4 失敗在哪裡？數字其實很直接 PALISADE-4 是一個美國多中心、隨機、雙盲、安慰劑對照的三期試驗，用來評估單次鼻噴 fasedienol 能不能在公共演講挑戰中，急性降低成人社交焦慮症患者的焦慮症狀。"},{"title":"Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job.","url":"https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html","date":"2026-07-11","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","drug development","CNS drug development","social anxiety disorder","fasedienol","PALISADE-4","Vistagen","clinical data","biotech valuation","clinical endpoints","biotech investing"],"summary":"Fasedienol's PALISADE-4 miss was not simply a failed Phase 3 headline. It exposed the core CNS drug-development problem: a beautiful mechanism and a real unmet need still have to survive subjective endpoints, placebo response, patient selection, and a commercial repositioning test.","key_points":[],"excerpt":"A drug is often most attractive at the moment when it is also most dangerous: the market falls in love with the story before the clinical evidence has finished asking its questions. That is the right way to read fasedienol. The original story was genuinely elegant. A nasal spray. A low-dose, rapid-onset approach. Not a traditional oral sedative. Not a medicine that asks patients to take a pill every day for weeks before waiting to feel a change. Fasedienol wanted to answer a real patient need: some people do not feel they need treatment every day, but they can be overwhelmed before a presentat"},{"title":"Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html","date":"2026-07-10","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","drug development","FDA CRL","NASP","Sobi","CMC","contract manufacturing","manufacturing quality","uncontrolled gout","URAT1","clinical data","biotech investing"],"summary":"FDA identified no clinical efficacy or safety concerns that affected NASP's approvability. The setback centered on CMC controls and contract-manufacturing deficiencies, showing biotech investors why manufacturing credibility becomes part of asset value near launch.","key_points":[],"excerpt":"Some drugs receive an FDA Complete Response Letter because efficacy is not strong enough. Others fail because the safety profile does not hold. Sobi's NASP is different. The investigational therapy for adults with uncontrolled gout received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration. At first glance, the headline is simple: the application did not win approval in this review cycle. But Sobi's disclosure makes the distinction that matters. The FDA did not identify a clinical efficacy or safety concern that affected approvability. It asked for additional infor"},{"title":"痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度","url":"https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html","date":"2026-07-10","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","FDA","NASP","Sobi","CMC","委託製造","製造品質","難治性痛風","URAT1","臨床數據","生技投資","台灣生技"],"summary":"FDA 並未指出影響 NASP 核准可能性的臨床療效或安全性問題，真正要求補強的是 CMC 控制策略與委託製造設施缺失。這封 CRL 提醒投資人：越接近上市，製造可信度越是藥品價值的一部分。","key_points":[],"excerpt":"有些新藥被 FDA 打回票，是因為療效不夠。 有些是安全性過不了。 但 Sobi 這次的 NASP，不太一樣。 這款針對成人難治性痛風的在研療法，收到 FDA 的 Complete Response Letter（CRL，完整回覆信）。表面上看，這就是「沒有在這一輪審查拿到核准」。可是細看 Sobi 公告，FDA 並沒有點出會影響核准可能性的臨床有效性或安全性疑慮；真正被要求補強的，是 NASP 生物製劑成分的製造控制策略，以及委託製造設施相關缺失。 這句話很關鍵。 它代表 NASP 不是在病人身上被否定，而是在上市前最後一哩路，被 CMC、製造與品質系統攔了下來。 對生技投資人來說，這比單純「痛風新藥遭拒」更值得看。因為它提醒市場：越是複雜的生物製劑，越不是只有臨床數據能決定命運。真正到 FDA 門口時，製程、品管、委外廠管理、法規文件完整性，都會變成藥品價值的一部分。 01｜NASP 是什麼？一款想解決尿酸酶免疫原性的痛風療法 痛風的核心問題，是血中尿酸過高，尿酸鹽結晶沉積在關節與組織裡，引發發炎、疼痛、痛風石，嚴重時會造成關節破壞。大多數病人可以靠口服降尿酸藥物控制，但有一小群患者即使用藥，血清尿酸仍降不下來，且反覆發作、痛風石明顯，這就是 NASP 想切入的族群。 NASP 的設計不是單一成分。 它是一種每 4 週一次的雙組分連續輸注療法，包含 nanoencapsulat"},{"title":"Why Has Japan Struggled to Build Global-Scale Biotech Companies?","url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html","date":"2026-07-09","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Japan biotech","Taiwan biotech","startup ecosystem","drug development","clinical data","CMC","BD licensing","biotech valuation","capital markets","big pharma"],"summary":"Japan has strong science, major pharmaceutical companies, and a large drug market. The harder question is why that foundation has not produced more global-scale biotech startups. The answer is not scientific weakness, but an ecosystem gap across assets, talent, capital, clinical execution, and exits.","key_points":[],"excerpt":"Japan's pharmaceutical industry contains a strange contradiction. If we look only at large drugmakers, Japan is not weak at all. Takeda, Astellas, Daiichi Sankyo, Eisai, and Ono Pharmaceutical are all familiar names in global pharma. Japan is also a major drug market, and its life-science research base has produced world-class work in induced pluripotent stem cells, regenerative medicine, immunology, neuroscience, and other fields. But if the question changes to a sharper one, the answer becomes much quieter: where are Japan's globally competitive homegrown biotech companies? That contrast is "},{"title":"日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態","url":"https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html","date":"2026-07-09","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","日本生技","Biotech ecosystem","startup ecosystem","創新藥","大藥廠","BD","臨床數據","CMC","資本市場","生技投資","製藥巨頭"],"summary":"日本不是缺少科學，也不是缺少大藥廠，而是缺少把大學技術、人才、資本、臨床與 BD 串成全球級 Biotech 的連續生態。","key_points":[],"excerpt":"日本製藥業有一個很微妙的反差。 如果只看大藥廠，日本一點也不弱。Takeda（武田）、Astellas（安斯泰來）、Daiichi Sankyo（第一三共）、Eisai（衛材）、Ono Pharmaceutical（小野製藥）都是國際醫藥市場熟悉的名字。日本也長期是全球重要藥品市場，生命科學基礎研究在 iPS 細胞、再生醫學、免疫學、神經科學等領域都曾有世界級成果。 可是，如果問題換成「日本有哪些具備全球競爭力的本土 Biotech？」 答案突然就變得安靜。 這個反差，是日本創新藥產業最值得拆解問題的地方。 美國可以持續長出 Moderna、Vertex、Alnylam、Regeneron、Argenx 這類從技術平台、臨床開發到商業化都能自成體系的公司。歐洲雖然市場分散，但仍能出現 BioNTech、Genmab、Galapagos、MorphoSys 等不同路線的 Biotech。韓國近年也透過三星生物製劑、Celltrion、Alteogen、LegoChem Biosciences 等公司，把 CDMO、抗體、ADC、平台授權推向國際市場。 反觀日本，科學不差，市場不小，大藥廠也很強，理論上應該是一片適合 Biotech 生長的土壤。 但現實是：日本創新藥舞台上的主角，長期仍由大型藥企壟斷。本土初創生物技術公司不是不存在，而是很難長成真正能連續融資、推進全球臨床、完成 BD"},{"title":"GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html","date":"2026-07-08","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","GLP-1","dorzagliatin","glucokinase activator","GKA","drug development","metabolic disease","type 2 diabetes","MASH","clinical data","BD licensing","biotech valuation","API / CDMO","capital markets"],"summary":"GLP-1 competition is moving from peak weight loss toward long-term use, tolerability, rebound control, and combination design. Dorzagliatin matters not as a GLP-1 replacement, but as a possible metabolic base for the next phase of chronic therapy.","key_points":[],"excerpt":"The GLP-1 arms race has moved from one question to another. The first question was whether these drugs work. The next question is whether patients can stay on them, tolerate them, stop them without rapid rebound, and maintain benefit at a dose that is realistic for chronic metabolic disease. Over the past two years, the market has mostly cared about weight-loss magnitude. Wegovy, based on semaglutide, and Zepbound, based on tirzepatide, pushed body-weight reduction into territory that used to look unrealistic for pharmacologic obesity treatment. Oral GLP-1 programs from Eli Lilly, Novo Nordisk"},{"title":"GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住","url":"https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html","date":"2026-07-08","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","dorzagliatin","多格列艾汀","glucokinase activator","GKA","代謝疾病","糖尿病","MASH","臨床數據","慢病管理","API / CDMO","台灣生技","生技投資","製藥巨頭"],"summary":"GLP-1 競爭進入長期維持與聯用下半場，dorzagliatin 的價值不在取代減重藥，而是可能成為代謝治療的可持續底座。","key_points":[],"excerpt":"GLP-1 的軍備競賽，已經從「有沒有效」進入「能不能長期用」。 過去兩年，市場最愛看的題目是減重幅度。Wegovy（semaglutide，司美格魯肽）、Zepbound（tirzepatide，替爾泊肽）一路把體重下降推到兩位數，口服 GLP-1 也開始被 Eli Lilly、Novo Nordisk 等大藥廠推進後期開發與商業化。乍看之下，這條賽道的勝負好像很簡單：誰減得更多，誰就贏。 但慢性代謝疾病沒有那麼單純。 這篇真正要看的，不是 GLP-1 又多了一個聯用故事。 而是當 GLP-1 從明星減重藥走向慢病長期治療平台後，整個產業會被迫回答一個更現實的問題：患者能不能持續用、願不願意用、停藥後會不會反彈、能不能用較低劑量維持效果。 這也是多格列艾汀（dorzagliatin）這類葡萄糖激酶活化劑（glucokinase activator，GKA）重新變得值得觀察的原因。 它不是要取代 GLP-1，而是可能成為 GLP-1 的「代謝底座」。 01｜GLP-1 已經證明有效，但真實世界的問題是長期依從性 GLP-1 receptor agonist（GLP-1RA，GLP-1 受體促效劑）在糖尿病、肥胖、心血管風險，甚至 MASH（metabolic dysfunction-associated steatohepatitis，代謝功能障礙相關脂肪性肝炎）上的應用正在擴張。"},{"title":"Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html","date":"2026-07-07","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","ADC","PD-1/VEGF","bispecific antibody","oncology","BD licensing","clinical data","drug development","biotech valuation","Big Pharma"],"summary":"After a Phase III setback for sigvotatug vedotin, Pfizer's $43 billion Seagen ADC bet is increasingly tied to whether 3SBio's PD-1/VEGF bispecific can become a new immuno-oncology combination backbone.","key_points":[],"excerpt":"Pfizer's oncology strategy is starting to look less like a clean product roadmap and more like a card game it cannot simply leave. After the COVID vaccine and antiviral cash-flow wave faded, Pfizer had to answer a harder question: where will the next decade of growth come from? The original answer seemed clear. In 2023, Pfizer spent about $43 billion to acquire Seagen, bringing one of the world's most mature antibody-drug conjugate platforms into its own oncology franchise. The strategic logic was obvious. Pfizer had not built the same central position in the PD-1 era that Merck achieved with "},{"title":"【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】","url":"https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html","date":"2026-07-07","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","ADC","PD-1/VEGF","雙特異性抗體","BD","臨床數據","生技投資","腫瘤藥物","製藥巨頭","台灣生技"],"summary":"sigvotatug vedotin Phase III 單藥失利後，輝瑞的 430 億美元 Seagen ADC 賭局正轉向 3SBio PD-1/VEGF 雙抗與聯合療法底座。","key_points":[],"excerpt":"輝瑞這幾年的腫瘤策略，看起來越來越像一場不能退場的牌局。 新冠疫苗與口服藥帶來的現金流退潮後，輝瑞必須重新回答一個問題：下一個十年的成長引擎在哪裡？ 答案本來很清楚。 2023 年，輝瑞用約 430 億美元買下 Seagen，把全球最成熟的 ADC 平台之一收入旗下，試圖用抗體藥物複合體（ADC, antibody-drug conjugate）補回自己在免疫檢查點抑制劑時代錯過的機會。輝瑞官方當時說得很直接：Seagen 加入後，腫瘤管線規模幾乎倍增，涵蓋 ADC、小分子、雙抗與其他免疫療法。 但問題也從這裡開始。 ADC 不是買下平台就會自動長成金雞母。它仍然要過臨床終點、適應症選擇、競品壓力、毒性窗口、商業化定位這幾道門。尤其當一家公司用 430 億美元買下整個平台，市場不會只問「有沒有技術」，而會問：這些資產能不能真的變成下一批 blockbuster？ 最近 sigvotatug vedotin 的 Phase III 單藥試驗未能達到主要終點，剛好把這個問題推到台前。 表面上看，這是輝瑞某一支 ADC 的臨床挫折。 這篇真正要拆的主線是：當 ADC 單藥敘事開始變硬，輝瑞正在把 3SBio（三生製藥）的 PD-1/VEGF 雙特異性抗體 SSGJ-707，也就是 Pfizer 代號 PF-08634404，放到整個腫瘤聯合療法策略的核心位置。 換句話說，輝瑞的 ADC "},{"title":"通用型 CAR-T 的 2026 從低谷回暖","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html","date":"2026-07-06","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資","細胞治療","CAR-T","異體細胞治療","自體免疫疾病","台灣生技"],"summary":"邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。","key_points":[],"excerpt":"通用型 CAR-T 又熱起來了。 幾年前，這曾是細胞治療領域最受期待的方向之一。 邏輯很簡單：傳統自體 CAR-T 需要取出患者自己的 T 細胞，送到工廠改造、擴增、檢驗，再回輸到患者體內。療效可以很強，但等待時間長、成本高、製程複雜，病情進展太快或 T 細胞品質太差的患者，常常等不到治療。 通用型 CAR-T 想解決的，就是這個痛點。 它用健康供者細胞作為原料，經過基因編輯與工程化改造後，做成「現貨型」細胞藥物。理想狀態下，醫師不需要等病人自己的細胞被送去製造，產品可以像藥品一樣提前備貨，患者需要時就能使用。這個願景太美，所以早期市場非常興奮。但第一批通用型 CAR-T 資料並沒有完全打動市場。療效持久性、宿主排斥、移植物對抗宿主病、細胞在體內存活時間、安全性，都讓投資人逐漸冷靜。過去兩三年，這條賽道一度從高峰跌入「幻滅低谷」。 現在，情況開始變了。 2026 年，Caribou、Allogene、Wugen 等公司陸續拿出更成熟的臨床資料，通用型 CAR-T 重新回到桌面上。它不再只是概念，而是開始回答一個真正關鍵的問題：通用型 CAR-T 能不能在療效接近自體 CAR-T 的同時，提供更快、更可及、更容易放大的治療選項？ 01｜Caribou 的 vispa-cel：17.1 個月 PFS，讓市場重新看見希望 這輪回暖最受矚目的公司，是 Caribou Biosciences"},{"title":"Off-the-Shelf CAR-T in 2026: Rebounding From the Trough","url":"https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html","date":"2026-07-06","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","cell therapy","CAR-T","allogeneic cell therapy","clinical data","drug development","autoimmune disease","biotech valuation"],"summary":"Off-the-shelf allogeneic CAR-T is no longer just a beautiful manufacturing story. In 2026, better clinical signals and clearer positioning are bringing the field back to the table.","key_points":[],"excerpt":"Off-the-shelf CAR-T is getting warm again. A few years ago, allogeneic CAR-T was one of the most exciting ideas in cell therapy. The logic was easy to understand. Conventional autologous CAR-T requires a patient’s own T cells to be collected, shipped to a manufacturing site, engineered, expanded, tested, released, and then infused back into the patient. The clinical effect can be powerful, but the process is slow, expensive, and operationally heavy. Patients with rapidly progressing disease, weak T-cell quality, poor access to major centers, or limited manufacturing slots may simply not make i"},{"title":"半年併購 1,340 億美元：Big Pharma 到底在搶什麼？","url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html","date":"2026-07-05","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","併購","臨床數據","生技投資","製藥巨頭","新藥開發","生技估值"],"summary":"2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。","key_points":[],"excerpt":"2026 年才過一半，全球製藥業的併購節奏已經快到讓人有點恍神。 6 月 22 日，AbbVie 宣布以約 109 億美元收購 Apogee Therapeutics，拿下以異位性皮膚炎、氣喘等免疫疾病為主的長效 IL-13 管線，核心資產是 zumilokibart。這是 AbbVie 五年多來最大的一筆收購，也被市場視為它為後 Humira 時代、甚至後 Skyrizi／Rinvoq 時代提前鋪路。 兩週前，GSK 才以 106 億美元收購 Nuvalent，把兩款進入 FDA 上市審查的肺癌標靶藥 zidesamtinib 和 neladalkib 收進囊中。這不是早期平台賭局，而是 GSK 直接買下兩個接近上市的肺癌資產。 Eli Lilly 也沒有停手。它在 6 月收購非鴉片疼痛藥公司 4E Therapeutics，補強非鴉片慢性疼痛藥物布局。這是 Lilly 延續疼痛領域併購與授權布局的一環。 這些不是孤立事件。 根據產業統計，2026 年前六個月，全球已有 33 筆估值超過 10 億美元的 Biotech 收購案，總金額約 1,340 億美元。相比之下，2025 年全年是 26 筆、1,120 億美元。換句話說，今年才過一半，大型藥廠已經花掉去年全年還更多的併購金額。表面上，Biotech 的好日子好像回來了。但這波併購潮真正值得問的，不是 Big Pharma 為"},{"title":"Big Pharma's $134 Billion M&A Rush: What Is It Really Buying?","url":"https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html","date":"2026-07-05","lang":"en","category":"商業分析系列","tags":["Business Analysis","Free Article","biotech business analysis","Taiwan biotech","BD licensing","biotech M&A","biotech valuation","clinical data","drug development","capital markets","Big Pharma"],"summary":"In the first half of 2026, Big Pharma's biotech M&A pace has accelerated sharply. The real question is not why large drugmakers have cash, but why they are suddenly less willing to wait.","key_points":[],"excerpt":"Only half of 2026 has passed, and the global pharmaceutical industry's acquisition pace already feels unusually fast. On June 22, AbbVie announced a roughly $10.9 billion acquisition of Apogee Therapeutics, gaining a long-acting IL-13 immunology pipeline led by zumilokibart for diseases such as atopic dermatitis and asthma. It was AbbVie's largest acquisition in more than five years, and the market read it as an attempt to prepare early for the post-Humira era and even the next stage after Skyrizi and Rinvoq. Two weeks earlier, GSK agreed to acquire Nuvalent for $10.6 billion, bringing in two "},{"title":"Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition","url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html","date":"2026-07-04","lang":"en","category":"商業分析系列","tags":["HHS","FDA","Operation TrialBlazer","clinical trial reform","biotech business analysis","Taiwan biotech","drug development","clinical data","BD licensing","biotech valuation","regulatory policy","capital markets"],"summary":"Operation TrialBlazer is not just an FDA efficiency program. It signals that the United States is treating clinical-trial speed as part of national biotech competitiveness, with direct implications for biotech valuation, financing windows, and regulatory strategy.","key_points":[],"excerpt":"On June 22, 2026, the U.S. Department of Health and Human Services, or HHS, launched a department-wide clinical-trial reform program called Operation TrialBlazer. This is not a small technical adjustment inside the FDA. The initiative pulls together several core agencies and offices across HHS, including the FDA, NIH, NCI, ARPA-H, and ONC, and tries to reset the U.S. clinical-trial system from the earliest stages of development to pivotal evidence generation. The scope is broad: IND submission, first-in-human readiness, dose selection, pivotal trial design, electronic health record-enabled rec"},{"title":"美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了","url":"https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html","date":"2026-07-04","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","FDA","HHS","臨床試驗","新藥開發"],"summary":"2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。","key_points":[],"excerpt":"2026 年 6 月 22 日，美國衛生與公共服務部，也就是 HHS，啟動了一項名為 Operation TrialBlazer 的部門級臨床試驗改革計畫。 這不是 FDA 單一部門的小修小補，而是把 FDA、NIH、NCI、ARPA-H、ONC 等核心機構一起拉進來，試圖從早期臨床、IND 申報、劑量選擇、關鍵性試驗設計、電子病歷招募、罕見病開發，到受試者報酬合規，重新調整美國臨床試驗體系。 HHS 官方聲明把目標講得很直白：恢復美國在臨床研究的領先地位，加快救命療法開發，讓患者更快接觸創新藥。 HHS 部長 Robert F. Kennedy Jr. 也在聲明中表示，美國曾經領跑全球醫療創新，現在要重新做到這一點。 📌 這句話背後的意思其實很清楚：美國覺得自己慢了。 尤其是在全球臨床試驗競爭愈來愈激烈、中國臨床開發效率快速提升、Biotech 資本又重新尋找高彈性資產的背景下，FDA 和 HHS 不能再用舊節奏面對新產業。 這次改革真正重要的，不只是幾條技術性指引，而是它釋放出一個訊號： 📌 美國正在把臨床試驗效率，提升到國家競爭力層級。 01｜早期臨床：最想縮短的，是 IND 到第一位病人入組的時間 對 Biotech 來說，最燒錢、也最容易卡死的階段，往往不是已經進入 Phase 3 之後，而是從臨床前走向首次人體試驗的這段路。 IND 資料準備、CMC、毒理、臨床方案"},{"title":"RevMed Says No to Being Bought: Biotech's Independent Era","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html","date":"2026-07-03","lang":"en","category":"商業分析系列","tags":["Revolution Medicines","RevMed","daraxonrasib","RAS oncology","biotech business analysis","Taiwan biotech","BD licensing","biotech valuation","clinical data","capital markets"],"summary":"Revolution Medicines is choosing not to make a sale its priority. The decision reflects a broader shift: top-tier biotech companies with breakthrough assets may once again have a credible path to grow into independent biopharma companies.","key_points":[],"excerpt":"The acquisition rumors around Revolution Medicines, or RevMed, have never really stopped. The reason is simple: RevMed holds one of the scarcest cards in global oncology development today: daraxonrasib. Earlier this year, the Financial Times reported that Merck had held talks to acquire RevMed, with market speculation placing the possible transaction value in the USD 28 billion to USD 32 billion range. The deal did not materialize. But the market's imagination around RevMed only became stronger. Once a clinical-stage biotech has been seriously studied by a pharmaceutical company at Merck's lev"},{"title":"拒絕被併購的 RevMed：Biotech 的獨立時代","url":"https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html","date":"2026-07-03","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。","key_points":[],"excerpt":"圍繞 Revolution Medicines（RevMed）的併購傳聞，一直沒有真正停過。 原因很簡單：它手上握著當前全球腫瘤研發最稀缺的一張牌——daraxonrasib。 今年稍早，《Financial Times》曾報導，Merck 曾洽談收購 RevMed，市場傳聞交易對價落在 280 億至 320 億美元區間。後來交易沒有成局，但外界對 RevMed 的想像反而更強。因為當一家 Biotech 已經被默沙東這種等級的大藥廠認真看過，市場自然會問： 它到底是下一個被併購標的？ 還是下一個獨立長大的 Biopharma？ RevMed CEO Mark Goldsmith 最近接受訪問時，態度其實很清楚：公司確實和多家藥廠有過溝通，但被收購不是當下優先事項。 這句話背後的意思，不是 RevMed 不知道自己值錢，而是它認為自己還沒到該把未來一次賣掉的時候。這在過去的 Biotech 世界裡，並不常見。以前，一家臨床階段 Biotech 做出漂亮資料，最常見的結局是被 Big Pharma 收走。因為自己做 Phase 3、自己做全球法規、自己建商業團隊，太貴、太慢、太冒險。 但 RevMed 似乎不想走這條老路，它想自己長大。 01｜RevMed 為什麼不急著賣？ RevMed 不急，第一個原因是手上有錢。 2025 年 6 月，RevMed 和 Royalty Pharm"},{"title":"Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html","date":"2026-07-02","lang":"en","category":"商業分析系列","tags":["synthetic lethality","PARP","PRMT5","MTAP","RAS","oncology","biomarkers","Taiwan biotech","drug development"],"summary":"PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.","key_points":[],"excerpt":"Synthetic lethality was once one of the cleanest and most elegant stories in precision oncology. In 2005, two landmark papers in Nature pushed the BRCA/PARP relationship into the spotlight. In 2014, olaparib, marketed as Lynparza, became the first drug to bring the synthetic lethality concept into clinical practice and commercial success. PARP inhibitors then expanded across ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, and other tumor types. They became one of the best-known examples of precision medicine. Market research groups estimate that the global PARP inhibitor mar"},{"title":"合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html","date":"2026-07-02","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。","key_points":[],"excerpt":"合成致死，曾經是精準腫瘤治療裡最漂亮的故事之一。 2005 年，《Nature》兩篇經典研究把 BRCA／PARP 這組關係推上舞台。 2014 年，olaparib（Lynparza，奧拉帕利）獲准上市，成為第一個真正把合成致死機制推進臨床、並做成商業成功的藥物。 此後，PARP 抑制劑陸續拓展到卵巢癌、乳癌、攝護腺癌與胰臟癌等癌種，成為精準醫療的重要代表。市場研究機構估計，全球 PARP inhibitor，也就是 PARP 抑制劑市場，2026 年規模約 85.7 億美元，2033 年可達 158.7 億美元。 這個故事太成功，也讓全球藥廠產生一個巨大期待：既然 BRCA／PARP 可以，為什麼不能再找到下一個 PARP？ 於是，過去二十年，產業開始瘋狂尋找新的合成致死配對。ATR、ATM、CHK1、CHK2、WEE1、DNA-PK、USP1、POLQ、WRN、PRMT5、MAT2A，一個又一個靶點被推到台前。臨床試驗數量快速增加，資本與 BD，也就是商務開發與授權交易，也跟著湧入。有研究整理指出，合成致死相關臨床試驗已超過 1200 項。 但現實很冷： PARP 之後，還沒有第二個全新合成致死靶點真正跑出上市重磅藥。 這條賽道理論上很美，臨床上卻走得很慢。問題不在於合成致死錯了，而是 BRCA／PARP 的成功太完美，完美到很難複製。 01｜合成致死為什麼迷人？因為它只打癌"},{"title":"Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html","date":"2026-07-01","lang":"en","category":"商業分析系列","tags":["ADHD","centanafadine","Otsuka","clinical data","neuroscience","non-stimulant ADHD therapy","Taiwan biotech","drug development"],"summary":"Otsuka’s centanafadine has reported positive Phase 3b data in adults with ADHD and comorbid anxiety. The FDA has accepted the NDA and granted priority review, making the program a useful lens for how ADHD treatment is shifting from behavioral stigma toward more precise neurobiological intervention.","key_points":[],"excerpt":"Attention-deficit/hyperactivity disorder, or ADHD, has just produced an important late-stage clinical update. The public conversation around discipline, school behavior, and “tough education” often creates a tempting but dangerous illusion: if a child is disruptive, inattentive, impulsive, or unable to sit still, the answer must be stricter control. That logic may feel emotionally satisfying in drama. In real life, it can easily turn into harm. Many children who are labeled disobedient, rebellious, lazy, or intentionally difficult are not morally defective. They may be struggling with a neurod"},{"title":"摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html","date":"2026-07-01","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","ADHD","centanafadine","Otsuka","臨床數據","神經科學","美時","瑩碩生技"],"summary":"Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。","key_points":[],"excerpt":"注意力不足過動症（ADHD）三期臨床成功。 最近，一部以韓國「鐵拳教育」為題的影劇引發討論。 劇中用雷霆手段整頓校園亂象，看得觀眾一時痛快。可一旦把戲劇裡的爽感搬進現實，後果往往不是正義，而是誤傷。現實裡，很多被貼上「不聽話」、「叛逆」、「故意搗蛋」標籤的孩子，並不是品行壞，也不是欠管教，而是可能正被一種神經發展疾病困住。 這個疾病叫 ADHD，也就是注意力不足／過動症。 ADHD 不是孩子懶惰，不是家長沒教好，更不是靠打罵就能「矯正」的行為問題。它牽涉大腦前額葉、注意力控制、衝動抑制、工作記憶、情緒調節與獎賞系統。當大腦的神經傳導訊號不夠穩，孩子就可能表現出分心、坐不住、衝動、拖延、情緒爆衝、無法完成任務。 可惜的是，社會常常先看見行為，卻看不見病因。於是，有些孩子被罵成問題學生，被送進高壓管教環境，被迫承受本不該落在他們身上的「鐵拳」。 真正該被打碎的，不是孩子，而是對 ADHD 的無知與偏見。也就在這樣的背景下，ADHD 藥物研發傳來一個重要進展。 Otsuka 旗下在研新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期臨床試驗積極結果。若順利獲 FDA 批准，centanafadine 將成為 ADHD 治療領域中首個獲批的 norepinephrine、dopamine、serotonin reuptake inhibitor，也就是同時抑制正"},{"title":"GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html","date":"2026-06-30","lang":"en","category":"商業分析系列","tags":["GSK","Nuvalent","Oncology","Lung cancer","ROS1","ALK","BD","M&A","Biotech investing","Big Pharma"],"summary":"GSK's $10.6 billion all-cash acquisition of Nuvalent is more than a late-stage lung-cancer pipeline deal. It is a strategic attempt to rebuild oncology, buy time before major revenue pressure, and regain a seat at the precision-oncology table.","key_points":[],"excerpt":"GSK has clearly raised the intensity. In June 2026, GSK announced a $10.6 billion all-cash acquisition of Nuvalent, offering $124 per share. This is not a small bolt-on transaction. It is one of the clearest moves yet by new CEO Luke Miels to put GSK back into the oncology conversation with assets that are close enough to launch to matter commercially. According to GSK, the deal brings in two late-stage non-small cell lung cancer drugs already under FDA review, zidesamtinib and neladalkib, plus an earlier HER2 inhibitor, NVL-330. After adjusting for Nuvalent's cash on hand, GSK's effective inv"},{"title":"GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌","url":"https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html","date":"2026-06-30","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","疫苗","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。","key_points":[],"excerpt":"GSK 這次真的上強度了。 2026 年 6 月，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元。這筆交易不是小修小補，而是新任 CEO Luke Miels 上任後，替 GSK 腫瘤版圖打下的一記重拳。GSK 官方表示，這筆交易包含兩款已進入 FDA 審查的後期非小細胞肺癌藥物 zidesamtinib 與 neladalkib，以及早期 HER2 抑制劑 NVL-330。扣除 Nuvalent 帳上現金後，GSK 的實際投資約 94 億美元。 這不是 GSK 平常「舒適區」裡的交易。年初 GSK 還被市場解讀為偏好 20 億到 40 億美元規模的補強型收購，結果 6 月直接端出百億美元級別併購。 市場一開始有些消化不良：Nuvalent 股價大漲，GSK 股價下跌。 這反映的不是交易沒有邏輯，而是投資人要重新評估一件事：GSK 是否準備從過去相對保守的研發與併購節奏，轉向更積極的「腫瘤重建模式」？ 答案看起來是肯定的。 01｜GSK 買的不是一家公司，而是兩個即將上市的肺癌入口 Nuvalent 最值錢的資產，是兩款下一代非小細胞肺癌標靶藥。 第一款是 zidesamtinib，一款新一代 ROS1 抑制劑。 ROS1 陽性非小細胞肺癌患者比例不高，但這類患者通常有明確驅動基因，對標靶治療依賴度高，用藥週期也可能很長。Zidesamti"},{"title":"The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors","url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html","date":"2026-06-29","lang":"en","category":"商業分析系列","tags":["Biotech IPO","Parabilis Medicines","Helicons","Zolucatetide","Wnt beta-catenin","Regeneron","Biotech investing","Capital markets"],"summary":"Parabilis Medicines' record-setting US biotech IPO is not a sign that speculative biotech is back. It shows that investors are willing to fund high-risk innovation when the platform, clinical asset, external validation, and capital-market window all line up.","key_points":[],"excerpt":"Parabilis Is Giving the Market a Lesson Taiwan's biotech sector is still struggling through a weak capital-market cycle. In the United States, however, the biotech market has just produced a striking contrast. On June 10, 2026, Parabilis Medicines listed on Nasdaq under the ticker PBLS. The company originally planned to raise roughly US$475 million. The offering was upsized to US$670 million, making it one of the largest biotech IPOs in US market history. Its first-day trading performance was also strong, suggesting that public-market appetite for selected clinical-stage platform companies is "},{"title":"美股迎來史上最大 Biotech IPO","url":"https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html","date":"2026-06-29","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。","key_points":[],"excerpt":"Parabilis 給市場上的一堂課 台股生技板塊還在低谷裡掙扎，美股生技市場卻突然打出一個極端反差。 2026 年 6 月 10 日，Parabilis Medicines 正式登陸 Nasdaq，股票代號 PBLS。 這家公司原本計畫募集約 4.75 億美元，最後 IPO 規模上修至 6.7 億美元，成為美股史上最大 Biotech IPO 之一。上市首日股價也大幅上漲，顯示公開市場對這類臨床階段平台型公司的風險胃口正在回溫。有趣的是，市場到現在也很難用一句話解釋：為什麼偏偏是 Parabilis 創下紀錄？ 它還沒有產品上市，核心藥物 zolucatetide 也還在臨床開發中，距離真正商業化仍有距離。從傳統財務角度看，Parabilis 不是一家已經有穩定現金流的藥廠，而是一家高度仰賴臨床資料與平台想像的 Biotech。但這正是它的代表性。Parabilis 的 IPO 說明，美股生技市場並不是不買創新藥了，而是更挑剔了。市場不再願意為空泛概念買單，卻仍然願意為「技術差異清楚、靶點邏輯明確、臨床資料已有初步驗證、管線延展性可被理解」的公司支付高估值。 換句話說，資本沒有離開 Biotech。 它只是從「故事驅動」轉向「臨床與資產邏輯驅動」。 01｜Parabilis 到底在做什麼？不是小分子，也不是抗體，而是 Helicons Parabilis 的核心技術是 Helic"},{"title":"The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html","date":"2026-06-28","lang":"en","category":"商業分析系列","tags":["FDA","Biotech rebound","Regulatory risk","Rare disease","Gene therapy","mRNA vaccines","M&A","Capital markets"],"summary":"Biotech’s recent rebound is not only a risk-on trade. FDA review signals, rare-disease flexibility, mRNA vaccine momentum, and renewed pharma M&A are changing how investors price clinical-stage assets.","key_points":[],"excerpt":"The mood around US biotech has changed. The XBI, the SPDR S&P Biotech ETF that represents many small and mid-cap biotech companies, has been moving strongly, and capital has started to flow back into the sector. In a world where interest rates have not fully relaxed and high-risk assets are still vulnerable to discount-rate pressure, biotech should not be an easy group to own. Yet the market has begun to buy the sector again. This is not just a simple “oversold rebound.” The more important change is that regulatory signals and pharma M&A activity are improving at the same time. Market reports "},{"title":"FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起","url":"https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html","date":"2026-06-28","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","疫苗","感染症","BD","臨床數據","生技投資"],"summary":"代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。","key_points":[],"excerpt":"最近美國生技股的氣氛，明顯不一樣了。 代表中小型 Biotech 的 XBI（SPDR S&P Biotech ETF）近期走勢強勁，資金也重新流入。照理說，在利率仍未完全放鬆、風險資產仍會被折現率壓制的環境下，高波動的 Biotech 不應該是最輕鬆的族群。但市場卻開始重新買回這個板塊，背後不是單純「跌深反彈」，而是監管風向與併購節奏同時出現變化。市場資料顯示，XBI 在過去 13 個月大漲逾九成，2026 年以來也有明顯漲幅，部分原因來自資金回流與 M&A 熱度升高。 真正的關鍵，出在 FDA。 過去一段時間，美國 FDA 經歷高層人事震盪，罕見疾病、基因療法、疫苗與加速核准標準都被市場反覆檢視。但最近幾個案例顯示，FDA 正從此前偏嚴、偏保守、甚至被業界認為「標準忽左忽右」的狀態，逐步轉向更務實、更願意溝通的路線。 對 Biotech 來說，這不是小事。 因為一家臨床階段公司最怕的，從來不只是試驗失敗，而是明明有資料，卻被監管路徑卡住； 明明患者族群很小，卻被要求做幾乎不可能完成的大型隨機對照試驗；明明前一次會議溝通過可行，下一次又被推翻重來。當 FDA 開始釋放更開放的訊號，很多原本被壓在谷底的 Biotech，估值邏輯就會重新被市場計算。 01｜Operation TrialBlazer：FDA 正在告訴市場，審評效率會被重新重視 6 月 22 日，美國 FDA 宣布 O"},{"title":"Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html","date":"2026-06-27","lang":"en","category":"商業分析系列","tags":["Pancreatic Cancer","RAS","PRMT5","MAT2A","Synthetic Lethality","Clinical Data","Biotech Investing","BD"],"summary":"Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.","key_points":[],"excerpt":"Pancreatic cancer, often treated as one of oncology's hardest tumors, is entering an unusually dense period of therapeutic progress. The first signal came from Revolution Medicines' daraxonrasib. In the RASolute-302 study, the RAS inhibitor nearly doubled overall survival in previously treated metastatic pancreatic ductal adenocarcinoma. Median overall survival reached 13.2 months with daraxonrasib, compared with 6.6 to 6.7 months for chemotherapy. For a tumor type that has lacked truly effective options for years, that is already enough to change how clinicians and investors think about the t"},{"title":"胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html","date":"2026-06-27","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","胰臟癌","RAS","PRMT5","MAT2A","臨床數據","生技投資","BD"],"summary":"胰臟癌正在進入 RAS 抑制劑與 PRMT5／MAT2A 合成致死聯合療法的新階段，市場開始重新評估 daraxonrasib 作為治療骨架的價值。","key_points":[],"excerpt":"「癌王」胰臟癌，正在進入少見的突破密集期。 先是 Revolution Medicines 的 daraxonrasib 在 RASolute-302 研究中，讓既往治療過的轉移性胰臟導管腺癌患者整體存活期幾乎翻倍。 研究顯示，daraxonrasib 組中位整體存活期達 13.2 個月，化療組為 6.6 至 6.7 個月。 這對長期缺乏有效治療的胰臟癌而言，已經是足以改寫臨床路徑的資料。 但更大的驚喜，來自 Tango Therapeutics 和 Revolution Medicines 的聯合療法。 Tango 的 vopimetostat 聯合 daraxonrasib，用於 MTAP 缺失、RAS 突變的轉移性胰臟癌患者，在早期 Phase 1/2 研究中交出驚人訊號： 12 名可評估患者中，客觀緩解率達 92%。 疾病控制率達 100%。 6 個月無惡化存活率達 90%。 中位無惡化存活期尚未達到。 這組資料樣本很小，還不能直接下結論。 但它已經足以讓市場重新思考： RAS 抑制劑真正的價值，可能不只是單藥，而是成為胰臟癌聯合療法的核心骨架。 01｜為什麼 Vopimetostat + Daraxonrasib 這麼震撼？ 胰臟癌的治療難，不只在於發現晚、進展快，也在於 KRAS 突變比例極高，且腫瘤微環境非常複雜。Daraxonrasib 已經證明 RAS 可以被有效"},{"title":"Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path?","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html","date":"2026-06-26","lang":"en","category":"商業分析系列","tags":["GLP-1","tirzepatide","Zepbound","Taltz","Omvoh","immunometabolism","autoimmune disease","psoriasis","IBD","Eli Lilly","biotech investing"],"summary":"Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.","key_points":[],"excerpt":"Tirzepatide is usually discussed as an obesity and diabetes drug. But Lilly's next strategic question may be larger: can a metabolic therapy become part of the treatment architecture for immune-inflammatory diseases? The reason this matters is simple. Autoimmune and inflammatory diseases are chronic. Psoriasis, psoriatic arthritis, inflammatory bowel disease, asthma, atopic dermatitis, and rheumatoid arthritis do not behave like short-course infections. Patients often remain inside the treatment system for years. That makes the market large, sticky, and commercially valuable. 1. Zepbound plus "},{"title":"神藥 猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？","url":"https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html","date":"2026-06-26","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。","key_points":[],"excerpt":"Tirzepatide 進軍自體免疫，只差臨門一腳：GLP-1 的下一個戰場，可能不是減重，而是免疫發炎 自體免疫疾病，一直是全球製藥業最肥沃、也最難攻下的戰場之一。 它不像急性感染，用藥幾天或幾週就結束。類風濕性關節炎、乾癬、乾癬性關節炎、發炎性腸道疾病、氣喘、異位性皮膚炎，這些疾病往往跟著患者一輩子。 用藥時間長，換藥路徑清楚，醫師黏著度高，支付體系也早已習慣為有效的免疫藥物買單。這也是為什麼自體免疫疾病能孕育出 Humira（adalimumab，阿達木單抗）這種史詩級藥王，也能讓 Skyrizi（risankizumab，瑞莎奇珠單抗）、Rinvoq（upadacitinib，烏帕替尼）、Taltz（ixekizumab，依奇珠單抗）、Dupixent（dupilumab，度普利尤單抗）這些產品持續放大。 但現在，這個長期由 TNF、IL-17、IL-23、JAK、IL-4R 等傳統免疫通路主導的市場，出現了一個跨界者。 它不是傳統免疫藥。 它來自代謝領域。 它就是 Eli Lilly 的 tirzepatide，商品名包括糖尿病用的 Mounjaro，以及肥胖治療用的 Zepbound。 過去，tirzepatide 的故事很清楚：它是 GLP-1／GIP 雙重受體促效劑，用來治療第二型糖尿病與肥胖。 現在，Lilly 正在把它推進自體免疫疾病的邊界。 這不只是多一個適應"},{"title":"Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet","url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html","date":"2026-06-25","lang":"en","category":"商業分析系列","tags":["Business Analysis","Protect Biotech","Companion Animal Medicine","Pet Precision Medicine","Platform Company","Biotech Investing","Roche","Animal Health"],"summary":"As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is whether a platform company can connect drugs, diagnostics, veterinary clinics, regulation, manufacturing, channels, and data into one defensible system.","key_points":[],"excerpt":"As companion animals age and owners become more willing to pay for serious-disease care, the next major question in pet medicine is no longer whether people will spend money on their pets. They already do. The more important question is whether any company can build the first true platform for severe companion-animal diseases: a system that connects drugs, diagnostics, veterinary clinics, regulation, GMP manufacturing, commercial channels, and clinical data feedback. That is why Taiwan’s Protect Biotech (7850) is worth reading through a more ambitious lens. Roche is not simply a large pharmace"},{"title":"邁向「寵物醫療界羅氏」的寶泰生醫","url":"https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html","date":"2026-06-25","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","寶泰生醫","寵物醫療","羅氏","平台型公司","生技投資","製藥巨頭"],"summary":"當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。","key_points":[],"excerpt":"當毛孩高齡化趨勢推動癌症、心臟病與自體免疫等重症治療的需求升級，市場的長期觀察核心，在於誰能率先打造一座寵物重症新藥平台，成為『寵物醫療界羅氏』。而這一改寫行業格局的答案，正於台灣的一家生技公司加速浮現。 羅氏（Roche）不是一家普通的大藥廠。 這家超過百年歷史的全球醫療巨頭，真正厲害的地方，不只是擁有許多重磅藥物，而是把製藥、診斷、研發、臨床開發、法規、全球商業化與疾病管理串成一個完整系統。也因為如此，羅氏在人類醫療市場中扮演的角色，早已不只是「賣藥的公司」，而是具備「診斷伴隨治療」與「全生命週期管理」能力的平台型醫療公司。 這才是羅氏真正的核心壁壘與估值溢價來源。 但有趣的是，相較於人類醫療早已誕生如羅氏般的平台型巨頭，全球寵物醫療領域迄今仍缺乏同等量級的整合者。 隨著毛孩高齡化、寵物擬人化與飼主醫療支付意願的顯著提升，寵物醫療正在從食品保健、疫苗與基礎用藥，加速跨入癌症、心臟病、自體免疫、慢性病與老年照護等重症治療領域。在此市場升級的關鍵點，尚無企業能將『寵物新藥、診斷檢測、獸醫臨床、法規轉譯、GMP製造、商業通路與臨床數據回流』完整串聯，形成具備高度防禦力的商業閉環。 那麼，誰有機會填補這個缺口？ 台灣登錄興櫃的寶泰生醫（7850），正以其獨特的商業模式回答這個問題。 寶泰生醫真正值得市場重新理解的地方，不只是它有 PT001、PT401 等寵物新藥管線，更在於它正在建構"},{"title":"Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html","date":"2026-06-24","lang":"en","category":"商業分析系列","tags":["AI drug discovery","zasocitinib","Takeda","Sotyktu","TYK2","psoriasis","PASI 100","Schrodinger","biotech investing","Big Pharma"],"summary":"Takeda's zasocitinib beat Sotyktu in a head-to-head Phase 3 psoriasis study, turning AI-enabled drug design into a real commercial test.","key_points":[],"excerpt":"For years, AI drug discovery has produced beautiful slides and ambitious claims. The market has been waiting for something more concrete: a molecule that survives real clinical competition. Takeda's zasocitinib is now entering that exam. In a Phase 3 psoriasis study, the oral TYK2 inhibitor showed superiority over Sotyktu in a head-to-head comparison. That does not automatically make it a blockbuster, but it does make the asset one of the clearest tests of whether AI-assisted design can translate into clinical and commercial value. 1. In psoriasis, the bar has moved higher The old benchmark in"},{"title":"AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu","url":"https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html","date":"2026-06-24","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","臨床數據","生技投資","製藥巨頭"],"summary":"過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizu…","key_points":[],"excerpt":"武田製藥闖入一場大考：Zasocitinib 頭對頭打敗 Sotyktu 乾癬治療的門檻，正在被快速拉高。 過去，口服藥在中重度乾癬市場裡，常常扮演的是「方便但療效有限」的角色。真正能把皮膚清得很乾淨的，仍然是 Skyrizi（risankizumab，瑞莎奇珠單抗）、Tremfya（guselkumab，古塞奇尤單抗）、Cosentyx（secukinumab，司庫奇尤單抗）、Taltz（ixekizumab，依奇珠單抗）這些生物製劑。 但這個格局正在鬆動。 先是 Johnson & Johnson 的 Icotyde（icotrokinra，口服 IL-23 受體拮抗劑）在 2026 年 3 月獲 FDA 核准，成為第一款口服 IL-23 受體拮抗劑，用於中重度斑塊型乾癬。這款藥的意義不是只有「又多一個口服選項」，而是直接把口服乾癬藥物的療效標準推向更高層級。FDA 核准 Icotyde 用於成人與 12 歲以上、體重至少 40 公斤的中重度斑塊型乾癬患者，也讓市場重新思考：如果口服藥能接近生物製劑，患者會不會重新選擇？ 緊接著，Takeda 的 Zasocitinib（TAK-279，口服 TYK2 抑制劑）又把火燒得更旺。6 月，Takeda 公布 Zasocitinib 在 LATITUDE Atlas 頭對頭 Phase 3 試驗中的結果。這是一項直接對比 BMS 已上"},{"title":"The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk?","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html","date":"2026-06-22","lang":"en","category":"商業分析系列","tags":["Obesity medicine","GLP-1","Eli Lilly","Novo Nordisk","Pfizer","Roche","AstraZeneca","Regeneron","Biotech investing","Capital markets"],"summary":"Lilly and Novo Nordisk dominate the first phase of the obesity-drug market. The next investment question is who can become the third major player by solving the problems GLP-1 leaders have not fully solved.","key_points":[],"excerpt":"This year's ADA, the American Diabetes Association's annual meeting, reignited the obesity-drug battlefield. Five years ago, Novo Nordisk used the STEP program for semaglutide to move GLP-1 drugs from diabetes control into obesity treatment. Four years ago, Eli Lilly counterattacked with tirzepatide's SURMOUNT-1 data and forced the market to accept a new reality: weight-loss drugs were no longer limited to modest body-weight reduction. They could approach levels that previously belonged only to bariatric surgery. The first round now has a clear answer: Lilly and Novo Nordisk have built a duopo"},{"title":"減重藥「第三名」爭奪戰：禮來 與 諾和諾德 之外，誰能成為下一個代謝巨頭？","url":"https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html","date":"2026-06-22","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"今年 ADA，也就是美國糖尿病學會年會，減重藥戰場又一次被點燃。","key_points":[],"excerpt":"今年 ADA，也就是美國糖尿病學會年會，減重藥戰場又一次被點燃。 五年前，Novo Nordisk 在這個舞台上公布 semaglutide（司美格魯肽）的 STEP 系列資料，正式把 GLP-1 類藥物從降血糖推向肥胖治療。四年前，Eli Lilly 用 tirzepatide（GLP-1／GIP 雙重受體促效劑）的 SURMOUNT-1 資料反攻，讓市場第一次意識到，減重藥不只可以做到 10% 以上，甚至可以逼近過去只有減重手術才做得到的區間。如今局面已經完全不同。 第一輪戰爭，答案很清楚：Lilly 與 Novo Nordisk 形成雙寡頭。 Mounjaro／Zepbound（tirzepatide）已經成為 Lilly 最強成長引擎。2026 年第一季，Mounjaro 銷售額達 87 億美元，Zepbound 美國銷售額達 41 億美元，兩者合計接近 128 億美元，幾乎就是 Lilly 這幾年市值重新定價的核心。Novo Nordisk 則靠 Ozempic／Wegovy／Rybelsus／Wegovy pill（semaglutide）守住龐大的腸泌素藥物帝國。 2025 年底，美國 FDA 核准 Wegovy pill（oral semaglutide，口服 semaglutide），這是第一個用於體重管理的口服 GLP-1 類藥物。2026 年 1 月正式在美國"},{"title":"Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html","date":"2026-06-21","lang":"en","category":"商業分析系列","tags":["Merck","Keytruda","PD-1 VEGF","MK-2010","Oncology","Bispecific antibodies"],"summary":"Merck's more serious positioning of MK-2010 suggests that PD-1/VEGF bispecifics are moving from a watch item to a strategic option in the post-Keytruda oncology landscape.","key_points":[],"excerpt":"Few companies understand PD-1 biology better than Merck. Keytruda has defined the modern immuno-oncology era and remains the foundation of Merck's oncology business. That is exactly why Merck's attitude toward PD-1/VEGF bispecific antibodies matters. For a long time, the company's tone was cautious. The core question was whether the class could turn progression-free-survival improvement into overall-survival benefit. If not, Keytruda's position would remain largely protected. After ASCO 2026, the tone looks different. Merck has given MK-2010, formerly LM-299 from LaNova, a clearer place in its"},{"title":"默沙東 對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近","url":"https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html","date":"2026-06-21","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"在全球腫瘤藥市場裡，很少有一家公司比 Merck（默沙東）更懂 PD-1。","key_points":[],"excerpt":"在全球腫瘤藥市場裡，很少有一家公司比 Merck（默沙東）更懂 PD-1。 也很少有一款藥，比 Keytruda（pembrolizumab） 更能代表過去十年的腫瘤免疫治療。Keytruda 幾乎是現代腫瘤免疫療法的中心。肺癌、黑色素瘤、頭頸癌、胃癌、膀胱癌、腎癌、子宮內膜癌，太多癌種都繞不開它。對 Merck 來說，Keytruda 不只是一款產品，而是整個腫瘤事業的地基。 也正因如此，Merck 對 PD-1／VEGF 雙特異性抗體 的態度，格外值得看。過去一年，Merck 對這類藥物的語氣一直很克制。不是完全否定，但也不急著承認它會改變格局。核心疑問很簡單：PD-1／VEGF 雙抗能不能把無惡化存活期的改善，真正轉化成整體存活期的改善？ 如果只能讓腫瘤晚一點進展，卻不能讓患者活得更久，那它對 Keytruda 的威脅就有限。但 2026 年 ASCO 之後，語氣開始變了。 Merck 在 ASCO 投資人簡報中，給了 MK-2010（LM-299） 這款 PD-1／VEGF 雙抗更清楚的位置。官方簡報中提到，MK-2010 在人體首次研究裡呈現鼓舞性的初步結果，20 mg/kg 每三週一次劑量下，在一線非小細胞肺癌回填隊列中未確認整體反應率為 55%，先前治療過患者為 18%；資料支持它作為單藥與多種聯合療法繼續探索。 這不是 Merck 第一次提到 MK-2010，但這次"},{"title":"Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html","date":"2026-06-20","lang":"en","category":"商業分析系列","tags":["Enlivex","RAIN token","Biotech treasury","Crypto","Capital markets"],"summary":"Enlivex's paper gain from RAIN tokens shows how fragile biotech business models can create unusual treasury stories when operating revenue is absent and capital markets are difficult.","key_points":[],"excerpt":"Enlivex is an unusual biotech case because the headline is not mainly about clinical data. It is about a paper gain linked to RAIN tokens. For a biotech company without meaningful product revenue, a sudden treasury-related gain can attract attention quickly. It changes the balance-sheet discussion, affects investor psychology, and can make the company look financially stronger than its operating business would otherwise suggest. But investors need to separate accounting optics from business fundamentals. A biotech company ultimately creates durable value through clinical evidence, regulatory p"},{"title":"【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】","url":"https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html","date":"2026-06-20","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"一家臨床階段 Biotech，沒有藥品銷售收入，卻在一年內做出 12 億美元級別的淨利。","key_points":[],"excerpt":"一家臨床階段 Biotech，沒有藥品銷售收入，卻在一年內做出 12 億美元級別的淨利。 這聽起來不像生技公司，更像加密貨幣基金。但這正是以色列 Biotech 公司 Enlivex 正在上演的故事。Enlivex 原本是一家臨床階段生技公司，核心管線是 Allocetra™，一款巨噬細胞重編程免疫療法，目前主要聚焦於年齡相關的中重度膝骨關節炎。照傳統 Biotech 劇本，這類公司在產品上市前通常沒有收入，依靠增資、私募、授權或債務融資支撐臨床開發。 但 Enlivex 走了一條非常不尋常的路。 它把大量資本配置到 RAIN token，也就是去中心化預測市場 Rain Protocol 的代幣，並把自己包裝成一家公司同時擁有兩個引擎：一邊是長壽醫學與骨關節炎新藥，一邊是預測市場數位資產國庫。 這讓 Enlivex 成為一個很罕見的案例：一家 Biotech，不靠藥賣錢，先靠代幣公允價值讓財報變漂亮。但這也帶來一個更關鍵的問題：這到底是創新的資本策略，還是把 Biotech 風險疊上加密貨幣風險？ 01｜0 收入，卻做出 12 億美元級淨利 2025 年，Enlivex 公告全年淨利約 12.3 億美元。 但這筆錢不是來自藥品上市，也不是來自授權金，更不是來自產品銷售。主要來源，是公司持有的 RAIN 代幣與相關衍生資產公允價值上升。換句話說，這是一種帳面上的未實現利益。 這裡要"},{"title":"GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases","url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html","date":"2026-06-19","lang":"en","category":"商業分析系列","tags":["GSK","Nuvalent","Lung cancer","Precision oncology","Resistance","Brain metastases"],"summary":"GSK is not merely buying three lung-cancer pipelines. It is buying a next-generation precision-oncology strategy around resistance, CNS activity, and cleaner kinase inhibition.","key_points":[],"excerpt":"GSK's agreement to acquire Nuvalent for roughly US$10.6 billion should not be read as simply buying three lung-cancer pipelines. The deeper logic is more specific: GSK is buying a position in the next phase of precision oncology. Lung cancer has already been transformed by targeted therapies. EGFR, ALK, ROS1, MET, RET, NTRK, and other drivers have turned subsets of non-small cell lung cancer into molecularly defined markets. But targeted therapy creates its own next problem. Patients respond, then resistance emerges. Many also develop or already have brain metastases, which require drugs that "},{"title":"GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法","url":"https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html","date":"2026-06-19","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資"],"summary":"2026 年 6 月 9 日，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元，較 Nuvalent 前一交易日收盤價溢價約 40%。這是 GSK 近年最大型的腫瘤併購之一，也讓它瞬間補上肺癌精準治療版圖中最缺的一塊。","key_points":[],"excerpt":"GSK 這次出手很重。 2026 年 6 月 9 日，GSK 宣布以 106 億美元全現金收購 Nuvalent，收購價格為每股 124 美元，較 Nuvalent 前一交易日收盤價溢價約 40%。這是 GSK 近年最大型的腫瘤併購之一，也讓它瞬間補上肺癌精準治療版圖中最缺的一塊。 這筆交易的核心，是三款非小細胞肺癌標靶藥物：Zidesamtinib（NVL-520），新一代 ROS1 抑制劑；Neladalkib（NVL-655），新一代 ALK 抑制劑；以及 NVL-330，針對 HER2 突變的早期小分子抑制劑。 其中 Zidesamtinib 與 Neladalkib 都已經進入美國 FDA 上市審查階段。Zidesamtinib 的審查目標日是 2026 年 9 月 18 日，Neladalkib 則是 2026 年 11 月 27 日。換句話說，GSK 買的不是一個還停在概念階段的早期平台，而是兩款距離商業化僅一步之遙的後期肺癌資產。 這也是這筆交易最有意思的地方。 GSK 不是為了追逐全新靶點，而是回到已經被充分驗證的肺癌驅動基因：ROS1、ALK、HER2。但它買的不是「老靶點的普通跟隨者」，而是在老靶點裡，專門解決兩個仍然困住臨床的難題： 耐藥突變。 腦轉移。 這才是 Nuvalent 值 106 億美元的真正理由。 01｜Nuvalent 的選擇：不搶新靶點，而"},{"title":"GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html","date":"2026-06-17","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","肥胖藥","Ecnoglutide","Wegovy","輝瑞","諾和諾德","臨床數據","生技投資"],"summary":"ADA 2026 剛落幕，GLP-1 賽道又被一組頭對頭資料點燃。Ecnoglutide 在 20 週減重數字上勝出，但真正的競爭不只看短期體重下降，而是長期健康結局、耐受性、產品矩陣與全球商業化。","key_points":[],"excerpt":"【Ecnoglutide 贏了 20 週數字，但真能撼動 Wegovy 王座嗎？】 ADA 2026 剛落幕，GLP-1 賽道又被一組「頭對頭」資料點燃。 這次站上擂台的，是 ecnoglutide（先維盈） 與 Wegovy（semaglutide）。 Ecnoglutide 是一款偏向性 GLP-1 受體促效劑，已在獲准用於成人超重或肥胖患者的長期體重管理，用於配合飲食控制與增加身體活動，進行成人體重管理。 真正引發討論的，是一項名為 SLIMMER-UP-SWITCH 的二期頭對頭研究中期分析。 在 20 週時，ecnoglutide 的平均體重降幅為 12.8%，Wegovy（semaglutide）為 9.5%。兩者都是每週一次、2.4 mg 維持劑量。研究也顯示，ecnoglutide 組有 74% 受試者達到至少 10% 體重下降，而 Wegovy 組為 40%。 這樣的數字很容易讓市場興奮。 「挑戰者打贏藥王」、「Pfizer 撬動 Novo Nordisk 王座」、「新一代 GLP-1 正面擊敗 semaglutide」——這些標題都很吸睛。 但如果把這組資料放回臨床研究與產業競爭的框架裡，就會發現事情沒有那麼簡單。一項 163 人、開放標籤、20 週中期分析的二期研究，確實提供了一個值得重視的訊號。但它還遠遠不足以改寫整個 GLP-1 市場。 真正的勝負，不在 "},{"title":"Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King","url":"https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html","date":"2026-06-17","lang":"en","category":"商業分析系列","tags":["GLP-1","Ecnoglutide","Wegovy","Pfizer","Novo Nordisk","Obesity medicine"],"summary":"Ecnoglutide's head-to-head weight-loss data versus semaglutide are interesting, but the GLP-1 race will be decided by long-term outcomes, tolerability, labels, supply, and global evidence.","key_points":[],"excerpt":"ADA 2026 gave the GLP-1 market another headline: ecnoglutide showed stronger 20-week weight loss than Wegovy in an interim Phase 2 head-to-head study. That is a meaningful signal. In the SLIMMER-UP-SWITCH study, ecnoglutide produced average weight loss of 12.8% at 20 weeks versus 9.5% for semaglutide. Both were given weekly at a 2.4 mg maintenance dose. A higher share of ecnoglutide patients also reached at least 10% weight loss. The data are interesting, but they are not enough to declare a new GLP-1 winner. This was a Phase 2, open-label, interim analysis with 163 participants. In obesity tr"},{"title":"Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies?","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html","date":"2026-06-16","lang":"en","category":"商業分析系列","tags":["Eli Lilly","Vaccines","M&A","Prevention medicine","Obesity medicine"],"summary":"Lilly's vaccine acquisitions show that the company is using obesity-drug cash flow to widen its long-term disease-prevention and immunology strategy.","key_points":[],"excerpt":"Eli Lilly is known today as one of the two dominant forces in obesity medicine. Mounjaro and Zepbound have turned incretin biology into one of the most important growth engines in global pharma. That is exactly why Lilly's vaccine acquisitions deserve attention. At first glance, vaccines look far away from obesity drugs. But from a capital-allocation perspective, the logic is clearer. A company with massive cash flow from metabolic medicine can use that position to buy optionality in areas that may matter for the next decade. The strategic question is not whether Lilly is abandoning obesity. I"},{"title":"禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？","url":"https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html","date":"2026-06-16","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","疫苗","感染症","BD","臨床數據","生技投資","製藥巨頭"],"summary":"市場現在最熟悉的禮來，是 Mounjaro、Zepbound 背後那個 GLP-1 巨頭。2026 年第一季，禮來營收達到 198 億美元，年增 56%，主要動能還是來自 Mounjaro 與 Zepbound 的放量。簡單說，禮來現在手上最強的現金流，是減重與糖尿病藥物。","key_points":[],"excerpt":"禮來這次的動作，看起來有點反直覺。 市場現在最熟悉的禮來，是 Mounjaro、Zepbound 背後那個 GLP-1 巨頭。2026 年第一季，禮來營收達到 198 億美元，年增 56%，主要動能還是來自 Mounjaro 與 Zepbound 的放量。簡單說，禮來現在手上最強的現金流，是減重與糖尿病藥物。 但就在這個時候，禮來一口氣宣布要買三家疫苗公司：Curevo、LimmaTech Biologics、Vaccine Company。三筆交易的潛在總金額最高大約 38.3 億美元。 這不是小錢，也不是單純補一條管線。 禮來買的不是熱門的癌症藥，也不是下一個 GLP-1，而是三個方向都很不一樣的疫苗平台：帶狀疱疹、抗藥性細菌感染、EBV 病毒。 表面上看，這像是禮來突然想回到感染症市場。可是如果把三家公司放在一起看，邏輯其實很清楚：禮來不是在追疫苗題材，而是在買「預防疾病源頭」的長線入口。 01｜禮來買 Curevo：不是挑戰 Shingrix，而是挑戰疫苗接種率 第一家公司 Curevo，核心資產是 amezosvatein，一款用於預防帶狀疱疹的佐劑型次單位疫苗。 帶狀疱疹不是小市場。GSK 的 Shingrix 已經是非常成功的疫苗，保護力也很強。但問題在於，Shingrix 的副作用體感不輕，很多人打完會有疲倦、發冷、注射部位疼痛，甚至因為第一劑反應太強而猶豫第二劑。"},{"title":"ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html","date":"2026-06-15","lang":"en","category":"醫學大會","tags":["ASCO","Oncology","RAS","ADC","PD-1 VEGF","In vivo CAR-T"],"summary":"ASCO 2026 showed that oncology is moving from single-mechanism breakthroughs toward platform combinations across RAS targeting, ADCs, PD-1/VEGF bispecifics, and in vivo CAR-T.","key_points":[],"excerpt":"The most important winner at ASCO 2026 was not a single drugmaker. It was the idea that several impossible-looking oncology problems are becoming clinically testable. The meeting showed a broader shift in cancer therapy. Oncology is no longer advancing through one mechanism at a time. RAS inhibitors, antibody-drug conjugates, PD-1/VEGF bispecific antibodies, in vivo cell engineering, and new combination strategies are all moving at once. For investors, that means the competitive map is becoming more complex and more platform-driven. The most striking data came from Revolution Medicines. Daraxo"},{"title":"2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代","url":"https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html","date":"2026-06-15","lang":"zh-Hant","category":"醫學大會","tags":["醫學大會","免費文章","ASCO","腫瘤治療","CAR-T","RAS","ADC","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年美國臨床腫瘤學會年會，也就是 ASCO，最該被記住的贏家，並不是任何一家藥廠，而是癌症患者。","key_points":[],"excerpt":"2026 年美國臨床腫瘤學會年會，也就是 ASCO，最該被記住的贏家，並不是任何一家藥廠，而是癌症患者。 這句話聽起來很大，但今年的資料確實配得上。 在胰臟癌這個長期被視為「最難治」的癌種裡，兩組資料讓會場氣氛完全不同。尤其是 Revolution Medicines 的 daraxonrasib，在轉移性胰臟癌中讓整體存活期幾乎翻倍，讓「改變臨床實務」這句話不再只是藥廠新聞稿的修辭，而是開始接近真實。Revolution 公布的 Phase 3 RASolute-302 試驗顯示，daraxonrasib 組中位整體存活期達 13.2 個月，化療組為 6.7 個月，死亡風險下降約 60%。 今年 ASCO 的主軸，其實很清楚：腫瘤治療正在從「單一機制突破」，走向「多技術平台同時開火」。 RAS 抑制劑讓胰臟癌看見新標準治療的可能。Keytruda 的王權仍在，但 Merck 也開始用抗體藥物複合體與聯合療法補強後專利懸崖。PD-1／VEGF 或 PD-L1／VEGF 雙特異性抗體，正成為下一代免疫腫瘤最擁擠也最有想像力的戰場。體內 CAR-T 則讓細胞治療第一次看見「不用抽細胞回工廠」的未來。 ADC、雙抗、小分子、體內基因遞送與 RAS 靶向療法，在今年 ASCO 上彼此交錯，讓腫瘤產業的下一輪格局逐漸成形。 這已經不是單純誰的數據比較漂亮，而是誰能代表下一代腫瘤治療平台。 0"},{"title":"Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html","date":"2026-06-14","lang":"en","category":"商業分析系列","tags":["RAS","Revolution Medicines","Daraxonrasib","Biotech financing","Pancreatic cancer","Capital markets"],"summary":"Revolution Medicines shows why next-generation biotech companies need to convert clinical momentum into capital momentum if they want to finish expensive global drug-development races.","key_points":[],"excerpt":"Revolution Medicines is one of the most important biotech stories of 2026 because it sits at the intersection of two forces: a hard scientific problem and an even harder capital-markets problem. The scientific story is RAS-addicted cancer. For decades, RAS was treated as one of oncology's most difficult drug targets. Revolution Medicines has pushed that idea into a different phase with its RAS(ON) inhibitor platform, especially daraxonrasib, also known as RMC-6236. In previously treated metastatic pancreatic ductal adenocarcinoma, the Phase 3 RASolute-302 study showed median overall survival o"},{"title":"Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑","url":"https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html","date":"2026-06-14","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"2026 年，全球最受矚目的 Biotech 之一，毫無疑問是 Revolution Medicines。這家公司站在一個極難、也極誘人的位置：RAS-addicted cancers。","key_points":[],"excerpt":"Revolution Medicines 的千億神話：會研發還不夠，會融資才撐得過新藥長跑 2026 年，全球最受矚目的 Biotech 之一，毫無疑問是 Revolution Medicines。這家公司站在一個極難、也極誘人的位置：RAS-addicted cancers。RAS 曾經長期被視為「難成藥」甚至「不可成藥」靶點，但 Revolution Medicines 透過 RAS(ON) inhibitor 平台，在胰臟癌、肺癌、結直腸癌等高未滿足需求腫瘤裡，逐步把這個故事從科學假說推進到臨床現實。 💰 尤其是 daraxonrasib（RMC-6236）。 這款口服 RAS(ON) multi-selective inhibitor 在 previously treated metastatic pancreatic ductal adenocarcinoma（PDAC）Phase 3 RASolute 302 試驗中，讓患者 median overall survival 達到 13.2 個月，而標準化療組為 6.7 個月，幾乎翻倍；這也是為什麼市場會把 Revolution Medicines 視為下一個可能改寫胰臟癌治療格局的公司。 但今天不只談管線，Revolution Medicines 最值得學的地方，不只是它會研發，而是它非常會融資。新藥開發不是只靠科學理"},{"title":"The Next Phase of AI Drug Development: Making Molecules Survive as Drugs","url":"https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html","date":"2026-06-13","lang":"en","category":"商業分析系列","tags":["AI Drug Development","AnHorn Medicines","AI+PROTAC","AIMCADD","NVIDIA","Clinical Asset Engine","Biotech"],"summary":"AI drug development is moving from molecular generation to clinical survival. AnHorn Medicines shows how AI+PROTAC, experimental feedback, and human translation may form a Taiwan-born clinical-asset engine.","key_points":[],"excerpt":"Why NVIDIA’s repeated recognition of AnHorn points to a Taiwan-born AI+PROTAC clinical-asset engine The first wave of AI-enabled drug discovery rewarded molecular generation. The next wave will reward something much harder: whether those molecules can become drugs. Across the industry, the AI drug-development landscape is being rebuilt. Over the past two years, NVIDIA and major pharmaceutical companies have started building AI Factory infrastructure, while AI-native platforms such as Isomorphic, Iambic, Valo, Relation, and VantAI have raised capital or signed billion-dollar-scale partnerships."},{"title":"AI製藥下半場：讓藥活下來","url":"https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html","date":"2026-06-13","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"AI 醫藥上半場比生成分子，下半場比成藥存活率。安宏真正值得被看見的，不是單純曝光，而是用 AI + PROTAC（蛋白質降解技術）、實驗閉環與人體轉譯，嘗試形成高資本效率的 clinical asset engine（臨床資產生成引擎）。","key_points":[],"excerpt":"輝達 NVIDIA 連續看見安宏背後，台灣 AI + PROTAC 成藥飛輪正在成形 AI 醫藥上半場比生成分子，下半場比成藥存活率。安宏真正值得被看見的，不是單純曝光，而是用 AI + PROTAC（蛋白質降解技術）、實驗閉環與人體轉譯，嘗試形成高資本效率的 clinical asset engine（臨床資產生成引擎）。 全球 AI 醫藥正在重新洗牌。 過去兩年，從 輝達 NVIDIA 與大型藥廠共建 AI Factory，到 Isomorphic、Iambic、Valo、Relation、VantAI 等 AI 原生平台拿下十億美元級交易，市場已經不再只是為「AI 可以生成分子」買單。 大藥廠真正押注的，是一件更核心的事：AI 能不能重構新藥開發流程，讓更多分子更快進入人體，並提高它活過臨床、走向商業化的機率。 這才是 AI 醫藥的下半場。 上半場，比的是模型、算力與生成能力。 下半場，比的是成藥性、人體轉譯與臨床資產生成能力。 因為螢幕上的分子，不是藥。 一個 AI 設計出的分子，要真正成為有價值的資產，必須穿過三道關卡：分子本身要能成藥，疾病生物學要成立，最後還要進入人體，通過安全性、暴露、藥效與臨床訊號的檢驗。所以，AI 醫藥真正值錢的，不是誰能生成更多分子，而是誰能用更少資本、更短時間，把分子推進人體，讓它活成臨床資產。 也正是在這個脈絡下，安宏生醫連續三年進入 NV"},{"title":"Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html","date":"2026-06-12","lang":"en","category":"商業分析系列","tags":["AI drug discovery","Clinical pipelines","Biotech investing","Business development","Drug development","Big Pharma"],"summary":"AI drug discovery has moved beyond the concept stage and into clinical validation. This article reviews Zasocitinib, GB-0895, Zovegalisib, and REC-4881 to examine how different AI strategies are being converted into real drug assets.","key_points":[],"excerpt":"Reading AI Drug Discovery Through Pipelines: Models Are Hot, But the Real Question Is Who Enters the Clinic AI drug discovery has been one of the hottest themes in biotech over the past few years. Large models, generative protein design, multibillion-dollar collaborations, Big Pharma deals, platform financings: every few months, another AI drug discovery story seems to take over the industry conversation. But for investors and industry observers, the most important question is not whether AI drug discovery sounds impressive. The real questions are: Can AI-discovered targets, AI-designed molecu"},{"title":"盤點整理，AI藥物開發走得如何了？","url":"https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html","date":"2026-06-12","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI 製藥","臨床管線","BD","生技投資","藥物開發"],"summary":"AI 製藥已從概念走向臨床驗證。這篇盤點 Zasocitinib、GB-0895、Zovegalisib、REC-4881 等代表管線，拆解不同 AI 路線如何轉化成真正的藥物資產。","key_points":[],"excerpt":"見微知著 AI 製藥管線：模型很熱，但真正要看的是誰走進臨床 AI 製藥這幾年太熱了。 大模型、生成式蛋白設計、數十億美元合作、Big Pharma 交易、平台融資，幾乎每隔一段時間就會刷屏一次。但對投資人和產業界來說，真正重要的問題不是「AI 製藥聽起來厲不厲害」。而是： 📌 AI 找到的靶點、設計的分子、重新定位的藥物，到底能不能走進臨床？ 📌 能不能通過 Phase 2？ 📌 能不能進 Phase 3？ 📌 能不能被 Big Pharma 用真金白銀買走？ 📌 能不能最後變成藥？ 這些問題不能靠概念回答，也不能靠融資金額回答。要看管線。 今天 AI 製藥已經不再只是「會不會成」的哲學辯論，而是進入更務實的階段：誰的 AI 能力真的轉化成臨床資產，誰的資料能被醫師、藥廠、監管與資本市場相信。從這個角度看，幾條代表性管線非常值得拆解。它們背後的 AI 路線完全不同：有的是物理模擬驅動的小分子設計，有的是生成式 AI 抗體設計，有的是蛋白動態與隱性口袋發現，有的是高通量細胞影像與老藥新用。 這些案例可以幫我們看清楚一件事：AI 製藥不是一種技術，而是一組不同解題方法。真正決定價值的，不是用了 AI，而是 AI 解決了哪個傳統研發痛點。 01｜Zasocitinib：用計算化學，把 TYK2 做到 Phase 3 📌 第一個最接近上市門口的案例，是 Zasocitinib"},{"title":"Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital","url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html","date":"2026-06-11","lang":"en","category":"商業分析系列","tags":["Biotech Valuation","Obesity medicine","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"GLP-1 is no longer only a weight-loss topic. It is redirecting biotech capital, BD urgency, manufacturing attention, and valuation imagination across global pharma.","key_points":[],"excerpt":"In the past few years, the most crowded field in the global biotech community has been tumors. PD-1, dual antibodies, ADCs, small molecule targets, and cell therapy are all coming one after another. From large pharmaceutical companies to early stage startups, almost everyone is trying to find ways to squeeze cancer. Because the cancer market is large, the price is high, and the unmet needs are clear, as long as the clinical data is good enough, there is a chance that it will be favored by major international pharmaceutical companies. But now, the market is undergoing a very cruel change, and t"},{"title":"減肥成王：GLP-1 正在把全球生技資本重新洗牌","url":"https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html","date":"2026-06-11","lang":"zh-Hant","category":"商業分析系列","tags":["GLP-1","減肥藥","生技資本","腫瘤管線","BD","代謝疾病"],"summary":"GLP-1 不只是減重藥題材，而是重新配置全球藥廠研發預算、產能投資、BD 談判與生技估值規則的核心變數。","key_points":[],"excerpt":"過去幾年，全球生技圈最擁擠的賽道一直是腫瘤。 PD-1、雙抗、ADC、小分子標靶、細胞治療，一波接一波，從大型藥廠到早期新創，幾乎都在想辦法往癌症裡面擠。因為癌症市場大、定價高、未滿足需求明確，只要臨床數據夠漂亮，就有機會被國際大藥廠看上。 但現在，市場正在出現一個很殘酷的變化，「普通腫瘤管線」的資本吸引力正在快速下降。真正把錢吸走的，不是另一個腫瘤藥，而是 GLP-1。 GLP-1 過去被很多人簡化成「減重藥」或「瘦瘦針」，但這個理解已經太淺。現在的 GLP-1，正在變成全球藥廠重新配置研發預算、產能投資、併購策略與授權談判籌碼的核心變數。 📌 GLP-1 正在造成一場生技資本市場的「抽水效應」。 【藥時事 與 CMoney 全曜財經共同打造減肥藥賽道投資課程】 藥時事團隊深度分析全球 減肥藥市場現況、新藥開發進程、臨床使用情況，並且完整講解了減肥藥物的投資邏輯，以及市場正在著重關注的標的。藥時事團隊的深度課程將能夠讓您成為專業的生技減肥藥專業達人、投資人：[線上課程 - 理財寶｜提供全方位投資線上課程](https://www.cmoney.tw/course-media/17141/intro) 【01｜德勤 7.0% 的漂亮數字，背後其實很不平均】 德勤（Deloitte）最新一版《Measuring the return from pharmaceutical inno"},{"title":"RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War","url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html","date":"2026-06-10","lang":"en","category":"商業分析系列","tags":["Company Research","Biotech business analysis","Drug development"],"summary":"Daraxonrasib opens a new pancreatic-cancer window, but the next value question is resistance management. Senhwa's CX-5461 matters if it can become a rational combination partner.","key_points":[],"excerpt":"RAS Target opens a new situation in pancreatic cancer: Shenghuake CX-5461 is stuck in the next battle of \"drug resistance management\" The treatment of pancreatic cancer is ushering in a long-awaited turning point. For a long time, pancreatic cancer has been almost the most difficult obstacle to overcome among solid tumors: late diagnosis, rapid progression, limited chemotherapy options, and highly immunosuppressive tumor microenvironment have caused many drugs to fail repeatedly. But as RAS targeted therapy began to produce key data, this core driving signal that was considered “undruggable” i"},{"title":"RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰","url":"https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html","date":"2026-06-10","lang":"zh-Hant","category":"商業分析系列","tags":["生華科","CX-5461","Pidnarulex","RAS","胰臟癌","抗藥性","Tislelizumab"],"summary":"Daraxonrasib 打開胰臟癌 RAS 標靶時代後，真正的下一場戰爭是抗藥性管理；生華科 CX-5461 的價值在於能否成為 RAS 標靶後時代的免疫增敏與聯合治療候選策略。","key_points":[],"excerpt":"胰臟癌治療，正在迎來一個久違的轉折。 長久以來，胰臟癌幾乎是實體瘤中最難攻克的高牆：診斷晚、進展快、化療選擇有限，腫瘤微環境又高度免疫抑制，讓許多新藥一再折戟。但隨著 RAS 標靶治療開始跑出關鍵數據，這個過去被視為「不可成藥」的核心驅動訊號，終於被真正撬開。 Revolution Medicines 的 Daraxonrasib 在 RASolute 302 三期試驗中，讓既往接受治療的轉移性胰臟導管腺癌患者，中位總存活期達 13.2 個月，對照化療組為 6.7 個月。對胰臟癌來說，這不是普通進展，而是一個重要里程碑。 因為胰臟癌中，超過九成與 RAS 訊號驅動有關。當 RAS(ON) 抑制劑在三期臨床拿出存活期資料，代表胰臟癌正式從化療主導，走向真正的 RAS 標靶治療時代。 但新的問題也隨之而來。 RAS 抑制劑不是終點。真正的下一場戰爭，是抗藥性。 01｜RAS 被壓下去後，癌細胞會往哪裡逃？ 不論是傳統偏 RAS-off 的抑制策略，或是近年最受矚目的 RAS-on 抑制劑，本質上都是在壓制癌細胞的 RAS 驅動訊號。但胰臟癌最難纏的地方，就是它不只會長，還很會逃。 當 RAS 這條主訊號被關掉後，癌細胞可能透過其他路徑重新找到生路： - MYC 活化。 - KEAP1 / NRF2 抗氧化壓力路徑。 - YAP / TAZ / TEAD 轉錄調控路徑。 - 腫瘤微環境重"},{"title":"Biotech IR Is Not Making Slides Prettier; It Is Turning Pipelines Into Trackable Capital-Market Stories","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story-en.html","date":"2026-06-10","lang":"en","category":"商業分析系列","tags":["IR and Capital Markets","Capital markets","Biotech business analysis","Drug development"],"summary":"Biotech IR is not cosmetic storytelling. Good IR turns clinical, CMC, regulatory, commercial, and financing milestones into a capital-market narrative that investors can actually track.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Biotech companies often fail to communicate because they present data points without explaining why those data points change value. Strong IR translates pipeline progress into an investable sequence of risks, milestones, and valuation drivers. Why It Matters For listed biotech companies, IR is a strategic function. It helps the market understand what to watch, how to interpret clinical and regulatory events, and why the company deserves"},{"title":"生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事","url":"https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html","date":"2026-06-10","lang":"zh-Hant","category":"商業分析系列","tags":["IR","資本市場故事","公開資訊","投資人溝通"],"summary":"好的 IR 內容不是宣傳話術，而是把臨床、CMC、監管、商業化與對標公司轉成投資人可以追蹤的節點。","key_points":[],"excerpt":"很多生醫公司談 IR，第一反應是簡報、新聞稿、活動或社群曝光。 這些都重要，但它們不是核心。 真正的核心是：投資人是否知道公司靠什麼創造價值，以及接下來應該追哪些事件。 投資人不缺資訊，缺的是可採用的結構 生醫公司資訊通常很複雜。臨床設計、CMC、監管路徑、競品、授權案例、醫療未滿足需求，單獨看都能寫成一份長報告。 但資本市場需要的是一個能被理解、被比較、被追蹤的故事。 一個好的 IR 內容應該回答四件事 - 公司核心管線解決哪個未滿足需求。 - 相對競品與對標公司，差異化在哪裡。 - 下一個會改變市場理解的事件是什麼。 - 如果事件兌現，估值模型裡哪個參數應該被調整。 合規邊界很重要 資本市場內容不能建立在未公開重大訊息上。 更穩健的做法，是用公開資訊、公司已公開或確認可使用資料，搭配外部文獻、競品資料與可驗證事件，形成可公開討論的研究內容。"},{"title":"The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era","url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html","date":"2026-06-09","lang":"en","category":"商業分析系列","tags":["BD and Licensing","Radiopharma","Business development","Biotech business analysis","Drug development"],"summary":"Curium's rumored interest in Lantheus is best read as a bid for nuclear-medicine infrastructure: isotope access, hospital channels, imaging workflow, and radiopharma commercialization depth.","key_points":[],"excerpt":"US$7 billion nuclear medicine merger and acquisition rumors: Curium wants to buy Lantheus, but what it really buys is a ticket to the nuclear medicine era The nuclear weapons circuit has dropped another big news in the past few days. According to media reports, Curium Pharma, backed by private equity fund CapVest, is rumored to have made an acquisition offer to Lantheus Holdings, with a potential transaction valuation of approximately US$7 billion. Let me make it clear first that this case is not yet a signed merger and acquisition, and Lantheus is still evaluating various possible sales optio"},{"title":"70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券","url":"https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html","date":"2026-06-09","lang":"zh-Hant","category":"商業分析系列","tags":["Curium","Lantheus","核藥","放射性藥物","併購","PSMA","PYLARIFY"],"summary":"Curium 傳出有意以約 70 億美元收購 Lantheus。這不只是核藥併購傳聞，而是診斷、製造、配送、院端網絡與治療端能力整合的產業訊號。","key_points":[],"excerpt":"核藥賽道這幾天又丟出一顆重磅消息。 媒體報導，私募基金CapVest支持的Curium Pharma，傳出已經向Lantheus Holdings提出收購要約，潛在交易估值大約70億美元。先說清楚，這筆案子目前還不是已經簽約完成的併購，Lantheus也還在評估各種可能的出售方案，所以不能當成定案來看待。 但如果只把它當成「又一筆核藥併購」，其實會漏掉更重要的訊號。這次最值得看的，不只是70億美元這個數字，而是買方Curium自己在2025年資本重組的時候，也被市場估到差不多70億美元。換句話說，這不是大型藥廠拿零用錢去買一家小公司，而是兩個核藥重量級平台之間，可能出現的產業整合。 如果交易最後真的成立，它不只是刷新核藥併購金額的紀錄，更像是在告訴市場一件事：核藥的估值邏輯，已經不再只看「手上有幾條管線」，而是開始看誰能把診斷、製造、配送、院端網絡跟治療端能力，全部串成一個可以真正放大的平台。 01｜Lantheus值錢的，不只是一支前列腺癌PET藥 Lantheus最核心的資產，是PYLARIFY（piflufolastat F 18），一種PSMA PET攝護腺癌影像藥物，主要用途是幫助醫師更精準找到攝護腺癌的病灶。用比較白話的方式講，PYLARIFY做的是「先看清楚癌細胞在哪裡」。在攝護腺癌治療裡面，能不能把病灶看得清楚，直接影響治療策略怎麼選、分期怎麼判斷、後續用藥怎麼走。"},{"title":"CAR-T Enters a New Era: From Blood Cancer to Autoimmune Disease","url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era-en.html","date":"2026-06-08","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","CAR-T","Regulatory risk","Immunology","Biotech business analysis","Drug development"],"summary":"CAR-T's move from blood cancer into autoimmune disease could redefine cell therapy, but the value depends on whether deep immune reset can justify manufacturing complexity, safety risk, and cost.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Autoimmune CAR-T is important because it changes the purpose of cell therapy. The goal is no longer only killing cancer cells, but potentially resetting pathogenic immune memory in diseases such as lupus and other antibody-driven disorders. Why It Matters Investors should focus on durability of remission, steroid-free outcomes, relapse patterns, safety, manufacturing scalability, and whether the therapy can move from elite centers into "},{"title":"CAR-T 迎接新時代：從血癌走向自體免疫","url":"https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html","date":"2026-06-08","lang":"zh-Hant","category":"商業分析系列","tags":["CAR-T","自體免疫","Kyverna","mivocabtagene autoleucel","細胞治療","FDA"],"summary":"Kyverna 啟動 mivocabtagene autoleucel 的 BLA 滾動式提交，象徵 CAR-T 從血癌治療走向自體免疫疾病的新階段，也重新打開細胞治療的商業想像。","key_points":[],"excerpt":"CAR-T 產業正在迎來一個新的標誌性時刻。 2026 年 5 月 12 日，Kyverna Therapeutics 宣布正式向美國 FDA 啟動滾動式提交 mivocabtagene autoleucel（miv-cel／KYV-101） 的 BLA，用於治療 Stiff Person Syndrome（SPS，僵人症候群）。這不只是 Kyverna 自己的里程碑，更是整個細胞治療產業的關鍵轉折：如果順利獲准，miv-cel 將有機會成為全球第一個上市的自體免疫疾病 CAR-T 療法。 🧬 單看 SPS 這個適應症，市場空間其實不大。 它是超罕見神經自體免疫疾病，患者人數有限，短期未必能為 Kyverna 帶來巨大營收。但這件事真正重要的地方，不是 SPS 本身能賣多少錢，而是它象徵 CAR-T 正式從血液腫瘤，走向自體免疫疾病的商業化門口。 過去十多年，CAR-T 最重要的戰場是 B-cell malignancies、multiple myeloma 這類血液腫瘤。Kymriah（tisagenlecleucel）、Yescarta（axicabtagene ciloleucel）、Breyanzi（lisocabtagene maraleucel）、Abecma（idecabtagene vicleucel）、Carvykti（ciltacabtagene autole"},{"title":"Drugmakers Without AI Capability May No Longer Be Called Drugmakers","url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future-en.html","date":"2026-06-07","lang":"en","category":"商業分析系列","tags":["IR and Capital Markets","AI drug discovery","Biotech business analysis","Drug development"],"summary":"AI is becoming a core operating capability for pharma, but its value comes from improving discovery, translation, trial design, and portfolio decisions rather than from marketing language alone.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Drugmakers without real AI capability may struggle because AI is moving from a slide-deck buzzword into the operating system of R&D. The important question is whether AI improves decisions that used to be slow, expensive, and failure-prone. Why It Matters For readers, the test is practical. Does AI help a company choose better targets, design better molecules, run smarter experiments, identify responders, reduce clinical failure, or all"},{"title":"沒有 AI 能力的藥廠，將不再被稱作藥廠","url":"https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html","date":"2026-06-07","lang":"zh-Hant","category":"商業分析系列","tags":["AI","藥廠","新藥研發","製藥產業","數位轉型","商業模式"],"summary":"AI 正在從工具變成製藥公司的底層能力。未來藥廠不只比管線，也會比資料、模型、實驗自動化與決策速度，沒有 AI 能力的公司將愈來愈難被視為現代藥廠。","key_points":[],"excerpt":"1913 年，Henry Ford 在美國密西根 Highland Park 工廠裝上第一條移動式生產線。 在那之前，一輛 Ford Model T 的組裝大約需要 12.5 小時；流水線導入後，時間被壓縮到約 93 分鐘。當時汽車業的反應很分裂：一批人拆掉舊工坊，重新設計工廠；另一批人則認為，這種標準化、快速化、看似粗糙的生產方式，怎麼可能取代手工打造的精密工藝？ 結果不用太久就出來了。那些堅守舊工坊邏輯的汽車公司，大多消失在歷史裡。 流水線改變的不只是汽車製造速度，而是整個製造業的底層邏輯。在流水線之前，製造能力長在工匠手上；在流水線之後，製造能力長在系統裡。 一百多年後，類似的邏輯切換，正在新藥研發產業發生。 這次的流水線，不是金屬零件、皮帶與輸送帶，而是 人工智慧、蛋白質結構模型、科學資料庫、藥物設計模型與自動化實驗系統。真正值得注意的，不是 AI 會不會讓藥廠「效率提升一點」，而是 AI 正在把新藥研發從「人類科學家手工試錯」推向「系統化、模型化、資料化、可重複迭代」的新型研發工廠。 這會改變藥廠的定義。 未來的藥廠，不只要有化學家、生物學家、臨床團隊、法規團隊和銷售隊伍，還必須有 AI 能力。 沒有 AI 能力的藥廠，未來可能就像沒有電力的工廠。不是不能存在，而是會越來越不像現代工廠。 01｜Google I/O 真正重要的，不是產品秀，而是科學研發的作業系統 2026"},{"title":"Old Targets Are Crowded, but They Can Still Make Money","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy-en.html","date":"2026-06-06","lang":"en","category":"商業分析系列","tags":["BD and Licensing","Business development","Biotech business analysis","Drug development"],"summary":"Crowded drug targets can still create value when companies differentiate through patient selection, formulation, route of administration, clinical design, pricing, or commercial channel strategy.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis An old target is not automatically a bad target. It becomes unattractive only when the new product cannot explain why it deserves a place against existing therapies. Differentiation may come from convenience, safety, combination logic, biomarker segmentation, or market access. Why It Matters The business lesson is that novelty and value are not the same thing. Investors should ask whether a company has a clear wedge into an existing mar"},{"title":"老靶點都很捲，但不是不能賺錢","url":"https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html","date":"2026-06-06","lang":"zh-Hant","category":"商業分析系列","tags":["熱門靶點","PD-1","BCMA","CD19","Biotech","BD","差異化"],"summary":"熱門靶點擁擠不代表沒有價值；真正關鍵是公司能否在身位、差異化、適應症切入、技術換代與 BD 對接中找到自己的獲利位置。","key_points":[],"excerpt":"PD-1、BCMA、CD19 都塞爆了，但不是不能賺錢 創新藥產業有一個很殘酷的現象：大家都說要創新，但真正願意離開熱門靶點的人，其實沒有想像中多。 隨便翻一份全球管線報告，PD-1／PD-L1、BCMA、CD19、HER2、TROP2、EGFR、KRAS G12C 這些靶點後面，往往都排著一長串公司。 🎯大藥廠在做。 🎯Biotech 在做。 🎯新創公司也在做。 🎯平台公司更要拿它們當技術驗證入口。 所以問題來了：靶點已經這麼擠，後面進去的人，還有機會賺錢嗎？ 答案不是簡單的有或沒有。更精準地說：靶點內捲不等於沒有價值，但如果沒有差異化、沒有定位、沒有商業策略，那就只是排隊送死。 01｜靶點到底有多捲？腫瘤是最典型的重災區 腫瘤領域，幾乎是靶點內捲最嚴重的地方。 2000 年左右，一個 腫瘤靶點 平均只有約 1.8 個項目在推進。到了 2022 年，這個數字已經飆到約 9 個。也就是說，二十多年來，一個腫瘤靶點背後的研發競爭者，增加了 5 倍以上。 更關鍵的是，腫瘤管線數量每年以約 7.6% 的速度成長，但真正的新機制、新靶點，每年只增加約 3.4%。 車子越來越多，路卻沒有變多，結果自然就是塞車。 🚦 PD-1／PD-L1 是最典型的例子。 Keytruda（pembrolizumab）、Opdivo（nivolumab）、Tecentriq（atezolizumab"},{"title":"Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html","date":"2026-06-05","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Biotech business analysis","Drug development"],"summary":"Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Ruxolitinib cream proved that a JAK mechanism can become a dermatology product, but that does not mean every JAK molecule can succeed topically. Formulation, tissue exposure, safety margin, and patient convenience are part of the drug's actual value. Why It Matters For biotech investors, topical delivery is a reminder that modality value depends on execution details. A familiar target can still produce a differentiated product if the co"},{"title":"從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html","date":"2026-06-05","lang":"zh-Hant","category":"商業分析系列","tags":["Ruxolitinib","JAK 抑制劑","外用藥","皮膚遞送","Incyte","安成生技","CMC"],"summary":"外用 JAK 抑制劑的核心不是單純抑制 JAK，而是分子能否穿過皮膚、留在局部、降低全身暴露，並在適應症與製劑設計上建立差異化。","key_points":[],"excerpt":"外用 JAK 抑制劑正在成為皮膚科新藥開發裡最值得關注的方向之一。 過去提到 JAK 抑制劑，多數人想到的是口服藥。例如 tofacitinib、baricitinib、upadacitinib、abrocitinib 這類藥物，已經在類風濕性關節炎、異位性皮膚炎、乾癬性關節炎、潰瘍性結腸炎、圓禿等自體免疫與發炎疾病中建立市場。 📌 但外用 JAK 抑制劑是另一個故事。 它的核心不是「JAK 抑制劑能不能抗發炎」，而是：這個分子能不能穿過皮膚，又不要大量進入全身循環。 這也是為什麼雖然全球已經有許多口服 JAK 抑制劑上市，但真正成功做成外用藥的品種並不多。目前國際市場最具代表性的外用 JAK 抑制劑，主要是 ruxolitinib cream 與 delgocitinib cream／ointment。 Ruxolitinib cream 的商品名是 Opzelura，由 Incyte 開發，是第一個獲美國 FDA 核准的外用 JAK 抑制劑，已用於異位性皮膚炎與非節段型白斑。2024 年，Opzelura 全年營收達 5.08 億美元，年增 50%，已經證明外用 JAK 抑制劑不只是皮膚科小眾產品，而是可以成為數億美元級商業品種。 Delgocitinib 則走出另一條路。它最早以 Corectim 在日本核准用於異位性皮膚炎，後來 LEO Pharma 推進 Anzupgo"},{"title":"Retatrutide Moves Toward Surgery-Level Weight Loss: Lilly's Triple-Agonist Pushes Obesity Treatment Into a New Arena","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss-en.html","date":"2026-06-04","lang":"en","category":"商業分析系列","tags":["Company Research","Obesity medicine","Big Pharma","Biotech business analysis","Drug development"],"summary":"Retatrutide pushes obesity-drug efficacy toward surgery-level territory, but the real competitive battle will be durability, tolerability, body composition, comorbidity benefit, and access.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Retatrutide is not just another GLP-1-related product. Its triple-agonist design suggests that obesity treatment is moving toward broader metabolic regulation, where weight loss, liver fat, cardiometabolic risk, and long-term maintenance may all matter. Why It Matters Investors should avoid judging the asset only by peak weight-loss percentage. The next phase of obesity medicine will be decided by sustained outcomes, gastrointestinal to"},{"title":"Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場","url":"https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html","date":"2026-06-04","lang":"zh-Hant","category":"商業分析系列","tags":["Retatrutide","Eli Lilly","肥胖治療","GLP-1","GIP","Glucagon","減重藥"],"summary":"Eli Lilly 的 retatrutide 在三期試驗中把減重幅度推向接近手術級別，代表肥胖治療正從單一路徑抑制食慾，走向多受體代謝調控的新戰場。","key_points":[],"excerpt":"肥胖治療正在被重新定義。 過去，重度肥胖患者常常面對一個兩難選擇：一邊是減重手術，效果明確，但要承擔手術創傷、麻醉風險、術後營養管理與長期併發症；另一邊是藥物治療，使用相對方便，但過去很長一段時間，療效天花板始終低於外科手術。 這個界線，正在被 禮來 （Eli Lilly） 的 retatrutide 打破。 2026 年 5 月 21 日，Eli Lilly 公布 retatrutide 在 TRIUMPH-1 三期臨床試驗中的頂線結果。這是一款每週一次注射的三重受體激動劑，同時作用於 GIP、GLP-1 與 glucagon receptor。用比較白話的方式說，它不是只靠單一路徑抑制食慾，而是同時調節飽足感、胰島素分泌、脂肪代謝與能量消耗等多條代謝路徑。 結果非常驚人。 在第 80 週時，retatrutide 12 mg 劑量組受試者平均減重 28.3%，約等於 70.3 磅；9 mg 劑量組平均減重 25.9%；即使是 4 mg 劑量組，也達到 19.0%。在 BMI ≥35 的重度肥胖受試者延伸研究中，持續使用 12 mg 到第 104 週時，平均減重進一步達到 30.3%。 這個數字為什麼重要？因為傳統主流減重手術，例如胃袖狀切除術，在 1 到 2 年內的體重下降幅度大約落在 25% 到 30% 區間。Retatrutide 的臨床結果，第一次讓藥物治療真正站到「接近"},{"title":"A Genetic Disease With No New Treatment for 40 Years Finally Enters a New Drug Era","url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing-en.html","date":"2026-06-03","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Immunology","Biotech business analysis","Drug development"],"summary":"AATD is entering a new treatment cycle after decades of limited options, with RNA and gene-based approaches trying to move the field beyond symptom control and protein replacement.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis The AATD story matters because it shows how rare respiratory and liver diseases are becoming addressable through newer genetic-medicine tools. The key question is whether these approaches can deliver durable biological correction without creating new long-term safety risks. Why It Matters For biotech readers, AATD should be watched as a translation case: mechanism, tissue delivery, durability, manufacturing, regulatory endpoints, and pa"},{"title":"40年沒藥的遺傳病迎來重磅進展","url":"https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html","date":"2026-06-03","lang":"zh-Hant","category":"商業分析系列","tags":["AATD","罕見疾病","Sanofi","Wave Life Sciences","Beam Therapeutics","RNA 編輯","基因編輯"],"summary":"AATD 治療在近 40 年後迎來新療法競速，Sanofi、Wave、Beam 分別以長效重組蛋白、RNA 編輯與基因鹼基編輯切入，代表罕見遺傳病治療正從補蛋白走向根源修正。","key_points":[],"excerpt":"打破 40 年僵局：AATD 迎來新療法競速，從補蛋白走向基因修正 一個沉睡了近 40 年的罕見遺傳病市場，正在被重新打開。 這個疾病叫做 α-1 antitrypsin deficiency（AATD，α-1 抗胰蛋白酶缺乏症）。近期在 2026 年美國胸腔醫學會年會（ATS 2026）上，Sanofi、Wave Life Sciences、Beam Therapeutics 同時公布 AATD 治療新資料，分別代表三條完全不同的開發路線：重組蛋白補充、RNA 編輯、基因鹼基編輯。 這不是一般罕見病新藥的單點突破，更像是一個疾病領域從「只能補蛋白」走向「修正疾病根源」的集體轉向。AATD 過去近 40 年缺乏重大創新。從 1987 年血漿來源的 α-1 抗胰蛋白酶補充療法被引入後，臨床長期依賴每週輸注的血漿製劑。這些療法可以補充血液中的功能性 α-1 抗胰蛋白酶，但不能真正修正基因缺陷，也不能處理肝臟裡錯誤蛋白堆積造成的問題。 現在，局面開始變了。 Sanofi 的 efdoralprin alfa 嘗試用長效重組蛋白改善傳統補充療法；Wave 的 WVE-006 嘗試在 RNA 層級把錯誤訊息改回來；Beam 的 BEAM-302 則更進一步，試圖用一次性鹼基編輯，在基因層級修正致病突變。 📌 這代表 AATD 正在從「慢性補充」進入「疾病修正」的前夜。 01｜AATD 是什"},{"title":"Biogen's High-Risk Bet: Can Tau Find a Way Out of the Alzheimer's R&D Graveyard?","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy-en.html","date":"2026-06-02","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","CNS","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"Biogen's BIIB080 tau program reflects a broader Alzheimer's reset: the field is no longer only asking whether amyloid matters, but whether tau biology can produce measurable disease-modifying benefit.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Biogen's tau bet is important because Alzheimer's drug development is searching for the next credible axis after years of amyloid controversy. BIIB080 can only change the story if biomarker movement translates into clinical slowing that physicians, regulators, and payers can trust. Why It Matters The investment question is not simply whether tau is a famous target. It is whether the study design, endpoints, patient selection, biomarker "},{"title":"Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？","url":"https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html","date":"2026-06-02","lang":"zh-Hant","category":"商業分析系列","tags":["Biogen","Alzheimer’s Disease","tau","BIIB080","diranersen","ASO","神經退化疾病"],"summary":"Biogen 在 BIIB080 / diranersen 的 Phase 2 CELIA 研究未達主要終點後仍推進 Phase 3，反映 AD 研發裡 tau 靶點的高風險、高需求與策略性押注。","key_points":[],"excerpt":"Alzheimer’s Disease（阿茲海默症，以下簡稱 AD）一直是全球新藥研發最昂貴、最殘酷、也最令人著迷的戰場之一。 這個領域燒掉了太多資金，也埋葬了太多希望。從 β-amyloid（乙型澱粉樣蛋白）到 tau protein（tau 蛋白），從 BACE inhibitor 到單株抗體，從基因療法到神經發炎調節，每一條路徑都曾經被寄予厚望，也幾乎都經歷過重挫。 但大型藥廠仍然不願離場。 原因很簡單：AD 的未滿足需求太大，患者人數太多，照護負擔太重。只要有一款藥能真正延緩疾病進展，它就不只是一個重磅藥，而可能是改寫全球神經退化治療史的資產。 📌Biogen 最近又做了一個高風險決定。 它公布 diranersen（BIIB080） 治療早期 AD 的 Phase 2 CELIA 研究頂線結果。這是一款反義寡核苷酸藥物，目標是降低 tau 蛋白生成。問題是，CELIA 研究沒有達到主要終點。照一般邏輯，這種結果通常會讓公司停下來，重新設計劑量、補做研究，或至少等待更完整資料後再決定。但 Biogen 選擇繼續往 Phase 3 註冊性開發推進。 這就是整件事最值得討論的地方，Biogen 究竟是在看到別人沒看到的訊號，還是又一次在 AD 戰場上賭得太重？ 01｜CELIA 沒有達主要終點，Biogen 卻說看到了「值得推進」的訊號 CELIA 是一項 Phase 2、隨"},{"title":"Pluvicto Is Selling Fast: What Radioligand Therapy Growth Really Means","url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth-en.html","date":"2026-06-01","lang":"en","category":"商業分析系列","tags":["Company Research","Radiopharma","Biotech business analysis","Drug development"],"summary":"Pluvicto's rapid growth shows radioligand therapy moving from specialist science into a real commercial infrastructure story, where isotope supply, hospital workflow, and patient selection become strategic assets.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis Pluvicto is not only a fast-selling oncology product. It is a signal that radioligand therapy is becoming an industrial system: isotope sourcing, manufacturing, logistics, imaging, physician workflow, and reimbursement must all work together before the market can scale. Why It Matters For investors, radiopharma should be analyzed less like a normal oncology pill and more like a complex healthcare infrastructure business. The winners are"},{"title":"核藥賣爆了","url":"https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html","date":"2026-06-01","lang":"zh-Hant","category":"商業分析系列","tags":["Pluvicto","Novartis","核藥","放射配體療法","攝護腺癌","PSMA","精準治療"],"summary":"Pluvicto 單季銷售達 6.42 億美元，顯示攝護腺癌治療正從荷爾蒙訊號攻防，走向 PSMA 核醫診療一體化與放射配體療法的新階段。","key_points":[],"excerpt":"單季 6.42 億美元：Pluvicto 把攝護腺癌精準治療推進新階段 攝護腺癌治療正在進入一個新的精準治療時代。 這一次，主角不是傳統荷爾蒙治療，也不是一般化療，而是 Pluvicto（lutetium Lu 177 vipivotide tetraxetan）。這款由 Novartis 推出的放射配體療法，2026 年第一季銷售額達 6.42 億美元，以固定匯率計算年增 70%。Novartis 在財報中指出，Pluvicto 的成長主要來自美國「化療前」轉移性去勢抗性攝護腺癌族群需求增加，以及美國以外市場可近性擴大。 這個數字不只是單季銷售好看，更重要的是，它代表攝護腺癌治療的邏輯正在改變。過去半個多世紀，攝護腺癌治療主軸幾乎都圍繞一件事：如何切斷雄性素訊號。但當腫瘤逐漸學會逃避雄性素受體藥物，產業就必須尋找新的戰術。 現在，Pluvicto 的爆發，正好說明攝護腺癌已經從「荷爾蒙訊號攻防戰」，走向 基因分型、蛋白降解、新靶點定點殺傷、核醫診療一體化 的多路線競爭。這也是為什麼 Pluvicto 的成長，不只是 Novartis 一家公司的勝利，而是整個攝護腺癌精準治療進入新階段的訊號。 01｜攝護腺癌治療的第一條主線：從去勢治療到 AR 抑制劑 攝護腺癌藥物開發的起點，可以追溯到 1941 年。 當時芝加哥大學醫師 Charles Huggins 發現，晚期攝護腺癌患者接受"},{"title":"The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal","url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis-en.html","date":"2026-05-31","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Regulatory risk","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Tavneos Crisis: Death Reports, Data-Integrity Questions, and an Amgen Rare-Disease Star at the Edge of Withdrawal, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization str"},{"title":"⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣","url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html","date":"2026-05-31","lang":"zh-Hant","category":"商業分析系列","tags":["Tavneos","Amgen","罕病藥","FDA","資料完整性","肝毒性","撤市風險"],"summary":"Tavneos 從罕病明星藥站上撤市邊緣，真正危機不只是日本死亡通報與肝毒性，而是 FDA 對 ADVOCATE 試驗資料完整性的嚴重指控。","key_points":[],"excerpt":"一款曾被寄予厚望的罕見病藥物，正在站上美國市場撤市邊緣。 這款藥是 Tavneos（avacopan，阿伐可泮）。 它原本是補體系統藥物裡很受關注的產品，機制是阻斷補體 C5a 受體，用於治療成人嚴重活動性 ANCA 相關血管炎。ANCA 相關血管炎，全名是抗嗜中性白血球細胞質抗體相關血管炎，包括 granulomatosis with polyangiitis（GPA，肉芽腫性多血管炎）與 microscopic polyangiitis（MPA，顯微鏡下多血管炎）。 這類疾病罕見但凶險，可能侵犯腎臟、肺部、神經與其他器官。傳統治療往往需要使用大量類固醇，搭配 rituximab、cyclophosphamide 等免疫抑制療法。Tavneos 當年最吸引人的地方，就是它有機會減少類固醇使用，降低長期高劑量類固醇帶來的感染、骨質疏鬆、糖尿病、體重增加、心血管與代謝副作用。 但現在，這款藥物的故事出現巨大反轉。 2026 年 4 月 27 日，美國 FDA 藥品審查與研究中心（CDER）正式提出撤回 Tavneos 核准的程序。FDA 的理由非常嚴重：一方面，新的資訊讓 FDA 認為 Tavneos 缺乏充分療效證據；另一方面，原始申請資料中包含重大事實不實陳述。FDA 也指出，Tavneos 目前仍會留在市場上，直到申請人自行撤回，或 FDA 局長最終下令撤回核准為止。這不是一般"},{"title":"The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy","url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling-en.html","date":"2026-05-30","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Best Partner for a Drug King? When Combination Therapy Doubles Efficacy, focusing on company strategy, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, "},{"title":"藥王的最佳搭檔？療效翻倍！","url":"https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html","date":"2026-05-30","lang":"zh-Hant","category":"商業分析系列","tags":["Keytruda","INBRX-106","OX40","腫瘤免疫","聯合治療"],"summary":"Keytruda 專利懸崖前，下一代聯合治療能否提高療效天花板與延長生命週期，是藥王商業價值的關鍵問題。","key_points":[],"excerpt":"Keytruda 的下一個最佳搭檔？INBRX-106 讓 OX40 重新回到腫瘤免疫牌桌 🧬 腫瘤免疫治療已經進入一個很微妙的階段。 PD-1／PD-L1 inhibitor 改寫了過去十年的癌症治療格局，Merck 的 Keytruda（pembrolizumab） 更是其中最具代表性的「藥王」。2025 年，Keytruda／Keytruda QLEX 全球銷售額達 317 億美元，幾乎是 Merck 製藥收入的核心支柱。 也正因如此，Keytruda 面對專利懸崖之後，Merck 最需要的不是再找到一個普通腫瘤藥，而是找到能延長 Keytruda 生命週期、提高療效天花板、並且可以跨癌種擴張的下一代組合療法。 這也是為什麼 Inhibrx Biosciences 的 INBRX-106 最新資料，會讓市場突然重新看向 OX40 agonist 這個曾經被許多大型藥廠嘗試、卻又反覆失敗的免疫共刺激靶點。 根據 Inhibrx 公布的 HexAgon 研究 Phase 2 中期分析，在一線復發／轉移性頭頸部鱗狀細胞癌，也就是 1L recurrent or metastatic head and neck squamous cell carcinoma（1L R/M HNSCC），且 PD-L1 高表現 CPS ≥20 的病人中，INBRX-106 + Keytruda（pe"},{"title":"Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming","url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions-en.html","date":"2026-05-29","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","AI drug discovery","Obesity medicine","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Weight-Loss Drugs Are No Longer Only About Body Weight: Where Next-Generation Therapies Are Aiming, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-d"},{"title":"減重藥物不只看體重了：下一代療法正在瞄準這些方向","url":"https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html","date":"2026-05-29","lang":"zh-Hant","category":"商業分析系列","tags":["減重藥物","GLP-1","肥胖治療","肌肉保留","代謝"],"summary":"下一代減重療法不只比體重下降，也要看肌肉保留、脂肪肝、心血管與代謝共病等更完整臨床價值。","key_points":[],"excerpt":"減重藥物不只看體重了：下一代療法正在瞄準這些方向 肥胖治療正在成為全球創新藥研發中最重要的戰場之一。 過去，市場討論減重藥物，焦點多半放在一件事：能瘦多少？ 但現在，這個問題已經不夠用了。隨著 Wegovy（semaglutide）、Ozempic（semaglutide）、Mounjaro（tirzepatide）、Zepbound（tirzepatide） 把減重療效推到過去難以想像的高度，肥胖藥物研發正在進入下一個階段。未來真正重要的問題，會從「體重下降多少」變成： - 減掉的是脂肪，還是肌肉？ - 能不能保護肌肉量？ - 能不能改善脂肪肝、心血管、腎臟、睡眠呼吸中止症與骨關節疼痛？ - 能不能做成口服？ - 能不能更便宜、更容易取得？ - 能不能停藥後不復胖？ - 能不能依照不同病人特徵，選擇最適合的療法？ 這代表減重藥物已經不只是「體重管理」的問題，而是走向 長期代謝健康管理。近期 Nature Reviews Drug Discovery 相關綜述也指出，肥胖藥物開發正在從單一 GLP-1 受體激動劑，往多重受體激動劑、口服療法、胜肽藥物偶聯、精準治療與體重維持策略演進。這不是單一產品的迭代，而是整個肥胖治療產業鏈的升級。 藥時事 與 CMoney 全曜財經共同打造減肥藥賽道投資課程 藥時事團隊深度分析全球 減肥藥市場現況、新藥開發進程、臨床使用情況，並且完整講解了減肥"},{"title":"Biotech Investing Needs a Judgment System, Not More News","url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system-en.html","date":"2026-05-28","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Biotech Investing Needs a Judgment System, Not More News, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way cap"},{"title":"🧬 生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統","url":"https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html","date":"2026-05-28","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","生技投資"],"summary":"生技新聞很多。但真正難的不是「知道發生了什麼」，而是看懂：🔍 這件事到底改變了公司的基本面嗎？一個臨床結果，是降低失敗風險，還是市場短線情緒？一個授權案，是有真實商業價值，還是只是在包裝題材？一家公司","key_points":[],"excerpt":"生技新聞很多。 但真正難的不是「知道發生了什麼」，而是看懂： 🔍 這件事到底改變了公司的基本面嗎？ 一個臨床結果，是降低失敗風險，還是市場短線情緒？ 一個授權案，是有真實商業價值，還是只是在包裝題材？ 一家公司股價上漲，背後是管線價值重估，還是資本市場敘事？ 這就是我們做 「生技投資圈」 的原因，我們想做的不是更多新聞，而是一套給台灣讀者看的生技醫藥基本面判斷系統。 🎯 會員版重點：找出公司的基本面 會員版會聚焦在四件事： 1️⃣ 公司基本面拆解 適應症、臨床節點、患者池、現金水位、競品壓力。 2️⃣ Pipeline 估值判讀 成功率、上市時間、銷售峰值、風險折現。 3️⃣ BD 預期預判 首付款、里程碑、分潤、區域、授權可能性。 4️⃣ 會後紀要整理 藥時事團隊拜訪公司後，整理真正值得投資人關注的重點。 🆓 免費內容看什麼？ 看觀點、看商業評論。 💎 會員內容看什麼？ 看公司基本面、管線潛力、BD 預期與會後紀要。 💰 首月 NT$1 💰 之後年費 NT$3,000 如果你不只想追新聞，而是想開始看懂： 🧩 「這家公司到底值不值得研究？」 📈 「這件事有沒有真的改變估值？」 歡迎加入 生技投資圈。 📌 免費文看觀點。 📌 會員版看完整基本面與估值判讀。 👉 藥時事 Drugnews的方案｜方格子 vocus 歡迎加入 100+ 醫藥菁英圈 在這邊我們分享最"},{"title":"The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio","url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework-en.html","date":"2026-05-27","lang":"en","category":"商業分析系列","tags":["Biotech Valuation","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The First Step in Valuing Taiwanese Biotech: Stop Forcing Every Company Into the Same P/E Ratio, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-deve"},{"title":"Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers","url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety-en.html","date":"2026-05-27","lang":"en","category":"商業分析系列","tags":["Company Research","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Sun Pharma, Teva, and the Transformation Anxiety of Global Generic Drugmakers, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and "},{"title":"台灣生技估值第一步：不要把所有公司都塞進同一個本益比","url":"https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html","date":"2026-05-27","lang":"zh-Hant","category":"商業分析系列","tags":["生技估值","本益比","rNPV","SOTP"],"summary":"台灣生技股最常見的錯誤，不是模型算錯一點，而是公司類型一開始就分錯。","key_points":[],"excerpt":"很多人分析生技股，一開始就問本益比、EPS、目標價。 但生技股真正麻煩的地方，是公司類型完全不同。同樣叫生技股，實際上可能是五種完全不同的資產。 五種生技資產 - 已商業化新藥公司：看患者池、滲透率、藥價、毛利率與銷售效率。 - 臨床開發型新藥公司：看臨床階段、成功率、競爭格局與 BD 條款。 - CDMO / 製造平台公司：看訂單能見度、毛利率、產能利用率與查廠能力。 - biosimilar / 授權合作型公司：看合作方、供貨、里程碑、權利金與放量。 - 併購整合現金流公司：看 EBITDA、自由現金流、產品組合與整合能力。 模型用錯，比參數算錯更危險。 為什麼本益比不夠 本益比適合已經有穩定獲利、商業模式成熟的公司。 但很多生技公司正在跨越研發、製造、授權、商業化或固定成本門檻。這時候真正要問的不是「現在 EPS 多少」，而是公司價值會不會因為下一個事件而重新定價。 台康這類公司為什麼難估 台康不能只放在單一類型。它至少同時有三層： - CDMO / CMC 製造底座。 - EG12014 / Herwenda 的 biosimilar 商業化選擇權。 - EG1206A 與後續管線的平台重複性。 所以台康不能直接用保瑞的成熟現金流倍數，也不能直接用藥華藥的孤兒藥 peak sales 模型。 更合理的方式是先給 CDMO 地板，再對 Herwenda 的分潤可見度和後續管線"},{"title":"太陽製藥、梯瓦製藥 與 全球學名藥廠的轉型焦慮","url":"https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html","date":"2026-05-27","lang":"zh-Hant","category":"商業分析系列","tags":["太陽製藥","梯瓦製藥","學名藥","轉型","製藥巨頭系列"],"summary":"全球學名藥巨頭面對價格壓力與成長瓶頸，轉型重點從傳統製造規模走向特殊學名藥、創新藥與更高門檻產品。","key_points":[],"excerpt":"💊 純粹的學名藥巨頭，不存在了 全球學名藥產業，正在進入一個新的階段。 過去，學名藥巨頭的優勢很清楚：規模、製造、法規、通路、成本控制。只要專利藥到期，學名藥公司就能用更低價格切入市場，用大量品項、大規模供應和全球銷售網路，換取穩定現金流。 這套模式曾經非常有效。 但現在，純粹靠傳統學名藥躺贏的時代，正在結束。 美國市場採購方集中化、價格持續承壓，學名藥競爭越來越激烈，品質與合規成本越來越高。即使是全球學名藥巨頭，也很難再只靠一般學名藥維持高成長與高估值。世界仍然需要廉價藥。但資本市場更青睞能定義自身價值的公司，所以我們看到一個很清楚的趨勢：學名藥巨頭正在集體「上岸」。 它們不想再困在低價競爭裡，而是往專科藥、品牌學名藥、生物相似藥、複雜學名藥、女性健康、神經科學、眼科、免疫疾病這些更有定價能力、更有品牌與臨床價值的位置移動。印度 太陽製藥 （Sun Pharma） 收購 Organon，是這個轉向最具代表性的事件。Teva 的反彈，則證明轉型不是口號，只要策略對，學名藥巨頭也能重新被市場定價。 01｜Sun Pharma 為什麼要花 117.5 億美元買 Organon？ Sun Pharma 是印度最大藥廠，也是全球重要學名藥巨頭。但它現在做了一件非常不「傳統學名藥」的事：用 117.5 億美元企業價值 收購美國藥廠 Organon。 這是印度藥廠史上最大型的海外併購之一。O"},{"title":"A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track","url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track-en.html","date":"2026-05-26","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Obesity medicine","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A New Weight-Loss Drug Side Effect Accidentally Opens a New Therapeutic Track, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality"},{"title":"減肥藥新副作用，意外帶出新賽道？","url":"https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html","date":"2026-05-26","lang":"zh-Hant","category":"商業分析系列","tags":["GLP-1","減肥藥","掉髮","副作用","皮膚科"],"summary":"GLP-1 減重潮帶出的掉髮與身體組成問題，正在讓頭皮護理、營養管理與皮膚科成為減重藥外溢新賽道。","key_points":[],"excerpt":"GLP-1 減重潮的新副作用：頭髮變少，卻意外催生一個新風口 過去幾年，全球代謝藥物市場幾乎被幾個名字改寫：Ozempic（semaglutide）、Wegovy（semaglutide）、Mounjaro（tirzepatide）、Zepbound（tirzepatide）。它們最醒目的標籤，是血糖控制、體重管理、心血管保護、睡眠呼吸中止症，以及更廣泛的心腎代謝疾病想像。但當 GLP-1 藥物從糖尿病與肥胖治療，逐漸走進日常消費語境後，一個更私人、也更容易引發焦慮的問題開始浮現：體重下降了，頭髮也變少了。 這件事不是單純的社群焦慮。Wegovy 與 Zepbound 的美國藥品標籤，都已經提到 hair loss／alopecia 相關訊號，而且標籤裡使用的關鍵描述，是這類 hair loss adverse reaction 與 weight loss 相關。這句話很重要，因為它暗示：掉髮不一定是 GLP-1 對毛囊的直接毒性，更可能與快速減重、營養攝取下降、身體壓力與毛髮週期改變有關。 換句話說，這不是簡單一句「GLP-1 會讓人禿頭」可以解釋的問題。更精準的說法是：GLP-1 帶來的快速減重，正在讓一群使用者提前面對頭髮、皮膚、肌肉與營養管理問題。也正因如此，GLP-1 的影響已經不只停留在藥品市場。它正在外溢到美容、頭皮護理、營養補充、醫美、皮膚科與個人化健康管理。 藥時"},{"title":"Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets","url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets-en.html","date":"2026-05-25","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Asthma Drugs Are Shifting Gears: From Triple Inhalers to Upstream Immune Targets, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, a"},{"title":"氣喘新藥正在換檔：從吸入三合一到上游免疫靶點!","url":"https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html","date":"2026-05-25","lang":"zh-Hant","category":"商業分析系列","tags":["氣喘","吸入三合一","免疫靶點","生物製劑","呼吸道疾病"],"summary":"氣喘治療正在從吸入三合一與症狀控制，走向上游免疫靶點、生物製劑與更精準的病人分型。","key_points":[],"excerpt":"氣喘是全球最常見的慢性呼吸道疾病之一，也是醫學上仍難以「根治」的疾病。WHO 估計，2019 年全球約有 2.62 億名氣喘患者，並造成約 45.5 萬人死亡；若採用較早期的全球估算，患者人數甚至可達 3.39 億。這不只是過敏體質或空氣品質的生活議題，也是一條正在被國際大藥廠重新定義的創新藥賽道。 過去氣喘治療的核心，是長期控制氣道發炎、避免急性發作。吸入型類固醇 ICS、長效 β2 受體促效劑 LABA、長效抗膽鹼藥 LAMA，構成臨床上最熟悉的基礎工具；但在真實世界中，即使使用 ICS/LABA 二合一治療，仍有相當比例患者控制不佳，肺功能下降、夜間症狀、急診與口服類固醇需求都會反覆出現。 這也是為什麼近年氣喘治療的重點，正在從「症狀控制」往兩個方向推進：一邊是吸入劑型的升級，讓三種機制濃縮在單一吸入器；另一邊則是生物製劑與雙抗、多抗，直接切入第二型發炎與上游免疫訊號。 吸入治療仍是地基，但三合一正在往前線移動 氣喘藥物大致可分成三類：控制型藥物、緩解型藥物，以及針對特定免疫路徑的生物製劑。控制型藥物的任務，是長期降低氣道發炎與發作風險；緩解型藥物則主要用於急性症狀；而生物製劑通常用在中重度、重度或特定表型患者。 吸入治療的基本邏輯並不複雜： ▸ ICS：降低氣道發炎，是長期控制的基礎。 ▸ LABA：放鬆支氣管平滑肌，改善氣流受限。 ▸ LAMA：抑制膽鹼路徑造成的支氣管收"},{"title":"Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity","url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity-en.html","date":"2026-05-24","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Why OX2R Is Heating Up: From Narcolepsy to the Next CNS Drug Opportunity, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and"},{"title":"OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間","url":"https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html","date":"2026-05-24","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","GLP-1","CNS","FDA","OX2R"],"summary":"【 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間】中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。這個靶點就是 Orexin Recept","key_points":[],"excerpt":"【 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間】 中樞神經系統藥物開發，很久沒有出現一個這麼清楚、這麼有生物學邏輯、又這麼接近臨床突破的靶點。 這個靶點就是 Orexin Receptor 2（OX2R）。 如果只用一句話解釋 OX2R 的重要性，它不是單純讓人「比較不想睡」的受體，而是大腦維持清醒、穩定睡眠—覺醒週期、避免突然進入 REM sleep 的關鍵開關之一。 這也是為什麼 OX2R agonist 近年在全球 CNS 領域快速升溫。 它最明確的第一個戰場，是 Narcolepsy Type 1（NT1，第一型發作性嗜睡症／猝睡症）。這類患者不是一般熬夜後的疲倦，也不是單純「愛睡覺」，而是一種嚴重慢性神經系統疾病。病人可能在白天任何時間突然無法控制地入睡，也可能在大笑、憤怒、驚訝等情緒刺激下，發生肌肉張力突然消失的 cataplexy（猝倒）。 過去治療多半只能症狀管理。 但 OX2R agonist 的出現，讓 NT1 第一次有機會走向更接近病因層級的治療。因為 NT1 的核心病理，正是 orexin／hypocretin 訊號缺失。這就是這個靶點最迷人的地方：它不是在模糊地「調節神經」，而是直接補上大腦清醒系統中缺失的訊號。 01｜NT1 不是犯困，而是大腦清醒開關失靈 💤 Narcolepsy Type 1 最容易被誤解。 很多人聽到發作性嗜睡"},{"title":"The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market","url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend-en.html","date":"2026-05-23","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Global Biotech Wave: Understanding the Main Phase and Scientific Pricing of the Five-Trillion Weight-Loss Market, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization st"},{"title":"全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價","url":"https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html","date":"2026-05-23","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","藥華藥","減重藥","生技投資"],"summary":"當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生","key_points":[],"excerpt":"當台灣資本市場的資金與目光被 AI 半導體全面虹吸時，全球生技產業正悄悄用另一種方式重新定義人類的未來——那就是減肥藥的瘋狂狂潮。 我們多次提到，AI 解決的是算力與效率問題，而生技醫療解決的是疾病與生命問題。這不是一場資源的對立，而是台灣必須並行的雙引擎。如果說 AI 半導體是矽基生產力的極致，那麼以減肥藥為首的生技巨浪，就是碳基生命力正在兌現的巨大商機。全球減肥藥市場規模預估將上看五兆，這不是題材，而是正在發生的營收與臨床數據。 問題是，生技投資的「知識護城河」極高，散戶經常陷入困境： 👉 看著外資報告與新聞利多衝進去，卻追在波段高點？ 👉 明明知道是趨勢，卻不知道怎麼精算合理的「飆股目標價」？ 生技投資不能只靠口號和信仰，必須回歸科學與財務模組的產品兌現。 為了讓投資人不再迷失在破碎的資訊中，我們特別與 CMoney 打造了這堂《五兆減肥藥獲利班》，用專業生技與法人投資的雙重濾網，帶你跨越生技業的知識門檻。 01｜限時超強早鳥：第一階段最高折抵開跑 這是一堂系統化的線上實戰班，我們將在課程中完整拆解生技飆股的結構。目前課程已正式開放報名，並提供最實質的早鳥回饋： 限時特惠（5/21～6/02）：早鳥價 $3,288（原價 $12,000，直接現省 $8,712）。 立即報名 👉 線上課程 - 理財寶｜提供全方位投資線上課程 https://cmy.tw/00Caj3 c"},{"title":"How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow-en.html","date":"2026-05-22","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on How Mid-Sized Biotechs Are Turning Blockbuster Drugs From Dreams Into Cash Flow, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionali"},{"title":"這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流","url":"https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html","date":"2026-05-22","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","GLP-1","CNS","FDA","藥華藥","BESREMi"],"summary":"在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。","key_points":[],"excerpt":"在很長一段時間裡，製藥業的 blockbuster drug，似乎是大型藥廠的專屬勳章。 年銷售額突破 10 億美元，代表的不只是產品好賣，而是公司必須同時具備臨床開發能力、法規溝通能力、保險給付能力、醫師教育能力、銷售組織能力，以及後續適應症擴張能力。 這些資源過去多半掌握在大型跨國藥廠手中。中小型 Biotech 比較常扮演的角色，是「創新源頭」或「被收購對象」。它們做出漂亮的 Phase 2 數據，然後授權給大藥廠；或者在 Phase 3 前後被併購，讓大型藥廠接手後續全球開發與商業化。 但這個格局正在改變。 2026 年第一季財報顯示，一批中型商業化 Biotech 已經不再只是靠臨床數據、監管節點或併購預期支撐估值，而是開始用真實銷售額、患者啟動、處方成長、適應症擴張與全年營收指引，證明自己有能力孵化出真正的 blockbuster brand。 這是一個很重要的轉折，因為當一家 Biotech 擁有年銷售額 10 億美元級別的核心產品，它就不再只是研發公司。它開始具備自我造血能力，它可以養銷售隊伍，可以投入下一代管線，可以做生命週期管理，也可以在資本市場上取得完全不同的估值語言，換句話說，blockbuster drug 對中型 Biotech 的意義，不只是「一個產品賣得很好」，而是公司階段的升級。 01｜ 中型 Biotech 的觀察重點，正在從臨床節點轉向商業兌現"},{"title":"How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight","url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect-en.html","date":"2026-05-21","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Regulatory risk","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on How AI Semiconductors Have Hidden the Biotech Opportunity in Plain Sight, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, an"},{"title":"AI半導體掩蓋生技光芒","url":"https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html","date":"2026-05-21","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","FDA","藥華藥","BESREMi","生技投資"],"summary":"台灣資本市場最近出現一個非 常清楚的現象：AI 半導體正在虹吸一切。","key_points":[],"excerpt":"【🏔️ 台灣資金被 AI 半導體虹吸，但生技醫療不能被放棄】 台灣資本市場最近出現一個非 常清楚的現象：AI 半導體正在虹吸一切。 台股的主旋律幾乎完全被 AI 伺服器、先進製程、CoWoS、CPO、散熱、PCB、電源、矽光子、機器人與資料中心吃掉。只要公司能被放進 NVIDIA、AWS、Google、Microsoft、Meta 的 AI capital expenditure 敘事裡，市場就願意給更高估值、更高成交量、更長的想像空間。相反地，生技醫療股明明有臨床進展、有 FDA 路徑、有國際授權、有商業化產品，卻經常被資金邊緣化。 台灣生技產業似乎突然失去投資價值，這是台灣股市正在經歷一場非常典型的 AI 半導體資金虹吸效應。 【就在今天！】 【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點 課程裡我們會講解生技醫藥股的估值邏輯，以及投資人如何抓住被低估的生技股票！ 我們更是會以台灣生技之光 藥華藥（6446）作為我們的案例拆解他的估值與目標價 以下為報名連結歡迎大家踴躍報名： 【限時免費-線上直播】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點｜CMoney 理財寶 藥時事 X CMoney 攜手打造，推出由藥時事主講的《【限時免費-線上直播】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點》課程，藉由藥時事的投資經驗分享，幫每一個人做好人生投資。20"},{"title":"A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion","url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding-en.html","date":"2026-05-20","lang":"en","category":"商業分析系列","tags":["Company Research","AI drug discovery","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A Record AI Drug-Discovery Financing: Why a Google-Backed Company Raised US$2.1 Billion, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development "},{"title":"破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元","url":"https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html","date":"2026-05-20","lang":"zh-Hant","category":"商業分析系列","tags":["AI 製藥","Isomorphic Labs","Google","融資","生技投資"],"summary":"Google 系 AI 製藥公司大型融資，真正要看的不是 AI 標籤，而是平台能否把模型轉成可臨床驗證與授權的藥物資產。","key_points":[],"excerpt":"--- 倒數 1 天！ 【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點 課程裡我們會講解生技醫藥股的估值邏輯，以及投資人如何抓住被低估的生技股票！ 我們更是會以台灣生技之光 藥華藥（6446）作為我們的案例拆解他的估值與目標價 以下為報名連結歡迎大家踴躍報名： 【限時免費-線上直播】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點｜CMoney 理財寶 藥時事 X CMoney 攜手打造，推出由藥時事主講的《【限時免費-線上直播】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點》課程，藉由藥時事的投資經驗分享，幫每一個人做好人生投資。2026年05月21日(四) 20:30-21:30開課，現在報名只要0元 (原價6666元)！限時限額開放，立即報名！ www.cmoney.tw 逾 20 億美元入局：Isomorphic Labs 讓 AI 製藥從「工具故事」走向「平台定價」時代 🧬 全球 AI 製藥產業，又出現一筆足以改寫市場想像的超大型融資。 2026 年 5 月 12 日，由 Google DeepMind 分拆而出的 AI 製藥公司 Isomorphic Labs 宣布完成 21 億美元 Series B 融資。這輪資金由 Thrive Capital 領投，Alphabet、GV、CapitalG、Temasek、MGX，以及英國 Soverei"},{"title":"HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal","url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth-en.html","date":"2026-05-19","lang":"en","category":"商業分析系列","tags":["Business Analysis","CAR-T","Targeted therapy","Regulatory risk","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on HIV Drugs Are Still Highly Profitable: What Gilead's Earnings Reveal, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capita"},{"title":"HIV 新藥很好賺呀...吉利德財報披露","url":"https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html","date":"2026-05-19","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","ADC","J&J","FDA","Pfizer","Gilead"],"summary":"【Gilead 的 HIV 王朝沒有老去：Yeztugo 超預期，正在把 PrEP 推進「半年打一針」時代】💉 Gilead 最新一季財報，表面看起來只是一份穩健的藥廠成績單。2026 年第一季，Gi","key_points":[],"excerpt":"【Gilead 的 HIV 王朝沒有老去：Yeztugo 超預期，正在把 PrEP 推進「半年打一針」時代】 💉 Gilead 最新一季財報，表面看起來只是一份穩健的藥廠成績單。 2026 年第一季，Gilead 總營收年增 4% 至 69.6 億美元，產品銷售額約 69 億美元；其中 HIV 產品組合銷售額達 50.3 億美元，較去年同期成長 10%，仍然是公司最重要、最穩定、也最具戰略意義的現金流來源。 但這份財報真正讓市場重新定價的，不是 Biktarvy 仍然強，也不是 Gilead 的 HIV 基本盤還在，而是半年一次的長效 HIV PrEP 注射劑 Yeztugo（lenacapavir）開始跑出超預期的上市曲線。 Yeztugo 第一季銷售額達 1.66 億美元，季增約 72%。Gilead 首席商務長 Johanna Mercier 直接用「unprecedented launch trajectory」形容這款產品的開局，公司也把 Yeztugo 2026 年銷售預期從原本的 8 億美元上修到 10 億美元。 這句話背後的意義很大。 因為這代表 Yeztugo 很可能在上市第一個完整年度，就直接站上 blockbuster，也就是年銷售額 10 億美元以上的重磅藥物門檻。對 Gilead 來說，這不只是一個新藥上市成功的故事。更重要的是，HIV 市場正在從「每日"},{"title":"Where Pfizer Misjudged the Vepdegestrant Strategy","url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake-en.html","date":"2026-05-18","lang":"en","category":"商業分析系列","tags":["Business Analysis","Targeted therapy","Regulatory risk","Big Pharma","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Where Pfizer Misjudged the Vepdegestrant Strategy, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital market"},{"title":"大藥廠 輝瑞在兩個判斷上栽跟頭？","url":"https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html","date":"2026-05-18","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","ADC","PROTAC","FDA","Pfizer","Gilead"],"summary":"【「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？】Pfizer 正站在一個很微妙的十字路口。一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA","key_points":[],"excerpt":"【「賤賣」重磅炸彈，Pfizer 為何在兩個判斷上栽跟頭？】 Pfizer 正站在一個很微妙的十字路口。 一邊，是它與 Arvinas 聯手研發的 Vepdegestrant（Veppanu） 獲 FDA 核准，用於治療 ER+/HER2-、帶有 ESR1 mutation 的晚期或轉移性乳癌。這不只是乳癌治療的一個新選項，更是全球第一款獲 FDA 核准上市的 PROTAC 蛋白降解藥物，正式把蛋白降解技術推進商業化元年。 另一邊，Pfizer 在最新管線調整中，終止了從 Trillium Therapeutics 收購而來的最後一款 CD47 資產 Maplirpacept。這意味著，當年斥資約 23 億美元押注 CD47 的交易，最後幾乎沒有留下可商業化的核心產品。 更尷尬的是，Pfizer 早年以 1,000 萬美元首付款授權出去的 Gedatolisib，如今卻在 Celcuity 手中跑出漂亮三期數據，展現出成為重磅乳癌藥物的潛力。Celcuity 先前公布的 Phase 3 VIKTORIA-1 數據顯示，Gedatolisib 與 Faslodex（fulvestrant）、Ibrance（palbociclib） 的組合，在 HR+/HER2- 晚期乳癌中顯著降低疾病進展或死亡風險，消息一出公司股價大幅上漲。 這就是大型藥廠最殘酷的日常： 📌 有時候高價買進的明星"},{"title":"Johnson & Johnson（嬌生）砍掉兩條 自體淋巴瘤 CAR-T","url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html","date":"2026-05-17","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","BD","ADC","J&J","FDA"],"summary":"【嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬】📌 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤","key_points":[],"excerpt":"【嬌生 CAR-T 戰略折戟：不是數據不夠漂亮，而是自體 CD19/CD20 CAR-T 的商業死循環開始反噬】 📌 誰能想到，幾個月前還被 Johnson & Johnson 管理層高度看好的淋巴瘤 CAR-T 管線，會在 2026 年 4 月底被突然送進歷史檔案夾。 這不是普通的管線微調。 Johnson & Johnson 宣布停止開發兩款 large B-cell lymphoma（LBCL）CAR-T 療法：一款是 CD20 mono CAR-T，另一款是 CD19/CD20 bi-CAR-T，也就是外界熟知的 JNJ-4496 / JNJ-90014496（prizloncabtagene autoleucel, prizlo-cel）。公司給出的官方理由很克制：這是基於「portfolio priorities」以及對「evolving large B-cell lymphoma treatment landscape」的評估所做出的策略性商業決策。換句話說，這不是單純臨床失敗，而是強生判斷這條賽道即使成功，也未必值得繼續燒錢。 這件事真正震撼的地方在於：JNJ-4496 不是一條毫無數據的管線。 2025 年 6 月，Johnson & Johnson 才在 EHA 發表 JNJ-4496 的 Phase 1b 數據，將它描述為一款 dual-targeting "},{"title":"Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs","url":"https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge-en.html","date":"2026-05-17","lang":"en","category":"商業分析系列","tags":["Business Analysis","CAR-T","Targeted therapy","Regulatory risk","Big Pharma","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Johnson & Johnson Cuts Two Autologous Lymphoma CAR-T Programs, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital marke"},{"title":"Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster","url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson-en.html","date":"2026-05-17","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","AI drug discovery","Targeted therapy","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Daiichi Sankyo's Most Expensive Lesson: How an ADC Capacity Bet Can Backfire After a Blockbuster, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-dev"},{"title":"第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？","url":"https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html","date":"2026-05-17","lang":"zh-Hant","category":"商業分析系列","tags":["第一三共","ADC","DXd","Enhertu","CDMO","CMO","供應鏈","浩鼎","永昕"],"summary":"第一三共因 ADC 供應鏈與產能承諾認列高額費用，提醒新藥公司與 CDMO：pipeline 要折現，產能也要折現。","key_points":[],"excerpt":"ADC 不只比臨床，也比產能 ADC 這幾年是全球腫瘤新藥最熱的賽道之一。 第一三共靠著 DXd ADC 平台，把 Enhertu 推成全球最成功的 ADC 之一，也讓 Datroway、patritumab deruxtecan、ifinatamab deruxtecan、raludotatug deruxtecan 這些後續管線成為市場關注焦點。 但 2026 年 5 月 8 日，第一三共給市場上了很貴的一課。 公司下修截至 2026 年 3 月 31 日財年的合併財測，營業利益從原先預估的 3,350 億日圓降至 2,290 億日圓，差額高達 1,060 億日圓。 真正刺眼的不是營收，而是兩筆與 ADC 供應鏈有關的成本： ◆ CMO 補償費用準備金：757 億日圓 ◆ 日本小田原工廠 ADC 相關資本設備減損與補償費用：193 億日圓 合計 950 億日圓的費用，指向同一件事：第一三共曾經為 DXd ADC 的爆發式成長預先鎖下產能，如今卻因臨床與上市節奏修正，被迫重新估算供應需求。 第一三共押注的不是一條產品線，而是一整套 DXd 帝國 第一三共的擴產並不是毫無理由。 Enhertu 已經證明 DXd 平台能改寫 HER2 腫瘤治療格局，並與阿斯特捷利康共同推進多個適應症。Datroway 則讓 TROP2 ADC 進入商業化階段。 更大的期待，來自第一三共與默沙東在 2"},{"title":"The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable","url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk-en.html","date":"2026-05-16","lang":"en","category":"商業分析系列","tags":["Business Analysis","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The FDA Commissioner's Exit: Why the World's Most Important Drug Referee Is Becoming Less Predictable, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-"},{"title":"FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測","url":"https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html","date":"2026-05-16","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","FDA","生技投資"],"summary":"2026 年 5 月 12 日，美國 FDA 局長 Marty Makary 正式辭職，結束他僅約 13 個月的任期。","key_points":[],"excerpt":"【FDA局長下台：當全球新藥最重要的裁判，也開始變得不穩定】 ⚠️ 美國 FDA 又變天了。 2026 年 5 月 12 日，美國 FDA 局長 Marty Makary 正式辭職，結束他僅約 13 個月的任期。川普政府隨後由負責食品事務的副局長 Kyle Diamantas 暫代 FDA 局長；而在此之前，Reuters、Politico、Washington Post、STAT 等媒體已經連續報導，白宮內部正討論撤換 Makary。換句話說，這不是單純的人事傳聞，而是一場已經落地的監管政治事件。 ⚠️ 但這件事真正值得關注的，不只是 Marty Makary 個人的去留。 真正重要的是：FDA 這個全球新藥產業最核心的監管錨點，正在進入一個更政治化、更高波動、更難預測的時期。 對生技製藥產業來說，這比「換一位局長」嚴重得多。因為 FDA 不是一般行政機關，它是全球新藥價值鏈裡最重要的定價器、門檻制定者與風險裁判。全球絕大多數創新藥資產，不管來自美國、歐洲、日本、韓國，甚至台灣，最後只要想進入國際資本市場、想做授權、想被大型藥廠收購，都繞不開一個問題：這個資產，有沒有清楚的 FDA 路徑？ 過去很多公司說「我們要走 FDA」，市場會把它視為加分項。因為 FDA 代表全球最高標準，也代表商業化上限。但現在問題變成：如果 FDA 本身的審查邏輯、組織穩定性與決策獨立性開始被市場懷疑，"},{"title":"A Complete Map of the New Antidepressant Drug Pipeline","url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline-en.html","date":"2026-05-15","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A Complete Map of the New Antidepressant Drug Pipeline, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital m"},{"title":"全網最全的「抗憂鬱新藥」最新進展盤點","url":"https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html","date":"2026-05-15","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","GLP-1","CNS","FDA","生技投資"],"summary":"【精神科藥物終於走出單胺時代？】📌 憂鬱症從來不是一個小市場。依 WHO 統計，全球約有 2.8 億人受到憂鬱症影響；若加上不同國家、不同診斷口徑下的未診斷與亞臨床族群，實際醫療負擔只會更高。這不是一","key_points":[],"excerpt":"【精神科藥物終於走出單胺時代？】 📌 憂鬱症從來不是一個小市場。 依 WHO 統計，全球約有 2.8 億人受到憂鬱症影響；若加上不同國家、不同診斷口徑下的未診斷與亞臨床族群，實際醫療負擔只會更高。這不是一個單純「心情不好」的問題，而是會影響工作能力、家庭關係、睡眠、認知、自殺風險，甚至整體慢性病預後的系統性疾病。但弔詭的是，這麼大的疾病負擔，過去幾十年的治療工具卻相當有限。 臨床一線仍以 SSRI、SNRI、NDRI、NaSSA、TCA、MAOI 等傳統單胺類藥物為主。這些藥物不是沒有效，而是有幾個長期痛點：起效慢，通常要 2–4 週甚至更久；部分患者療效不足；性功能障礙、體重增加、嗜睡、焦慮加劇等副作用影響依從性；更重要的是，對難治型憂鬱症患者而言，多次換藥之後仍可能無法達到真正緩解。所以，抗憂鬱新藥真正的競爭，不只是「再多一個藥」。 它要回答的是三個問題： 🧠能不能更快起效？ 🧠能不能治療過去治不好的族群？ 🧠能不能用更精準的機制，把憂鬱症從「症狀治療」推向「分型治療」？ 2025–2026 年，抗憂鬱藥物研發的確出現了一些值得注意的變化。這個領域正在從傳統單胺假說，走向 谷氨酸、GABA、神經類固醇、5-HT2A、orexin、V1b、NK1、GLP-1 / GIP、數位療法與神經調控設備 的多路線競爭。精神科藥物，終於開始不像過去那麼「慢」了。 01｜監管端：Cap"},{"title":"How PharmaEssentia's Besremi Opens a Larger Valuation Imagination","url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation-en.html","date":"2026-05-14","lang":"en","category":"商業分析系列","tags":["Business Analysis","Targeted therapy","Regulatory risk","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on How PharmaEssentia's Besremi Opens a Larger Valuation Imagination, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the wa"},{"title":"藥華藥 打開估值想像空間","url":"https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html","date":"2026-05-14","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","ADC","FDA","藥華藥","BESREMi","生技投資"],"summary":"因為 BESREMi（ropeginterferon alfa-2b）在台灣正式獲衛福部核准用於原發性血小板過多症（Essential Thrombocythemia, ET）成人病人，適用於接受 Hydroxyurea 治療後產生抗藥性或無法耐受的患者。","key_points":[],"excerpt":"(已編輯) 【藥華藥不是只靠一個 PV 適應症：BESREMi 正在把「台灣新藥」推進 MPN 全球市場】 💡 今天藥華藥（6446）漲停！ 因為 BESREMi（ropeginterferon alfa-2b）在台灣正式獲衛福部核准用於原發性血小板過多症（Essential Thrombocythemia, ET）成人病人，適用於接受 Hydroxyurea 治療後產生抗藥性或無法耐受的患者。 這代表藥華藥的核心產品正在從真性紅血球增多症（Polycythemia Vera, PV），往更大的骨髓增生性腫瘤（Myeloproliferative Neoplasms, MPN）版圖擴張。BESREMi 不是一般的幹擾素，它真正的價值在於：用一個高度純化、長效、可長期給藥的 ropeginterferon alfa-2b，把過去被視為「控制血球數」的慢性血液腫瘤治療，逐步推向「疾病修飾」的方向。 台灣生技公司過去常被市場貼上「研發夢很大、商業化很遠」的標籤，但藥華藥持續兌現對投資人的承諾！證明台灣的生技依然是有全球化能力的。從台灣出發，直接挑戰歐美血液腫瘤市場，靠臨床數據、藥證、指南、商業化和適應症擴張，一步一步建立全球產品價值。而最重要的，這個新的適應症將打開 藥華藥 的市場銷售空間，估值想像力再次飛升！ 01｜為什麼 BESREMi 不是普通幹擾素？ 🧬 干擾素不是新東西。 "},{"title":"Could Neuroinflammation Bring CNS Drug Development Back?","url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback-en.html","date":"2026-05-13","lang":"en","category":"商業分析系列","tags":["Business Analysis","CNS","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Could Neuroinflammation Bring CNS Drug Development Back?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may "},{"title":"中樞神經新藥要靠「神經發炎」？","url":"https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html","date":"2026-05-13","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","CNS","Pfizer"],"summary":"【屢敗屢戰的中樞神經新藥，能否靠「神經發炎」打贏翻身仗？】中樞神經系統新藥研發，一直是創新藥裡最難啃的一塊骨頭。🧠 不是市場不大。恰恰相反，阿茲海默症、帕金森氏症、肌萎縮性脊髓側索硬化症、多發性硬化症","key_points":[],"excerpt":"【屢敗屢戰的中樞神經新藥，能否靠「神經發炎」打贏翻身仗？】 中樞神經系統新藥研發，一直是創新藥裡最難啃的一塊骨頭。 🧠 不是市場不大。 恰恰相反，阿茲海默症、帕金森氏症、肌萎縮性脊髓側索硬化症、多發性硬化症、癲癇、憂鬱症、思覺失調症、腦中風，幾乎每一個疾病背後，都是長期照護、家庭壓力、醫療支出與生活品質崩塌。 🧠 真正的問題是：中樞神經疾病太難做。 資料顯示，中樞神經藥物從一期臨床走到核准上市的平均成功率僅約 5.9%，在所有治療領域中屬於倒數；平均開發時間更長達 11 年以上，是醫藥研發裡最耗時、最燒錢、也最容易失敗的領域之一。如果再縮小到阿茲海默症、帕金森氏症這類神經退化性疾病，戰況更慘烈。過去幾十年，主流治療假說集中在清除大腦中的毒性蛋白堆積，例如 β-類澱粉蛋白、Tau 蛋白、α-突觸核蛋白。但這些路線一路走來，伴隨無數臨床失敗、論文爭議、資料重估，以及核准藥物臨床意義被反覆辯論。 🧠 問題是，病人等不起。 阿茲海默症患者失去記憶，不只是病人本人被疾病慢慢吞掉；照顧者、家庭經濟、長期照護系統也會一起被拖進去。帕金森氏症和漸凍症也是一樣。這些病不是單一器官疾病，而是會改變整個家庭生活結構的疾病。 所以問題來了：在 β-類澱粉蛋白、Tau 蛋白、多巴胺、α-突觸核蛋白這些路線之外，中樞神經新藥研發還有沒有新的突破口？近幾年，答案逐漸指向一個方向：神經發炎。不是把神經發炎當"},{"title":"The Autoimmune Twins That Could Save Johnson & Johnson","url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition-en.html","date":"2026-05-12","lang":"en","category":"商業分析系列","tags":["Business Analysis","CAR-T","Regulatory risk","Big Pharma","Business development","Immunology","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Autoimmune Twins That Could Save Johnson & Johnson, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may "},{"title":"自體免疫 雙子星 拯救 嬌生","url":"https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html","date":"2026-05-12","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","BD","J&J","Stelara","FDA","生技投資"],"summary":"【Johnson & Johnson 自免「雙子星」崛起：Stelara 退場後，Tremfya 與 Icotyde 正在重寫免疫版圖】📌 2026 年第一季，Johnson & Johnson（J&","key_points":[],"excerpt":"【Johnson & Johnson 自免「雙子星」崛起：Stelara 退場後，Tremfya 與 Icotyde 正在重寫免疫版圖】 📌 2026 年第一季，Johnson & Johnson（J&J）交出了一份很有訊號意義的財報。 表面上看，這是一份漂亮的成績單：第一季全球銷售額達 240.6 億美元，年增 9.9%；公司也上調 2026 年全年指引，預估全年銷售額將達 1003 億至 1013 億美元，中位數約 1008 億美元，年增約 7.0%。其中，創新製藥業務銷售額達 154.3 億美元，年增 11.2%，仍是公司最重要的成長引擎。 但真正值得看的，不是 Johnson & Johnson 今年能不能跨過千億美元營收，而是它如何在 Stelara（ustekinumab）專利懸崖後，重新拼出下一個免疫學成長曲線。 這是一個典型的大藥廠轉身故事：昔日百億美元級王牌快速下滑，但新一代產品已經接上。Tremfya（guselkumab）和 Icotyde（icotrokinra）這對自免「雙子星」，正在成為 Johnson & Johnson 抵抗免疫業務衰退、延續 IL-23 王朝的核心答案。 01｜Stelara 的時代結束了，但 Johnson & Johnson 沒有被專利懸崖拖垮 🧩 Stelara（ustekinumab）曾經是 Johnson & John"},{"title":"DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？","url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html","date":"2026-05-11","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","ADC","PROTAC"],"summary":"【強強聯手！當 ADC 遇上 PROTAC】生醫圈有兩個絕對頂流。📌 一個是 ADC（Antibody-Drug Conjugate，抗體藥物複合體）。📌 另一個是以 PROTAC（Proteolys","key_points":[],"excerpt":"【強強聯手！當 ADC 遇上 PROTAC】 生醫圈有兩個絕對頂流。 📌 一個是 ADC（Antibody-Drug Conjugate，抗體藥物複合體）。 📌 另一個是以 PROTAC（Proteolysis Targeting Chimera）、molecular glue 為代表的 TPD（Targeted Protein Degradation，標靶蛋白降解）。 前者像一枚有導航系統的飛彈，負責把高毒性 payload 精準送進癌細胞。後者像一台蛋白質粉碎機，不是單純抑制致病蛋白，而是直接把它送進細胞裡的蛋白酶體系統，讓它被分解、消失。 那麼問題來了：如果把 ADC 的「精準遞送」和 PROTAC / TPD 的「蛋白降解」結合在一起，會發生什麼？ 答案就是近年開始被大型藥廠和前沿 biotech 盯上的新興 modality：DAC（Degrader-Antibody Conjugate，降解劑－抗體偶聯藥物）。 這個概念聽起來像是把兩個熱門技術硬湊在一起，但如果拆開來看，它其實有很清楚的藥物開發邏輯：用抗體負責找細胞，用 linker 負責運輸與釋放，用 degrader payload 負責在細胞內摧毀特定致病蛋白。 📌 簡單說，ADC 是「標靶化療」。 📌 DAC 則更像是「標靶化蛋白擦除」。 這個差別，可能會決定下一代腫瘤藥物、甚至部分自體免疫疾病治療的走"},{"title":"Could DAC Become the Next Breakout Format in Targeted Therapy?","url":"https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy-en.html","date":"2026-05-11","lang":"en","category":"商業分析系列","tags":["Business Analysis","Targeted therapy","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Could DAC Become the Next Breakout Format in Targeted Therapy?, focusing on targeted therapy, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way c"},{"title":"Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?","url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay-en.html","date":"2026-05-10","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","CNS","Regulatory risk","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Trump Delays the Policy Signal: Did Weight-Loss Drugs Cut Prices for Nothing?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality"},{"title":"川普放政策鴿子，減肥藥價格白降了？","url":"https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html","date":"2026-05-10","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","GLP-1","Tirzepatide","FDA","減重藥"],"summary":"【川普政府放了 Eli Lilly（禮來）、Novo Nordisk （諾和諾德）的「鴿子」？GLP-1 進 Medicare，為什麼臨門一腳又卡住了】📌 2026 年 4 月下旬，美國減重藥市場出現","key_points":[],"excerpt":"【川普政府放了 Eli Lilly（禮來）、Novo Nordisk （諾和諾德）的「鴿子」？GLP-1 進 Medicare，為什麼臨門一腳又卡住了】 📌 2026 年 4 月下旬，美國減重藥市場出現一個很微妙的政策轉折。 美國 Centers for Medicare & Medicaid Services（CMS）宣布，原本規劃在 2027 年導入 Medicare Part D 的 BALANCE Model，將延後啟動 Part D 端的正式實施。這個模型原本被視為美國 Medicare 正式覆蓋 GLP-1 肥胖治療的一次政策破冰，牽動的自然是兩大贏家：Eli Lilly 與 Novo Nordisk。但在正式上路前，保險公司先踩了煞車，CMS 也選擇把 Medicare Part D 端的全面試點往後延。CMS 同時宣布，短期過渡方案 Medicare GLP-1 Bridge 將延長到 2027 年底，讓符合資格的 Medicare Part D 受益人仍可透過橋接方案取得部分 GLP-1 藥物。 這不是單純行政延期，而是一場美國醫療支付體系對 GLP-1 財政壓力的真實壓力測試。 表面上看，是保險公司不願意進入一個結構還不夠清楚的自願模型。更深層看，這件事其實揭開了 GLP-1 商業化下一階段最關鍵的問題：藥效已經被證明，需求也已經存在；但誰來付錢，仍然沒有真正"},{"title":"Clinical-Trial Fraud and an FDA Withdrawal Storm","url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal-en.html","date":"2026-05-09","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","Regulatory risk","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Clinical-Trial Fraud and an FDA Withdrawal Storm, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets "},{"title":"臨床試驗作假，FDA 撤市風暴！","url":"https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html","date":"2026-05-09","lang":"zh-Hant","category":"商業分析系列","tags":["Tavneos","FDA","資料完整性","罕病藥","撤市風險"],"summary":"FDA 對 Tavneos 提出撤市程序，核心不是單純療效不足，而是 ADVOCATE 試驗資料完整性與事後重判問題。","key_points":[],"excerpt":"Tavneos 面臨 FDA 撤市風暴：一款明星罕病藥，為什麼會從「類固醇替代希望」變成資料完整性教科書？ - 美國 FDA 這次對 Tavneos（avacopan）出手，訊號非常重。 2026 年 4 月 27 日，FDA 藥品審查與研究中心 CDER（Center for Drug Evaluation and Research）正式提議撤銷 Tavneos（avacopan）的上市批准。理由不是單純「療效不夠好」，而是更嚴重的兩件事：第一，新的資訊顯示 Tavneos 並未被充分證明對核准適應症有效；第二，當初申請上市的資料中，包含「重大事實不實陳述」。FDA 在公告中甚至明確指出，關鍵性 Phase 3 試驗 ADVOCATE 中，有未盲態研究人員操縱主要終點結果，讓原本不支持療效的分析看起來變成有效。 這件事之所以震撼，不只是因為 Tavneos 是 Amgen 旗下成長最快的產品之一，更因為它原本代表了一個非常漂亮的罕病創新藥故事：一款 first-in-class 口服補體藥物，切入罕見自體免疫血管炎，試圖降低患者對高劑量 glucocorticoids 的依賴。 但現在，這個故事被重新打開審視。 問題已經不只是 Tavneos 還能不能賣，而是整個產業必須重新面對一個更根本的問題： 當一款藥物的療效證據本身被質疑，而上市後又出現嚴重安全性訊號時，監管機構還能不能繼"},{"title":"Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth-en.html","date":"2026-05-08","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","CAR-T","Targeted therapy","CNS","Big Pharma","Capital markets","Biotech business analysis"],"summary":"A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Weight-Loss Drugs Are Still Too Strong: Lilly's Mounjaro Keeps Printing Money, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality"},{"title":"減肥藥還是太強了，禮來 猛健樂 賺爛！","url":"https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html","date":"2026-05-08","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","GLP-1","Tirzepatide","ADC","CNS"],"summary":"2026 年第一季，Eli Lilly 交出了一份讓整個製藥業都很難忽視的成績單：單季總營收 197.99 億美元，年增 56%；調整後 EPS 達 8.55 美元，大幅優於市場預期。真正撐起這份財報的，仍然是那個已經把全球代謝藥市場打穿的名字：tirzepatide。","key_points":[],"excerpt":"【禮來加冕 GLP-1 GOAT：一邊用 tirzepatide 印鈔，一邊用 210 億美元買下下一個十年】 📌 古神睜眼了。 2026 年第一季，Eli Lilly 交出了一份讓整個製藥業都很難忽視的成績單：單季總營收 197.99 億美元，年增 56%；調整後 EPS 達 8.55 美元，大幅優於市場預期。真正撐起這份財報的，仍然是那個已經把全球代謝藥市場打穿的名字：tirzepatide。其中，糖尿病適應症 Mounjaro（tirzepatide） 第一季營收 86.62 億美元，年增 125%；減重適應症 Zepbound（tirzepatide） 營收 41.60 億美元，年增約 80%。兩者合計單季營收超過 128 億美元。這不是一個普通大藥品的成長曲線，而是一個產品家族正在改寫大型藥廠現金流結構的訊號。如果說 Novo Nordisk 用 semaglutide 教育了全球 GLP-1 市場，那麼 Eli Lilly 正在用 tirzepatide 重新定義這個市場的終局。 這一季 Eli Lilly 在 GLP-1 賽道完成了一次 GOAT 加冕。 01｜GLP-1 的量價關係：禮來真正厲害的，不是漲價，而是降價後還能成長 🔹 GLP-1 這場仗，Eli Lilly 可以說是贏麻了。 在美國第二型糖尿病 GLP-1 市場，Mounjaro（tirzepati"},{"title":"The Shadow Behind the Next Century-Defining Drug","url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war-en.html","date":"2026-05-07","lang":"en","category":"商業分析系列","tags":["Business Analysis","CAR-T","Targeted therapy","CNS","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Shadow Behind the Next Century-Defining Drug, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may repric"},{"title":"下一代世紀大藥的陰影？","url":"https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html","date":"2026-05-07","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","RAS","ADC","CNS"],"summary":"【Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影】📌 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。","key_points":[],"excerpt":"【Pan-RAS 戰爭升級：Erasca 數據驚艷，卻撞上 Revolution 的專利戰與安全性陰影】 📌 RAS 賽道，正在從「誰的療效更強」進入「誰能同時守住安全性、IP 與商業化窗口」的新階段。 過去幾十年，RAS 一直被視為 oncology 裡最難攻克、也最有價值的聖杯之一。尤其在 pancreatic ductal adenocarcinoma（PDAC）裡，KRAS / RAS 變異幾乎是疾病的核心驅動之一；如果能真正用口服小分子打穿這條路徑，意義不只是多一個新藥，而是可能重寫胰臟癌這個最難治實體瘤之一的治療格局。 也正因如此，Revolution Medicines 的 daraxonrasib（RMC-6236）才會讓市場如此興奮。4 月中旬，公司宣布 daraxonrasib 在經治轉移性 PDAC 的 Phase 3 RASolute 302 試驗中達到主要與關鍵次要終點，整體族群中位總存活期 13.2 個月，對照組標準化療為 6.7 個月，死亡風險大幅下降，這被市場視為泛 RAS 抑制劑走向註冊成功的分水嶺。 但真正精彩的地方在於，Revolution 剛把 RAS 靶點推上神壇，競爭者就開始從後方高速追擊。 4 月 27 日，Erasca 公布其 pan-RAS molecular glue ERAS-0015 的 Phase 1 劑量爬坡資料。公司將"},{"title":"Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points","url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop-en.html","date":"2026-05-06","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Free Taipei Workshop: Using an NPV Framework to Identify Biotech Re-Rating Points, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development option"},{"title":"【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點","url":"https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html","date":"2026-05-06","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","藥華藥","生技投資"],"summary":"✨講座介紹，生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。藥時事 作為擁有超過 35，000 名生醫","key_points":[],"excerpt":"✨講座介紹 生技醫藥股往往囊括了市場單日最大漲幅與最大跌幅，是極具爆發力的投資領域。然而，多數人將其視為妖股，是因為缺乏一套系統性的估值體系來了解其內在價值。 藥時事 作為擁有超過 35,000 名生醫菁英（包含醫師、科學家與專業投資人）關注的平台，將帶領你建立專業的投資判讀框架。 建立你的生醫投資「去風險化」雷達 1. 鎖定全球熱錢賽道：看懂銷售版圖 ✨全球前 20 大藥物銷售賽道拆解 利用「泡泡樹」圖表，直觀掌握腫瘤、代謝/肥胖、免疫/發炎等最熱三大塊的資本趨勢。 ✨趨勢判讀 藉由 2025 年全球前十名藥物如何高度集中在特定賽道，提早卡位下一個獲利主線。 2. 掌握新藥估值 4 大步驟：算出真實價值 ✨錨定適應症潛力 教你從患者池、可診斷率到滲透率，精算出標的的潛在銷售峰值與市場規模。 ✨臨床階段決定成功率 理解臨床數據不只是好消息，更是把未來現金流的兌現機率往上推的關鍵過程。 ✨時間與專利折現 學會將未來 10-20 年的現金流折現回今天，算出標的的內在價值，而非盲目看本益比。 ✨加總公司市值 學會分析標的如何從單一資產加總成公司整體市值。 3. 實戰案例拆解：看穿股價重估的真相 ✨以台股指標標的為例 拆解 藥華藥 等實戰案例，分析已上市資產如何成為公司最硬的估值「底座」。 ✨判讀資產價值 教你區分「研發故事」與「近上市資產」，精準衡量不同階段的折現風險。 ✨回頭看股價 教"},{"title":"What Makes a Pipeline Attractive to Big Pharma?","url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction-en.html","date":"2026-05-05","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Targeted therapy","CNS","Regulatory risk","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on What Makes a Pipeline Attractive to Big Pharma?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets "},{"title":"讓大藥廠心動的管線到底做了什麼？","url":"https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html","date":"2026-05-05","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","BD","GLP-1","ADC","CNS","FDA","藥華藥"],"summary":"📌 醫藥產業的併購邏輯，正在發生一場非常明顯的結構性變化。過去幾年，許多 Biotech 都想往最大、最熱門、最容易被資本市場理解的賽道擠：腫瘤、ADC、自體免疫、GLP-1、雙抗、細胞治療。這些方向","key_points":[],"excerpt":"📌 醫藥產業的併購邏輯，正在發生一場非常明顯的結構性變化。 過去幾年，許多 Biotech 都想往最大、最熱門、最容易被資本市場理解的賽道擠：腫瘤、ADC、自體免疫、GLP-1、雙抗、細胞治療。這些方向當然仍然重要，但問題也很現實：當所有人都擠進同一條路，原本的藍海很快就變成紅海。 到了 2026 年，跨國藥廠的買法開始變得更精準，也更冷酷。 它們不再只是追逐「最大市場」，而是開始尋找那些競爭格局乾淨、臨床需求極明確、剛剛完成關鍵 PoC 去風險化的細分資產。這些公司不一定有龐大的管線，也不一定站在最熱的靶點上，但只要數據夠乾淨、機制夠清楚、買方能立即放進自己的商業體系裡，就可能被光速買走。 2026 年第一季的兩筆交易，幾乎把這個趨勢講得一清二楚。 Eli Lilly 以初始 63 億美元、最高可達 78 億美元收購 Centessa Pharmaceuticals，核心資產是針對睡眠覺醒障礙的 cleminorexton（formerly ORX750），一款 orexin OX2 receptor agonist。Neurocrine Biosciences 則以 29 億美元現金收購 Soleno Therapeutics，取得 VYKAT XR（diazoxide choline extended-release tablets），也就是第一款 FDA 核准用於 Pra"},{"title":"The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment","url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough-en.html","date":"2026-05-04","lang":"en","category":"商業分析系列","tags":["Clinical and CMC","AI drug discovery","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Hair-Growth Drug That Jumped 47%: Why It Could Rewrite Three Decades of Hair-Loss Treatment, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-deve"},{"title":"最強生髮藥暴漲 47%， 為什麼可能改寫掉髮治療三十年僵局？","url":"https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html","date":"2026-05-04","lang":"zh-Hant","category":"商業分析系列","tags":["Veradermics","生髮藥","掉髮治療","口服 minoxidil","皮膚科"],"summary":"Veradermics 的緩釋型口服 minoxidil 讀出正向臨床資料，讓掉髮治療從醫師經驗用藥走向正式新藥開發與市場重估。","key_points":[],"excerpt":"最強生髮藥暴漲 47%：Veradermics 為什麼可能改寫掉髮治療三十年僵局？ - 4 月 27 日，美國皮膚科新藥公司 Veradermics（NYSE: MANE）因為一組掉髮臨床數據，股價單日大漲近 48%。這家公司主打的不是癌症、不是自體免疫，也不是 GLP-1，而是一個長期被醫藥市場低估、卻有巨大真實需求的領域：雄性禿與女性型落髮。觸發這波行情的，是其核心產品 VDPHL01 在男性 pattern hair loss 的 Phase 2/3 Study 302 中讀出正向結果。 VDPHL01 本質上是一款 extended-release oral minoxidil tablet，也就是緩釋型口服 minoxidil。它不是全新靶點，而是把一個已經被皮膚科醫師熟悉幾十年的老成分，用新的藥物釋放設計重新包裝成真正為掉髮而生的口服製劑。這件事的意義很大，因為過去口服 minoxidil 雖然在臨床實務中常被 off-label 使用，但原始口服版本其實是從心血管用藥借來的，並不是為長期治療掉髮而設計。Veradermics 這次做的，是把「醫師經驗用藥」變成一個有劑型邏輯、有臨床終點、有 FDA 路徑的正式藥物開發案。 01｜掉髮市場一直很大，只是長期沒有真正的新答案 💇 掉髮是一個很特別的市場。它不是危及生命的疾病，卻高度影響自信、社交、情緒與生活品質。Vera"},{"title":"In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly-en.html","date":"2026-05-03","lang":"en","category":"商業分析系列","tags":["Business Analysis","CAR-T","Big Pharma","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on In Vivo CAR-T: Bubble or the Most Expensive Ticket to Next-Generation Cell Therapy?, focusing on car-t, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and"},{"title":"體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？","url":"https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html","date":"2026-05-03","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","CAR-T","Kelonia","J&J","Gilead","生技投資"],"summary":"📌 4 月 20 日，Eli Lilly 宣布將以最高 70 億美元收購臨床階段生技公司 Kelonia Therapeutics，其中包含 32.5 億美元現金預付款，其餘則取決於後續臨床、監管與商","key_points":[],"excerpt":"📌 4 月 20 日，Eli Lilly 宣布將以最高 70 億美元收購臨床階段生技公司 Kelonia Therapeutics，其中包含 32.5 億美元現金預付款，其餘則取決於後續臨床、監管與商業里程碑；交易預計在 2026 年下半年完成。若再加上 Lilly 在 2 月以最高 24 億美元收購 Orna Therapeutics，Lilly 在不到三個月內，已對體內 CAR-T 相關平台砸下接近 94 億美元。這不是零星補管線，而是明確把 in vivo CAR-T 拉到公司未來十年技術佈局的核心位置。 真正值得注意的，不是金額本身，而是 Lilly 買進來的都不是成熟資產。KLN-1010 雖已進入 Phase 1，但截至 2025 年 ASH 公布的首批人體資料，也只治療了 4 位復發／難治性多發性骨髓瘤患者；ORN-252 則甚至還只是 clinical trial-ready 的臨床前／送件前項目。換句話說，Lilly 這次押的不是某一個已經去風險化的分子，而是兩條不同的體內 CAR-T 技術路徑，以及它們未來可能重寫細胞治療經濟學的機會。 01｜為什麼估值愈來愈貴？ 💡 先看 Kelonia。Lilly 願意把這筆交易做到 70 億美元，不是沒有依據。根據 Kelonia 在 2025 年 ASH 年會公布的首個人體資料，KLN-1010 以一次性靜脈輸注的方"},{"title":"The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker","url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition-en.html","date":"2026-05-02","lang":"en","category":"商業分析系列","tags":["Business Analysis","Big Pharma","Business development","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Ambition of an Indian Pharma Giant: Acquiring a US Drugmaker, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capit"},{"title":"印度製藥巨頭的野望！併購美國藥廠！","url":"https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html","date":"2026-05-02","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","Sun Pharma","Organon","BD","Stelara"],"summary":"【Sun Pharma 117.5 億美元收購 Organon：印度學名藥巨頭「抄底」百年女性健康平台，全球藥廠版圖正在重新排位】📌 4 月 26 日，印度最大製藥公司 Sun Pharmaceuti","key_points":[],"excerpt":"【Sun Pharma 117.5 億美元收購 Organon：印度學名藥巨頭「抄底」百年女性健康平台，全球藥廠版圖正在重新排位】 📌 4 月 26 日，印度最大製藥公司 Sun Pharmaceutical Industries（Sun Pharma）與美國醫療健康公司 Organon 正式宣布簽署最終併購協議。Sun Pharma 將以每股 14 美元現金收購 Organon 全部已發行流通股，對應企業價值 117.5 億美元。這筆交易已獲雙方董事會批准，仍需取得監管核准與 Organon 股東同意，預計於 2027 年初完成。 這不是一筆普通的跨國併購，而是一個非常清楚的產業訊號：印度學名藥巨頭正在從低成本供應商，升級成真正有全球產品組合、全球商業化網絡與跨區域整合能力的綜合型藥廠。 過去，外界看印度藥廠，最常想到的是學名藥、ANDA、低成本製造與美國市場價格競爭。但 Sun Pharma 這次買下 Organon，真正買的不是一個單一產品，也不是一條高風險研發管線，而是一整套已經建好的全球商業底盤：女性健康、成熟品牌藥、生物相似藥、全球市場通路，以及穩定現金流。 01｜這筆交易買到的，不只是 Organon，而是一套全球商業化平台 🌍 Organon 是 2021 年自 Merck & Co.（美加以外稱 MSD）分拆出來的全球醫療健康公司，總部位於美國新澤西州，在紐約"},{"title":"Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?","url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse-en.html","date":"2026-05-01","lang":"en","category":"商業分析系列","tags":["Business Analysis","CNS","Regulatory risk","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Is the 20-Year Amyloid Hypothesis in Alzheimer's Disease Starting to Collapse?, focusing on cns, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the wa"},{"title":"阿茲海默症20年來的假說開始崩盤？","url":"https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html","date":"2026-05-01","lang":"zh-Hant","category":"商業分析系列","tags":["Dcard","免費文章","Alzheimer","amyloid","FDA"],"summary":"【阿茲海默症的 Aβ 信仰，真的開始崩了嗎？】📌 4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度","key_points":[],"excerpt":"【阿茲海默症的 Aβ 信仰，真的開始崩了嗎？】 📌 4 月 16 日，一篇來自 Cochrane 的系統性綜述，再次把阿茲海默症領域最核心、也最具爭議的主軸，推回風暴中心。這份綜述的訊息極其刺耳：對輕度認知障礙（MCI）或輕度失智的阿茲海默症患者而言，amyloid-beta targeting monoclonal antibodies 在 18 個月時點對認知功能與失智嚴重程度的改善只是 trivial，對日常功能的幫助也僅是 small at best；相對地，卻會增加 amyloid-related imaging abnormalities（ARIA），也就是腦部腫脹與微小出血的風險。更直接地說，就算這些藥真的把腦中的 amyloid 清掉了，患者未必能換到足夠有感的臨床利益。 這不是一篇邊角料式的評論，而是一份系統性綜述。作者群納入了 17 項隨機對照試驗、共 20,342 名受試者，評估的不是單一藥物，而是整個 anti-amyloid antibody 類別，涵蓋 aducanumab、bapineuzumab、crenezumab、donanemab、gantenerumab、lecanemab、ponezumab、remternetug、solanezumab 等多個世代的 Aβ 單株抗體。也正因為它不是在談某一個藥，而是在談整個類別，所以這份報告一出，衝擊的"},{"title":"Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition","url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia-en.html","date":"2026-04-30","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Amazon Enters AI Drug Discovery and Challenges Nvidia's Pharma Ambition, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and"},{"title":"亞馬遜（Amazon） 參戰 AI 製藥，挑戰輝達（Nvidia）","url":"https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html","date":"2026-04-30","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","生技投資","製藥巨頭"],"summary":"過去幾年，科技巨頭切入生命科學，大多還停留在兩個角色：一種是賣算力，另一種是賣通用 AI。真正難的，是再往前跨一步，直接碰觸藥物發現這個最核心、也最挑剔的環節。因為這不只是把模型丟給研究員用而已，而是要同時解決模型選擇、資料標準、實驗流程、濕實驗驗證、結果回流與團隊協作這一整串問題。","key_points":[],"excerpt":"不只賣雲，Amazon 也要下場定義 AI 製藥：40+ 生物模型、抗體基準資料庫與 lab-in-the-loop，亞馬遜想吃下的是新藥研發的作業系統 📌 過去幾年，科技巨頭切入生命科學，大多還停留在兩個角色：一種是賣算力，另一種是賣通用 AI。真正難的，是再往前跨一步，直接碰觸藥物發現這個最核心、也最挑剔的環節。因為這不只是把模型丟給研究員用而已，而是要同時解決模型選擇、資料標準、實驗流程、濕實驗驗證、結果回流與團隊協作這一整串問題。4 月 14 日，Amazon Web Services 正式推出 Amazon Bio Discovery，很明顯就是衝著這一層來的。這不是一個單純的生命科學工具箱，也不是把幾個生物模型包成介面而已；它更像是一個面向早期藥物發現的 AI 工作平台，試圖把計算設計、模型評估、實驗對接與資料回流，全部拉進同一個系統裡。 這件事之所以值得關注，不在於 Amazon 現在才進入醫藥，而在於它過去其實早就卡在產業裡面。AWS 自己披露，全球前 20 大藥廠中已有 19 家使用 AWS 來承載 generative AI 與 machine learning 工作負載。也就是說，Amazon 原本就已經是藥廠的底層基礎設施供應商，只是多數時候扮演的是「看不見的水電系統」：資料放在它的雲上，運算跑在它的 GPU 與服務上，安全與隱私由它兜底。但這次不一樣。A"},{"title":"A Clear Read on Lilly's Current M&A Logic","url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300-en.html","date":"2026-04-29","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Obesity medicine","Big Pharma","Business development","Immunology","Clinical development","Biotech business analysis"],"summary":"A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A Clear Read on Lilly's Current M&A Logic, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may r"},{"title":"一篇文章講通現在的“禮來”併購邏輯","url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html","date":"2026-04-29","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","自體免疫","BD","臨床數據"],"summary":"💡 四個月，五筆交易，若把交易上限全部加總，Eli Lilly 在 2026 年前四個月已經丟出超過 187 億美元的併購火力：1 月的 Ventyx Biosciences、2 月的 Orna Therapeutics、3 月的 Centessa Pharmaceuticals、4 月的 Cro…","key_points":[],"excerpt":"當現金多到必須花掉：Lilly 四個月五筆併購，買的不是資產，而是 GLP-1 之後的下一個十年 💡 四個月，五筆交易，若把交易上限全部加總，Eli Lilly 在 2026 年前四個月已經丟出超過 187 億美元的併購火力：1 月的 Ventyx Biosciences、2 月的 Orna Therapeutics、3 月的 Centessa Pharmaceuticals、4 月的 CrossBridge Bio，再加上 4 月底最新的 Kelonia Therapeutics。這種密度，放在大型藥廠裡已經不是「正常 BD 節奏」，而是明確的資本配置宣言。Lilly 顯然不是在做例行補貨，而是在主動把 tirzepatide 時代創造出的巨量現金，換成下一輪估值敘事的籌碼。 很多人第一直覺會把這波併購，直接解讀成「專利懸崖焦慮」。但若只用 patent cliff 去解釋 Lilly，反而會看錯方向。Lilly 2025 年全年營收為 651.79 億美元，年增 45%；其中 Mounjaro（tirzepatide）全年營收 229.65 億美元，Zepbound（tirzepatide）全年營收 135.42 億美元，兩者合計 365 億美元以上，已經構成一台極其罕見的現金機器。更關鍵的是，Lilly 的核心產品保護並不是明天就塌：Verzenio（abemaciclib"},{"title":"When a Gray-Market Industry Gets a Seat at the Table","url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952-en.html","date":"2026-04-28","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on When a Gray-Market Industry Gets a Seat at the Table, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital ma"},{"title":"灰色產業上牌桌","url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html","date":"2026-04-28","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"🌪️ 在一處私人莊園裡，矽谷創業者、生技極客與華爾街資金坐在同一張桌上，話題從 AI、加密貨幣一路滑向更隱密的領域：BPC-157、MOTS-c、TB-500、Semax、Epitalon。這些名字不像藥，更像暗號。","key_points":[],"excerpt":"(已編輯) 一場灰市轉正的風暴：胜肽熱潮，正在重寫全球新藥與供應鏈版圖 🌪️ 在一處私人莊園裡，矽谷創業者、生技極客與華爾街資金坐在同一張桌上，話題從 AI、加密貨幣一路滑向更隱密的領域：BPC-157、MOTS-c、TB-500、Semax、Epitalon。這些名字不像藥，更像暗號。它們長期遊走在「研究用」與「人體使用」之間，被健身圈、抗老圈、功能醫學診所與生物駭客社群反覆轉傳。如今，美國監管層終於不再假裝沒看見這件事。2026 年 4 月，美國 FDA 宣布將在 7 月 23 日至 24 日召開 Pharmacy Compounding Advisory Committee（PCAC）會議，討論 BPC-157、KPV、TB-500、MOTS-c、Emideltide、Semax 與 Epitalon 等胜肽（peptides），是否應納入 503A bulks list；Robert F. Kennedy Jr. 也公開表態支持讓更多胜肽（peptides）回到合規調劑體系，而不是繼續被擠在黑市與灰市之間。這不是小眾圈子的八卦，而是監管開始正面承認：需求沒有消失，只是被逼到監管看不見的地方。 📌 不是全面開放，而是把需求拉回可監管框架 ✨ 不過，這波轉向若要說得精準，並不是一句「直接回到 Category 1」就能帶過。更正確的說法是：FDA 先把部分胜肽（peptid"},{"title":"Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break","url":"https://drugnews.com.tw/articles/2026-04-27-car-t-en.html","date":"2026-04-27","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","CAR-T","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Goodbye Autologous CAR-T: Why Taiwan's Cell-Therapy Bubble Also Needs to Break, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionali"},{"title":"再見自體CAR-T，台灣的泡沫也該破了","url":"https://drugnews.com.tw/articles/2026-04-27-car-t.html","date":"2026-04-27","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資"],"summary":"當市場還在用過去十年對自體 CAR-T 的理解框架看細胞治療時，異體 CAR-T 其實已經悄悄走到一個更關鍵的節點。","key_points":[],"excerpt":"異體 CAR-T 的歷史性一跳：Cema-cel 為什麼可能是細胞治療真正走向成藥的分水嶺 當市場還在用過去十年對自體 CAR-T 的理解框架看細胞治療時，異體 CAR-T 其實已經悄悄走到一個更關鍵的節點。2026 年 4 月 13 日，Allogene Therapeutics 公布了 pivotal Phase 2 ALPHA3 試驗的中期無效性分析：在第一線鞏固治療的大 B 細胞淋巴瘤（large B-cell lymphoma, LBCL）病人中，接受 cemacabtagene ansegedleucel（cema-cel）的病人，Day 45 的微小殘留疾病（minimal residual disease, MRD）清除率達 58.3%，而觀察組只有 16.7%；更值得注意的是，cema-cel 組同時出現 97.7% 的 ctDNA 中位數下降，且沒有 cytokine release syndrome（CRS）、沒有 immune effector cell-associated neurotoxicity syndrome（ICANS）、沒有 graft-versus-host disease（GvHD），也沒有治療相關嚴重不良事件。10 位病人全程門診完成治療，另外 2 位短暫住院，事件也都被判定與 cema-cel 無關。幾天後，公司又宣布 ALPHA3 "},{"title":"The Healthcare-Giant Spin-Off Wave","url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593-en.html","date":"2026-04-26","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Healthcare-Giant Spin-Off Wave, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may repri"},{"title":"醫療巨頭分拆潮？","url":"https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html","date":"2026-04-26","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","生技投資"],"summary":"這幾年，全球大型企業在醫療產業做了一個很有意思、而且愈來愈頻繁的動作：把原本放在大集團裡的醫療業務拆出來，讓它獨立上市、獨立融資、獨立做決策。","key_points":[],"excerpt":"這幾年，全球大型企業在醫療產業做了一個很有意思、而且愈來愈頻繁的動作：把原本放在大集團裡的醫療業務拆出來，讓它獨立上市、獨立融資、獨立做決策。 表面上，這看起來像是一場財務操作。 但如果把時間拉長來看，它其實更像是一場組織結構的重新定價：資本市場愈來愈不願意替「什麼都做一點」的老式巨頭付高估值，反而更願意為聚焦、清晰、容易講成長故事的專業公司買單。尤其在醫療器材、診斷、醫療資訊化這些需要快速產品迭代、併購整合與全球市場執行的領域，放在大集團裡看似安全，實際上卻常常意味著資源被稀釋、節奏被拖慢、決策被層層稀釋。 但分拆這件事，從來不是一顆萬靈丹。 有些公司拆完之後，母體與子公司真的出現了「1+1＞2」的效果；有些則只是把原本就不太好做的業務，單獨丟到市場上接受更殘酷的檢驗。也就是說，分拆本身不是答案，分拆後的業務本質才是答案。 最近最值得拿來做案例的，就是 Solventum。 🔹一、Solventum：3M 斷開醫療業務後，市場為什麼重新開始認真看它？ 如果今天單獨把 Solventum 拿出來講，很多人第一眼可能還是會有點陌生。但只要補上一句「它就是 3M 拆出來的醫療公司」，整件事就瞬間合理了。 3M 在 2024 年 4 月 1 日正式完成醫療事業分拆，讓 Solventum 以獨立公司身分在紐約證交所掛牌。3M 當時就已明確說明，Solventum 是其原本醫療保健業務的"},{"title":"Why Platform Biotechs Can Generate Five Times More Licensing Revenue","url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5-en.html","date":"2026-04-25","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Why Platform Biotechs Can Generate Five Times More Licensing Revenue, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and"},{"title":"平台型 Biotech 的授權收入是同業的 5 倍？","url":"https://drugnews.com.tw/articles/2026-04-25-biotech-5.html","date":"2026-04-25","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"如果把 Biotech 的商業模式拆開來看，最容易被低估、但其實最值錢的一種公司，往往不是手上只有一顆明星分子的資產型公司，而是那些擁有底層技術引擎的平台型公司。","key_points":[],"excerpt":"為什麼平台型 Biotech 的授權收入，常常是同業的 5 倍？ 如果把 Biotech 的商業模式拆開來看，最容易被低估、但其實最值錢的一種公司，往往不是手上只有一顆明星分子的資產型公司，而是那些擁有底層技術引擎的平台型公司。這不是一句抽象口號，而是已有回顧分析支持的現象：一項針對 220 家公司、追蹤 10 至 15 年發展軌跡的回顧指出，平台型公司不只更常做成 out-licensing，60% 至少完成過一筆授權交易，明顯高於非平台型公司的 39%；更重要的是，它們平均可拿到的總潛在交易價值約 7.48 億美元，而非平台型公司平均只有 1.36 億美元。這不是小幅領先，而是結構性的差距。 🔹不是比較會講故事，而是比較容易讓大藥廠相信：你買到的是一台機器 很多人看到這組數字，第一反應是：平台型公司是不是比較會講故事？ 其實剛好相反。平台型公司之所以授權收入明顯更高，核心不在於它們比較會講，而在於它們比較容易讓大藥廠相信：你今天買下的，不只是一顆分子，而是一台可以持續產生分子的機器。 對大型製藥公司來說，單資產型 Biotech 的價值，通常集中在一個特定標靶、一個特定適應症，甚至就是一個特定 readout；但平台型公司賣的，是一套可被複製、可被延伸、可被移植到多個標靶與疾病上的生產能力。只要這個前提成立，平台天然就會創造更多潛在授權標的，也更容易談出高價值合作。Recon"},{"title":"Investors Should Pay Attention: Drug Delivery Is a Blue Ocean","url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193-en.html","date":"2026-04-24","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Investors Should Pay Attention: Drug Delivery Is a Blue Ocean, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the wa"},{"title":"投資人請注意，給藥方式是藍海！","url":"https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html","date":"2026-04-24","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"這幾年，如果你把跨國藥廠的動作連起來看，會發現一個非常一致、幾乎帶著戰略共識的方向：把原本靠靜脈輸注（IV）的重磅生物藥，盡可能改造成皮下注射（SC）版本。","key_points":[],"excerpt":"大藥廠為何集體把生物藥推向皮下？未來 3 到 5 年，真正的大藍海可能不在分子本身，而在給藥方式 這幾年，如果你把跨國藥廠的動作連起來看，會發現一個非常一致、幾乎帶著戰略共識的方向：把原本靠靜脈輸注（IV）的重磅生物藥，盡可能改造成皮下注射（SC）版本。 Roche 把 trastuzumab、rituximab、pertuzumab/trastuzumab，一路做到 Herceptin Hylecta、Rituxan Hycela、Phesgo；之後又把 atezolizumab 做成 Tecentriq Hybreza。Johnson & Johnson 則把 daratumumab 從 IV 推到 DARZALEX FASPRO。Merck 更進一步，在 2025 年讓 KEYTRUDA QLEX（pembrolizumab and berahyaluronidase alfa）獲 FDA 核准，並在同年拿下歐盟皮下給藥核准。這不是單點優化，而是一場明顯的產業級轉向。 表面上，這場轉向很溫和，也很容易被包裝成「以患者為中心」的醫療進步：原本要在醫院坐上幾個小時吊點滴，現在可能幾分鐘，甚至幾十秒到幾分鐘內就能完成皮下注射；病人省時間，醫護省椅位，醫療系統也省資源。這些都是真的。但如果只看到這一層，還是低估了大藥廠的真正用意。更深一層看，SC 化其實是大型藥廠面對專利懸崖與生物相"},{"title":"Do COPD Patients Finally Have Another New Drug Option?","url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566-en.html","date":"2026-04-23","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Do COPD Patients Finally Have Another New Drug Option?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capit"},{"title":"慢性阻塞性肺病患者又有新藥可以用了？","url":"https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html","date":"2026-04-23","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2025 年，對 IL-33/ST2 這條曾被寄予厚望的發炎路徑而言，幾乎是一整年的信心潰散。","key_points":[],"excerpt":"🔹 IL-33 靶點從連番受挫到強勢翻盤，Tozorakimab 為何能一戰翻身 2025 年，對 IL-33/ST2 這條曾被寄予厚望的發炎路徑而言，幾乎是一整年的信心潰散。 先是 Sanofi / Regeneron 的 itepekimab 在兩項 COPD 三期研究裡只打出「一勝一負」：AERIFY-1 達標，但 AERIFY-2 未達主要終點。接著又輪到 Roche 的 astegolimab，其關鍵開發計畫同樣呈現分裂結果：Phase IIb ALIENTO 正向，但 Phase III ARNASA 失利。當兩家跨國藥廠、兩條相近機制、接連交出這樣的成績單時，市場很自然地開始追問：是不是大家一開始就高估了 IL-33/ST2 在 COPD 的位置？ 這種懷疑不是沒有道理。 慢性阻塞性肺病（COPD）本來就是最不容易做出漂亮創新藥結果的疾病之一。它不只是全球主要死因之一，還是一個病理高度異質、病人來源極雜、吸菸史與發炎表型交織在一起的複雜疾病。根據近年的全球資料，COPD 影響的人數已超過 4 億，並持續被視為全球第三大死因之一。問題不在於市場夠不夠大，而在於這個市場太大、太重、也太難打，導致每一次機制失敗，幾乎都會被放大成整條路線的信任危機。 就在這種悲觀情緒幾乎定型的時候，2026 年 3 月，AstraZeneca 公布了 tozorakimab 在兩項複製性三"},{"title":"The Three AI Giants Battling Inside Medicine","url":"https://drugnews.com.tw/articles/2026-04-22-ai-en.html","date":"2026-04-22","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Three AI Giants Battling Inside Medicine, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets ma"},{"title":"AI三巨頭在醫藥裡廝殺","url":"https://drugnews.com.tw/articles/2026-04-22-ai.html","date":"2026-04-22","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","BD","臨床數據","生技投資","製藥巨頭"],"summary":"ChatGPT、Claude、Gemini 這三大通用大模型，現在打的已經不只是消費端流量，也不是一般企業辦公市場，而是開始往生醫製藥產業鏈的深水區插旗。","key_points":[],"excerpt":"ChatGPT、Claude、Gemini 這三大通用大模型，現在打的已經不只是消費端流量，也不是一般企業辦公市場，而是開始往生醫製藥產業鏈的深水區插旗。真正值得注意的，不是哪一家又多發了一個模型版本，而是它們切入醫藥行業的方式其實完全不同：有的先吃下長文本與監管文書，有的直接往底層生物學與藥物設計滲透，還有的則試圖把整家藥廠變成一個由 AI 驅動的營運系統。這不是同一場仗，只是都發生在同一張牌桌上。 ✦【先看 Claude：先吃下最重、最密、最不能出錯的知識工作】 如果說製藥是一條由標靶發現、臨床開發、CMC、法規申報、醫學事務與商業化串起來的長鏈條，那麼 Claude 目前最強的切入點，不在最前端的分子生成，而在那些文本極重、知識密度極高、錯誤成本極高的環節。Anthropic 在 2025 年推出 Claude for Life Sciences，2026 年又進一步發布 Claude for Healthcare 與生命科學擴展工具，等於正式把這條路線產品化。更重要的是，Sanofi 已公開表示，Claude 已成為其 AI 轉型的重要核心，多數員工每天都在使用，並已在整條價值鏈上帶來效率提升。這說明 Claude 在製藥領域當前最強的定位，不是「幫你發明新藥」，而是先把知識工作最重、最煩、最不能出錯的那一層吃下來。 Claude 更值得注意的，是它並不滿足於只做文件型工具"},{"title":"Did Lilly's Oral Drug Ignite the Market?","url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270-en.html","date":"2026-04-21","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Obesity medicine","Big Pharma","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Did Lilly's Oral Drug Ignite the Market?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may re"},{"title":"禮來口服藥引爆市場？","url":"https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html","date":"2026-04-21","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年 4 月，Eli Lilly 的 Foundayo（orforglipron） 獲 FDA 核准，用於成人肥胖，或合併體重相關共病的過重族群。","key_points":[],"excerpt":"Orforglipron 引爆口服減重藥第二戰場：狂歡背後，真正的考題才剛開始 2026 年 4 月，Eli Lilly 的 Foundayo（orforglipron） 獲 FDA 核准，用於成人肥胖，或合併體重相關共病的過重族群。這不只是另一顆減重藥上市，而是一個足以改寫產業節奏的事件：它是美國最新一輪快速審查機制下核准的新分子實體，也是目前唯一獲准用於減重、且可不受進食與飲水限制的口服 GLP-1 藥物。根據 Lilly 公布的資料，ATTAIN-1 研究中，高劑量組完成治療者平均減重約 27.3 磅（12.4%）。這意味著，減重藥市場真正的第二戰場，已經從注射劑正式延伸到口服劑型。 🔹 口服減重藥，不只是更方便而已 問題在於，Orforglipron 的上市，帶來的不只是「更方便的 Wegovy 替代品」這麼簡單。它把整個市場的競爭邏輯往前推了一步：過去，GLP-1 類藥物的第一階段競爭，核心是療效能不能成立；現在，這個問題基本上已經被回答。接下來真正決定市場天花板的，會變成誰更容易被開始使用、誰更容易被長期使用、誰更容易被支付體系接受。而這三件事，恰恰都是口服劑型最有可能改寫的地方。 這也是為什麼，口服減重藥不只是劑型創新，而是一場結構性市場擴張。注射型 GLP-1 藥物已經證明，對重度肥胖與高代謝風險族群，它們能提供非常強的臨床價值；但在真實世界裡，很多潛在使用者並不"},{"title":"A Historic Moment: The Next Century-Defining Drug Has Arrived","url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702-en.html","date":"2026-04-20","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A Historic Moment: The Next Century-Defining Drug Has Arrived, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way ca"},{"title":"歷史性一刻，世紀大藥來了","url":"https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html","date":"2026-04-20","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資"],"summary":"4 月 13 日，Revolution Medicines 公布 daraxonrasib（RMC-6236） 在三期臨床 RASolute 302 的頂線結果。","key_points":[],"excerpt":"歷史性一夜：daraxonrasib 如何把 RAS 靶向治療推進新紀元 4 月 13 日，Revolution Medicines 公布 daraxonrasib（RMC-6236） 在三期臨床 RASolute 302 的頂線結果。對於既往接受過治療的轉移性胰臟導管腺癌（metastatic PDAC）患者，這顆口服藥把整體意向治療族群的中位總生存期，從化療組的 6.7 個月 拉高到 13.2 個月，死亡風險比為 0.40，且 p < 0.0001。對一個五年存活率長期徘徊在約 13%、幾乎總是被視為「最難打」的實體腫瘤來說，這不是單純的正面數據，而是一個足以改寫臨床心理預期的時刻。 🔹 這組結果之所以震撼，不只是因為數字漂亮，而是因為它發生在胰臟癌 胰臟癌的殘酷，從來不只是惡性度高，而是它往往在診斷時就已經太晚，能切除的病人不多，能真正受益於後線治療的選項更少。當二線或後線治療長期只能在有限化療與少數分子分層藥物間勉強周旋時，daraxonrasib 這種把總生存幾乎拉到翻倍的結果，自然會被視為一種帶有里程碑意味的突破。Revolution 也表示，將把這批數據提交全球監管機關，並擬透過 Commissioner’s National Priority Voucher 加速 NDA 審查。 若只把這件事看成「又一顆新藥在胰臟癌成功」，其實還低估了它真正的產業意義。darax"},{"title":"Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know","url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10-en.html","date":"2026-04-19","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","CNS","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Neuralink and the Next Trillion-Dollar Race: Ten Brain-Computer Interface Companies to Know, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-developm"},{"title":"馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！","url":"https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html","date":"2026-04-19","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","臨床數據","生技投資"],"summary":"到了 2026 年，腦機介面（brain-computer interface, BCI）已經不再只是科幻敘事或實驗室展示，而是逐漸分化成幾條很清楚的產業路線：一條走侵入式植入，目標是讓癱瘓患者重新溝通、操作設備甚至恢復部分功能；一條走非侵入式穿戴，強調腦訊號量測、認知監測與日常應用；還有一條則更像…","key_points":[],"excerpt":"腦機介面，真正值得追的 10 家公司：不是只有 Neuralink，而是 10 條不同的未來路線 到了 2026 年，腦機介面（brain-computer interface, BCI）已經不再只是科幻敘事或實驗室展示，而是逐漸分化成幾條很清楚的產業路線：一條走侵入式植入，目標是讓癱瘓患者重新溝通、操作設備甚至恢復部分功能；一條走非侵入式穿戴，強調腦訊號量測、認知監測與日常應用；還有一條則更像底層基礎建設，提供研究設備、資料平台、演算法環境與神經復健系統。 BioPharmaTrend 在 2025 年底整理的 10 家代表公司之所以值得看，不是因為它們都會變成同一種公司，而是因為它們分別定義了 BCI 產業未來可能長成的 10 種樣子。 真正理解這份名單的方式，不是把它當成單純排名，而是把它視為一張產業地圖。因為今天的腦機介面，早已不是單一技術賽道，而是材料、晶片、植入手術、無線訊號、AI 解碼、神經復健、消費性裝置與數位健康服務同時交錯的集合體。以下這 10 家公司之所以重要，正是因為它們各自抓住了這個產業最關鍵的一塊拼圖。 ✦【1. Neuralink：把侵入式 BCI 從概念推向工程化量產的人】 如果說哪一家公司把腦機介面真正推上全球主流媒體與資本市場的舞台，答案幾乎就是 Neuralink。這家公司成立於 2016 年，核心價值不只在於做出腦植入物，而在於它試圖把侵入式"},{"title":"Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?","url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai-en.html","date":"2026-04-18","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Capital markets","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Could This Taiwanese Biotech Capture the Entire AI Infrastructure Dividend?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality,"},{"title":"台灣這家Biotech將吃下AI基礎建設的所有紅利？","url":"https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html","date":"2026-04-18","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","自體免疫","臨床數據","生技投資"],"summary":"AI 吃電，核電回來了：為什麼麗寶新藥，可能站在下一個被重估的位置？","key_points":[],"excerpt":"AI 吃電，核電回來了：為什麼麗寶新藥，可能站在下一個被重估的位置？ 這兩年，市場都在追 AI。 有人追 GPU，有人追伺服器，有人追資料中心，也有人追電力股。 但如果再往下看一層，AI 真正推動的，從來不只是算力軍備競賽，而是整個能源供應鏈與安全備援體系的重新估值。 國際能源總署預估，到了 2030 年，全球資料中心用電量將成長到約 945 TWh，AI 是最重要的推動力量之一；同時，國際能源總署也明白指出，為了支撐資料中心新增的龐大用電需求，核能在這個世代後半段的重要性會愈來愈高。 放到核能供給端來看，國際原子能總署的資料顯示，截至 2026 年 3 月，全球有 413 座核電反應爐正在運轉，另有 69 座在建；世界核能協會的統計則更高一些，認為全球約有 440 座正在運轉，約 70 座在建，另有約 120 座已規劃。 這代表一件事：核能不是過去式，而是重新進入成長期的產業。 而當核能回到牌桌，真正會被重估的，不會只有發電設備。 因為核能從來不只是反應爐與電網，它背後還有一整套安全體系。世界衛生組織在 2023 年更新「輻射與核緊急事件關鍵藥物清單」時，就明確把這個領域分成幾大類，包括穩定碘、去除體內放射性污染的藥物，以及用來處理急性放射線症候群、尤其是骨髓與造血系統損傷的細胞因子藥物。 換句話說，核安醫療不是一個空泛概念，而是一套早就被世界衛生組織與各國政府正式定義出來的備援"},{"title":"The Valley of Death in Innovative Drug Development","url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054-en.html","date":"2026-04-17","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Valley of Death in Innovative Drug Development, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital m"},{"title":"創新藥開發的「死亡之谷」","url":"https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html","date":"2026-04-17","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"創新藥研發最殘酷的地方，不在於它難，而在於你往往在一開始就知道，它極可能失敗，卻還是必須投入多年時間、巨額資本，以及一整個團隊的職業生涯去把它往前推。","key_points":[],"excerpt":"真正吞噬專案的，從來不只是不夠努力 創新藥研發最殘酷的地方，不在於它難，而在於你往往在一開始就知道，它極可能失敗，卻還是必須投入多年時間、巨額資本，以及一整個團隊的職業生涯去把它往前推。 所謂「死亡之谷（Valley of Death）」之所以在生技醫藥圈反覆被提起，正是因為它不是一句危言聳聽的行話，而是整個產業最真實的結構性命題：從一個在實驗室裡看起來很有希望的發現，到真正成為能改變病人命運的藥物，中間隔著的不是單一道門檻，而是一整片高失敗率、高成本、高不確定性的無人區。 「死亡之谷」這個比喻本來就不是生醫圈獨有的詞。它在 1990 年代美國的科技政策與創新融資討論中逐漸成形，1998 年美國國會《Unlocking Our Future: Toward a New National Science Policy》已明確用它來描述基礎研究與產業化之間那段最容易失血、也最容易失去支持的斷裂帶；到了 2008 年，Nature 以〈Crossing the valley of death〉為題討論生醫轉譯困境後，這個概念才真正進入今日大家熟悉的「從 bench 到 bedside」語境。 後來，轉譯醫學又把它進一步拆得更細：不只是一個谷，而是沿著 T1、T2、T3、T4 轉譯光譜分布的多重斷點；其中最核心、最致命的，依然是 T1 與 T2，也就是從基礎發現走到人體試驗，以及從早期臨床"},{"title":"The 2026 Q2 Drug Catalysts Biotech Readers Need to Know","url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2-en.html","date":"2026-04-16","lang":"en","category":"商業分析系列","tags":["Business Analysis","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The 2026 Q2 Drug Catalysts Biotech Readers Need to Know, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital market"},{"title":"生技人必須知道的 2026 Q2 重磅藥物","url":"https://drugnews.com.tw/articles/2026-04-16-2026-q2.html","date":"2026-04-16","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資","製藥巨頭"],"summary":"2026 年第二季，全球生技醫藥產業正走進一個少見的高密度催化期。若把臨床讀數、監管決策與關鍵會議節點一起看，從 4 月到 6 月前後，至少有 17 個值得緊盯的重磅資產將陸續揭曉方向；更早一步，Eli Lilly 的口服減重藥 orforglipron（Foundayo） 已在 4 月 1 日獲 …","key_points":[],"excerpt":"17 個重磅藥物，正在把 2026 年 Q2 變成生醫產業的分水嶺 2026 年第二季，全球生技醫藥產業正走進一個少見的高密度催化期。若把臨床讀數、監管決策與關鍵會議節點一起看，從 4 月到 6 月前後，至少有 17 個值得緊盯的重磅資產將陸續揭曉方向；更早一步，Eli Lilly 的口服減重藥 orforglipron（Foundayo） 已在 4 月 1 日獲 FDA 核准，也等於替整個季度先開了一槍。這一波催化之所以重要，不只是因為數量多，而是因為其中多數資產都已走到晚期臨床、關鍵監管或平台定錨階段，結果將直接改寫未來幾年的賽道排序。 ✦更精確地說，這不是一個單純「消息很多」的季度，而是一個會同時回答多個產業級問題的季度： 🔹 CRISPR 體內編輯到底成熟到哪裡了？ 🔹 allogeneic CAR-T 能不能真的走出個體化製造限制？ 🔹 Lp(a) 降低到底會不會轉成心血管事件下降？ 🔹 晚期腫瘤裡的 KRAS、LAG-3 與 PD-1/VEGF 雙抗組合是否真的能撬動標準治療？ 🔹 眼科長效遞送、口服免疫調節與神經退化新抗體，又能不能把給藥模式與疾病機制一起往前推。 嚴格來說，並非所有事件都會在同一個季度內完整揭露，例如 PMN310 的 blinded interim analysis 已由公司更新為早期 Q3；但市場關注的高峰，毫無疑問就是這個 Q2。 ✦"},{"title":"The Fall of Two Star Biotechs","url":"https://drugnews.com.tw/articles/2026-04-15-biotech-en.html","date":"2026-04-15","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Fall of Two Star Biotechs, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may reprice the co"},{"title":"兩家明星 Biotech 的隕落","url":"https://drugnews.com.tw/articles/2026-04-15-biotech.html","date":"2026-04-15","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","BD","臨床數據","生技投資","製藥巨頭"],"summary":"2025 年的生技產業，表面上看起來不像 2022 年那麼驚慌，但真正懂產業的人都知道，市場其實正在經歷一場更深層的重估。","key_points":[],"excerpt":"2025 年最殘酷的訊號，不是沒技術，而是活不到商業化 2025 年的生技產業，表面上看起來不像 2022 年那麼驚慌，但真正懂產業的人都知道，市場其實正在經歷一場更深層的重估。依 Fierce Biotech 年底的 graveyard 清單，2025 年美國共有 16 家 Biotech 正式關門，另有 3 家已一腳踏進墳場；雖然低於 2024 年的 22 家，但更值得警惕的不是數量，而是倒下公司的質地愈來愈高：不再只是沒人記得的小型早期平台，而是那些曾拿過大額融資、擁有明星科學家、甚至已經走到臨床後段的「明星 Biotech」。 ✦【如果要用兩家公司，概括這個新時代最殘酷的真相】 如果要用兩家公司來概括這個新時代最殘酷的真相，Carisma Therapeutics 與 Lyndra Therapeutics 幾乎是最有代表性的兩個案例。前者代表的是「技術成立，但資本與合作關係先斷掉」；後者代表的是「臨床幾乎走到終點，卻 still die on the last mile」。這兩種死法不同，但共同指向同一件事： 今天的 Biotech，臨床成功已不再等於公司能活下去。 ✦【Carisma Therapeutics：不是科學先死，而是資本先走】 先看 Carisma Therapeutics。它曾是 CAR-M 路線最具代表性的公司之一，也拿過 Moderna 的合作背書，原"},{"title":"Investors Should Pay Attention to the Autoimmune Mega-Drug Race","url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358-en.html","date":"2026-04-14","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Investors Should Pay Attention to the Autoimmune Mega-Drug Race, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the "},{"title":"投資人請注意，自體免疫超大藥賽道","url":"https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html","date":"2026-04-14","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"自體免疫藥物市場，從來都不是「穩定但無聊」的成熟市場。恰恰相反，它一直是全球最容易長出重磅藥物的沃土之一，而乾癬（psoriasis），正是這條價值鏈裡最具代表性的試驗場。","key_points":[],"excerpt":"自體免疫超大藥賽道全面升級：從乾癬紅海到 IBD 雙路徑革命 自體免疫藥物市場，從來都不是「穩定但無聊」的成熟市場。恰恰相反，它一直是全球最容易長出重磅藥物的沃土之一，而乾癬（psoriasis），正是這條價值鏈裡最具代表性的試驗場。光看 2025 年幾個關鍵產品的銷售表現，就足以感受到這條賽道的厚度：risankizumab（Skyrizi） 年銷售已達 175.62 億美元，upadacitinib（Rinvoq） 達 83.04 億美元，secukinumab（Cosentyx） 為 66.68 億美元，apremilast（Otezla） 為 23 億美元，bimekizumab（Bimzelx） 也已衝到 22.27 億歐元；即使仍處於放量初期的 deucravacitinib（Sotyktu），2025 年也已做到 2.91 億美元。這不是一個已經飽和、只剩價格競爭的市場，而是一個仍在持續升級、持續長出新機會的市場。 乾癬這條線，本來就是一部治療升級史 如果把乾癬藥物的發展史拉長來看，它本質上是一部「治療機轉不斷更新、臨床標準不斷上修」的產業進化史。從早期的 TNF-α inhibitors（腫瘤壞死因子α抑制劑），到後來的 IL-12/23、IL-17、IL-23 生物製劑，再到 PDE4、TYK2 等口服小分子，乾癬治療一路從「能不能壓住發炎」走向「能不能更深度清除"},{"title":"The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?","url":"https://drugnews.com.tw/articles/2026-04-13-78-en.html","date":"2026-04-13","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The King of Weight-Loss Drugs: Did US$7.8 Billion Buy the Next Era of Metabolic Medicine?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-developmen"},{"title":"減肥藥之王 78億美元，買下一個「清醒時代」？","url":"https://drugnews.com.tw/articles/2026-04-13-78.html","date":"2026-04-13","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","BD","臨床數據","生技投資"],"summary":"當 Eli Lilly（禮來） 以最高 78 億美元 收購 Centessa Pharmaceuticals，這筆交易表面上看，是大藥廠再一次用高溢價把一條中期臨床資產收入囊中；但若把時間線再拉長一點，它其實更像是一場很有方向感的提前卡位。","key_points":[],"excerpt":"禮來重押睡眠與 OX2R 賽道 當 Eli Lilly（禮來） 以最高 78 億美元 收購 Centessa Pharmaceuticals，這筆交易表面上看，是大藥廠再一次用高溢價把一條中期臨床資產收入囊中；但若把時間線再拉長一點，它其實更像是一場很有方向感的提前卡位。因為 Lilly 買下的不只是 cleminorexton 這一顆藥，而是整個 orexin receptor 2（OX2R） 機制在睡眠—覺醒障礙、神經退化疾病，甚至更廣泛中樞神經系統場景中的長期選擇權。 這也是為什麼，若只把這筆交易理解為「Lilly 想補一條神經科學管線」，其實還不夠。更準確的說法是：在 tirzepatide 已經把代謝與體重管理從嚴肅醫療推向更大消費場景之後，Lilly 正在尋找下一個既有明確醫學需求、又有可能外溢到更大生活方式市場的機制。睡眠與清醒，剛好符合這個條件。Lilly 自己也早已把睡眠議題從代謝場景往前推進，因為 Zepbound（tirzepatide） 已在 2024 年底取得 FDA 核准，用於治療合併肥胖的中重度阻塞型睡眠呼吸中止症（OSA）。這意味著，Lilly 並不是突然看見睡眠，而是早就開始把睡眠視為下一個值得做大的臨床與商業介面。 一場不是單純追價的併購 根據 Lilly 與 Centessa 公布的交易條款，Lilly 將以 每股 38 美元現金收購 Cent"},{"title":"Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase","url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303-en.html","date":"2026-04-12","lang":"en","category":"商業分析系列","tags":["Business Analysis","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Idiopathic Pulmonary Fibrosis Is Entering an Acceleration Phase, focusing on immunology, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capita"},{"title":"特發性肺纖維化 迎來爆發","url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html","date":"2026-04-12","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資"],"summary":"特發性肺纖維化，idiopathic pulmonary fibrosis（IPF），從來都不是一個容易講出樂觀故事的領域。這是一種慢性、進行性、不可逆的纖維化肺病，預後差、死亡風險高，過去長年幾乎等同於「只能拖慢，不能扭轉」。","key_points":[],"excerpt":"IPF 真的要熱起來了：雙寡頭鬆動之後，下一輪肺纖維化大戰已經開打 雙寡頭鬆動的起點 特發性肺纖維化，idiopathic pulmonary fibrosis（IPF），從來都不是一個容易講出樂觀故事的領域。這是一種慢性、進行性、不可逆的纖維化肺病，預後差、死亡風險高，過去長年幾乎等同於「只能拖慢，不能扭轉」。現行治療雖然已有 nintedanib（Ofev） 與 pirfenidone（Esbriet） 兩個抗纖維化標準藥物，但兩者本質上都更像是「延緩惡化」而不是真正改寫病程；而且不論是 nintedanib 常見的腹瀉、噁心、嘔吐與肝功能異常，還是 pirfenidone 常見的噁心、皮疹、腹痛、腹瀉與光敏感，都讓耐受性與長期依從性成為臨床現場始終無法迴避的問題。這也是為什麼，儘管肺纖維化在美國約影響 10 萬人、IPF 在全球的整體盛行率並不低，而更廣義的進行性纖維化間質性肺病人群又遠大於 IPF 本身，這個領域至今仍被視為典型的「有藥，但遠遠不夠」的未滿足需求市場。 如果把時間拉長來看，IPF 市場真正的分水嶺其實已經出現。過去十多年，市場基本上由 Ofev 與 Esbriet 兩個品牌主導；但 2022 年起，美國首批 generic pirfenidone 上市，Esbriet 的品牌護城河開始被快速侵蝕。相對之下，Ofev 不只守住了地位，2025 年銷售還進一步成"},{"title":"Why Did the Market Like This Company More After a Clinical Failure?","url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232-en.html","date":"2026-04-11","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Why Did the Market Like This Company More After a Clinical Failure?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the"},{"title":"這家公司臨床試驗失敗，反而被更加看好？","url":"https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html","date":"2026-04-11","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"甲狀腺相關眼疾（thyroid eye disease, TED）這條賽道，最近又迎來一次很典型、也很殘酷的產業教育。","key_points":[],"excerpt":"III 期失利不是句點：當 batoclimab 倒下，IMVT-1402 還有機會挑戰 Tepezza 嗎？ 甲狀腺相關眼疾（thyroid eye disease, TED）這條賽道，最近又迎來一次很典型、也很殘酷的產業教育。2026 年 4 月 2 日，Immunovant 宣布其第一代 FcRn 抑制劑 batoclimab（IMVT-1401） 在兩項 TED 的 III 期試驗中雙雙失利，未達主要終點。對一家押注自體抗體清除邏輯的公司來說，這當然不是好消息；但更值得玩味的是，這場失敗很可能不只是終點，而是一次把機制邊界、臨床門檻與下一代產品策略全部照亮的事件。 ✦【batoclimab 為什麼輸？問題不是沒有訊號，而是訊號不夠強到能撐過劑量下修】 從試驗設計來看，batoclimab 的 TED III 期研究其實不是單純「藥物完全沒作用」。兩項試驗的主要終點，都是在第 24 週評估眼球突出改善至少 2 mm 的反應率；而給藥策略則是先用 12 週高劑量，再接 12 週低劑量。根據 Immunovant 自己的說明，兩項研究雖然都沒有達標，但病人在前 12 週高劑量期間的突眼改善，明顯優於後 12 週低劑量階段。這一點很關鍵，因為它代表失敗的本質並不是「FcRn 壓低 IgG 完全沒有臨床價值」，而是需要更深 IgG 抑制時，安全性卻不允許你把高劑量一路維持下去。 而這"},{"title":"When Should a Company Decisively Abandon a Clinical Trial?","url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760-en.html","date":"2026-04-10","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on When Should a Company Decisively Abandon a Clinical Trial?, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way c"},{"title":"何時果斷放棄新藥臨床試驗開發？","url":"https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html","date":"2026-04-10","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資","製藥巨頭"],"summary":"新藥開發最難的，往往不是立項那一天，而是明明已經看見風險，卻仍不願按下停止鍵的那一天。每一個研發專案開始時，幾乎都帶著同樣的想像：要做到 first-in-class、要走到 pivotal study、要送件、要上市、要成為下一個成長引擎。然而現實比願景殘酷得多。","key_points":[],"excerpt":"如何優雅地終止一個新藥開發案：真正成熟的藥廠，懂得在對的時點收手 新藥開發最難的，往往不是立項那一天，而是明明已經看見風險，卻仍不願按下停止鍵的那一天。每一個研發專案開始時，幾乎都帶著同樣的想像：要做到 first-in-class、要走到 pivotal study、要送件、要上市、要成為下一個成長引擎。然而現實比願景殘酷得多。新藥研發通常要走超過十年，成本估計從數億美元到數十億美元不等，而進入臨床的候選藥最終能獲批上市的比例，長期都不到一成。真正穿越週期、持續推出產品的公司，幾乎都不是因為它們「很少失敗」，而是因為它們更早承認限制、更快做出取捨，也更有紀律地把資源撤離那些已經不再值得繼續的案子。 這件事在全球大型藥廠的研發管理邏輯裡，早就不是消極防守，而是核心能力。AstraZeneca 曾把研發決策明確收斂到 5R framework：right target、right tissue、right safety、right patient、right commercial potential，並強調研發團隊必須主動提出會「殺死自己假說」的 killer questions。Pfizer 近十年的公開經驗也很接近：它把 end-to-end success 當成系統工程來管理，到 2020 年時其整體臨床成功率已提升到 21%，遠高於過去 2010 年約 2% 的水準。這些案例"},{"title":"A New Drug Finally Arrives for This Group of Rare-Disease Patients","url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509-en.html","date":"2026-04-09","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on A New Drug Finally Arrives for This Group of Rare-Disease Patients, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the "},{"title":"這一批罕見病患者終於等來新藥！","url":"https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html","date":"2026-04-09","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","AI","臨床數據","生技投資"],"summary":"美國 FDA 近日加速核准 Denali Therapeutics 的 AVLAYAH（tividenofusp alfa-eknm），用於治療 Hunter syndrome （韓特氏症），也就是 mucopolysaccharidosis type II（MPS II） 的神經學表現。","key_points":[],"excerpt":"近 20 年來，美國終於等到一個能碰到腦部病程的 Hunter syndrome 新藥 美國 FDA 近日加速核准 Denali Therapeutics 的 AVLAYAH（tividenofusp alfa-eknm），用於治療 Hunter syndrome （韓特氏症），也就是 mucopolysaccharidosis type II（MPS II） 的神經學表現。 這次核准之所以重要，不只是因為它讓 Denali 拿下第一個美國上市產品，更因為它同時寫下兩個里程碑： ✨ 一是自 Elaprase（idursulfase） 於 2006 年在美國獲批以來，Hunter syndrome 近 20 年終於出現新的 FDA 核准治療選項。 ✨ 二是它成為 FDA 首個核准、明確利用 transferrin receptor（TfR） 機制穿越血腦障壁的酵素替代療法。 這代表罕病領域最難翻越的那道牆——不是法規，也不是商業化，而是 blood-brain barrier（血腦障壁）——第一次在美國監管層面被真正打穿。 更準確地說，FDA 這次核准的適應症並不是「所有 Hunter syndrome 患者」，而是體重至少 5 公斤、尚未進入 advanced neurologic impairment 的 presymptomatic 或 symptomatic pediatri"},{"title":"The Abivax Story: How a European Biotech Became a 14-Fold Market Myth","url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14-en.html","date":"2026-04-08","lang":"en","category":"商業分析系列","tags":["Business Analysis","Business development","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Abivax Story: How a European Biotech Became a 14-Fold Market Myth, focusing on business development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, an"},{"title":"歐洲生技公司Abivax 一年暴漲14倍的神話","url":"https://drugnews.com.tw/articles/2026-04-08-abivax-14.html","date":"2026-04-08","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","BD","臨床數據","生技投資","製藥巨頭"],"summary":"Abivax 近幾個月的股價與話題熱度，幾乎都圍繞著同一件事打轉：它到底會不會成為下一個大型藥廠出手收購的標的。","key_points":[],"excerpt":"150 億美元併購緋聞背後，市場真正想買下的，不只是 obefazimod Abivax 近幾個月的股價與話題熱度，幾乎都圍繞著同一件事打轉：它到底會不會成為下一個大型藥廠出手收購的標的。 1 月，市場一度傳出 Eli Lilly（禮來）有意以約 150 億歐元、折合約 175 億美元的價格收購 Abivax，之後遭法國官方與公司管理層否認；3 月，又有法媒稱 AstraZeneca（阿斯利康）可能出價約 157 億美元，Abivax 隨後同樣公開駁斥，稱相關說法只是「毫無根據的傳聞」。 但值得玩味的是，這些傳聞雖然一再被否認，卻沒有因此消失，反而愈傳愈密。 這其實透露出一個更重要的現象：市場正在重新評估 Abivax 的價值，而它被重估的理由，既不是單純的題材炒作，也不只是潰瘍性結腸炎（ulcerative colitis, UC）的一支後期資產，而是 obefazimod 與其背後 miRNA 成藥路徑可能同時進入兌現期。 第一層價值：市場真正先看見的，還是 obefazimod 真正撐起 Abivax 估值的第一根樑柱，當然還是 obefazimod 本身。 這是一個口服、每日一次的小分子藥物，Abivax 將其定義為 first-in-class 的 miR-124 enhancer。它目前最核心的適應症是中重度活動性 UC，而這個市場本來就是全球慢性發炎疾病裡最有價值、也"},{"title":"While the US CDC Was Still Looking for a Director","url":"https://drugnews.com.tw/articles/2026-04-07-cdc-en.html","date":"2026-04-07","lang":"en","category":"商業分析系列","tags":["Business Analysis","Regulatory risk","Capital markets","Immunology","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on While the US CDC Was Still Looking for a Director, focusing on regulatory risk, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets"},{"title":"當美國 CDC 還在找主任...","url":"https://drugnews.com.tw/articles/2026-04-07-cdc.html","date":"2026-04-07","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據"],"summary":"真正值得擔心的，從來不只是美國疾病管制與預防中心（CDC）這個位子到底由誰來坐，而是當一個國家的公共衛生指揮中樞長期處於權責模糊、科學威信受損、政策方向反覆擺盪的狀態時，它原本在全球健康治理與醫藥監管上的領導角色，也會跟著一起鬆動。","key_points":[],"excerpt":"當美國 CDC 還在找主任，全球新藥創新已經開始改寫地圖 真正值得擔心的，從來不只是美國疾病管制與預防中心（CDC）這個位子到底由誰來坐，而是當一個國家的公共衛生指揮中樞長期處於權責模糊、科學威信受損、政策方向反覆擺盪的狀態時，它原本在全球健康治理與醫藥監管上的領導角色，也會跟著一起鬆動。2026 年 3 月 25 日，白宮錯過了為 CDC 提出正式主任人選的關鍵時點；依據聯邦代理任命規則，Jay Bhattacharya 的 210 天代理期限本已走到盡頭，但白宮仍選擇讓他繼續以「可委派職責」的方式管理 CDC。換句話說，美國最重要的公共衛生機構，至今仍沒有真正意義上的正式領導者。 這場真空，不是偶然 這場真空不是偶然，而是一連串政治與科學衝突累積後的結果。Reuters 的報導指出，Susan Monarez 去年 8 月遭撤換，導火線是她反對衛生部長 Robert F. Kennedy Jr. 推動、但她認為缺乏科學依據的疫苗政策變更；她離職後，四名資深 CDC 官員相繼請辭。之後 Jim O’Neill 接手代理主任，再到 2026 年 2 月由同時身兼 NIH 院長的 Jay Bhattacharya 暫代。短短幾個月內，CDC 不只換了多位領導者，還出現了 Ralph Abraham 這位首席副主任上任不久便以家庭因素辭職的情況。對一個本來就要面對疫苗政策、麻疹疫情、州"},{"title":"The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means","url":"https://drugnews.com.tw/articles/2026-04-06-420-en.html","date":"2026-04-06","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on The Cut-Rate Weight-Loss Injection Has Arrived: What a NT$420 Monthly Price Really Means, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development "},{"title":"骨折價 瘦瘦針來了，每月420塊台幣","url":"https://drugnews.com.tw/articles/2026-04-06-420.html","date":"2026-04-06","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","BD","臨床數據","生技投資"],"summary":"2026 年 3 月，semaglutide （瘦瘦針）在印度迎來一個足以寫進產業教科書的時刻。","key_points":[],"excerpt":"當 semaglutide （瘦瘦針）在印度跌到每月 14 美元，真正被顛覆的不是減重藥價格，而是整個 GLP-1 市場的商業邏輯 2026 年 3 月，semaglutide （瘦瘦針）在印度迎來一個足以寫進產業教科書的時刻。隨著 Novo Nordisk 在印度的核心專利到期，這個過去幾年幾乎重新定義全球減重與代謝治療想像的分子，第一次在一個具備龐大人口基數、成熟學名藥工業與高度自費特性的超大型市場，正式進入白熱化的專利後競爭。 這不是單純多了幾個便宜版 Ozempic 或 Wegovy，而是整個 GLP-1 產業第一次被迫面對一個真正尖銳的問題：當明星分子失去專利保護後，它究竟會繼續維持「高價神藥」地位，還是迅速被打回大宗慢病產品的本質？ 價格崩塌，不只是便宜，而是價格體系被整個改寫 印度給出的答案，比市場原本預期得更激烈。就在專利到期後幾天內，多家印度藥廠同步推出學名版 semaglutide，首波產品已把治療成本壓低約 70%；不同品牌、不同劑量與不同裝置形式的月治療費，大致落在 ₹750 到 ₹4,200 之間。 更具象徵意義的是，市場最低入門版本甚至已經壓到每月 ₹1,290，約 14 美元。和 Novo Nordisk 在 2025 年 11 月主動下修後、仍落在每月 ₹10,850 至 ₹16,400（約140美元） 的 Wegovy 價格相比，這已經不是折扣，而"},{"title":"How Far Are We From a Real Anti-Aging Drug?","url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352-en.html","date":"2026-04-05","lang":"en","category":"商業分析系列","tags":["Business Analysis","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on How Far Are We From a Real Anti-Aging Drug?, focusing on clinical development, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets "},{"title":"我們離真正的抗老藥，究竟還有多遠？","url":"https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html","date":"2026-04-05","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","臨床數據","生技投資"],"summary":"「抗老化」這三個字，很容易讓人聯想到不老神話、富人專屬科技，甚至公平性與可近性的爭議。","key_points":[],"excerpt":"週末大家好！我們剛好聊點輕鬆的！ 「抗老化」這三個字，很容易讓人聯想到不老神話、富人專屬科技，甚至公平性與可近性的爭議。 但若把問題問得更精準，真正值得討論的其實不是「人能不能活到 150 歲」，而是能不能把失能、慢性病纏身、長期照護依賴的時間往後推。 換句話說，抗老藥物真正想處理的核心，不是單純延長壽命，而是延長 healthspan（健康壽命）。 WHO 對 healthy ageing（健康老化）的定義，本來就不是「完全沒有疾病」，而是盡可能維持一個人能夠生活、移動、思考、做決策、維持關係與參與社會的 functional ability（功能能力）。 這也是為什麼 geroscience（老化生物醫學）近年會快速升溫：它想處理的是高齡社會最現實的問題，而不是科幻式的長生不老。 問題的第一道門檻：老化還不是一個成熟的藥物適應症 真正的難題在於，老化在監管上還不是一個成熟的藥物適應症。 現有回顧指出，FDA、EMA 與 Health Canada 目前都沒有把 aging（老化）正式視為疾病，這使得開發者很難直接以「治療老化」作為新藥申報路徑；臨床試驗多半只能改以糖尿病、心血管疾病、失智症、衰弱、肌少症或其他老化相關疾病為切入點。 也就是說，科學界已經越來越相信「老化機制可以被干預」，但監管體系仍然主要是以單一疾病為單位在運作。 這不是語言遊戲，而是整個產業能不能被資本支持、能"},{"title":"Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?","url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633-en.html","date":"2026-04-04","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Capital markets","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Did Weight-Loss Injections Backfire and Trigger Pancreatitis Risk?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the w"},{"title":"瘦瘦針翻車？導致胰臟炎？","url":"https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html","date":"2026-04-04","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","臨床數據","生技投資"],"summary":"GLP-1 類藥物近兩年幾乎成了全球醫療市場最耀眼的明星。從 liraglutide（利拉魯肽）、semaglutide（司美格魯肽），到雙重受體機制的 tirzepatide（替爾泊肽），這一波藥物不只改變了第二型糖尿病治療，也快速跨入體重管理、心血管風險降低等更大的市場。","key_points":[],"excerpt":"當減重神藥撞上監管逆風：英國強化致命胰臟炎警示，FDA 點名 Novo Nordisk（諾和諾德）藥物警戒失靈 GLP-1 類藥物近兩年幾乎成了全球醫療市場最耀眼的明星。從 liraglutide（利拉魯肽）、semaglutide（司美格魯肽），到雙重受體機制的 tirzepatide（替爾泊肽），這一波藥物不只改變了第二型糖尿病治療，也快速跨入體重管理、心血管風險降低等更大的市場。也正因為使用人數急速放大，監管機構如今開始更用力地追問同一件事：當一款藥從特定代謝疾病用藥，變成被廣泛討論、甚至被當成生活型態干預工具時，它的安全監測體系，究竟有沒有跟上成長速度？ 英國先出手：不只是提醒，而是把警示門檻整體往前拉 2026 年 1 月 29 日，英國藥品暨醫療產品管理局（MHRA）更新整個 GLP-1 類與 GLP-1/GIP 雙重受體藥物的安全資訊，點名 dulaglutide（度拉糖肽）、exenatide（艾塞那肽）、liraglutide（利拉魯肽）、semaglutide（司美格魯肽） 與 tirzepatide（替爾泊肽），要求進一步強化「急性胰臟炎」風險警示，特別是壞死性與致命性個案。 MHRA 公布的資料顯示，英國在 2007 年到 2025 年 10 月之間，累計收到 1,296 件與這類藥物相關的胰臟炎黃卡通報，其中 19 件為死亡通報，24 件為壞死性胰臟炎。更"},{"title":"After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?","url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197-en.html","date":"2026-04-03","lang":"en","category":"商業分析系列","tags":["Business Analysis","Obesity medicine","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on After GLP-1 and Mounjaro, What Is Happening in Weight-Loss Drug R&D?, focusing on obesity medicine, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the"},{"title":"瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？","url":"https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html","date":"2026-04-03","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","GLP-1","BD","臨床數據","生技投資","製藥巨頭"],"summary":"過去幾年，**司美格魯肽（semaglutide）與替爾泊肽（tirzepatide）**幾乎重寫了肥胖治療的市場想像。它們不只把減重從「意志力問題」拉回醫療管理，更把投資人、藥廠與臨床醫師對減重藥的預期，直接拉高到一個全新標準。","key_points":[],"excerpt":"過去幾年， 司美格魯肽（semaglutide）與替爾泊肽（tirzepatide） 幾乎重寫了肥胖治療的市場想像。它們不只把減重從「意志力問題」拉回醫療管理，更把投資人、藥廠與臨床醫師對減重藥的預期，直接拉高到一個全新標準。 問題是，當 GLP-1 已經證明自己之後，下一階段的競爭，已經不再只是「誰減得更多」，而是「誰能減得更聰明、更久、更有品質」。這也意味著，減重藥物研發正在從單純的食慾抑制，轉向更深層的代謝重塑、身體組成優化，以及併發症分層管理。 真正的範式轉移，不是 GLP-1 被取代，而是 GLP-1 開出的戰場開始分裂成多條主線：有些公司想在 GLP-1 的基礎上疊加新機制，做出更強的體重下降；有些公司想修補 GLP-1 的弱點，例如肌肉流失與胃腸道耐受性；還有些團隊乾脆從肝臟、脂肪組織或基因沉默下手，試圖把減重這件事，從「少吃一點」升級成「整個代謝系統重新調頻」。 如果說 2021 到 2024 年是 GLP-1 單一路線確立統治地位的時代，那麼 2025 到 2026 年，更像是下一波平台競爭正式開打的起點。 第一條新主線：胰淀素（amylin）不再只是配角，而是 GLP-1 後時代最像「基礎骨架」的機制 過去很多人把 amylin 類藥物視為 GLP-1 的輔助選項，但現在越來越多數據在提示，amylin 可能不是配菜，而是下一代減重方案的底層搭檔。 它之所以重要"},{"title":"Can Merck Build Another Oncology Empire?","url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419-en.html","date":"2026-04-02","lang":"en","category":"商業分析系列","tags":["Business Analysis","Big Pharma","Capital markets","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Can Merck Build Another Oncology Empire?, focusing on big pharma, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optionality, and the way capital markets may reprice t"},{"title":"默沙東還能再造一個腫瘤帝國嗎？","url":"https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html","date":"2026-04-02","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","生技投資","製藥巨頭"],"summary":"2026 年才過了不到三個月，默沙東已經用兩個動作，把自己對「後 Keytruda 時代」的答案講得愈來愈清楚。","key_points":[],"excerpt":"67 億美元買下 Terns，默沙東真正要買的，是 Keytruda 之後的時間 2026 年才過了不到三個月，默沙東已經用兩個動作，把自己對「後 Keytruda 時代」的答案講得愈來愈清楚。 第一個動作，是在 ASCO GU 端出 pembrolizumab（Keytruda） 合併 enfortumab vedotin（Padcev） 的 KEYNOTE-B15 成績：在可接受順鉑治療的肌層浸潤性膀胱癌患者中，這套術前加術後方案把復發、進展或死亡風險降低 47%，死亡風險降低 35%，兩年無事件存活率約 79.4%，顯著高於傳統新輔助化療加手術的 66.2%。 第二個動作，則是 3 月 25 日宣布以每股 53 美元現金、總股權價值約 67 億美元收購 Terns Pharmaceuticals，將 TERN-701 這個口服 allosteric BCR::ABL1 inhibitor 收進版圖。 把這兩件事放在一起看，意思其實很直白：默沙東已經不再只是替 Keytruda 找補強，而是在替整個腫瘤帝國重寫下一階段的權力結構。 壓力其實早就擺在財報上 這種急迫感不是市場過度解讀，而是默沙東自己財報已經把壓力攤在陽光下。 公司 2025 年全年營收為 650.1 億美元，其中 KEYTRUDA／KEYTRUDA QLEX 貢獻 316.8 億美元，年增 7%，依然是最核心的成"},{"title":"Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?","url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001-en.html","date":"2026-04-01","lang":"en","category":"商業分析系列","tags":["Business Analysis","AI drug discovery","Business development","Clinical development","Biotech business analysis","Drug development"],"summary":"A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications.","key_points":[],"excerpt":"This English edition is adapted from Drugnews' Chinese analysis for global biotech, pharmaceutical, investor-relations, and capital-market readers. Core Thesis A Drugnews English brief on Innovent's Globalization Train: Did Taiwan's Forward Therapeutics Get On Board?, focusing on ai drug discovery, clinical evidence, company strategy, business development, and biotech capital-market implications. The central question is not whether the headline looks exciting. The real question is what the event changes about asset value, clinical risk, commercialization strategy, business-development optional"},{"title":"信達的全球化列車，台灣的圓祥搭上了？","url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html","date":"2026-04-01","lang":"zh-Hant","category":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"3 月 24 日，信達生物公布 efdamrofusp alfa（IBI302） 在中國新生血管型老年黃斑部病變（nAMD）關鍵三期 STAR 試驗達成 52 週主要終點。乍看之下，這像是一則典型的臨床里程碑新聞；但若把它放回全球眼科產業的競爭結構裡看，這件事的重要性遠不只是一款新藥在單一市場報捷。","key_points":[],"excerpt":"當 IBI302 三期達標，信達與圓祥真正想拿下的，不只是中國藥證 3 月 24 日，信達生物公布 efdamrofusp alfa（IBI302） 在中國新生血管型老年黃斑部病變（nAMD）關鍵三期 STAR 試驗達成 52 週主要終點。乍看之下，這像是一則典型的臨床里程碑新聞；但若把它放回全球眼科產業的競爭結構裡看，這件事的重要性遠不只是一款新藥在單一市場報捷。對信達而言，這是它把眼科從「附屬業務」做成「平台型事業」的關鍵一步；對台灣的圓祥生技（AP Biosciences）而言，這則數據則等於替 IBI302 從中國敘事推向國際授權敘事，補上了最硬的一塊臨床籌碼。 真正值得注意的是，nAMD 從來不是一個「缺藥」的市場。過去十多年，ranibizumab、aflibercept、conbercept，再到近年的 faricimab，已經把抗 VEGF 眼底治療推到相當成熟的階段。問題從來不是有沒有藥，而是現實世界裡太多患者撐不到理想治療強度：需要反覆玻璃體內注射、頻繁回診、家庭陪病與長期自費或共付壓力，最後把理論上的療效折損成「治療不足」。也因此，下一代眼底藥物真正的競爭點，早就不只是視力字母數能不能再多幾個，而是能不能把給藥間隔拉長、把長期結構傷害壓低，讓更多患者真的走得完治療路徑。AP Biosciences 也在其公司資料中明確把 AMD 描述為高齡族群失明的重要來源，"}]